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Abstract 
The advent of born-global bio-tech firms signal the genesis of a new business 
model that is emerging in the biotechnology sector. Born globals are small 
firms whose knowledge supply-chain includes global resources from multiple 
countries. Their innovation ‘ecosystems’ consists of experienced scientists, 
science parks, academics, well-established bio-pharmaceutical firms and 
government institutions. The firms plan their business based on global 
strategic perspectives and this significantly increases their productivity and 
innovativeness. But surprisingly, little is known about their capability 
development processes in the specialised networks of the biotechnology 
sector. As a result, this study explores the connectivity of various elements, 
within their knowledge supply-chain, and how they influence their capacity to 
generate new scientific knowledge and technical know-how.  
 
The study employs a multi-case approach. It examines five cases of bio-tech 
firms from the East Midlands region of the United Kingdom which have an 
entrepreneurial flair synonymous with born-global firms. The findings from 
within and across cases, secondary data analysis and results from a ‘pilot 
study’ led to the construction of a new conceptual framework of knowledge 
and innovative capability development. The model is created from the ideas 
of Freeman and others and it contributes to an understanding of the concepts 
of dynamic capabilities and network theories. The study infers that the 
business and social connections of small born-global biotech firms along with 
the building blocks of competence & goodwill trust, inter-organisational 
collaborations, tacit & explicit knowledge, prior learning & absorptive capacity 
significantly influence how they develop their innovative capabilities. The 
study also concludes that there is a strong connection between the building 
blocks. The findings of the research are invaluable to a number of 
stakeholders that include: other researchers, large, small firms & the central 
authorities particularly for their role in formulating strategies through policy-
making that either help or hinder the norms of ‘open science’. 
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Chapter 1          
1. Introduction 
The advent of small born-global bio-tech firms particularly in the life 
science sector significantly contributes to a wide range of economic 
effects including: the exchange of scientific knowledge, the transfer of 
technical know-how and the creation of jobs (Ho & Wilson, 2006). 
Crucially, the desire to obtain valuable resources appears to be the main 
driver behind the collaborative behaviours of these science-based firms 
(Schilling, 2008; Rafols et al., 2012).  
 
The biotechnology sector is one that is science intensive and it is 
dominated by small firms which are usually connected to a web of 
established businesses, research and academic institutions within their 
geographical area and they have established strong global links (Hisrich, 
2012). As such, small born-global bio-tech firms have high expectations 
of growth and development. From that perspective, this study argues that 
the formation of business & social networks along with the building blocks 
that include: inter-organisational collaborations, competence & goodwill 
trust, tacit & explicit knowledge, prior learning & absorptive capacity are 
the necessary developmental steps for small born-global bio-tech firms. 
Indeed, by developing these resource-laden connections small born-global 
bio-tech firms have an opportunity to acquire crucial innovative 
capabilities. Early studies (see Schumpeter 1934’s theory of innovation) 
closely associate entrepreneurial behaviour with innovation. In Anderson 
(2000); Mathews & Zander (2007) innovative and entrepreneurial firms 
were described as business ventures that have the vision and the 
flexibility needed to identify and exploit the benefits offered by existing 
and new overseas markets.  
 
2 
 
The extant literature on international entrepreneurship (see Oviatt & 
McDougall, 1994; Li & Ferreira, 2006) characterises born-global firms as 
enterprises which take risks, innovate and have the vision to anticipate 
economic events. This is necessary because in science-intensive 
industries, technology and firm-based capabilities evolve at a fast pace. 
Therefore, for born-global bio-tech firms operating in these constantly 
evolving market conditions, escapades that involve risk such as 
networking across the globe can be crucial for bridging the knowledge and 
capabilities gap (Ferreira et al., 2010) or in enabling new resource 
combinations (Schumpeter, 1950). More work still needs to be done to 
understand the various elements that manifest in the knowledge supply-
chain of small born-global bio-tech firms.  
 
More importantly, how these elements influence the processes of 
developing innovative capabilities that include: scientific knowledge and 
technical know-how necessary for drug discoveries and the development 
of new clinical products respectively. As such, this study brings to light 
the extent to which elements/variables including: business & social 
networks, inter-organisational collaborations, competence & goodwill 
trust, tacit & explicit knowledge, prior learning & absorptive capacity 
within the knowledge supply-chain of small born-global bio-tech firms, 
operating from the East Midlands region of the United Kingdom outside 
the Golden Triangle of Cambridge, London & Oxford, influence their 
process of developing innovative capabilities. Born-global firms have 
global foci – a strategy formulated when the entrepreneurial ventures 
started trading (see Knight & Cavusgil, 1996; Madsen & Servais, 1997; 
Freeman et al., 2010). In that sense, it is reasonable to suggest that, 
from inception, these types of firms enhance their ability to generate new 
ideas and knowledge by engaging in globalised networks (Lasserre, 2012; 
Thompson & Martin, 2010).   
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This position does not assume that born-global firms are immune to the 
foreign market morass including: socio-economic and political-legal 
environment that international businesses, in general, have to contend 
with when they venture into unfamiliar territories (see Hill, 2011). 
Nonetheless, the economic benefits of doing so outweigh the perceived 
risks (Willebrands et al., 2012). Indeed, entrepreneurial firms in the form 
of born globals are able to take advantage of their business and social 
networks by using them as platforms in their process of acquiring 
strategic capabilities that include: technical know-how, fluid scientific 
knowledge and best practice as well as broaden the size of their market 
(Johnson et al., 2008; Lasserre, 2007).  
 
This assumption is consistent with Johnson & Vahlne (2009, p.1423) who 
claim that business relationships are essential “because they make it 
possible to identify and exploit opportunities”. Ferreira et al. (2010) insist 
that social networks are important for an entrepreneurial firms’ 
identification of market related opportunities and they also provide access 
to novel information, knowledge, innovations and physical resources. 
Furthermore, Mathews & Zander (2007) observe that social ties 
accelerate the knowledge development of entrepreneurial firms that seek 
to be at the fore front of new innovations. Admittedly, a firm can enhance 
its innovative capabilities by engaging in collaborative activities but the 
main issues to be addressed in this study are the connectivity of various 
elements and their level of influence on the process of developing those 
capabilities for small born-global bio-tech firms. Consistent with other 
researchers (Welter, 2012; Hart & Dowell, 2011; Maritan & Peteraf, 2011) 
the findings of this study illuminate the genesis of the sophisticated 
processes involved in the development of innovative capabilities of small 
born-global bio-tech firms.          
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1.1 Setting the scene  
Science can be related to almost everything. Horsley (2012, p.6) claims 
that science is about, “discovering new things, creating life and giving 
reason to life and it is also the study of all that makes up the world and 
how it works”. As such, this study focuses on the biotechnology sector in 
which a number of discoveries have been adding to the better life of 
human beings and other species on earth. 
 
The biotechnology sector is a business sector that is gradually growing: 
the sector has emerged from the basic work done by universities in 
science which has completely changed the way science is done. In 
particular, the innovations in the pharmaceuticals, food industry, and 
energy sectors have really transformed the sector. The sector comprises 
of three distinct technologies namely: DNA technology, first discovered by 
Boyer & Cohen in 1973, monoclonal antibody, or “Mabs” technology, first 
discovered by Kohler & Milstein in 1975; and protein engineering 
technology, developed during the 1980s (Liebeskind et al., 1994, p.3). In 
today’s modern science, biotechnology has been classified into three 
broad groups: healthcare and pharmaceutical applications; industrial 
processes and manufacturing; and agriculture, livestock, veterinary 
products and aqua-culture. This study investigates multiple firms that are 
involved in the healthcare and pharmaceutical applications.  
 
Clearly, the bio-tech industry is a science-based sector. It is a market that 
is driven by the flow of fluid scientific knowledge and technical know-how 
to make new innovations. Citing this heavy reliance on scientific 
knowledge any business that operates in this sector must make things 
happen by constantly generating new knowledge and ideas through 
collaborating with other key stakeholders (Owen-Smith & Powell, 2004; 
Powell & Grodal, 2005).  
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In the East Midlands there is overwhelming evidence of collaborative 
activities that have occurred and continue to occur for example, the 
discovery of an essential life-saving drug the flu drug – ibuprofen which 
was first discovered by Dr Stewart Adams at the Boots Nottingham 
laboratories in 1961 (Crocker, 2010; Graves, 2012). The life-saving 
magnetic resonance imaging (MRI) scanner is another example of 
scientific development that has originated from the science city of 
Nottingham.   
 
In the 1950s Boots collaborated with an American company Upjohn to 
develop improved processes for the mass production of the cortisone drug 
in the United Kingdom for its domestic market (Martin, 1987). The 
establishment of a regional science “incubator” BioCity Nottingham (BCN) 
in 2003 is further evidence indicating that the region is vibrant in bio-
science and it is strategically crafting a unique way of getting scientists, 
academic institutions and bio-entrepreneurs to talk to each other with a 
view to enhancing their drug discovery activities and their technological 
know-how for developing new clinical products (NSC, 2012).  
 
According to Crocker (2010) and Reid (2012) in the last decade BCN has 
been very effective in terms of facilitating networking opportunities as 
well as providing discussion forums for small bio-tech firms in the East 
Midlands and from overseas. Evidently, it is through these networking 
forums that technical know-how and scientific knowledge is generated, 
shared, exchanged and transferred between firms (Powell & Grodal, 
2005). In other words, knowledge “hubs” provide a platform that enables 
the development of business and social ties credited in the literature with 
allowing the movement of knowledge and human capital between 
participating firms (see Owen-Smith & Powell, 2004; Cooke, 2003; 
Breschi & Malebra, 2005). The current government (the Conservatives) 
and the EU have both made considerable efforts to develop policies aimed 
at enhancing R&D activities regionally (BIS, 2012).  
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The Prime Minister pledged to support academic institutions and 
businesses to engage in collaborative activities (BIS, 2011). The 
strategies for support that the government put forward included: 
investing in the best British life science ideas at an early stage; to remove 
regulatory barriers that small businesses face; and crucially, to open up 
the NHS to new innovations and new clinical trials.  
 
Science experts Graves (2012) and Crocker (2012) claim that strategies 
including: the setting up of Enterprise Zones Strategy and the EU’s FP7 
Funding Strategy for science-related projects have resulted in the 
establishment of innovation network, science specific research forums, 
infrastructure development and an increase in research institutions e.g. 
the iNet, Medipark  (the knowledge hub), and Pera Innovation Network. 
From that perspective, it makes it intriguing and fascinating to probe 
further the complicated actions and R&D activities that help to generate 
scientific knowledge and stimulate its exchange in the business and social 
networks of small born-global bio-tech firms. Graves (2012) stresses that 
business and social networks are essential for new drug discoveries, the 
exchange of technical know-how and the development of new clinical 
products in the East Midlands. By exploring the complicated collaborative 
actions and activities of small born-global bio-tech firms in the East 
Midlands region the study aims to enlighten the reader about the R&D 
activities of these highly productive types of ventures or firms that appear 
to form in high numbers throughout the region in England.  
 
According to EMDA’s 2010 report regarding the developments in the 
biotechnology sector; since the closure of AstraZeneca’s R&D facilities in 
Loughborough small bio-tech firms have proliferated. The development 
agency highlights that the reasons for this sudden increase in the number 
of small bio-tech firms is directly linked to the closure of AstraZeneca’s 
operations at its Charnwood facility in Loughborough and other R&D sites.  
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While these developments were happening in the East Midlands, Lund in 
Sweden was also closing down (EMDA, 2010). Evidently, there is a global 
strategic shift which is unfolding in Europe within the pharmaceutical 
industry. Clearly, this type of action by large pharmaceutical companies 
was not restricted to AstraZeneca in the East Midlands; the rationalisation 
of R&D facilities has been taking place internationally as the wider 
pharmaceuticals industry re-configures its business models and 
approaches to drug discovery and development (Rafols et al., 2012). In 
their 2010 annual report AstraZeneca point out that it intends to increase 
its externalisation efforts to access the best, most cutting edge science, 
whatever its origin, with a target of 40% of its pipeline sources from 
outside its laboratories by 2014. It appears that the strategy of 
collaborating/outsourcing is very actively pursued by “Big 
Pharmaceuticals” (Rafols et al., 2012). Swain (2012, p.12) explains this 
point more clearly; “the Big Pharma model is undergoing a painful 
evolution, moving from competition to collaboration, from one-size-fits-all 
to more tailored approaches, and a longer-term view of basic research”.  
 
This developing trend merits further investigation and it is the purpose of 
this study to inform the reader about the advent of the new ventures and 
in particular their collaborative activities that have resulted in the 
discovery of new drugs and clinical products following the worldwide 
operational restructuring by large pharmaceuticals.  
1.2 The scope of the research 
The research addresses the knowledge development processes of small 
born-global bio-tech firms. In particular, the work is mainly concerned 
with the connectivity of various elements within the knowledge supply-
chain of these firms and how they influence their capacity to generate 
new scientific knowledge and technical know-how. In doing so, the work 
is limited to investigate the activities of bio-tech firms which use the East 
the East Midlands as their home market.  
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Using multiple cases, various factors/variables including; business & social 
networks, competence & goodwill trust, inter-organisational 
collaborations, explicit & tacit knowledge, prior learning & absorptive 
capacity are examined to understand how they are connected and their 
influence in the knowledge supply-chain of the research phenomenon. 
Empirical evidence from within and cross case analysis was subsequently 
utilised to modify Freeman’s et al. (2010) conceptual framework so as to 
adequately explain the specific circumstances of the research 
phenomenon. The newly developed conceptual framework is useful to 
small and large organisations especially for those that are in the science-
based sector where the concept of networking appears to be the 
cornerstone to resource acquisition, growth and firm-based development.      
1.3 Aims  
The broad aim of the study is to understand the effects of business & 
social networks, competence & goodwill trust, inter-organisational 
relationships, tacit & explicit knowledge, prior learning & absorptive 
capacity on small born-global bio-tech firms’ ability to develop their 
innovative capabilities. It investigates the connectivity of these various 
elements within the knowledge supply-chain of bio-tech firms and how 
they influence their strategy of generating fluid scientific knowledge and 
technical know-how.  
 
It is also the author’s goal to make policy recommendations for political 
institutions and government policy-makers as they play an important in 
role in facilitating firm development patterns in market-oriented 
economies, especially in uncertain economic times (Halkier et al., 2010). 
The attainment of the broad aims of this study is possible through the 
gradual achievement of the following research objectives. 
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1.3.1 Research objectives 
Below the author outlines specific research objectives.  
Objectives 
 
• To map out the main elements of knowledge supply-chain of born-
global bio-tech firms.  
• To explain the connectivity of the main elements of the knowledge 
supply-chain of small born-global firms and the extent to which they 
assist their innovative capability development process. 
• To contribute to the theoretical concepts of the dynamic capabilities 
and networking 
 
The research uses elements of both inductive and deductive research 
philosophies and it assumes a qualitative research approach in the form of 
a multi-case research strategy. It also uses both qualitative methods and 
techniques including: qualitative conversations and secondary data 
analysis (documentary evidence), within and across case analysis. The 
main focus is on small born-global bio-tech firms within the East Midlands 
region of the United Kingdom. Yin (2003) and Stake (1995) advise that to 
avoid pursuing a study that has too many objectives it is necessary to 
determine your case(s). From that perspective, the researcher uses a 
technic known as case binding which includes: using time and place 
(Creswell, 2003); time and activity (Stake, 1995); and by definition and 
context (Huberman & Miles, 1994). Baxter & Susan (2008, p.546) 
supports the use of the case binding technic claiming that “binding the 
case will ensure that your study remains reasonable in scope”. Following a 
“pilot” study data is collected from a systematically selected sample of 
five biotechnology firms which exhibit entrepreneurial behaviours. Expert 
opinion is also sought from three key science research institutions within 
the East Midlands that have been identified as the “champions of 
innovation”.  
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The main reason for using the multi-case research approach for this study 
is to allow the researcher to examine the research subject(s) more closely 
so that rich data is collected to ensure the validity and the reliability of 
the research findings (Bellamy & Perri, 2009). More importantly, to 
demonstrate to the reader that the research findings are grounded within 
and across case analysis of small born-global bio-tech firms operating in 
the East Midlands. Results achieved in this way can be taken to be reliable 
(see Gerring, 2005; Huberman & Miles, 1994; Yin, 2009). Baxter & Jack 
(2008) insists that a multiple case-study (Yin, 2003) or a collective case-
study (Stake, 1995) allows the researcher to analyse data within and 
across settings. Crucially, the researcher prefers this method of research 
in particular because the evidence it generates is considered to be robust 
and reliable (see Huberman & Miles, 1994; Baxter & Jack, 2008).   
 
The market categories of born-global firms to be studied were classified  
by Crocker (2010) into three distinct classes as follows: (1) the Medical 
Technology Markets a term used to define companies included in the 
medical technology and diagnostics sector; (2) Medical Biotechnological 
Markets, i.e. pharmaceutical companies that develop drugs or 
manufacture medical clinical products and (3) the Industrial 
Biotechnology Markets i.e. companies that are developing, manufacturing 
and marketing industrial products and services based on biotechnology. 
1.3.2 Research questions 
The research aims to answer the following sub-questions in order to 
satisfy the stated research objectives located on p.9 while providing some 
explanations to the proposed research problem: 
 
• What are the main elements of the knowledge supply-chain of small 
born-global biotech firms?  
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• How are the main elements of the knowledge supply-chain of small 
born global bio-tech firms connected and to what extent do they 
help or hinder their capabilities development processes? 
• What are the specific interactions of small born-global bio-tech firms 
that lead to capability development?   
 
The sub-question one above is designed to map out the main elements of 
the knowledge-supply of small born global bio-tech firms. The path for 
developing innovative capabilities followed by small born global bio-tech 
firms would say something about the connectivity of these elements with 
their knowledge supply-chain. Sub-questions two and three are partly 
related to sub-question one. Sub-question two helps to explain more 
specifically, about the connectivity of various elements within the 
knowledge supply chain of small born global bio-tech firms and the extent 
to which they assist/affect how they develop their innovative capabilities. 
Sub-question three asks for casual trends regarding more specific links or 
connections that are essential to how the bio-tech firms develop their 
innovative capabilities.             
1.4 Research contribution  
This section informs the reader about the contribution of this study. The 
contribution is in three folds. Firstly, the study brings to light the complex 
processes involved in the development of innovative capabilities by small 
born-global bio-tech firms in the East Midlands that have resulted in the 
development of biotechnology products. Accordingly, Smith et al. (2012) 
claim that, the East Midlands region possesses an important local 
concentration of pharmaceutical (R&D) activities hence, the need to 
highlight the actions of the key stakeholders operating in this 
biotechnology sector.  
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Secondly, the study makes a theoretical contribution by modifying 
Freeman’s et al. (2010) influential conceptual model of rapid knowledge 
development for smaller born-global firms. The modified model is used to 
explain the specific situation of small born-global bio-tech firms and their 
ability to develop their innovative capabilities. Thirdly, the study has value 
to a number of stakeholders. It informs other researchers about the 
activities of small born-global bio-tech firms and it helps science 
institutions, policy-makers including: the UK government, and the EU 
Commission to assess whether their strategies are enabling firms to make 
innovations in the biotechnology sector given the amount of investment in 
the sector which is in the region of £5.5bn (HM Government, 2010).  
 
The idea behind reaching a wide range of audiences was rather nicely 
summed up by Todtling et al. (2009) who understood the innovation 
systems model as encompassing the business sector, the science sector, 
and policy actors. This is consistent with Easterby et al. (2012, p.237) 
who argue in favour of research that contributes to a field of study in 
different ways. The scholars postulate that, “theoretical contribution is 
most important, and it may be supplemented by each of the others”. This 
is in line with the way this study contributes to the field of science and 
business management.        
1.4.1 Knowledge gap   
Since collaboration in the production of scientific knowledge has become a 
central policy issue for governments and institutions globally (Canton et 
al., 2005), it is surprising that only a few researchers have studied the 
dynamics of the capability development processes of small born-global 
bio-tech firms.  
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Other scholars (see for example Elfring & Hulsink, 2003; Johannisson, 
2000; Hite & Hesterly, 2001; Rowley et al., 2000; Gerard et al., 2009; 
Demirkan & Demirkan, 2011; Powell & Grodal, 2005; Owen-Smith & 
Powell, 2004; Breschi & Malebra, 2005; Cooke, 2003) have carried out 
extensive research on the general contributions of networks for small  
firms. But little is known about the development processes of small born-
global firms in the specialised networks of the biotechnology sector.  
As such, this study fills the gap by exploring how inter-organisational 
collaborations of small born-global firms outside the Golden Triangle of 
Cambridge, London and Oxford influence their capacity to develop 
innovative capabilities. The study also explains the connectivity of various 
elements with the knowledge supply-chain of these firms. Furthermore, 
the study expounds how knowledge can be used by small born-global 
firms to not only improve their business processes but to accelerate new 
drug discoveries and the development of life-saving clinical products 
otherwise not known before. This fulfils the call for more research by 
Corner & Wu (2012) on how innovative capabilities in younger, emerging 
ventures are developed and, in particular, the processes whereby these 
important capabilities are born and nurtured (Zahra et al., 2006).  
To explain the scientific knowledge, technical know-how development 
processes and the activities that enable drug discoveries the study 
explores how prior learning influences the ability to absorb useful 
scientific knowledge and technical know-how through collaborating in pre-
existing or newly established business and social networks.  
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1.4.2 Theoretical contribution 
The researcher wishes to start by acknowledging Freeman’s et al. (2010) 
model of rapid knowledge development for smaller born-global firms (the 
model is located on p.79). The scholars have made a huge contribution to 
the understanding of how smaller born-global firms appear to 
acquire/develop knowledge. Nonetheless, the researcher believes that the 
framework can be further modified to adequately explain the specific 
activities of small born-global bio-tech firms and enhance our 
understanding the connectivity of various elements within their knowledge 
supply-chain and how they influence their capacity to generate fluid 
scientific knowledge and new technology.  
 
Even Freeman et al. (2010) recommend the need for further studies to 
refine their conceptual framework and its applicability to a knowledge 
based view (KBV), resource based view (RBV) and network perspectives. 
In that sense, this study builds on the significant contribution that they 
have made. Before a detailed discussion of the modifications to the 
concept of rapid knowledge development proposed by Freeman et al. 
(2010), the researcher feels that it is essential that the study evaluates 
the discourse regarding case-oriented studies in terms of their 
contribution to developing theoretical concepts.  
 
The extant literature on case-study research offers a wide range of 
explanations about what constitutes theoretical contribution (Ridder et al., 
2009). For example Eisenhardt & Graebner (2007) express that the 
output of case-oriented research designs take various forms including: a 
new concept, theoretical construct, conceptual framework, propositions, 
and in other cases a mid-range theory. As such, this study proposes 
concepts that are deemed necessary for small born-global bio-tech firms 
in their process of developing innovative capabilities.  
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Sigglekow (2007) maintains that using rich data acquired through closely 
examining instances of occurrences, in cases, can inspire new ideas in 
theory construction. Glaser & Strauss (1967) make a strong connection 
between empirical reality and secondary data insisting that the connection 
between the two permits the development of a testable, relevant and 
valid theory. Consistent with this view Eisenhardt & Graebner (2007), 
Ridder et al., (2009) agree that case studies have the potential to 
uncover unusual phenomena and of repeating or countering the 
replication of findings of other cases which eliminates alternative 
explanations and elaborates the emerging theory. In the same vein, 
Stake (2005) argues that case studies are valuable when a researcher 
intends to refine a theory.   
 
It is in light of this that the study makes significant contribution by 
modifying Freeman’s et al. (2010) general model of rapid knowledge 
development for smaller born-global firms through inferring with empirical 
evidence from within and across cases, results from a “pilot” study and 
preliminary literature review. This allows the researcher to develop a 
frame of reference that is testable, reliable and valid (Glaser & Strauss, 
1967). The researcher believes that their model (Freeman’s and others) 
cannot be adequately applied to the specific situations of small born-
global bio-tech firms that are operating as contract research organisations 
(CROs) to explain specifically the key elements that influence their 
capacity to make innovations. From that point of view, the study modifies 
five of seven propositions represented on their model to increase its 
explanatory power (Ridder et al., 2009). The original propositions on the 
model for rapid knowledge development for small born-global firms are 
identified as: relational trust, inter-firm partnerships, tacit knowledge, 
absorptive capacity and development of new knowledge.  
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But because Freeman’s et al. (2010) inspirational model falls short of 
explaining the specific situations of small born-global bio-tech firms an 
improved model “Knowledge and Innovative Capability Development 
Model” is proposed (see figure 8 section 4.5, p.206) illustrating new 
concepts including: competence & goodwill trust, tacit & codified 
knowledge, prior learning & absorptive capacity that more closely reflect 
the world of a special type of small born-global bio-tech firms in the 
biotechnology sector.  
 
Established and newly developed business and social networks 
propositions remain unchanged as part of the knowledge supply-chain of 
the small born-global bio-tech firms needed to facilitate the development 
of innovative capabilities. The new propositions are influenced by the 
evidence emerging from a preliminary literature review (conducted as 
part of the pilot study) and empirical data gathered from a detailed within 
case analysis of small born-global bio-tech firms from the East Midlands.  
This is consistent with a number of scholars (see Yin, 2003; Stake, 
1995/2005; Vaughan, 1992) who emphasise on the power of case-
oriented research strategies in contributing to theory building. Sigglekow 
(2007) makes an important contribution suggesting that within and 
across case analysis significantly contributes towards honing/sharpening 
existing theory by identifying holes and filling them (also see Gerring, 
2001; Andersen, 1993; Goertz, 2005 for discussion on theory 
adjustment). Crucially, the study claims that these elements can be 
combined into the theoretical concepts of the dynamic capabilities view 
and network theory to better explain their impact on the science-based 
sector where it is unlikely that a single individual or firm will possess all 
the resources and capabilities necessary to develop and implement a 
significant innovation (Hegedoorn, 2002; Schilling, 2010). This is 
consistent with the network approach which focuses on specific, well 
selected relationships in the innovation process with specific actors within 
the same innovation ‘ecosystem’ and beyond.  
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The network theory stresses the motives for engaging in collaborations 
such as technological complementarities or access to resources and 
specific knowledge, and it emphasises the role of trust and social capital 
for the development of networks. Thus, this research makes a huge 
contribution to the network theory and the dynamic capabilities view.  
1.4.3 Research implications 
The study is valuable to a number of key stakeholders in the 
biotechnology sector. It may help other researchers, bio-entrepreneurs & 
bio-tech firms, entrepreneurial small born-global firms, regional science 
institutions and policy-makers (e.g. the UK government and the European 
Union Commission).  
 
Policy-makers should initiate targeted schemes that combine support for 
start-ups, internationalisation and innovation, mainly by providing 
technical and business advice, international networking opportunities with 
peers, suppliers and clients and access to finance in the form of subsidies, 
favourable loans or contacts with investors. Research collaborations in 
science-based sectors are vital to the development of life-saving drugs 
and clinical products as well as the survival of a firm in the 
hypercompetitive global markets. This is particularly important given the 
crucial role the biotechnology sector plays in saving the lives of ordinary 
people and its contribution to the economic development of the world 
markets (Hisrich, 2012). Smith & Bagchi-Sen (2006) suggests that for 
bio-tech firms operating in these harsh economic conditions there is 
greater need to develop business models and strategies that incorporate 
science into new product development, not only with local actors but also 
with geographically distant actors.  
 
 
 
18 
 
To create stakeholder awareness about whether their current strategies 
for networking are achieving the intended outcomes and the researcher 
intends to disseminate the findings of this research through research 
publications such as the Science Direct, Technovation, Journal of Local 
Economy, Nottingham Science City publications and by presenting at 
seminars on networking in biotechnology at networking forums organised 
by BioCity Nottingham (BCN) involving international players. The 
researcher also intends to work as a consultant for bio-tech firms 
championing the idea of working in collaborative projects highlighting its 
benefits to the parties involved.      
1.5 Structure of the thesis 
The entire thesis is divided into six main chapters which are further 
subdivided into various sections with subsections.  
  
Chapter 1: Introduction  
The chapter introduces the scope of the research. It sets out the research 
objectives and questions to be answered in the study and the reasons for 
undertaking it. It also provides a summary of the research sector and the 
structure of the thesis. In a nutshell the chapter sets the scene of the 
study. It outlines the research contribution. The contribution is in three 
parts including: theoretical contribution, knowledge about small born-
global firms operating in the East Midlands and the value of the research 
to key policy-makers, other researchers, bio-tech firms and science 
experts. 
 
Chapter 2: Literature Review 
The literature review chapter provides an overview of what is known 
about born-global firms. The chapter shares with the reader the results of 
other studies that are closely related to this research.  
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The literature review chapter relates to the larger on-going dialogue about 
born-global firms and it evaluates prior studies (Copper, 2010; Marshall 
and Rossman, 2011). Specifically, the chapter synthesises the literature, 
organises it into a series of related topics and it summarises the literature 
by pointing out the central issues concerning born-global firms. 
 
Chapter 3: Methodology 
The methodology chapter provides a detailed discussion of the research 
philosophy, approach, and design. The chapter also explains the reasons 
for using a pilot study in this research. Crucially, this part of the study 
presents the epistemological positions in social science that this study 
takes. It also discusses the rationale for using a multi-case research 
strategy. Ethical considerations for the study are also discussed. It also 
informs the reader about the limits of the research. The methodology 
chapter provides a chronological account of how data for this study was 
collected, analysed and measured. The section also outlines how data was 
categorised and structured. The chapter also explains the 
operationalisation of the main themes of the study.   
 
Chapter 4 Research findings 
This chapter provides the research findings following within and across 
case analysis. Thematic analysis is used to analyse data collected from 
small born-global bio-tech firms. Themes are used as the unit of analysis 
for each case as illustrated in the new model for “Knowledge and 
Innovative Capability Development” for small born-global firms. The main 
propositions for the study include: business & social networks, 
competence & goodwill trust, inter-organisational collaborations, tacit & 
codified knowledge, prior learning & absorptive capacity.  
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The analysis draws its explanations from the data collected from case 
samples, preliminary literature review, and qualitative discussions. The 
chapter also provides findings from inferences derived from data collected 
for the purpose of the research.  It also summarises case findings and it 
highlights some similarities and differences across the research sample as 
well as explaining their implications to the research.  
 
Chapter 5: Conclusions 
This is the final chapter and it is divided into three distinct sections. The 
first section summarises the key points of the research project taking into 
perspective its findings and results from within and cross case findings in 
chapter 4. Recommendations to key stakeholders and suggestions for 
future research are made.   
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Chapter 2 
2. Literature review  
To further underscore the significance of a literature review this chapter 
provides a critique of the literature related to small born-global bio-tech 
firms. The study sifts through existing data in order to examine and to 
provide some insights into the key themes including: the orientation of 
born-global bio-tech firms, their characteristics, the individual 
characteristics of bio-entrepreneurs, the international dimension of born-
global bio-tech firms, their innovation clusters and networks and their 
business models. More importantly, the study informs the reader about 
how small born-global bio-tech firms use their business and social 
networks through collaborating to acquire scientific knowledge for drug 
discoveries and technical know-how for new clinical equipment 
development. This is consistent with Saunders et al. (2003) who believe 
that inductive research cannot be taken without a competent knowledge 
of the subject area being investigated.  
Furthermore, Easterby-Smith (2012) suggests that it is essential for social 
science researchers to conduct a critical review of the literature in the 
field of their study in order to form the foundation on which to build their 
research. Saunders et al. (2007) explain that the main purpose for doing 
this is to develop a good understanding and an insight into relevant 
previous research and the trends that have emerged. To illustrate their 
point of view regarding the purpose of doing a literature review Saunders 
et al. (2007) utilise the example of a scientist arguing that it is important 
for a scientific researcher investigating the causes of cot death to read the 
literature to develop an understanding of the findings of other cot death 
researchers before they start their own research. 
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Following an examination of specific and related data about born-global 
bio-tech firms the study modifies Freeman’s et al. (2010) propositions 
outlined in their model of rapid knowledge development for smaller born-
global firms.   
2.1 Defining born globals 
The word born-global is used, in this study, to describe small firms in the 
bio-tech sector which engage in global collaborative activities; meaning 
they take part in science-related projects within and outside their 
immediate vicinity. Gabrielsson & Kirpalani (2004) agree that depending 
on the school of thought and characteristics of companies under 
investigation scholars have used different criteria to define born globals.  
 
The literature is littered with different definitions of what born globals are. 
For example, Oviatt & McDougall (1994) define them as international 
ventures that seek to derive competitive advantage from the use of 
resources and the sale of outputs in multiple countries. Other scholars 
(see Knight & Cavusgil, 1996; Knight, 2001) use a variety of measures as 
criteria for defining these international ventures such as: the vision and 
strategy to become global, time of internationalisation and overseas sales 
volumes. Considering the different labels used to define born-globals a 
distinguishing feature in all their definitions is that, they adopt a global 
strategy evidenced by their structural dimension which encompasses 
various actors in multiple countries (Oviatt & McDougall, 1994). Equally, 
important to this discourse Oviatt & McDougall (2005) suggest that there 
is evidence which points to the fact that university and high-tech 
company spin-offs often become born globals. In spite of this observation, 
there still is no universal agreement to a single definition of born-globals.  
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In all the confusion and misconceptions regarding the definition of born-
global firms, this study follows a commonly used definition of born globals 
which accentuates that at least 25% of their sales had to come from 
outside their home market in the first three years of their inception (see 
for example Gabrielsson and Kirpalani, 2012; Oviatt, and McDougall, 
2005b; Knight and Cavusgil, 1996). Tanev (2012) insists that the 
majority of born-global firms advance through subsequent stages of 
internationalisation, collaboration with foreign partners, or undertaking of 
direct foreign investment (FDI). Accordingly, Ferreira et al. (2010) claim 
that irrespective of the label used to define the entrepreneurial behaviour 
of born-global firms, the concept is the outcome of a trend towards 
commercialising their products or services on a global scale. This rather 
new and emerging strategy of acquiring innovative capabilities which 
appears to be gaining momentum in the biotechnology sector can be 
attributed to the developments in information systems and technology, 
transportation, marketing and diminishing tariff and non-tariff barriers 
(Schilling, 2010; Lasserre 2007/2012; Ferreira et al., 2010). As such, 
developments of this nature significantly give rise to the formation of 
entrepreneurial firms with an international flair from the day they start to 
operate.  
2.2 The orientation of small born-global bio-tech firms 
It is an important step for this study to construct a clear picture of born-
global bio-tech firms in order to enhance our comprehension of how they 
became global. According to the Mandl & Celikel-Esser (2012) born-global 
firms are mainly set-up by former employees/industrial practitioners 
quitting their job and starting a business with an innovative product. 
Arguably, born-global bio-tech firms investigated in this study have no 
connection with their parent company. This is the case because the 
majority of the scientists who became bio-entrepreneurs were made 
redundant as a result of a restructuring exercise which saw the closure of 
AstraZeneca’s R&D sites as a way of saving costs.   
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In that sense, they are not receiving any form of support from their 
former employers but they have developed local and international 
connections which have become part of their knowledge supply-chain. 
Therefore they cannot be classified as spin-offs. Nordman & Melén (2008) 
maintain that born-global firms can also develop as a result of academic 
researchers who develop an innovative product from their work in a lab. 
Tanev (2012) insists that managers of born-global firms proactively and 
aggressively compete in international markets; they take risks, and 
innovate. Nordman and Melén (2008) contend that regardless of their 
degree of international knowledge what is evident is the fact that their 
firms are located close to academic institutions or high-tech regions. This 
is evident in the all the firms sampled for this study. In Oviatt & 
McDougall (1997) born-global ventures are described as firms which from 
birth seek to maintain a leading role by utilising unique capabilities that 
are usually acquired from overseas actors. The dominant feature of these 
firms is their focus on global markets and the desire to take advantage of 
the opportunities that new markets offer (Knight & Cavusgil, 2004).  
This observation is in line with the dated but influential remarks of 
Utterback & Abernathy (1975). The authors argue that the process of 
developing new products in young and innovative firms is fluid and 
dynamic and it requires a strategic approach to enable firm specific 
resource-building. The literature on the entrepreneurial behaviour of firms 
(Oviatt & McDougall, 1994; Li & Ferreira 2006) characterise born-global 
firms as enterprises with strong entrepreneurial behaviours including: risk 
taking, innovative and proactive. Admittedly, when operating in science-
based industries such as the biotechnology sector it is essential that firms 
engage in cross border inter-organisational collaborations which present 
them with an opportunity to acquire unique capabilities including: 
technical know-how, robust business processes and advanced scientific 
knowledge (Barney, 1991).  
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In science intensive industries, technology and firm-based capabilities 
evolve at a fast pace therefore for small born-global bio-tech firms 
operating in such volatile conditions the ability to network across the 
globe can be crucial in bridging the knowledge and capabilities gap 
(Ferreira et al., 2010) or in enabling new resource combinations 
(Schumpeter, 1950).  
The primary drivers for taking this position can be attributed to 
entrepreneurial behaviours including: innovativeness, risk taking and the 
ability to spot opportunities (Ferreira et al., 2010). In Lumpkin & Des 
(1996) innovativeness is conceptualised as a way of generating new 
ideas, creating novel products and services, developing new business 
processes and experimenting with new concepts moving away from the 
traditional business model. More often than not in science-based firms 
there is a high level of uncertainty therefore committing large volumes of 
resources can be seen as risk taking for small born-global bio-tech firms 
that are usually conceived with an international dimension to their 
operations (Miller & Friesen, 1982).  
In this study small born-global bio-tech firms are assumed to use the 
network strategy by forming relationships with domestic and international 
partners to gain market access and to augment their core competences. 
In other words, they are risk takers who provide an impetus for change, 
innovation and they progress in economic life (Deakins & Freel 2009). 
Indeed, in today’s fragile global economy small born-global bio-tech firms 
appear to have come up with the winning formulas and huge strides have 
been made in the biotechnology sector in terms of developing essential 
life-saving drugs and clinical products. For example, the discovery of 
revolutionary products such as treatment drugs for previously untreatable 
diseases; fuels and plastics produced directly from plant materials; and 
substances which can convert toxic and other wastes to useful materials 
(Liebeskind et al., 1994).  
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Similarly, Schumpeter (1950) offers an interesting definition of this very 
elusive word by pointing out that, “The Schumpeterian entrepreneur 
changes technological possibilities, alters convention through innovative 
activity and, hence, move production constrains”. The next section 
explores the characteristics of born-global firms which then put into 
context how entrepreneurial firms operating in a science-based sector 
behave.   
2.3 Characteristics of born-global bio-tech firms 
The way born-global bio-tech firms operate bears some resemblance to 
traditional entrepreneurial firms (Standing et al., 2008). Ferreira et al. 
(2010) hold that, “it may be true that to some extent these traits are also 
observable in purely domestic entrepreneurial firms, but because 
international entrepreneurial firms operate in foreign markets they are 
more salient”. Indeed, the majority of born-global bio-tech firms 
encounter operational problems similar to those of a typical 
entrepreneurial firm would navigate through on a daily basis. They both 
exhibit characteristics that can be summarised under the following key 
categories: 
 Resources: small born-global bio-tech firms at their infant stages 
will have limited resource but their technological resources and 
intellectual capital could have the potential to generate high 
returns. 
 Innovativeness: usually born-global bio-tech firms are small high 
technology ventures that heavily rely on their business and social 
networks to generate scientific knowledge and make crucial 
product developments. The emphasis on the concept of creativity 
advances the idea of inter-organisational collaborations that are 
often credited with creating a platform for knowledge sharing 
which results in the discovery of new drugs and life-saving 
clinical products.    
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 Products: their products are mainly science-based and require a 
strong financial base. 
 Competitive Environment: the biotechnology sector is a highly 
competitive business arena therefore the commercialisation of a 
new invention i.e. securing a patent for the invention usually 
yields high returns. 
 Market Share: similar to SMEs, bio-tech firms have a relatively 
small market share due to product awareness within their 
markets and in overseas markets.  
 History: for every new firm there is a dearth of financial 
resources and management capabilities. Therefore, investors 
may have concerns in investing in such ventures.   
 
There are also other organisational-related characteristics such as 
informal structures which are flatter in nature and they allow direct 
communication among the actors involved (Standing et al., 2008). More 
importantly, entrepreneurial firms are well known for their dynamic and 
flexible decision-making processes. Notably, born-global bio-tech firms 
operate in volatile global markets (Lasserre 2012). Therefore, in order to 
respond to frequent changes in the market it is paramount that strategic 
decisions are made with the least amount of delay to improve lead time. 
All of the above discussed characteristics underpin success and they 
highlight the vital role of inter-organisational collaborations for born-
global bio-tech firms as sources for strategic capabilities such as fluid 
scientific knowledge. In that sense, strategic alliances have never been as 
crucial as a source for innovative capabilities and new product 
development (Ohmae, 1989).    
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2.4 Individual capabilities of the bio-entrepreneur 
In the science intensive healthcare and medical sectors innovation 
‘ecosystems’ are the main source of economic effects that include 
knowledge and technical know-how (Ho & Wilson, 2006). Research labs, 
academic institutions, science parks, small and large organisations co-
exist within the maze and they purposefully interact with each other.  
 
Collectively, they work towards supporting technology development and 
the free flow of information (Bramwell et al., 2012). In such complex 
systems of multiple relationships, significant amounts of science-related 
data are generated. This has huge implications for bio-entrepreneurs in 
the sense that, they have to effectively utilise their history and experience 
(antecedent influences) in science in order to identify and acquire useful 
knowledge that can facilitate the development of their born-global bio-
tech ventures. Burns (2012) elaborates on the antecedent influences of 
entrepreneurs highlighting that they are shaped by their business and 
social connections, culture, previous employment, and educational 
attainment.  
 
Considering the operational structures within small entrepreneurial firms, 
there is sufficient evidence to signify that their bio-entrepreneurs are 
actively involved in formulating their business strategies (see Gurău, et 
al., 2010; Burns, 2012; Bessant & Tidd 2011). From that perspective, 
there is logic in suggesting that their personality traits are replicated in 
their firms (Allen, 2012). In Storey (1994) seventeen multivariate studies 
were reviewed to examine the effects of antecedent influences on the 
establishment of entrepreneurial ventures. Storey’s study inferred that 
there is a strong association between an entrepreneur’s educational 
attainment (prior-learning) and the development of their venture. Kuratko 
(2013) contends that as entrepreneurs react to a diverse, multi-faceted, 
and imposing array of activities, events and developments they 
considerably influence the development of their ventures.  
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Bessant & Tidd (2011) insist that the competences of owner-managers 
strongly influence the scope and the direction of their ventures. Karra et 
al. (2008) place strong emphasis on individual entrepreneurs in 
organising born-global firms. The scholars maintain that the most salient 
factor in rapid internationalisation of firms is not necessarily the nature of 
products or the market, but rather the individual characteristics of the 
entrepreneur. An entrepreneur’s experience, skills and networks allow the 
firm to develop the resources that enable it to become a born global firm 
(Altshuler, 2012). 
2.5 The International dimension of small born-global firms 
Over the past three decades the concept of internationalisation has been 
a subject of academic debate. A number of scholars have defined it from 
different angles. In Johanson & Vahlne (1977) internationalisation is seen 
as a step-by-step process adopted by a firm in order to operate on the 
international scene. They posit that this strategic direction involves 
calculated risk. The dynamic perspective of internationalisation was given 
by (Welch & Luostarinen, 1988).  
 
The scholars observed that the process of venturing or taking a firm’s 
operations into overseas territories should involve both internal and 
external resources. Adding to the growing debate about the concept of 
internationalisation Beamish (1990, p.77) conceptualises 
internationalisation as a process “by which firms both increase their 
awareness of the direct and indirect influences of international 
transactions on their future, and establish and conduct transactions with 
other countries”. Likewise, Ohmae (1998) makes an important 
contribution to this debate which is core to this study. He refers to 
business networks as key sources of capability development. Ohmae’s 
point is that in knowledge intensive industries such as the science-based 
firms it is important to continuously generate new knowledge for the 
process of innovating to keep occurring.  
30 
 
Indeed, based on this perception it is reasonable to claim that for small 
born-global bio-tech firms there is pressure to generate scientific 
knowledge which can be acquired or enhanced by penetrating 
international business networks. The process of building a firm’s 
innovative capabilities is exceedingly complex but at the same time 
rewarding in terms of acquiring unique capabilities which makes a huge 
difference in making new innovations (Cohen, 1994). Small born-global 
bio-tech firms operate in extremely hyper-competitive business 
environments which require the firms to react to these market conditions 
by positioning themselves in a way that allows them to take advantage of 
the opportunities offered by globalisation.  
2.5.1 International entrepreneurship  
The term international entrepreneurship is not new; it was first mentioned 
in the late 1980s. Morrow (1988) used the term to describe the many 
untapped foreign markets that were available to new ventures reflecting a 
new technological and cultural environment. McDougall (1989, p.389) 
described international entrepreneurship as “the development of 
international ventures or start-ups that, from their inception, engage in 
international business thus viewing their operational domain as 
international from the initial stages of operation”. McDougall & Oviatt 
(2000, p.903) defined international entrepreneurship in a border sense as 
a, “combination of innovative, proactive and risk taking behaviour that 
crosses or is compared across national borders and it is intended to create 
value in the business”. In the hyper-competitive biotechnology sector, 
entrepreneurial behaviour of such magnitude is very important if a firm 
needs to leverage its internal knowledge base and/or generate new 
knowledge using its external connections. Hisrich (2012) maintains that 
this nature of international entrepreneurship takes into account the notion 
of innovation, risk taking and proactive behaviour.  
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Ferreira et al. (2010) brings in a similar perspective and they insist that 
entrepreneurial firms that are born-global, exhibit unique characteristics 
that heighten their need to integrate and rely on networks to generate 
novel information. 
2.5.2 Motivations for collaborating in science 
The need for working in collaborative teams in science has been 
recognised ever since the professionalisation of science took place during 
Napoleon’s time in France and later in England and Germany (Beaver & 
Rosen, 1978; Mattsson, 2011).  
 
According to Mattsson (2011) the benefits of research collaborations are 
many including those that are related to scientific, economic and political 
factors. In Georghiou (1998) a distinction between direct and indirect 
benefits was made. Direct benefits were seen as those benefits that 
accrue to a firm when it has access to complementary expertise, 
knowledge and skills that help the firm to bridge its knowledge gaps and 
enhance its scientific as well as technical know-how (Mattsson, 2011). On 
the contrary Georghiou (1998) suggests that indirect benefits are as a 
result of collaborations that are driven by external goals usually political 
or cultural related. Indeed, in the biotechnology sector where government 
policies play a crucial role in creating platforms that enhance R&D, 
indirect benefits are a reality for all the actors involved. Consistent with 
Georghiou (1998), Beaver (2001) using a motivation-centred approach to 
explore the benefits of collaborating that motivate firms to collaborate 
with other firms. Table 1 on p.32 provides a comprehensive list of 
purposes for the collaboration of proactive business entities.  
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Table 1: Purposes for scientific collaborations 
1. Access to expertise 
2.  To access equipment, resources or “stuff” that one does not have 
3.  To improve access to financial resources 
4.  To obtain prestige or visibility so as to grow professionally  
5. To improve efficiency of the firm 
6. To aid rapid progress especially for smaller firms 
7.  To tackle “bigger” problems that have become global and sophisticated 
8. To enhance productivity  
9. To get to know people, to create a network  
10. To leverage internal knowledge base i.e. acquire new skills techniques to increase 
chances of new product discoveries  
11. To satisfy curiosity and intellectual interest  
12. To share the excitement of new discoveries with other firms  
13. To reduce mistakes and errors and to uncover any flaws in discoveries at an early 
stage    
14. To focus on research and development  
15. To reduce isolation by keeping abreast with developments in science, and to 
recharge one’s energy and excitement. 
16. To educate (a student, graduate student, or, oneself). 
17. To advance knowledge and learning  
18. For fun amusement and pleasure 
          Sources: Beaver, 2001; Mattsson, 2011 and author’s ideas  
 
A different perspective concerning factors that drive inter-organisational 
collaborations was offered by Kazt & Martin (1997). The scholars divided 
the factors into four distinct categories covering: (a) financially related 
reasons i.e. access to financial resources and working space including 
science labs, office etc.; (b) social factors including reputation within the 
science community, developing social networks; Mattsson (2011) adds 
that social connections are also important here as people prefer to work in 
groups/teams rather than in isolation; (c) collaborations that give rise to 
knowledge sharing and exchange in the form of analytical skills, technical 
know-how and observational learning; and (d) political factors related to 
government initiatives to encourage scientists to work together. Sörlin, 
(2004) explains that collaborations taking an international dimension have 
been in existence even in the early days of modern science.  
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This observation is important to the central discussion in this thesis as it 
is anchored on the activities of born-global firms which operate on a 
global scale. As the study has already explained that born-global firms are 
both proactive and reactive (see Hisrich, 2012; Rasmussen & Madsen 
2002; Knight & Cavusgil 2004). It is, therefore, this behaviour which 
motivates their desire to operate on a global scale. Entrepreneurial firms 
operate globally from day one to gain economies of scope. Johnson et al. 
(2008) defines economies of scope as intangible resources and 
capabilities including skills and technology. In Campbell & Luchs (1992) 
the benefits of scope are referred to as the benefits of synergy. In other 
words, the benefits gained by born-globals from their international 
collaborative partners where they complement each other to the extent 
that their combined effect is greater than when they operate on their 
own.   
 
Table 2: Motivations for going global 
Unique products and services 
Competitive pressures 
Unique market opportunities 
Technological advantages 
Economies of scale and scope 
Tax benefits 
Cost related benefits  
               Source: Adapted from Hisrich, Peters & Shepard, 2010, p. 142   
 
The opportunities offered by foreign markets impact on the decisions of 
born-global firms. Hasegawa & Noronha (2009) point out that the 
technological strength of countries such as China and India are 
opportunities that technology-based firms can take advantage of to 
leverage their core competences as well establish their operations at very 
low costs.    
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2.5.3 Strategic effects of going global  
While trading on a global scale presents born-global bio-tech firms with a 
variety of new environments (Hisrich, 2012) and new ways of going to the 
market (Piercy, 2002) it would be naïve to ignore the new array of 
challenges that a firm has to deal with when establishing its operations in 
new territories. A number of scholars Driscoll (1995); Lasserre (2007); 
Johnson et al. (2008); Hisrich (2012) and Morrison (2011) highlight firm 
and environmental factors as the main factors that influence the strategic 
decisions of a firm intending to trade globally.  
 
Driscoll’s mode choice framework clearly outlines firm-specific advantage, 
experience and strategy as firm factors and demand/competition, socio-
cultural conditions and political/economic conditions as environmental 
factors. The variable moderators were identified as follows: host/home 
government policies, corporate policies and firm size. Figure 1 on below 
neatly illustrates Driscoll’s and the author’s ideas.  
 
Figure 1: Factors that influence strategic decisions of born-global firms   
      Farm Factors 
 
 
 
 
    
 
 
     
     Environmental  
      Factors 
 
 
 
 
                           Moderators 
        
                   Source: Driscoll, 1995 and author’s ideas 
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Similarly, when discussing international vs. domestic entrepreneurship 
Hisrich (2012) identified five factors that are different as follows: 
economics, language stage of economic development, types of economic 
system, political and legal environment and language. Furthermore, Kazt 
& Martin (1997) point out that the process of going global comes with 
increased financial burdens and administrative costs as well as costs 
associated with travelling from the domestic market to overseas markets. 
Georghiou (1998) highlights the differences in the centre of interest, 
research activity and policy support as real challenges for firms operating 
internationally. Mattsson (2011) agrees that different policies and foci in 
different countries have the potential to hinder the intended goals of 
collaborating even if the research agendas are the same. Indeed, these 
factors have a profound effect on how small born-global bio-tech firms 
enter the global stage. They give rise to market ambiguity for these 
proactive firms hence, the presumed importance of business and social 
networks (Freeman et al., 2010; Johnson & Vahlne, 2009; Lasserre, 
2007).  
2.5.4 Risk in global markets 
The risk of failure for born-global bio-tech firms operating in global 
markets is very high and most studies show that there is a high rate of 
failure for small firms ranging from 50% to 80% (see Das & Teng, 1999; 
Dye et al., 2001; and Mol, 2000). In classical decision theory, risk is most 
commonly conceived as reflecting variation in the distribution of possible 
outcomes, their likelihoods, and their subjective values (March & Shapira, 
1987). Synthesising most of the literature on risk taking behaviour Sitkin 
& Pablo (1992) define three important variables including: risk 
preference, risk perception and risk propensity. For risk preference they 
associate it with individual characteristics suggesting that the traits of an 
individual influence their actions (Brockhaus, 1980).  
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For risk propensity they refer to an individual’s tendency to engage in 
risky activities and risk perception is defined as a decision maker’s 
assessment of the risk inherent to a situation. In total it is reasonable to 
suggest that entrepreneurs who enjoy the challenges of venturing into 
global markets irrespective of the size or their resource bases are more 
likely to engage in risky actions than those who are risk averse (Sitkin & 
Pablo, 1992, Willebrands et al., 2012). Given the motivations and drivers 
that have been outlined in Table 1 on page 32 it is reasonable to claim 
that the desire for born-global firms to achieve more in the way of unique 
capabilities can be seen to be stronger than for those firms which chose 
to avoid venturing into new market territories for fear of failure 
(McClelland, 1961). In theoretical economic literature Arrow’s (1971) and 
Pratt’s (1964) parameter of risk aversion (see Cressy, 2006), cogently 
indicate that there is a strong correlation between risk taking behaviour 
and improved business performance.  
 
Indeed, as suggested by the standard economic theory that 
entrepreneurs who avoid taking risks when making investment decisions 
are willing to accept lower returns in exchange for less exposure to risk. 
The same cannot be said of those entrepreneurs who are willing to take 
risks in exchange for higher profit margins (Cressy, 2006; Willebrands et 
al., 2012). On that account, it is safe to claim that the performance of 
small born-global bio-tech firms and the attitude of entrepreneurs may be 
related in several ways. Admittedly, small born-global bio-tech firms have 
very limited resource bases however; market opportunities offered by 
global markets present them with a chance to boost their economic 
returns through their actions. Willebrands et al. (2012) maintains that, 
“market activities inherently carry risk and will only be undertaken by 
those who do not shy away from it”.  
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From the author’s understanding small born-global bio-tech firms which 
from the day they started trading adopted a global strategy, their 
behaviour can be described as risky nonetheless, their expectations are to 
improve their innovative capabilities by having access to fluid scientific 
knowledge and technical know-how essential for drug discovery activities 
and the development of new clinical products.     
2.5.5 Trust and small born-global bio-tech firms  
Networks are assumed to be the main catalysts that make it possible for 
information to flow – is this the reality? Perhaps there are other key 
components that allow the exchange and transfer of knowledge to occur 
(Wever, 2005). The extant literature on trust reveals that trust facilitates 
knowledge transfer and exchange between the actors involved (see 
Welter, 2012; Nahapiet & Ghoshal, 1998; Tsai & Ghoshal 1998; Adler & 
Kwon, 2002; Inkpen & Tsang, 2005; Lui, 2009). By evaluating the 
discourse on trust, this section aims to develop some understanding of 
how small firms acquire strategic capabilities in networks through social 
interactions. A number of related studies have conceptualised trust as an 
important part of a jigsaw puzzle needed for starting and growing a new 
venture (Welter, 2012). Included in these studies about human resource 
flexibility (Zolin et al., 2011), are small business relationships with 
venture capitalists, banks or business angels (Maxwell & Lévesque, 2011; 
Strätling et al., 2011; Howorth & Moro, 2006). More importantly, trust is 
seen as a crucial aspect for the internationalisation of entrepreneurial 
firms which aim to take advantage of global markets (Fink & Kessler, 
2010). Welter (2012) argues that in small family run businesses trust 
plays a central role for their prosperity. Other related studies highlight the 
crucial role trust plays in family businesses as a governance mechanism 
(Eddleston et al., 2010) as well as a tool for their strategic advantage 
(Fink, 2010).  
 
38 
 
In other studies (see Manolova et al., 2007; Puffer et al., 2010; 
Smallbone & Welter, 2001; Yan & Manolova, 1998) trust is mainly seen as 
one of the key components that reduces transaction costs and risks small 
entrepreneurial businesses face in often uncertain and constantly 
changing global business environments. In the bio-tech industry today, 
bio-tech firms often require firms to work/engage in collaborative projects 
with external partners (Jones & Lichtenstein, 2008) because of their 
constantly changing market conditions. Indeed, in this knowledge 
intensive sector, firms work in inter-organisational projects where they 
share risks and they pool their resources to deliver joint drug discoveries 
and clinical products which otherwise would not have been possible when 
they were to go it alone (Powell et al., 1996). Thus, the aspect of trust 
becomes crucial in such partnerships. Wong et al. (2008) agree that trust 
is a vital component in collaborative projects which strengthens as well as 
improves the relationships of the parties involved in a collaborative 
project.  
 
In the literature on inter-organisational collaborations outside information 
has been credited with enabling the flow of technological developments, 
product innovations and enhanced business opportunities (White & 
Fortune, 2002; Maurer, 2009). According to Nahapiet & Ghoshal (1999) 
the act of trusting makes it possible to access such knowledge. 
Furthermore, Welter (2012, p.194) “trust is seen to assist in lowering the 
transaction costs of commercial actions and the risks inherent in 
entrepreneurship”. The concept of trust is a very elusive concept and in 
literature there is no single definition that has been agreed upon. The 
concept is defined in a number of different ways (Welter, 2012). Maurer 
(2009, p.630) contends that “trust is a complex and multifaceted 
construct”.  
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Co-operation and risk are the two main principal concepts that have 
consistently emerged when scholars explore the notion of trust (Sengun, 
2009; Gambetta 1988; Curran & Judge 1995). The two principal concepts 
are strongly linked throughout the literature. Gambetta (1988, p.217-
218) claims that in real life when we say we trust “we implicitly mean that 
the probability that he will perform an action which is beneficial or at least 
not detrimental for us to consider engaging in some form of co-operation 
with him”. Accordingly, in Curran & Judge (1995, p.153) trust is seen as 
an individual’s “behaviour reliance on another person under a condition of 
risk”. From these perspectives, trust can be taken to be based on one’s 
perception that others will behave positively towards them under 
conditions of risk (Gubbins & MacCurtain, 2008). Accordingly, Welter 
(2012) claims that trust is based on the perception of the probability that 
other agents will behave in a way that is expected and benevolent. 
Mainstream literature on trust focuses on dyadic relationships (Anderson 
et al., 1984; Cowan & Jonard, 2004; Breschi and Malebra, 2005). De 
Wever et al. (2005) combine two dimensions of trust i.e. resiliency 
reflecting the extent to which trust is “resilient” rather than “fragile” 
(Ring, 1996) and specificity concerning the degree to which trust may 
exist without direct information and/or without previous interaction, 
simply by association (De Wever et al., 2005).  
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From the combination of these two dimensions of trust four different 
types of trust were obtained and they are outlined in Table 3 below: 
 
Table 3: Four types of trust         
Dyadic Resilient Trust   This type of trust is based on frequent and direct interactions 
and incorporates a kind of benevolence based on those 
frequent contacts. 
Dyadic Fragile Trust Although this type of trust is based on frequent and direct 
interactions, these interactions do not cause the feeling of 
benevolence. This type of trust is a calculative type; there are 
perceptions of the immediate likelihood of rewards whether it 
concerns a long-term or short-term relationship. 
Generalised Resilient 
Trust   
Although this type of trust exists without much previous 
interaction, the feeling of benevolence is present, simply by 
associating. 
Generalised Fragile 
Trust   
Concerning this type of trust, there are perceptions of 
immediate return and not feelings of benevolence linked to 
the cause of the trust: association 
          
                                     Source: De Wever et al. 2005, p.1530-31 
 
The different types of trust demonstrate that different dimensions of trust 
do exist that are closely related to either associations or feelings. This 
implies that there is a belief that trust also exists in social and business 
networks that are being studied in this project. Schoorman et al. (2007) 
expresses that trust is an element of dyadic relations involving the trustee 
and the trusted. Şengün & Önder (2012) suggest that trust is a multi-
level and cross level phenomenon which exists at three different levels 
namely; personal, organisational and inter-organisational levels. Similarly, 
Welter (2012) argues that trust stems from characteristics of a 
community or organisation and he identifies such communities as 
networks, firms, associations, ethnic groups or an industry. Other 
scholars argue that it is multi-dimensional (see Lewicki et al., 1998; 
Nooteboom, 2002; Schoorman et al., 2007). In the same way, Igarashi et 
al. (2008) make a distinction between generalised and pluralistic trust. In 
Sheppard & Tuckinsky (1996) three types of trust were suggested i.e. 
deterrence based, knowledge based and identification based.  
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Şengün & Önder (2012) claim that in previous research a common 
distinction is made between competence and goodwill trust. It is these 
two types of trust that seem to be very critical for small born-global bio-
tech firms which enter into strategic alliances with business partners who 
may have a different complementary foci at some cognitive distance 
(Nooteboom, 2005). In the same vein, Nooteboom & Six (2003) point to 
trust in competence and trust in intention as the two main aspects 
attached to trust that exists in organisations. Trust in competency refers 
to the perceptions of the trustor concerning the trustee’s technical, 
cognitive and communicative competences (Şengün & Önder, 2012; and 
Nooteboom 2009). Blomqvist (1997) and Ganesan (1994) express similar 
views; they claim that competence trust is based on the school of thought 
that there is a high probability, between collaborating parties that agreed 
strategic objectives will be successfully accomplished which increases the 
reliability and the predictability of partners in a relationship.  
 
On the other hand, Şengün & Önder, (2012) suggest that trust in 
intention (goodwill trust) signifies the absence of opportunism or presence 
of benevolence reflecting dedicated behaviour including: fully participating 
in knowledge exchange actives, paying attention to each other’s needs 
and avoiding a one way flow of information (De Wever et al., 2005). 
Blomqvist (1997) concludes that trust in intentions entails the moral 
obligations and the positive intentions of partner to the other and towards 
the relationship.     
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2.5.6 Global alliances 
A strategic alliance is where two or more companies share resources and 
activities to pursue a strategy (Johnson et al., 2006). Schilling (2008) 
insists that an alliance is a general term that can refer to any type of 
relationships between firms which can be short or long term and may 
include formally contracted agreements or can be entirely informal in 
nature. In science-driven businesses, especially for small born-global bio-
tech firms, this kind of joint development of new strategies has gained 
momentum (Hisrich, 2012; Newman, 2001; Ahuja 2000). This way of 
doing business is mainly attributed to the globalised nature of trade 
together with the dynamism and rapid changes in technology that 
technology-based companies have to contend with in order to achieve 
company goals including: capability development, new product & business 
development and creating value for the customer through continuous 
innovation (Schilling, 2008; Lasserre, 2007/2012). Indeed, in the 
biotechnology sector there is a growing trend where research institutions, 
universities and science institutions are forming strategic alliances which 
have resulted in the development of revolutionary products. The 
development of life saving drugs in the medical sector is one example of 
this phenomenon.  
 
Taking that into perspective, it is safe to claim that strategic alliances 
between businesses and research centres worldwide are the cornerstone 
for innovation. In particular, their ability to stimulate and provide a 
platform for knowledge sharing, exchange of ideas and the transfer of 
technologies which has the potential to bring “the new order out of the 
old” Standing et al. (2008, p. 790). In Teece (1986) it was suggested that 
small firms can form alliances with big firms to tap into the larger firm’s 
greater capital resources, distribution and marketing capabilities, or 
credibility. 
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Schilling (2010) uses the example of small biotechnology firms that form 
partnerships with large pharmaceutical firms for their mutual benefit. She 
claims that by forming an alliance pharmaceutical firms can gain access to 
the drug discoveries of the biotechnology companies and likewise the 
biotechnology company gain access to the capital resources, 
manufacturing & distribution capabilities of the pharmaceutical firms. 
Since the fragmentation of the “Big Pharma” model this has been a 
common occurrence in the life science sector (Rafols et al. 2012).   
 
In the literature on strategic alliances it has been made clear that 
strategic alliances enable partners to learn from each other and develop 
competences (see Chan & Wang, 1994; Ohmae 1982; Freeman et al. 
(2010). According to Schilling (2008, p.160) “alliance partners may hope 
to transfer knowledge between firms or to combine skills and resources to 
jointly create new knowledge”. For small born-global bio-tech firms rapid 
access to important complementary assets enhances their flexibility i.e. 
they can either commit their resources to a venture or shift them to 
another opportunity as they operate in multiple countries.  
 
Alliances vary considerably in their complexities from simple, two partner 
alliances, to one with a number of partners sharing capabilities and 
expertise (Ohmae, 1989; Chang & Wang, 1994). It is also important to 
note that although scientific knowledge acquired from strategic alliances 
can be crucial, managing it has always been a challenge for small born-
global bio-tech firms and yet, it is valuable for continuous innovation. 
Standing et al. (2008 p.271) posit that, “knowledge management has 
become a critical imperative in inter-organisational interactions as it 
provides short-term operational efficiencies and long-term new knowledge 
creation”. 
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The process of going global for small bio-tech firms can occur in two 
distinct parts: First, it occurs when a firm intends to exploit or take 
advantage of the existing opportunities in new national markets. Second, 
it occurs when an ambitious firm intends to develop unique capabilities by 
drawing on the capabilities that exist in different parts of the world 
(Lasserre, 2007). In doing so, a firm is able to exploit advantages that are 
related to specific technological and scientific capabilities (Johnson et al., 
2008). In the literature on internationalisation such firms are described as 
born-globals, entrepreneurial firms or international new ventures (INV) 
that seek to derive significant competitive advantage from the use of 
strategic resources acquired from more than one country (Oviatt & 
McDougall, 1997).     
      
The concept of going global can be analysed at different levels ranging 
from: firm level, industry level and national level (Cantwell, 1991). The 
choices and the strategic direction that an organisation pursues in a 
globalised marketplace are driven by a number of factors including: 
seeking strategic capabilities, market opportunities, market 
attractiveness, market conditions and as an expansion strategy (Kale & 
Singh, 2007; and Arova 2005). In a hyper-competitive global market bio-
tech firms should seek to take advantage of the market opportunities 
offered by new and emerging markets. Johnson et al. (2008) suggest that 
the strategies a firm can rely upon to exploit new market opportunities in 
new market territories include; being unpredictable, disrupting the 
market, re-positioning and product diversification. Making a choice 
regarding the strategic direction and scope can be a challenge for 
managers particularly for entrepreneurial managers operating in rather 
ambitious small born-global bio-tech firms. Crucially, Ohmae (1982) 
argues that strategic alliances become a requirement for firms intending 
to access international markets. Similarly, Brouthers et al. (1995) contend 
that in the majority of cases strategic alliances with complementary skills 
significantly contribute to each other.  
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As such, for science-based firms, especially the small born-global bio-tech 
firms that have limited resources venturing into new territories through 
strategic alliances gives them access to scientific knowledge and technical 
know-how. Furthermore, McDougall & Oviatt (2003) claim that networks 
provide a platform for risk taking entrepreneurial firms to access global 
markets and the types of relationships significantly influence the choice of 
the overseas market more than their psychic distance. The social and 
business networks provide numerous benefits for born-global firms and 
they equally pose challenges and risks for them. In the literature on 
international ventures Brouthers et al. (1995) stress that despite the risk 
associated with the social and business networks, it is often necessary for 
firms to enter into strategic alliances to boost their resource bases. Nohria 
& Garcia-Pont (1991) contend that strategic alliances are formed to 
accelerate the acquisition of strategic capabilities more rapidly. From that 
perspective, it is reasonable to claim that strategic alliances of born-global 
firms in the global markets are the cornerstone to resource acquisition.         
 
In Lin & Chen (2002, p.2) strategic alliance are defined as “an inter-
organisational co-operative arrangement over a given economic space 
and time for the attainment of some strategic objectives”. Inter-
organisational alliances have become more common due to the 
liberalisation of international markets and the accelerating pace of 
technological change (Das & Kumar, 2007). In the life science sector this 
kind of joint development of new strategies has dominated the industry. 
In particular, their ability to stimulate and provide a platform for 
knowledge sharing, exchange of ideas and the transfer of technologies 
which has the potential to bring “the new order out of the old” (Standing 
et al., 2008, p.790).  
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Furthermore, Das & Kumar (2007) claim that strategic alliances can be 
used as a platform for sharing costs and research and development 
(R&D), for accelerating the introduction of new products in the global 
marketplace, for gaining access to resources and as a source for strategic 
capabilities including: new technology and information from partner firms.  
Similarly, Chan & Wong (1994) express that strategic alliances are used 
to share costs and risks and to penetrate new markets. In alliances, trust 
is an important component underpinning the development of enduring a 
business relationship. In a study involving 37 companies from 11 different 
countries aimed at understanding the importance of strategic alliances 
Kanter (1994) concluded that trust was fundamental to the success of an 
alliance. Scholarship on entrepreneurial behaviour Oviatt & McDougall 
(1994); Li & Ferreira (2006) characterises born-global firms as firms with 
strong entrepreneurial behaviours. Admittedly, when operating in science-
based industries it is essential that firms engage in collaborative activities 
thus giving themselves an opportunity to absorb unique capabilities 
including: robust business processes, advanced scientific knowledge and 
new ways of going to the market (Barney, 1991).  
 
In science intensive industries, technology and firm-based capabilities 
evolve at a fast pace. Therefore, for bio-tech firms immersed in such 
volatile conditions the ability to network across the globe can be crucial in 
bridging the knowledge and capabilities gaps (Ferreira et al., 2010) or in 
enabling new resource combinations (Schumpeter, 1950). The primary 
drivers for taking this position can be attributed to entrepreneurial 
behaviours including: innovativeness, risk taking and the ability to spot 
opportunities (Ferreira et al., 2010). In Lumpkin & Des (1996) 
innovativeness is conceptualised as a new way of generating new ideas, 
creating novel products and services, developing new business processes 
and experimenting with new concepts moving away from the traditional 
business methods. More often than not in science-based firms there is a 
high level of uncertainty.  
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Therefore, committing large volumes of resources can be seen as risk 
taking for small firms that usually have limited resources (Miller & 
Friesen, 1982). According to Schumpeter (1950) entrepreneurs who are 
successful have the ability to spot a market opportunity and they shift 
economic resources to take advantage of those opportunities (Drejer, 
2004). In this study bio-tech firms are assumed to use the network 
strategy by forming relationships with their international partners to gain 
market access and to augment their core competences.               
2.6 Innovation clusters and networks 
In Carayannis & Wang (2008 p.65), innovative clusters are defined as 
“concentrations of interrelated innovative agents located in a specific 
geographic area”. Clusters are mainly shaped by organisational 
structures, geographic scope, density, breadth and depth and the special 
characteristics of population, culture and technology (Chesbrough, 2006; 
Carayannis & Wang, 2008).  
 
Effective and productive clusters are those that are complementary to 
innovative activities, selective in network development, and, more 
importantly, effective in knowledge sharing and technological transfer 
(Owen-Smith & Powell, 2004). It is also important to acknowledge the 
differences in innovative clusters and innovative networks. Carayannis & 
Wang (2008) identify three significant ways in which innovative clusters 
and innovative networks differ. Firstly, the scholars claim that innovative 
clusters cut across many clusters and sectors. Secondly, they maintain 
that usually clusters are formed and developed as a result of linkages or 
connected firms in a value chain (OECD, 1999). Thirdly, they suggest that 
all organisations that have a relationship in a dominant sector, for 
instance, the biotechnology sector, share a dominant technology in that 
cluster to produce novel products (OECD, 1999).  
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Innovative networks on the other hand, link several value chains at the 
same time (Malebra & Breschi, 2005). The difference between innovative 
clusters and innovative networks is that the later share more 
complementary science knowledge than common technology (OECD, 
1999). Innovative networks have common features such as flexibility and 
are less bonded which makes them different from clusters. Notably, in a 
cluster the main players are more likely to remain the same over time 
and Carayannis & Wang (2008) suggest that unless one or more key 
factors that include technology have evolved in that time. Contrary, in 
innovative networks members are likely to depend on the project. This 
has become common occurrence in the biotechnology sector in which 
small born-global bio-tech firms engage in multiple projects both locally, 
nationally or internationally. Cooke (2003) agrees with this observation 
and he contends that key players in an innovative network are known to 
partner with the best performers of a sector regardless of their locations.  
 
According to Carayannis & Wang (2008) innovative networks are less 
sensitive to density due to the fact that an innovative network achieves 
its ideal network at any particular number of relationships. The number of 
relationships in a network is heavily dependent on the nature of 
technology and managerial capacity (Todtling et al., 2009). Given the 
variations in innovative clusters and networks, it is clear that there is an 
element of competiveness and synergy among the firms or nodes 
involved. Central to the purpose of this study is the fact that innovative 
networks accelerate innovations and technological development. It is also 
important to note that clusters and networks have their own advantages 
and constraints.  
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Owen-Smith & Powell (2004) contend that there are certain factors that 
favour clusters, for example, they suggest that knowledge sharing and 
technological transfer are more prevalent in innovative clusters as 
opposed to innovative networks. In innovative networks these factors 
cannot easily replace many complex inter-linkages in clusters, on the one 
hand. On the other hand, innovative clusters have the capacity to bring 
novel information and new ideas to a firm. This is particularly important 
for small born-global bio-tech firms due to the fact that their industry is 
knowledge-based and requires them to constantly update their knowledge 
bases in order to improve their innovative capabilities and to develop their 
business processes.               
2.6.1 The business networks of born-global firms  
According to Holm et al. (1996) business relationships are entities that 
can be analysed entirely on their own but they can be better understood 
when looked at in context rather than in isolation. Therefore, in the 
literature on business networks the cooperation in relationships with the 
parties and the dyadic relationship has been considered within the context 
of the direct exchange network surrounding the dyad (Achrol et al., 1983; 
Anderson et al., 1994; Kogut et al., 1992).  
 
Scholarship on inter-organisational collaborations acknowledges that firms 
seeking value-generating resources should venture beyond their 
immediate proximity and develop strong relationships. This is because it 
is through the networks they have that they may have access to and 
subsequently acquire those strategic resources (Ireland et al, 2002; Tsai, 
2001; Cooke 2003; Owen-Smith & Powell, 2004; Freeman et al., 2010; 
and Ferreira et al., 2009). Taking the social exchange perspective on 
dyadic relations within social exchange networks the assumption here is 
that dyadic relationships can be used to analyse cooperation in business 
relationships within business networks (Anderson et al., 1994).  
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Networks are defined as a set of nodes (persons, organisations) linked by 
a set of social, friendship of a specific type (Cooke, 2001; Breschi & 
Malebra, 2005). They are distinct from hierarchical or market 
relationships in their reliance on reciprocity, collaboration, complementary 
independence and orientation towards mutual gain. Breschi & Malebra 
(2005, p.47) suggests that, “resource pooling, risk sharing and the 
formation of critical masses provide incentive to create a group of 
interlinked agents”. Adding to the growing discourse on business 
relationships a recent study by Johnson & Vahlne (2009) provide two core 
arguments. Firstly, it stresses that markets are networks of relationships 
where firms are connected to each other in different formats including 
complex and visible patterns. This perspective is critical in understanding 
the collaborative activities of entrepreneurial firms or small born-global 
bio-tech firms. Secondly, it suggests that relationships at organisational 
level facilitate learning and the potential to build trust and commitment of 
the parties involved. These can be seen as the pre-conditions for 
capability development for small born-global bio-tech firms.  
 
The theory on social exchange clearly demonstrates the differences 
between relations that have a positive connection and the ones that have 
a negative connection. In those relations where there is a positive 
connection the flow and exchange of information is bi-directional whereas, 
in those with a negative connection information flows in one direction 
(Cooke, 2003; Ahuja, 2000). The underlying assumption of the business 
network concept is that the co-ordination of activities between parties 
involved in a business relationship has to take place within a wider 
network context (Anderson et al., 1994). Accordingly, in connected 
business relationships along the value-chain business networks are 
conceived which provide a platform for learning through social exchange 
overtime for bio-tech firms (Anderson et al., 1994). 
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Stanek (2004) emphasises that a network can often be superior for a 
stand-alone firm due to its greater knowledge diversity and a pool of 
talent found within. Furthermore, Freeman & Cavusgil (2007) claim that 
strong camaraderie is found to exist between smaller born-global firms 
and their foreign customers and is frequently based on long standing past 
associations of the senior management team. From that perspective, 
trust-like relationships exist by default in established networks which is 
the bedrock of inter-organisational partnerships. Moreover, established 
networks can lead to newly-formed business and social networks 
(Freeman et al., 2010). This occurrence can be witnessed in well-
developed business networks including:  Basel area, Boston metropolitan 
area and Cambridge cluster. From the perspective of these well-
developed business networks, it is possible for entrepreneurial or born-
global firms to develop and supplement their core competences and at the 
same time take advantage of new market opportunities.  
 
Admittedly, one of the ways in which a firm can successfully exploit global 
markets is by augmenting its core competences through business 
networks thereby creating new opportunities. When analysing the 
globalisation of R&D Lasserre (2007) stressed that firms can learn about 
different markets, different problem-solving techniques, and different 
competitors. Consequently, the rapid diffusion of that learning throughout 
the entire firm is significantly enhanced by creating international networks 
of laboratories. Indeed, in science-based businesses the ability to 
leverage core competences across geographic units and product business 
units help firms to achieve economies of scale and scope, important for 
successful international diversification and access to international talent 
(Hitt et al., 1998; Johnson et al., 2006). International social and business 
partnerships create new scientific knowledge for small born-global bio-
tech firms however; managing that knowledge can be a challenge. 
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Hughes et al. (2009) suggest that because knowledge exists in the minds 
of the knower, it makes it very difficult, for small firms, in particular those 
whose resources are very thinly spread, to ensure that it is retained 
within their firms. Daud & Yusoff (2010) claim that knowledge 
management (KM) is a process which involves organising knowledge that 
has been created within the firm or acquired from strategic alliances and 
applying it in such a way that allows it to become formalised and 
accessible for future use. In international business partnerships, the 
management of knowledge acquired externally is a very complex process 
for born-global bio-tech firms and it requires diligence due to constant 
changes in science technology which is vital for making disruptive 
innovations and improvements to business processes.    
 
Indeed, this is crucial for small born-global bio-tech firms which may 
require technological capabilities to leverage their rather limited resources 
in order to produce innovative products as well as develop their 
businesses.  Accordingly, in connected business relationships along the 
value-chain business networks are conceived providing a platform for 
learning through social exchange overtime for born-global bio-tech firms 
(Anderson, et al., 1994). In regional networks including: Basel area, 
Boston metropolitan area and Cambridge cluster, inter-organisational 
collaborations make it possible for all the firms involved in a network to 
pursue a collective regional strategy that has the potential to not only 
enhance regional innovations but also raise the economic prospects of the 
whole nation (Owen-Smith & Powell, 2004).  
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2.6.2 The social networks of born-global firms 
In management research on social capital it is largely agreed that social 
capital is beneficial for the success of networks (see De Wever et al., 
2005; Jeffries & Reed, 2000). Accordingly, the literature on social capital 
is in total agreement that social capital contributes to a firm’s functioning 
in a number of ways. In Nahapiet & Ghoshal (1998) and Tsai & Ghoshal 
(1998) for instance, it is argued that social capital embedded in a firm 
saves as a conduit facilitating and enabling the positive conditions for the 
exchange of knowledge and the combination of resources to occur.  
 
De Wever et al. (2005) identified the conditions as follows:  
 
• the access to partners for combining and exchanging resources; 
• the anticipation of the value of interaction (will it prove 
worthwhile?); and, 
• the motivation to combine and exchange resources 
 
This implies that for small born-global bio-tech firms their social networks 
can be vital for strategic resource acquisition through inter-organisational 
collaborations. As a valuable resource, social capital has been the main 
focus of interest by researchers from a wide range of disciplines. It has 
been defined by many scholars from different perspectives. For example, 
Lin (2001) and others, Bourdieu (1986) define social capital as a resource 
available in one’s network of relationships. Pretty & Ward (2001) detailed 
four core aspects of social capital: (1) relations of trust; (2) reciprocities 
and exchanges; (3) common rules, norms and sanctions; and (4) 
connectedness in networks and groups. Inkpen & Tsang (2005) argue 
that social capital is the aggregate of resources embedded within, and 
derived from the network of relationships processed by an individual or 
organisation.  
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This therefore makes the social connections of small born-global firms 
essential as sources for scientific knowledge and technological know-how. 
Bourdieu (1986); Nahapiet & Ghoshal (1998) and Wever et al. (2005, 
p.1525) broadly define “social capital as the sum of the actual and 
potential resources embedded within, available through and derived from 
the network of relationships possessed by an individual or social unit”. A 
number of scholars view social capital as a multi-dimensional construct 
that can facilitate action for an organisation (see Putnam, 1993; Nahapiet 
& Ghoshal, 1998; Galunic & Moran, 2000; Bolino et al., 2002; Batjargal, 
2003; De Wever et al., 2005). As a multi-dimensional construct three 
prominent dimensions are mainly identified in literature as follows:  
 
(a) Structural dimension – it is composed of network ties and the overall 
configuration of those ties (Burt, 2002; Wever et al., 2005) 
(b) Relational dimension - focuses on trust, trustworthiness, norms and 
obligations in a network (Fukuyama, 1995; Coleman, 1990; Putnam, 
1993)  
(c) Cognitive dimension - refers to those resources providing “shared 
representations, interpretations, and systems of meaning among parties’’ 
(Nahapiet & Ghoshal, 1998, p.244).  
 
This is consistent with strategy scholars regarding social capital as both 
ties between cluster members and other (‘remote’) firms (Harrison, 1992; 
1994; Saxenian, 1994) and the overall industry network structure 
(Storper & Harrison, 1991). As such, the central proposition of social 
capital within network environments is that network relationships 
constitute a valuable resource for the conduct of social affairs which 
provides the participant with a relational “credit”. The wider field of 
network theory recently experienced an upsurge of interest in the 
dynamics of networks (Baum et al., 2003; Snijders, 2001).  
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Assessing the embeddedness view of social capital from a different angle 
(Polanyi, 1956) defines social capital as the on-going contextualisation of 
economic activity in social relations. Hence, embeddedness theories focus 
both on social relations and individuals, as well as the outcomes of their 
interactions, by differentiating structural and relational embeddedness 
(Adler & Kwon, 2002; Gabbay & Leenders, 1999; Granovetter, 1982; 
Nahapiet & Ghoshal, 1998). Specifically, Baker (1990) argues that social 
capital derives from the social structure of the network.  
 
Hence the form and the design of the network relations themselves are 
considered as resources that allow the actors to generate value. 
Therefore, social capital comprises both the network and the assets that 
may be mobilised through the network. Whether it is regarded as 
relational or embedded, sociology and management scholars are 
increasingly using social capital and network theory to examine and 
analyse the entrepreneurial and managerial issues of firms’ 
internationalisation process (Burt, 1992, 2004; Han, 2006; Jones and 
Coviello, 2005; Tsai, 2001). This study follows the same pattern.  
 
The direct and indirect benefits of social capital are supported by prior 
research (Etemad, 2004) and this brings a new perspective and 
contributes to the body of international entrepreneurship research. 
Specifically, it was proposed theoretically (Oviatt & McDougall, 2005), and 
found empirically (Sharma & Blomstermo, 2003) that firms’ social capital 
can influence firms’ international expansion and performance. For 
example, most of the studies documented a positive impact of social 
capital and network ties on international start-ups, new ventures and 
SMEs’ performance (Arenius, 2005; Dana et al., 1999; Johanson & 
Vahlne, 2003; 2006; McDougall et al., 2003; McNaughton & Bell, 1999; 
Oviatt & McDougall, 1994; Oviatt & McDougall, 2005).  
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Most of these studies mainly focus on the use of social capital for 
international new ventures (INVs) and/or Born-global firms which make 
analysing social capital a vital step in the process of this research. 
2.6.3 The cognitive distance of born globals 
A firm’s ability to generate new knowledge and ideas is directly linked to 
its ambition of developing strategic alliances in a given geographic area or 
even beyond in order to supplement its internal research and 
development (R&D) capacity. Su et al. (2009, p.312) indicate that, “A 
firm’s R&D capability reflects its ability to generate new scientific 
discoveries and technological breakthroughs”. Successful clusters such as 
the Cambridge cluster, Silicon Valley and the Boston metropolitan area 
are well known for their innovative capabilities and their push towards 
inter-organisational corporations and the sharing of ideas in those close 
knit communities (DTI, 2004). Powell & Grodal (2005) suggest that 
diversity is an essential condition which is facilitated by firms coming 
together and sharing capabilities, specialities, ideas and best practice.  
 
The concept of cognitive distance emanates from a social constructivist 
view of knowledge, which advances the idea of perception, interpretation, 
understanding and value judgment. It entails mental constructions on the 
basis of mental categories that are developed in interacting with the 
physical and social world (Pittaway, 2000). At organisational level 
cognitive structures constitute absorptive capacity which relates to the 
idea of exploring knowledge (Lichtenthaler & Lichtenthaler, 2009). 
Accordingly, Nooteboom (2005) suggests that when absorptive capacity is 
aligned with organisational goals and aims not only does it enable 
organisational cognition, but also constrains what gives rise to 
organisational myopia that can only be compensated for by interacting 
with other firms which may have a different complementary foci at some 
cognitive distance.  
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Therefore, it is reasonable to claim that the business and social 
connections of born-global bio-tech firms give them a new purpose for 
inter-organisational collaboration and the need for them to make a trade-
off between their original identity in terms of clear focus and the wide 
scope of their core competences (Schilling, 2008; Nooteboom, 1992, 
2004, 2009; Johnson et al., 2006). In the context of network dynamics 
the analysis of optimal cognitive distance has huge implications for small 
born-global bio-tech firms in terms of the period their alliances are likely 
to last (Wuyts et al., 2005). According to Nooteboom (2005) cognitive 
distance between firms can be reduced in proportion to the life time of an 
alliance, particularly in cases where the alliance is restricted to a group of 
firms.  
 
Strategic alliances are usually developed between firms that share the 
same values and have high levels of trust (Şengün & Önder, 2012). Under 
those circumstances there is the danger of dependency syndrome which 
leads to reduced innovation activities (Cooke, 2001). Crucially, 
Nooteboom (2005) identified variables that have an impact on the 
absorptive capacity of firms including: educational facilities, research and 
development (R&D) in firms, government R&D activities and the transfer 
of outcomes to firms. There are also other variables that include 
knowledge diversity and cognitive distance in the network, the life time of 
an alliance and external linkages such as international links that can be 
seen as catalysts to innovation as they supply novel information inflows. 
This underscores the impact of cognitive distance and knowledge diversity 
on the innovative capabilities of small born-global bio-tech firms. 
2.6.4 Regional networks 
Regional clusters consist of a number of different innovative networks and 
they all have varying types of relationships. The construction of social 
networks such as the ones mentioned above has a huge impact on the 
economic outcomes of a region.  
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This is mainly impacted upon by the flow of information in these different 
networks (Granovetter, 2005). It is often assumed that strong ties in 
social networks usually yield high flows of information and data. More 
importantly, to knowledge-sharing due to shared common values, aims, 
trust and the use of a common language for communication (Melkas & 
Harmaakorpi, 2008). On the other hand, weak ties have been described, 
by a number of authors (Granovetter, 2005; Burt 2004; Zaheer & Bell, 
2005), as productive for innovation to flourish because they are credited 
with allowing the flow of quality information or data directly to individuals 
in seemingly weak ties as opposed to strong ties.  
Furthermore, Burt (2004, p.349) argues that “in weak ties innovations are 
likely to be identified in strategic positions within the highly populated 
network structures”. On that account, it is safe to claim that in populated 
regional networks where those strategic positions can be identified, small 
born-global bio-tech firms are presented with an opportunity to acquire 
essential knowledge which underpins innovation, growth and business 
development. It is, however, naive for the author to claim that these 
positions are easy to identify in these densely populated networks. This 
made complex by the fact that knowledge transfer has to take place 
between research institutions, academics and partners from different 
disciplines on the same level (Owen-Smith & Powell, 2004).  
2.6.5 Biotechnology in Boston  
Porter et al. (2005, p.261) in their study about “the institutional 
embeddedness of high-tech regions” use the example of the USA leading 
biotechnology clusters – the Boston Metropolitan area, the San Francisco 
Bay Area and the San Diego County which came into existence following a 
joint effort from both public and private institutions to scientific and 
technical advancement (Owen-Smith et al., 2002). To examine the 
concept of clusters in the biotechnology sector Owen-Smith et al. (2002) 
use the Boston and Massachusetts metropolitan areas.  
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The Boston metropolitan area which is home to one of the largest 
concentrations of the dedicated bio-tech firms in the world (Porter et al., 
2005) is of particular interest. The metropolitan area is famous for its 
well-known and established institutions that include public research 
centres and universities such as Harvard, MIT, and Tufts. In addition to 
that rich array of renowned institutions, the area is house to research 
hospitals that include Massachusetts General Brigham and Women’s and 
medical research institutes such as Dana Farber Cancer Centre (Porter et 
al., 2005). These institutions have over the years produced revolutionary 
life-saving drugs as well as innovative business processes. Figure 2 below 
neatly demonstrates a geographical layout of these clusters in the Boston 
area.   
 
 
 
 
Figure 2: Boston Contractual Networks 
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During the 1990s, the Boston cluster embarked on a drive to promote 
bio-entrepreneurs, the metropolitan area developed a group of investors 
(venture capitalists) whose sole purpose was to provide financial support 
to bio-tech start-up firms (Powell et al., 2002). This proved to be a key 
development due to the fact that funding enabled organisations to engage 
in R&D activities achieve their goals without the costs of the project as 
their least worry.   
Furthermore, the institutional diversity of organisations that populate the 
Boston region offered organisations the possibility to closely examine the 
effects that node demographics have on innovation (Owen-Smith & 
Powell, 2004). Indeed, the Boston clusters create an environment which 
facilitates knowledge-sharing hence, the expectation of the firms within 
the cluster, to be innovative in their processes which underpin new 
product development (Powell et al., 2002).  
2.6.6 R&D and open science 
Similar to Owen-Smith’s et al. (2002) open innovation concept Porter et 
al. (2005) identified the key features of a cluster as the predominance of 
research institutions committed to the norms of open science. The norm 
being that, research is debated in seminars, published, and subsequently 
publications are patented. According to Porter and others the Boston 
metropolitan area’s emphasis on open science allows ideas to be debated, 
honed and utilised by others. Similarly, Rafols et al. (2012, p.8) suggest 
that, “open science is based on the pursuit of priority, for example to 
claim credit for discovery and to hasten diffusion of knowledge, and as 
such encourages the rapid disclosure of research findings in scientific 
journals”. Given the emphasis on open science in the Boston cluster it is 
safe to conclude that, the development of vital life-saving drugs can be 
enhanced. This is in line with Steffenson et al. (2008, p.322) who contend 
that the “open innovation” concept is “regarded as the hallmark of most 
innovative firms”.  
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Furthermore, Porter et al. (2005) expressed that the commercial world of 
biotechnology in the Boston metropolitan area was made possible by a 
combination of the intellectual capital of clinical researchers and research 
academics. In addition to that, a number of researchers (Owen-Smith & 
Powell, 2006; & Porter et al., 2005) attribute the growth of biotechnology 
in Boston to the complementary multiple knowledge networks that 
connect the world’s best universities, hospitals and science-driven 
companies. Crucially, Porter et al. (2005) maintain that the most 
important lesson learnt from their study about the biotechnology 
community within the Boston metropolitan area is that, the community’s 
productive capabilities deeply depend on inter-organisational collaboration 
and open science.  
 
According to Khanna (2012, p.1088) ‘innovation has always been the 
backbone and the underlying strength of the pharmaceutical industry’. 
Productive R&D activities, within a network provide the ideas and 
products for future development. In Taks et al. (2012) it is suggested 
that, for knowledge-intensive firms which have insufficient internal 
knowledge bases for generating innovative capabilities, collaborating with 
external R&D partners is the way forward. Indeed, for born-global bio-
tech firms global R&D networks are vital sources of new ideas and 
technology. Synthesising recent literature (see Taks, et al., 2012; 
Gassmann et al., 2010; Gurau, et al. 2010, Hardwick, et al., 2013) there 
is an agreement that innovation ‘ecosystems’ in the bio-pharmaceutical 
industry are continuing to expand. In that context, the R&D activities of 
firms involved in the sector should be viewed in an increasingly global 
context. Howells et al., (2012, p.142) insist that, “the research and 
knowledge boundaries of the firm are becoming more open, porous and 
indistinct”. Scholars Hardwick et al. (2013); Tolstoy & Agndal (2010) hold 
that, the ability to make new discoveries in the biotechnology sector is 
directly anchored on collective efforts through collaboration.            
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Innovative capabilities in the bio-pharmaceutical industry are widely 
dispersed in networks and new scientific knowledge is created by 
accessing complementary assets.    
2.6.7 Cambridge clusters  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
There are a lot of factors that contribute to the formation of successful 
clusters. According to the Cambridge Cluster Report published in 2004, 
the St. John’s Innovation Centre has been home to a large number of 
innovation-based start-ups since the 1980s. The centre has also been 
credited with the creation of wealth for business parks and science 
institutions as indicated by the diversity of the business community within 
its cluster (see figure 3 above). One of the notable features of the 
Cambridge cluster is its ability to nature the entrepreneurial spirit and in 
particular, the belief in a shared common purpose in the entire business 
community. The cluster is also well known for its emphasis for promoting 
enterprise and entrepreneurship just like the open science concept 
promoted in the Boston region.  
Figure 3: The Cambridge Network 
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This is achieved in a number of ways that include: multiple networking 
communities (as illustrated in figure 3 on p.62), formal and informal 
mentoring programmes, inclusion of entrepreneurship teaching at the 
University and establishment of the Cambridge University 
Entrepreneurship Centre (The Cambridge Cluster Report, 2004). For a 
period spanning over six hundred years Cambridge has gradually 
transformed. In addition to St. John’s Innovation Centre the city is also 
home to Cambridge University, Newton, Rutherford, Turing, Crick and 
Watson seemed destined to continue its primary existence as a seat of 
learning.  In the last forty years, similar to the Boston metropolitan area, 
the Cambridge cluster has emerged as the epicentre of one of the world 
class renowned cluster of technology and innovation-based companies in 
Europe and a cluster that other regions aim to emulate.  
 
Indeed, we have noticed the model being replicated throughout the 
regions in the UK, the M1 corridor which encompasses Nottingham, 
Sheffield and Leeds. One of the main envisaged reasons for promoting 
clusters and networks is to drive regional prosperity. In a similar fashion 
the MIT has been instrumental in designing the Route 128 Cluster and 
Stanford University to Silicon Valley. The Cambridge cluster has 
performed a significant role in transforming the city and the surrounding 
area from a medieval centre of learning to a great educational centre and 
wealth creation knowledge-based business nexus (The Cambridge Cluster 
Report, 2004). Increasingly, there is a common purpose within the 
business community and commitment to innovation and entrepreneurship 
at the University – all which are complementary to its world class science 
base (The Cambridge Cluster Report, 2004). Over the last decade the 
cluster has acted as a magnet attracting supportive infrastructure 
comprising of a number of key players such as venture capitalist firms 
(VCs), banks and patent agents among other stakeholders. Such a 
development has been crucial in fostering an open culture in which 
innovation strives.  
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Like in any other clusters or networks, collaborations are fundamental 
steps that a firm needs to take in order to access novel information 
inflows.       
2.7 Born-globals’ business models 
According to Chesbrough (2008) a business model is a useful framework 
to link technical decisions to economic outcomes and the term is usually 
applied in the context of entrepreneurial firms. In the biotechnology 
sector bio-entrepreneurs need a framework that can help them to have a 
good understanding of what their firms are capable of achieving 
(Christensen & Overdorf, 2000).  
 
If small born-global bio-tech firms apply the open business model 
effectively it forces them to consider the integrative nature of their 
business activities in an open innovation perspective. As this study has 
already demonstrated, networks are critical steps for small born-global 
bio-tech firms to access knowledge. Davey et al. (2010) suggest that an 
open business model’s great strength, as a planning tool, is that it focuses 
attention on how the elements of the system fit into a working practice as 
a whole. Admittedly, the way in which most small born-global bio-tech 
firms conduct their businesses can sometimes act as a barrier preventing 
them from engaging with other firms or knowledge centres thereby 
restricting access to knowledge.  
 
Accordingly, Leydesdorff & Meyer (2003) suggests that “economic 
exchange intellectual organisation and geographical constraints can all be 
considered as different dynamics that interact in the complex system that 
constitutes a knowledge-based economy”. Chesbrough (2008 p.64) claims 
that in such situations “technological managers must expand their 
perspectives to find an appropriate business model to capture value from 
that technology”. A business model according to Davey et al. (2010) has 
two key functions: it creates and it captures a portion of that value. 
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Davey and others argue that a business model captures value by 
establishing a unique resource, asset or proposition within a series of 
activities which may involve networking. Aligning that to small born-
global bio-tech firms it is reasonable to claim that open models make it 
possible for bio-entrepreneurs to acquire many more ideas given their 
links with a variety of external concepts. To this end, Chesbrough (2006) 
suggests that open business models that are successful create heuristic 
logic connecting technical potential to economic value.   
2.7.1 Dynamic capabilities 
The dynamic capabilities view builds on the resource-based view, which 
sees a firm as a bundle of static resources (McKelvie & Davidsson, 2009). 
According to Grant (1991), the resource-based view is based on the idea 
that rival firms possess varied resource repositories. Following the 
realisation of the static nature of the resource based view, scholars have 
emphasised the dynamic capabilities view since the late 1990s (Teece et 
al., 1997; Narayanan et al., 2009; and Dixon et al., 2010). The dynamic 
capabilities based view sees a firm as a constant belt of novel information 
inflows. It highlights a firm’s ability to adopt a flexible business model, 
which allows it to react to uncertainty and disruptive technology. McKelvie 
& Davidsson (2009, p.36) argue that, “dynamic capabilities can be seen 
as those processes where resources are acquired, integrated, transformed 
or reconfigured to generate new value-creating firm-based activities”.  
 
Autio et al. (2010) interpret dynamic capabilities as a firm’s capacity to 
deploy strategic resources and improve business processes with purpose 
in order to achieve its goals. Accordingly, Nelson & Winter (1982) and 
Winter (2003) collectively agree that dynamic capabilities are routines or 
repetitive patterns that are project based involving multiple firms.  
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From these analyses, there is evidence of a growing body of researchers 
who agree that dynamic capabilities have an impact on a firm’s capacity 
to innovate (Wheeler, 2002; Teece, 2007; Narayanan et al., 2009; and 
George et al, 2009). Visser (2009) highlights a strong relationship 
between diverse knowledge networks and innovative capabilities. 
Easterby-Smith et al. (2009) insists that dynamic capabilities are a 
response to the need for change or new opportunities. Their observation 
is very useful for small born-global bio-tech firms which are faced with 
changing market conditions which require constant knowledge generation 
and business re-engineering.  
 
Dixon et al. (2010) argue that for a firm to be able to respond to 
changing market conditions; there is need to make fundamental 
transformations in its organisational processes, the allocation of resources 
and operations. The crucial part of dynamic capabilities for small born-
global bio-tech firms is their ability to strategically facilitate the allocation 
and utilisation of their resources with a view to make crucial innovations 
(Teece et al., 1997; Nooteboom, 2009). These resources can take various 
forms of economic effects including human capital, technological capital, 
knowledge-based capital, and tangible-asset-based capital (Easterby-
Smith et al., 2009). Since the introduction of the dynamic capabilities 
theory by Teece, Pisano and Shuen in 1997, many scholars have 
emphasised the operational (zero level) and the dynamic nature of 
capabilities (Eisenhardt & Martin, 2000 and Winter, 2002/05) and 
heterogeneous learning of firms (Cobbett, 2007). Building on these 
typologies, Ambrosini et al. (2009) proposes three levels of capability 
development including: incremental, renewal, and regenerative 
capabilities. Notably, the strategy of regenerative dynamic capabilities 
(Easterby-Smith et al., 2009) is important because of its ability to 
completely overhaul existing business processes and adapt to new 
business processes that open new channels for novel information inflows.  
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It is assumed that “organisations can have several different kinds of 
dynamic capabilities such as idea generation capabilities, market 
disruptiveness capabilities, new product development capabilities, 
marketing capabilities or new process development capabilities” 
(Easterby-Smith et al., 2009, p.4). Furthermore Teece (2007, p.1319) 
suggests that “the capacity to sense and shape opportunities and threats, 
to seize opportunities, and to maintain competitiveness through 
enhancing, combining, protecting, and, when necessary, reconfiguring the 
business enterprise’s intangible and tangible assets”.  In the context of 
the biotechnology sector in which constant novel information inflows are 
crucial towards drug discovery and the development of new clinical 
products, it is important to reconstruct existing business processes in 
order to strategically position the firm on course to achieve its corporate 
objectives. The literature on organisational management (Mullins, 2006 
and Torrington et al., 2005) emphasises the need for top management to 
take a lead in shaping business processes and gearing the business 
towards achieving its strategic goals. Developing innovative capabilities 
requires a lot of input from bio-entrepreneurs in providing vision and 
purpose and for identifying the types of capabilities to be sought after.  
 
Martin et al. (2011) examine the process of dynamic capability 
development in large pharmaceutical firms and makes similar conclusions 
that top managers are the key drivers in terms of strategic intent.  
Narayanan et al. (2009) found that senior managers play a major role in 
the development of capabilities by imprinting an organisation with their 
specific cognitive orientation and then orchestrating the multi-level 
organisational routines necessary for actualisation of a capability. More 
importantly, their inspirational study identified key underlying processes 
and mechanisms that are pertinent to small born-global bio-tech firms in 
terms of capability development and these processes were identified as: 
research and development (R&D) strategies, knowledge transfer 
processes, and knowledge exploring mechanisms.  
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This highlights the impact of dynamic capabilities on the innovative 
capabilities of born-globals, bio-entrepreneurs or bio-tech firms and the 
capacity to make innovations.                 
2.7.2 The global R&D networks of born-global bio-tech firms 
Networks consist of a number of positions or nodes occupied by 
individuals, firms, academic institutions, the central and local authorities 
(Bessant & Tidd, 2011). They are distinct from hierarchical or market 
relationships in their reliance on reciprocity, collaboration, complementary 
independence and orientation towards mutual gain. Thus, the global R&D 
networks of born-global firms provide them with four key benefits that 
include: proximity to markets, access to geographical clusters of 
knowledge creation and development, learning and access to low cost and 
good quality scientists and engineers (Taks, et al. 2011; Lasserre, 2012). 
It is increasingly becoming clear, in the life science sector, that companies 
cannot do everything from R&D to product commercialisation and this 
condition has considerably contributed to the establishment of innovation 
‘ecosystems’ (Ernst & Young, 2012).  
 
In the literature the concepts underpinning the chain and the network are 
well-represented and they have, for a long-time, occupied a central 
position in the field of business management studies however, in the 
recent past innovation ‘ecosystems’ as a new concept appear to be 
gaining momentum. In their working paper about how global technology 
start-ups access modern business ecosystems Tahvanainen & Steinert 
(2013) suggest that an ecosystem is ‘a network of networks, converging 
entire industries and technologies into complex, interwoven and global 
economic structures’. Innovation ‘ecosystems’ or networks are designed 
to facilitate inter-dependence and close co-operation amongst individuals, 
investors, research institutions and labs (Bramwell, 2012). In actual fact, 
they increase productivity and innovation.  
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Jackson (2011) maintains that innovation ‘ecosystems’ are sustainable 
when they provide the assets and resources essential for building 
relationships between partners. Johnson’s & Vahlne’s (2009) study 
concerning business relationships provides two core arguments. Firstly, 
the study suggests that markets are networks of relationships where 
firms are connected to each other in different formats including complex 
and visible patterns. Secondly, the study draws attention to the fact that 
relationships developed at an organisational level facilitate learning and 
the potential to develop trust. This is crucial for the resource-impecunious 
born-global bio-tech firms which rely, to a greater extent, on innovation 
‘ecosystems’ to jointly develop new science technology and life-saving 
drugs for economic development. Gurau et al. (2010, p.348) contend 
that, ‘biopharmaceutical firms require a large amount of resources for 
survival and development’.    
2.7.3 Bio-entrepreneurial Learning & Experience  
Effective entrepreneurs are exceptional learners (Smilor, 1997). Learning 
as concept is a very broad topic and it is by no means fully explored in 
this study. It is partially covered in this thesis to inform the debate on 
entrepreneurial learning and absorptive capacity (AC). In Huczynski & 
Buchanan (2007, p.107) learning is described as the “process of acquiring 
knowledge through experience which leads to an enduring change in 
behaviour”. From that perspective, the most effective strategies for 
recognising new scientific knowledge for bio-entrepreneurs are informed, 
to a large extent, by their prior-learning and experience in life science 
(Simba, 2013). Similarly, King & Lakhani (2011) agree that there is an 
association between individual learning and the stock of prior-related 
knowledge one holds. Continuing in the same vein, Huczynski & Buchanan 
(2007) discuss procedural and declarative learning. The scholars express 
that procedural learning or ‘know how’ is concerned with one’s ability to 
carry out skilled actions. They also insist that declarative learning or 
‘know that’ is one’s ability to store factual knowledge.  
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Furthermore, Kolb (1984, p.26) expounds the underlying principles of 
experimental learning stating that, “ideas are not fixed and immutable 
elements of thoughts but, are formed and re-formed through experience”. 
Scholarship on entrepreneurial learning collectively acknowledge that 
experimental learning is a process which attempts to explain how 
entrepreneurs acquire knowledge and enact new behaviours in 
recognising and acting on opportunities as well as organising and 
managing their born-global bio-tech firms (see Petkova, 2008; Cobbett, 
2007; Toiviainen, 2003; Cope, 2005). Deakins & Freel (1998) and 
Sarasvathy (2001) collectively claim that the majority of learning that 
occurs within an entrepreneurial context takes the form of an experiment. 
Schilling (2010) discusses experimentation that takes place in innovation 
‘ecosystems’. She maintains that the process of experimenting is an 
important step in the development process of science-based firms as it 
enables them to test what works and what doesn’t. Similarly, Petkova 
(2008) presents a model of entrepreneurial learning from performance 
errors with a view to extend the psychology models of error-based 
learning. Petkova’s (2008, p.4) model proposes that entrepreneurs,’ 
“prior knowledge and cognitive biases can perform a significant role at 
each stage of the learning process and may determine whether the 
processes of error-detection and error-correction that leads to learning 
will actually occur”.  
 
Schilling’s and Petkova’s propositions have huge implications for born-
global bio-tech firms as they are directly intertwined in their mental 
modes of learning particularly, their bio-entrepreneurs. Using Kolb’s 
(1984) view of learning by trying different configurations until one finds a 
combination that works, Cobbett (2005) makes a convincing argument. 
He argues that ‘cognitive mechanisms’ or the mental processes through 
which entrepreneurs acquire, store, transform, and use information are 
the output of individual learning.  
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2.7.4 Absorptive Capacity (AC)  
An understanding of the concept of AC at a firm level is essential to how 
this study explains the significance of learning by individual entrepreneurs 
to how born-global bio-tech firms develop their innovative capabilities. 
According to Cohen & Levinthal (1990) AC is the ability of a firm to 
recognise, assimilate and apply external knowledge. In Zahra & George 
(2002) a clear distinction between potential and realised AC was made. 
Potential AC was related to knowledge acquisition and assimilation 
capabilities and realised AC was associated with knowledge 
transformation and exploitation. Lichtenthaler & Lichtenthaler (2009) 
conceptualises AC as the ability to explore external knowledge. King & 
Lakhani (2011, p.2) introduce the notion of ‘adoption capacity’ which 
means the ability of a firm to adopt ideas from external connections. This 
is consistent with Cope (2005, p.481) who maintains that individuals 
transform (using cognitive properties) their experiences (situative) into 
new knowledge.  
 
Furthermore, Lichtenthaler & Lichtenthaler (2009) claim that new 
knowledge acquired from outside the firm (in innovation ‘ecosystems’) 
becomes useful when it is integrated with internal knowledge bases. A 
recent study by Jones et al. (2010) presents the idea of generative 
learning in global networks stressing that it is a critical step that informs 
the accumulation of specific and useful knowledge. Tidd & Bessant (2011) 
contend that AC is about accumulated learning and the embedding of 
capabilities. Crucially, in Cope & Down (2010, p.4) a strong link is 
constructed ‘between the outcomes of learning (information, knowledge, 
expertise) that impact on the entrepreneur's cognitive frameworks and 
the participative process by which these socio-cognitive resources are 
acquired’.  
 
 
72 
 
The dated but inspirational works by a number of scholars (see Estes, 
1970; Ellis, 1965; Bower & Hilgard, 1981) highlight that an individual’s 
learning is cumulative and that learning performance is enhanced when 
the primary goal of learning (to understand the new knowledge to be 
acquired) is related to what the individual already know. Cohen & 
Levinthal (1990) also make a crucial point suggesting that AC is a by-
product of prior-innovation and problem solving which is dependent on 
individual ACs of members of an organisation.  
 
When individual ACs of members in a firm and the firm’s ability to value, 
assimilate and commercially utilise new external knowledge are combined 
Lane et al. (2006) and Kim (1993) collectively agree that the duality 
modifies mental modes. In other words, the dualism modifies 
assumptions about the lived world. This is a fundamental point to make in 
the sense that, for global-oriented born-globals their bio-
entrepreneur’s/owner-manager’s prior-learning and science-related 
experience can modify their cognitive biases which plays a decisive role in 
their economic development given that they source scientific knowledge 
in multiple countries. Indeed, sourcing knowledge from established or 
newly developed business or social networks (innovation ‘ecosystems’) 
domestically and in other countries  consequently lead to a point of 
‘knowledge saturation’ hence sifting, sorting and decoding useful 
information requires prior-learning and industry-specific experience. 
2.7.5 The innovation ‘ecosystems’ of bio-tech firms 
The process of developing innovative capabilities is directly anchored on 
the greater connectivity and enhanced collaborations in the life science’s 
innovation ‘ecosystems’ described by Booth (2009, p.705) as a ‘brave 
new world’. The connectivity and collaboration between various actors 
within the East Midlands network can be seen as performing a key part in 
the process of ensuring continued development of scientific knowledge 
and technical know-how by providing financial support and infrastructure. 
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BCN provides firms with specialised premises which have state of the art 
lab equipment while Nottingham City Council (NCC) and Mobius provide 
seed funding to promising ventures. A similar observation was made by 
Laine et al. (2008), the scholars maintain that, at the core of innovation 
‘ecosystems’ are firms and enterprises which are involved in innovative 
collaborations with academic institutions and investors. A convincing 
argument concerning the logic behind facilitating the development of 
innovation ‘ecosystems’ was made by Hautamäki (2007) arguing that the 
‘ecosystems’ approach places great emphasis on close co-operation and a 
culture of creativity which refers to adventurism, entrepreneurship and 
innovativeness.  
 
Adner (2006) insists that an innovation ‘ecosystem’ facilitates integration 
risks of having the solution adopted across the value-chain. This is 
consistent with Bramwell et al. (2012) conceptualisation of an innovation 
‘ecosystem’ approach. The scholars see it as a sophisticated way of 
holistically looking at mechanisms that interact within an economic 
system. Crucially, for policy makers such innovation systems will enable 
them to pay close attention to the collaborative, the inter-dependent 
nature of the innovation processes and to identify the best means of 
stimulating productive networks and relationships within and across 
disciplines and sectors of comparative advantage’ (Bramwell et al., 2012, 
p.49). Additionally, Wolfe et al. (2011a) describes the regional knowledge 
‘ecosystem’ approach insisting that it leverages regional infrastructures 
with a view to stimulate/support regional innovation processes through 
the collaborations of multiple partners that include: research and 
academic institutions, investors, other firms and investors.  
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2.7.6 Government R&D support 
Government support to promote innovations in the biotechnology sector 
can be justified by a clear theoretical economic rationale (Kang & Park, 
2012). Scientists have argued for government intervention to cushion 
R&D costs as the financial crisis has made it difficult to maintain the “big 
Pharma” model (Rafols et al., 2012). The state support in the form of 
funded research can be vital in increasing innovation and innovation-
related activities (Schilling, 2008; Romijn & Albaladejo, 2002). According 
to Kang & Park (2012) governments can encourage innovation and 
economic prosperity by supporting R&D projects that have the potential to 
generate social capital. A study in the US by Block & Keller (2008) which 
was based on the top 100 innovations recognised in the R&D Magazine 
covering the period from the 1970s to 2006 showed that about 90% of 
American firms that produced award winning innovations were supported 
by the American government through its funding pot.  
 
A number of scholars investigated the relationship between government 
funding and innovation. Using small Israel firms Lach (2002) found a 
strong link between government related spending on R&D and innovation. 
Hall & Bagchi-Sen (2007) focussed their study on US biotechnology 
companies and they found a strong association between government 
funding for research and technical know-how with the intensity of R&D 
activities. Even studies that have been undertaken across diverse 
manufacturing sectors show a positive correlation between R&D resources 
and firms’ innovation performances (see Belussi et al., 2010; Hall & 
Bagchi-Sen 2002, 2007; Hitt & Tyler, 1991; Parthasarthy & Hammond, 
2002). Cohen & Levinthal (1990) and Visser (2009) highlight that firm-
level R&D resources significantly boost a firm’s capacity to recognise, 
assimilate and apply new knowledge which underpins innovations. Kang & 
Lee (2008) pointed out that a lack of experienced and qualified technical 
personnel may severely impact on firm innovation.  
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Other studies also show that government-engineered networks have 
stimulated inter-organisational collaborations which are used by the 
parties involved to promote innovations (Kang & Park, 2012). As has 
already been mentioned in this study the Golden triangle of Cambridge, 
London and Oxford was designed to promote innovation and economic 
prosperity. In the USA the Boston Metropolitan area is another example of 
the federal efforts to promote innovation. In sum, it can be argued that 
funding plays an important role in research-based science firms and 
government institutions are a key part in that process. Their support 
strategies such as the introduction of science parks and incubators can be 
a catalyst to the development of innovative products and services.                       
2.8 Conceptual framework  
In Santori (1970) a concept is described as a word or phrase which 
captures the common features of a particular class of empirical 
phenomenon. From that perspective, revising Freeman’s et al. (2010) 
rapid knowledge development concept will ensure the precision of the 
findings of this study. A theory is a “way of seeing and thinking about the 
world rather than an abstract representation of it. As such, it is seen as 
the “lens” one uses in observation than a mirror of nature” (Alvesson & 
Deetz, 2000, p.37). The role of theory in this research study is to direct 
attention, organise experience and enable useful responses (Alvesson & 
Deetz, 2000). Theory also plays a crucial part in social science by 
analysing and exposing the hiatus between the actual and the possible, 
between the existing order of contradictions and a potential future state 
(Held, 1980). In Bellamy & Perri (2009) framing concepts in case-oriented 
research (COR) is seriously considered to vital. Bellamy & Perri argue that 
the research procedure enable researchers to draw warranted inferences 
from their data.  
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In that sense, the modification of Freeman’s et al. (2010) model of rapid 
knowledge development for born-global firms enabled the author to make 
stronger inferences with the data emanating from small born-global bio-
tech firms in the East Midlands in England and come to a set of 
conclusions that can be trusted.   
2.8.1 Internationalisation theories  
Scholarship on the internationalisation of small firms is littered with 
various models aimed at explaining their internationalisation processes. 
From early on Johnson & Vahlne (1977) developed the inspirational 
Uppsala internationalisation model (U-model) and it became a widely used 
model in business management. The model was based on the assumption 
that an enterprise develops in foreign markets by adopting a process 
which evolves incrementally in stages “progressing like rings in the water” 
to use Bhowmick’s (2004, p.760) felicitous description. Put in a different 
way, the enterprise passes from one stage to another as it acquires more 
and more international experience as well as deepening its resource 
commitments. In the late 1970s and the beginning of the 80s there was a 
surge of behavioural and process-oriented internationalisation theories 
that were developed around the same time as the Uppsala theory (e.g. 
Bilkey & Tesar, 1977; Reid, 1981). According to Nordman (2009) the 
innovation-related internationalisation theories and models regarded the 
development of export activities as either innovation-adoption cycles or 
export development learning curves. A close examination of the Uppsala 
theory and the innovation theories depicts that the theories adopt an 
incremental stages approach to export development and generally 
support the notion of psychic distance. Arguably, both schools attribute 
the gradual pattern of export development to two things: firm’s 
knowledge deficiency and the uncertainty associated with the decision to 
acquire resources from multiples countries (Ghanatabadi, 2005).  
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The main difference between behavioural internationalisation process 
theories described by the two schools of research is that: the Uppsala 
theory is less bound to time and space concerns and, therefore, can be 
said to be more general. More so, the theory offers a more in-depth 
discussion about the dynamics of knowledge and learning than the other 
theories (Andersen, 1993). Perhaps as a consequence of these 
differences, the innovation theories have not been as commonly used in 
research on international business and international marketing. 
 
Expeditiously moving forward, in 1997 Teece, Pisano, and Shuen 
proposed the dynamic capabilities theory, they defined the theory as “the 
ability to integrate, build, and reconfigure internal and external 
competences to address rapidly-changing environments”. The dynamic 
capabilities view is based on the notion that externally acquired 
capabilities are an attempt to bridge a firm’s capability gaps by adopting a 
process approach: and by acting as a buffer between firm resources and 
the changing business environment (Teece et al., 1997). According to 
Helfat & Peteraf (2003) dynamic resources help a firm to adjust its 
resource mix thereby enhancing its innovative capabilities which 
underpins its ability to make new innovations. In that sense, the dynamic 
capabilities model enriched the authors understanding of the process of 
developing innovative capabilities.  
 
A further contribution in this regard was made by Karlsen (2007). The 
scholar proposed a conceptual framework that explains the pace at which 
born-global firms internationalise. Karlsen’s model proposes that personal 
experience, personal networks, industry globality and product 
characteristics influence a firm’s knowledge development and the pace of 
its internationalisation. More recently, Freeman et al. (2010) proposed an 
inspirational model for rapid knowledge development for smaller born-
global firms.  
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Freeman’s and others model which has some similarities with the dynamic 
capabilities concept extends the resource-based view (RBV) and network 
theory. Their theory specified the level of interaction required for the 
development of the new knowledge process to occur in rapidly 
internationalising smaller born-global firms. The author was attracted to 
adopt their inspirational model for the purpose of this study. The move 
was based on the fact that Freeman’s and others model contained 
appropriate variables within the knowledge supply-chain of smaller born-
global firms that could be easily applied to small born global bio-tech 
firms. On that account, the theorisation of the key concepts for this study 
is fundamental in terms of structuring and shaping it. Perhaps the last 
word on this can be left to Gerring (2005) who insists that the process of 
concept formation is a fraught exercise which includes a set of choices 
that may have no best solution but rather a range of more or less 
acceptable alternatives.      
2.8.2 The rapid knowledge development model 
In the following section the author outlines Freeman et al. (2010) 
proposed model of rapid knowledge development as well as presents the 
rationale for modifying the their framework so that it suits the needs of 
this particular study. Freeman’s, et al. (2010) model addresses how tacit 
knowledge is integrated and transferred quickly through the international 
supply chains of smaller born-global firms. Their model is influential in the 
study of new emerging small firms that appear to be internationally-
oriented with a view to take advantage of the capability development 
opportunities offered by global markets. Figure 4 at the bottom of p.79 
neatly illustrates the main variables contained in Freeman’s and others 
conceptual framework. Their model illustrates the rapid 
internationalisation of smaller firms. The scholars suggest that managers 
can use both pre-existing and newly formed relationships, to quickly and 
proactively develop new knowledge for rapid commercialisation of their 
products.  
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Freeman et al. (2010) maintain that, proactive, advanced relationship-
building capability is based around locating partners with technological 
knowledge with a view to ensuring ease of sharing knowledge. Their study 
explores the development of trust and inter-firm partnerships in 
established and newly formed networks and how these lead to tacit 
knowledge, absorptive capacity and new knowledge generation. The 
scholars explain why knowledge-sharing is able to proceed quickly. They 
acknowledge that shared ‘‘technological knowledge’’ allows rapid transfer 
and development of new knowledge and the drive to commercialise a 
product before a competitor. The scholars also agree that technological 
knowledge promotes the ‘‘mutual need’’ (co-dependency) to act quickly. 
They claim that, as an outcome of the born-global manager’s ability to 
locate new partners through existing networks, new international links 
may be quickly developed, with internationalisation being an outcome. 
 
Figure 4: A Model of Rapid Knowledge Development: The Smaller Born-
global Firm   
 
  
                             Sources: Freeman, Hutching and Lazaris, 2010, p.76  
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The model makes the following seven propositions for the rapid 
internationalising born-global firm: 
Proposition 1: The early internationalising smaller born-global firms 
build relational trust through long standing, pre-existing connections 
accessed through established network partners. 
Proposition 2: Newly-formed networks in early internationalising smaller 
born-global firms are based on long standing, pre-existing connections 
accessed through established network partners 
Proposition 3: Strong inter-firm partnerships in early internationalising 
smaller born-global firms are based on relational trust developed through 
established network partners. 
Proposition 4: Relational trust-like outcomes in early internationalising 
smaller born-global firms is based on inter-firm partnerships built through 
newly-formed networks developed through established network partners. 
Proposition 5: Relational trust and relational trust-like outcomes in early 
internationalising smaller born-global suppliers develops tacit knowledge 
between customers and their firms. 
Proposition 6: Tacit knowledge amongst early internalising smaller born-
global firms increases absorptive capacity. 
Proposition 7: Absorptive capacity generates new knowledge in the 
international supply-chain for early internationalising smaller born-global 
firms. 
 
Based on Freeman’s and others’ central argument it is clear to see that in 
general their model is a very powerful tool for analysing smaller born-
global firms and it significantly adds to earlier international business 
theories such as KBV and network theory. Interestingly, it explains the 
building blocks of networks, inter-firm partnerships, trust, tacit 
knowledge, and absorptive capacity of developing new knowledge in the 
international supply-chain of early internationalising smaller born-global 
firms.  
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In that sense, the model illustrates some key variables that are useful for 
this study hence the need to modify it so that it is used to explain the 
knowledge and the capacity of small born-global bio-tech firms to make 
crucial innovations. The main idea is not to undermine the categorisation 
of the concepts contained in Freeman’s and others’ model of rapid 
knowledge development but rather, to adapt the model with a view to 
maximise its applicability. Learning from Gerring’s 2001; Turnbull’s 
(1987); Anderson’s (1983) and Bhowmick’s (2004) critical analyses of the 
stages models it is sensible to adjust a theory so that it reflects the 
specific circumstances surrounding the research phenomenon. 
Collectively, the scholars acknowledge that contextual range i.e. the 
scope, reach and stretch of a concept determines whether it needs to be 
adjusted to accommodate or to maximise its performance. Indeed, when 
examining specific units of a phenomenon e.g. born-global bio-tech firms 
being examined for this study, their contextual range can be a decisive 
factor in terms of the extent to which the new conceptual framework can 
be generalised (Gerring, 2001; Santori, 1970).  
2.8.3 Justification for selecting conceptual framework 
The process of developing innovative capabilities for born-global bio-tech 
firms is so complex. The firms are involved in sophisticated relationships 
with other firms, science and academic institutions. In order to investigate 
their complicated situation Freeman’s et al. (2010) model of rapid 
knowledge development for smaller firms was selected because it explains 
how international ventures rapidly develop knowledge. Its emphasis on 
the mechanisms involved in generating knowledge for smaller born-global 
firms made it attractive to the researcher. Specifically, the variables 
contained in the framework were adaptable to fit the specific 
circumstances of the research phenomenon.  
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This is consistent with Santori (1970) who insist that concepts are most 
useful when they have large powers of discrimination; that is when they 
allow us to determine clearly for their purposes for a specific research 
project. Gerring (1999) share the same views and he argues that the 
“field utility” of a concept may be more important than its theoretical 
utility.               
2.8.4 Rationale for adjusting conceptual framework  
By the time the researcher became aware that Freeman’s, Hutching’s & 
Lazaris’s model of rapid knowledge development for smaller born-global 
firms could be relevant for explaining the knowledge supply-chain of small 
born-global bio-tech firms, a sizeable store of data had been absorbed 
making it relatively easy to assess the applicability of the model. The 
researcher’s awareness that Freeman’s, Hutching’s and Lazaris’s model 
contained some of the key concepts was significantly enhanced when he 
was collecting, sifting, sorting and analysing data related to born globals 
(Irvine & Gaffikin, 2006). The results of the preliminary study influenced 
the theory construction process of the final study. Following this thorough 
“soul searching” phase the researcher was convinced that some of 
Freeman’s et al. (2010) variables on their Rapid Knowledge Development 
Model for Smaller Born-global Firms were very useful for this study. The 
model was subsequently modified with a view to improve its applicability.  
In doing so the author utilised emerging theories from the literature, 
results from a “pilot” study and empirical evidence emanating from a 
detailed analysis of five small born-global bio-tech firms sampled from the 
East Midlands region which is part of the growing M1 Corridor in the UK. 
In light of the new empirical evidence the model is then adjusted so that 
it becomes a more suitable description of the actions (behaviours) of the 
small born-global biotech firms whose actions are greatly influenced by 
world activities. Gerring (2001) supports theory adjustment suggesting 
that changes in the social world imply the dynamic nature of concepts.  
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Collier & Mahoney (1993, p.845) express similar views and they insist 
that “as scholars seek to apply their models and hypotheses to more 
cases in the effort to achieve broader knowledge, they must often adapt 
their categories to fit new context”. In other words, concepts are not 
static. They have to be manipulated to take into account the world’s 
changing terrain and how people make sense of things happening around 
them (Weber, 1905/1949). Andersen (1993, p.214) makes more sense of 
all of this and he argues that, “it is hard to imagine that a theory could be 
evaluated to be entirely satisfactory by all criteria”.  
 
The theory development process diagram represented in figure 5 below 
neatly illustrates how new empirical evidence, secondary data and the 
researcher’s understanding of Freeman’s, Hutching’s and Lazaris’s model 
informed his perceptions and comprehension of the impact of business 
and social networks on the innovative capabilities of small born-global 
bio-tech firms. This led to the development of a robust “Knowledge and 
Innovative Capability Development Model” that captures the key themes 
offered by new evidence emerging from a close examination of multiple 
cases of small born-global biotech firms, “pilot” study results and from the 
secondary data presented in this chapter.  
 
Figure 5: The theory developing process   
 
 
 
            
            
 
 
 
 
            Source: Irvine and Gaffikin, 2006, p.134, including author’s ideas  
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Following an in-depth and rigorous process for developing a frame of 
reference for this study outlined above the author contributes to the 
development of new theory by proposing a comprehensive and improved 
conceptual framework for this study located in section 5.5 under research 
findings in chapter 4 on p.206 of this thesis. 
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Chapter 3  
3. Methodology 
Methodology refers to the theory of how research should be undertaken, 
including the theoretical and philosophical assumptions upon which 
research is based and the implications for the methods adopted 
(Saunders et al., 2012). On that account, this chapter provides a detailed 
discussion of the research philosophy, research approach, research 
design, and research ethics.  
3.1 Research philosophy 
Philosophy of science deals with “the nature of the phenomenon examined 
(ontology) and methods for understanding it (epistemology)” (Bechara & 
Van de Ven, 2007, p.36). Variations in ontology, epistemology are defined 
by different paradigms. Easterby-Smith et al. (2012) claim that, most of 
the debates among philosophers’ concern matters of ontology and 
epistemology. Conducting research is understood to be an original 
investigation of a phenomenon which is undertaken to gain knowledge 
and understanding (Mahmoud, 2009). As such, this study aims to gain an 
understanding of the collaborative actions of small born-global bio-tech 
firms and the connectivity of various elements contained in their 
knowledge supply-chain. In Burns (2002, p.47) research is defined as a 
“systematic investigation to find answers to a problem”.  
 
In the same vein, Eldabi et al. (2002) agree that when undertaking any 
type of a research, it is important that a study follows a methodology 
which is well-defined. This is consistent with Hussey & Hussey (1997) who 
maintains that there are several ways in which research can be classified. 
Figure 6 p.86 provides a research map outlining the methodological 
paradigm for this study.  
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Figure 6: Research Paradigm  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        
 
            
 Source: Author’s view & ideas 
 
Hussey & Hussey (1997) suggest that research can be classified according 
to the reasons for conducting the study i.e. the purpose of the study – 
given on figure 6. Secondly, they claim that research can be classified 
according to the research methods used by the researcher to collect and 
analyse data i.e. the process of the research. Thirdly, the scholars 
maintain that research can be classified from the perspective of the 
direction which it has followed. In other words, is the study moving from 
the general to the specific or vice-versa, i.e. what is the logic of the 
research? Lastly, they argue that research can be classified according to 
whether there is a particular issue/problem to be investigated or to fill a 
knowledge gap by contributing to a body of knowledge.  
Human Nature 
Determinist 
Purpose 
To investigate the dynamic impact of business & social Networks, 
competence & goodwill trust, inter-organisational collaboration, tacit 
& explicit knowledge, prior learning & absorptive capacity on the 
innovative capabilities of small born global bio-tech firms in the 
East Midlands region of the United Kingdom    
Heuristic   Social constructionism  Realism  
Methodology  Ontology  Epistemology  
Interpretive Paradigm   
Theoretical Context  
Dynamic capabilities bridge capability gaps for 
small born global bio-tech firms by adopting a 
process approach and by acting as a buffer 
between firm resources and the changing 
business environment  
Research Question 
What role does knowledge networks in the East 
Midlands region play in enabling innovations for small 
born global bio-tech firms within the region? 
Methods 
Research techniques that are in conformity with the 
research philosophy for this study    
Semi-structured Interviews 
The researcher listens to what people tell 
about their lived world 
Case studies 
A source for collecting rich data about the behaviour, 
attitudes, values and personal experiences of small 
born global bio-tech firms in the East Midlands (A 
sample of 5 firms is used)    
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The last classification neatly summarises how this thesis is organised. 
Creswell (2014) makes an important contribution to the debate regarding 
choosing an appropriate research method by suggesting that the choice of 
a particular research method is mainly depended on the research 
philosophy or research paradigm (presented on p.86) that a researcher 
follows in order to conduct research. In that sense, it therefore makes it 
essential to have an understanding of the philosophical issues of research 
including: understanding various statements that deal with; (1) the 
search for truth and (2) how the issues are reflected in the 
accomplishment of the aims of the research being undertaken. Easterby-
Smith et al. (2002, p.87) proposes three convincing reasons why it is 
essential to understand philosophical issues by insisting that:    
 
There are at least three reasons why an understanding of philosophical issues is 
very useful. First, since it can help to clarify research designs. Second, knowledge 
of philosophy can help the researcher to recognise which designs will work and 
which will not. It should enable a researcher to avoid going up too many blind 
alleys and should indicate the limitations of particular approaches. Third, 
knowledge of philosophy can help the researcher identify, and even create, designs 
that may be outside his or her past experience. And it may also suggest how to 
adapt research designs according to the constraints of different subject of 
knowledge structures.      
 
      
Other scholars (Burrell & Morgan, 1979; Chua, 1986; Laughlin, 1995) 
agree that given the nature of the world in most studies the process of 
research makes two assumptions namely, explicit and implicit. Mahmoud 
(2009) and Easterby-Smith et al. (2012) acknowledge that assumptions 
can be made based on the nature of social science and the nature of 
society. Burrell & Morgan (1979) suggest that assumptions are related to 
ontology, epistemology, human nature and methodology. Epistemology 
and ontology assumptions have direct implications for the research 
methods chosen for this study. Particularly, for the methods that underpin 
how the collaborative activities of small born-global bio-tech firms are 
investigated including: an examination of how the knowledge pertaining 
to the business and social world of small born-global firm is created, 
acquired, and used in the firm.    
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3.1.1 Subjective and objective dimensions 
The subjective view follows that social phenomena are created from the 
perceptions and consequent actions of the social actors while the 
objective view takes the position that social entities exist eternally to 
social actors (Saunders et al., 2007). This study uses the lens of a 
subjective view because the goal is to understand how social actors (e.g. 
small born-global bio-tech firms) engage with the social world (e.g. their 
social and business connections). This is consistent with Remenyi et al. 
(1998, p.35) who emphasises the necessity to study “the details of the 
situation in order to understand the reality or perhaps a reality working 
against them”. 
 
Saunders et al. (2012) maintains that social phenomena are created from 
the perception and consequent actions of social actors. As social 
interactions between actors are continual social phenomena are in a 
constant state of revision. In that sense, this research studies the details 
of the knowledge supply-chain of born-global bio-tech firms with a view to 
understand the connectivity of various elements within the knowledge 
supply-chain. Crucially, how they influence the development of innovative 
capabilities. Burrell & Morgan (1979) proposes a model of organisational 
analysis which classifies sociological theories along two orthogonal 
dimensions. The scholars classified the two theories as regulation vs. 
change and subjectivity vs. objectivity. Their classification distinctively 
divides sociology into four paradigm clusters. Noticeably, their 
classifications highlight internal consistency under each paradigm, in 
terms of assumptions about individuals, groups, societies, goals of study 
and accepted forms of evidence. As such, the following section of the 
study discusses the research philosophy (assumptions about human 
beings), approach and design (case study strategy) explaining different 
forms of reasoning that can be deployed to gain a better understanding of 
the phenomena being studied (Bassey, 1990). 
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3.1.2 Epistemology 
Epistemology refers to the branch of philosophy concerned with studying 
the nature of knowledge and justification (Bryman, 2008). According to 
Saunders et al. (2012) epistemology concerns what constitutes 
acceptable knowledge in a field of study. Bryman & Bell (2007) insist that 
epistemology is concerned with the issue of knowledge that is or ought to 
be considered to be relevant to a discipline. Proctor (2005) maintains that 
it is concerned with how a researcher can know things.  
 
Saunders et al. (2012) discusses two fundamental epistemological 
positions in social science that include: interpretivism and the philosophy 
of positivism. The scholars suggest that a positivist is a researcher who 
adopts the philosophical stance of a natural scientist. According to Gill & 
Johnson (2010) a positivist prefers collecting data about observable 
reality and searches for regularities and casual relationships from the data 
with a view to create law-like generalisations like those produced by 
scientists. This study does not follow the traditions of a positivist.  
 
Interpretivism is philosophical approach which is mainly associated with 
social scientists. The interpretivist approach takes the view that the social 
world of business and management is far too complex to lend itself to 
theorising by definite ‘laws’ in the same way as the physical science 
(Saunders, et al. 2012. The study of the social world requires a research 
procedure that reflects the distinctiveness of humans against the natural 
science (Bryman, 2008). In that sense, this study is heavily influenced by 
the traditions of interpretivism. According to Cohen et al. (2007) 
researchers who adopt this research approach share a view that the 
subject matter of the social sciences (e.g. born-global bio-tech firms and 
their knowledge supply chain) is fundamentally different from that of the 
natural sciences.  
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Consistent with this Farquhar (2012) maintains that interpretive traditions 
are concerned with grasping individual and unique truths with an 
emphasis on understanding or verstehen, as described by Weber (1947). 
Denzin (1983) makes more sense regarding this debate and he defines 
interpretive interactionism as: “the study and imputation of meaning, 
motive, intention, emotion and feeling, as these mental and interactive 
states are experienced and organised by interacting individuals” (p.129). 
Clearly, the interpretive research approach is related to data gathering, 
generating solid descriptions and interpretations allowing theory building. 
In this study the central phenomena for enquiry are the situations small 
born-global bio-tech firms construct e.g. their collaborative actions and 
how they give meaning to how various elements impact on their ability to 
make drug discoveries. In other words, the inquiry is about the inter-
relationship or the connectivity of key variables/factors that include: 
business and social networks, inter-organisational collaborations, 
competence & goodwill trust, tacit & explicit knowledge, prior learning & 
absorptive capacity within the knowledge supply-chain of small born 
global bio-tech firms. Additionally, the study intends to explain how the 
linkages between these variables help or hinder the process of developing 
their innovative capabilities such as scientific knowledge development and 
technical know-how.  
 
The traditions of an interpretivist which include phenomenology (Remenyi 
et al., 1998), hermeneutics and social constructionism (Easterby-Smith et 
al., 2012; Bryman, 2008) are based on the belief that humans interpret 
the world that they inhabit and attribute meaning to it (Farquhar, 2012). 
According to Creswell (2014) constructivism or social constructivism are 
often associated with interpretivism. In that sense, this study assumes a 
social constructivists view because it seeks an understanding of how small 
born global firms develop their innovative capabilities as well as 
comprehending the interplay of various elements that manifest in their 
knowledge supply-chain.  
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It takes the view that bio-entrepreneurs develop subjective meanings of 
their experiences – i.e. meanings directed towards business and social 
networks, inter-organisational collaborations and absorptive capacity for 
example. These meanings are varied and multiple as such, the intentions 
of the study are to look for the complexities or similarities of views as 
opposed to narrowing meanings to a few ideas. In that respect, the main 
goal of the research is to rely as much as possible on the participants’ 
views concerning how they develop their innovative capabilities. The 
study also intends to interpret or make sense of the meanings small born 
global bio-tech firms attach to the world they live in. From that 
perspective, rather than to commence the study with a theory as with the 
philosophy of positivism, this study inductively develops a pattern of 
meanings with regards to the variables within the knowledge supply-chain 
of small born-global bio-tech firms.  
 
The discussion of the concept of constructivism by Crotty (1998) 
identified several assumptions that have informed the philosophical 
approach for this study. Crotty expressed that: (1) humans beings 
construct meanings as they engage with the world they are interpreting 
as such, qualitative researchers utilise open-ended questions so that the 
participants can share their views, (2) humans engage with their world 
and make sense of it based on their social perspectives. Similarly, 
Creswell (2014) suggests that in order to interpret the actions of the 
social actors researcher should seek to understand the context or setting 
of the participants through visiting this context and gathering information 
personally. Lastly, Crotty (1998) suggests that the basic generation of 
meaning is always social, arising in and out of interaction with a human 
community. According to Saunders et al. (2012) the process of a 
qualitative researcher should largely be inductive. Admittedly, this study 
is of a qualitative nature and this approach allowed the study to generate 
meanings attached to the social world of small born-global bio-tech firms.  
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To sum up the approach adopted by this particular study Table 4 below 
neatly summarises the characteristics of an interpretivist that have 
considerably contributed to attainment of the main goals of this research 
study.  
 
Table 4: The characteristics of an interpretivist  
Element  Description  
 
Understanding 
 
 
 
Subjectivity  
 
 
 
Subjective  
 
Setting 
 
 
 
Holistic  
 
 
Rich insight 
 
Reality is viewed as socially embedded and it exists with the mind. It is fluid and changing and 
multiples realities are presumed 
 
This involves interpreting the meanings and actions of the actors (small born-global bio-tech firms) 
according to their subjective frame of reference. 
 
Knowledge is constructed and shared in signs and symbols recognised by members of a culture. 
Research encompasses researcher’s own views and how they have been constructed.     
 
The emphasis is on natural setting, and the subject of research is not removed from what surrounds 
it in everyday life. It involves an in-depth investigation 
 
To interpret a phenomenon the researcher must look at its parts in terms of its whole and in terms 
of its parts 
 
By exploring in detail the researcher can gain a much fuller understanding of the phenomenon.     
 
  Sources: compiled from Creswell (2007), Saunders et al. (2007), Gribich (2007), Lee & 
Lings (2008); and Farquhar (2012) 
3.1.3 Ontology 
Ontology refers to “theories of being or existence and the ways in which 
our existence is shaped by the nature of knowledge” (Aitchison, 2003, 
p.196). Coghlan & Brannick (2005, p.10); Bryman & Bell (2007, p.25) 
define ontology as “the nature of the world”. Bryman & Bell (2007) argues 
that questions of social ontology must be linked to issues concerning the 
conduct of business research. Proctor (2005) insists that ontology 
increases the need to answer questions regarding the nature of reality 
and is linked with the assumption of the kind of things that are found in 
the world. Contribution to this debate Bryman (2008) adds that, the 
central point of orientation for ontological considerations relates to the 
question of whether social entities can and should be considered objective 
entities that have a reality external to social actors, or whether they can 
and should be considered social constructions built up from the 
perceptions and social actions of social actors.  
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In Johnson & Duberley (2000) the objective view of ontology is described 
as assuming that social and natural reality existed before human 
consciousness while subjectivist ontology takes it for granted that what 
we consider to be reality is an output of the human cognitive process. 
Bryman & Bell (2007, p.22) adds that, “ontological assumptions and 
commitments will feed into the ways in which research questions are 
formulated and research is carried out”. 
 
In Saunders et al. (2012) two aspects of ontology that have their 
devotees among business and management researchers namely: 
objectivism and constructionism were discussed. The scholars highlight 
that objectivism represents the position that social entities exist in reality 
external to and independent to social actors. According to Docherty et al. 
(2002) researchers who adopt this position try to isolate variables when 
testing a theory. They measure a given effect and offer a quantitative 
result in relation to a single outcome. This approach has been criticised 
for its lack of depth and richness (Robson, 2002). An objectivist ontology 
position assumes an objective form of knowledge, to measure 
relationships using quantitative research. Clearly, this study utilises 
qualitative techniques to measure and to explain the connectivity of 
various elements with the knowledge supply-chain as opposed to 
quantitative measures.    
 
The constructionism position is an ontological position that asserts that 
social phenomena and their meanings are constantly being brought into 
being by social actors (Saunders et al. 2012). This position challenges the 
suggestion that “categories such as organisation and culture are pre-
given and therefore confront social actors as external realities that they 
have no role in fashioning” (Bryman & Bell, 2007, p. 792). This position 
also accepts a degree of interaction between the researchers and the 
subject of the research to form an agreed, informed construction through 
dialectical exchange (Denzin & Lincoln, 1994).  
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Saunders et al. (2009) maintains that this approach is used when the 
researcher seeks some patterns in reality and looks forward to drawing a 
conclusion; in this case it is concerned with building theory which is 
central to the wishes of the researcher. This study is sturdily aligned to 
the main purpose of this approach which aims to describe, analyse and 
understand the impact of various elements, the behaviour of individuals 
and/or groups of people/firms from the perspective of the subject being 
studied (Myers, 1997).  
  
Those who advocate this constructionist ontology suggest that it has 
many advantages: it helps the researcher to ask the right questions and 
even gives him/her additional confidence in his/her conclusions (King et 
al., 1994), it has the purpose of allowing important social phenomena to 
be investigated by immersing the investigator for prolonged amounts of 
time (Slavin, 1992) and it rejects the idea that one reality is founded 
regardless of the influence of individual people (Allan, 1998). These 
advantages do not mean that this position does not have any 
disadvantages. According to Allan (1998) and Creswell (2004) the results 
of qualitative research give rise to questions regarding their 
generalisability to other situations or a larger population, because 
qualitative data is difficult to test for statistical significance.  
 
The research reported here is constructionist in its ontology. It focuses on 
the discovery and exploration of the social phenomena to assert how 
social entities - born-global bio-tech firms value and evaluate their 
business and social connections, competence and goodwill trust, prior 
knowledge and their absorptive capacity and the impact of their linkages 
on their ability to make new drug discoveries. In order to discover and 
explore their knowledge supply-chain some form of interaction between 
the researcher and the subject of the research was necessary. This 
enabled the researcher to seek some patterns in reality and look forward 
to drawing a conclusion.          
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3.2 Research logic 
An important consideration in creating the foundations of a research is 
whether the study is using an inductive or a deductive approach. In order 
to maintain the coherence of this study this section addresses the 
fundamental differences between these two approaches of logic and how 
they relate to the reasoning in this study. Farquhar (2012) makes an 
important point regarding the use of an inductive or a deductive approach 
to doing research. She argues that, if a researcher knows the shape 
(inductive, deductive or elements of both) that their study should take, it 
significantly reduces running the danger of making mistakes regarding its 
structure and overall integrity. Consistent with this Saunders et al. (2012) 
emphasises that, the degree to which a researcher is clear about the 
theory they are using, from the onset of their study, it becomes less 
difficult for them to address questions concerning its design. The scholars 
claim that this is often portrayed as two approaches based upon a 
researcher’s reasoning. As such, this study evaluates inductive and 
deductive approaches as they have influenced the reasoning underpinning 
how theory was developed. Additionally, the study explores ethnography 
and grounded theory because the research methods have a direct 
relationship with research logic assumed for this study.   
3.2.1 Inductive and deductive approaches 
The study borrows aspects of a deductive approach with an inductive 
approach being very much prominent. This is consistent with Perry (1998, 
p.788) who argues that “it is unlikely that any researcher could genuinely 
separate the two processes of induction and deduction”. According to 
Collis & Hussey (2003, p.15) inductive research is a study in which theory 
developed from the observation of empirically generated reality; i.e. 
“general inferences are induced from particular instances”. From that 
perspective, the study exhibits processes of induction; it starts with a 
problem which is identified as an investigation of how small born-global 
bio-tech firms develop their innovative capabilities.  
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Theory then emerges through that process of enquiry. This way of doing 
research is consistent with Eisenhardt & Graebner (2007) who point out 
that the question is framed in terms of the importance of the 
phenomenon being studied and the lack of plausibility of the existing 
theory. Saunders et al. (2007) agree that using an inductive approach, 
theory would follow rather than the other way around as with deductive 
approach.  
 
Maylor & Blackmon (2005) suggest that in some cases the goal is to 
generate theory from the data which is achieved by looking for instances 
where a pattern is beginning to emerge and that advocates for inductive 
research. Processes of deduction in this study can be identified when the 
researcher adopts theories contained in Freeman’s et al. (2010) model of 
rapid knowledge development for smaller born-global bio-tech firms to 
assess the ones that hold in terms of explaining the specific situation of 
small born-global bio-tech firms in the East Midlands. This is supported by 
Richards (1993, p.40) who suggests that “both (prior theory and theory 
emerging from the data) are always involved almost simultaneously”.  
 
On that account, it is therefore “impossible to go theory free in any 
study”. Using co-ordinated designs (both induction and deduction) is also 
consistent with Miles & Huberman (1994) who advise against favouring 
one extreme in multi-case research designs. Miles & Huberman claim that 
“tightly co-ordinated designs yield more economical, comparable and 
potentially generalisable findings and they are less case-sensitive and 
they allow bending data out of contextual shape to answer cross-case 
analytic question” (p.17). Figure 7 on p.97 neatly illustrates a visual 
representation of deduction and induction processes that were adopted 
for the purpose of this study. 
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Figure 7: Induction and Deduction  
 
          Deduction  
 
 
 
 
 
 
 
 
 
 
 
 
          Induction  
 
  
 
Source: Farquhar 2012, p.24 
 
The research benefited by using both elements of induction and 
deduction. As Perry (1998) puts it, a pure induction potentially prevents a 
researcher from enjoying the use of existing theory and a pure deduction 
restrict a researcher from developing new and useful theory. Parkhe 
(1993, p.256) emphatically dismisses following a purely inductive or 
deductive approach arguing that it is untenable and not necessary 
because the process of on-going theory development requires “continuous 
interplay” between induction and deduction. Indeed, the use of both 
elements of induction and deduction was very instrumental to this 
research in that the researcher was able to satisfy the third objective 
stated as: 
 
“To contribute to the theoretical concepts of the dynamic capabilities and 
networking” 
 
Observation 
Tentative 
Hypothesis  
Theory 
Pattern/ 
Occurrences 
Theory 
Hypothesis 
Observation  
Confirmation  
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Admittedly, the refined conceptual framework based on the insights from 
case studies was used as additional evidence to triangulate on the 
external reality of small born-global bio-tech firms in terms of their 
capacity to generate scientific knowledge. This also informed the types of 
research questions for the main study. Perry (1998, p.970) explains this 
more fully:  
Prior theory informs all main data collection equally and theory is generated 
from all cases in one operation of cross-case data analysis across all the 
main cases.  
 
Based on this assumption, it is safe to claim that theory has a key role to 
perform in case-study oriented research (COR). For this study, theory was 
developed from secondary data, within case analysis and the data from 
the “pilot” study this can be seen as the first stage of the theory 
development process. Perry (1998) makes a strong argument in favour of 
a two stage theory construction process. Perry argues that the position is 
consistent with the realism paradigm’s search for realities than 
regularities, for analytical generalisation as opposed to statistical 
generalisation (Farquhar, 2012; Yin, 2009). In concluding the debate on 
induction and deduction Emory & Cooper (1991, p.62) stress that “fact 
and theory (induction and deduction) are each necessary for the other to 
be of value”.   
3.2.2 Ethnography  
Ethnography emanates from the field of anthropology and it is firmly 
grounded in the inductive approach (Saunders et al., 2003). The research 
approach was chosen because of its ability to allow the researcher to 
engage with the subject under the microscope i.e. the researcher was 
invited to attend seminars on partnering held at various venues 
throughout the East Midlands. Engaging with the research subject this 
way enabled the researcher to collect rich data which significantly 
enhanced his understanding of their actions when are seeking business 
partners.  
 
99 
 
This is consistent with Saunders et al. (2003) who suggest that 
interacting with the subject is very important for qualitative researchers 
as they are able to interpret the social world the subjects inhibit and the 
way in which they interpret it. Remenyi et al. (1998) add that 
ethnography is used in business and management research because it 
allows a deeper understanding of organisational culture. Farquhar (2012) 
advises that although the research technique takes more time it is 
worthwhile as it helps to gain detailed insight into the research 
question/problem. Crucially, the research technique was chosen because 
of its ability to allow flexibility i.e. it enabled the researcher to respond to 
changes in the way small born-global firms engage with their partners in 
their search for scientific knowledge and technical know-how.  
3.3 Research design 
According to Churchill (1999 p.45) a research design is the “framework or 
plan for collecting and analysing data”, and he also adds that, “it is a blue 
print that we ought to follow in completing a study”. The chronologies of 
key data were constructed for each case; this is consistent with existing 
research focused upon new venture processes (Santos & Eisenhardt, 
2009). Furthermore, data were collected through what Van de Ven (2007) 
calls ‘conversations’ with the entrepreneurs consistent with the 
researcher’s practitioner engagement approach which helps to identify the 
participant’s view of a phenomenon. Data gathering sessions are 
considered conversations instead of interviews, given the interactive 
engagement between the researcher and the practitioner in the research 
process (Van de Ven, 2007). To illuminate the various aspects of this 
research the following research methods are adopted. Other instruments 
that could be used for data collection are also discussed.  
3.3.1 Case-study method  
According to Ellram (1996, p.93) the case-study method is “one of the 
least understood” and yet it “remains one of the most challenging of all 
social science endeavours” (Yin, 2009, p.3).  
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But it is one of the most widely used in business management studies 
(Voss et al., 2002). In the literature concerning the contribution of case 
studies towards developing theory there is a range of understandings 
from various scholars (see Farquhar, 2012; Sigglekow 2007; Yin 2009; 
Stake 2005; Eisenhardt & Graebner, 2007). The understandings 
considerably vary, from one end; case studies are seen as essential to 
researchers because they provide them with the opportunity to uncover 
new ideas and develop new concepts which help to construct new theory. 
On the other end of the scale case studies can be used to challenge, 
confirm, refine, sharpen, modify, revise, expand or to extend existing 
theory.  
 
The later contribution of case-study research is consistent with the aims 
of this study. The study aims to modify concepts outlined on the 
influential model proposed by Freeman’s et al. (2010) – see figure 4 p.79. 
The main reason for doing this is to enable the study to comprehensively 
explain the connectivity and the influence of business and social networks 
along various elements that include: trust, inter-organisational 
collaborations, knowledge, learning and absorptive capacity that are part 
of the knowledge supply-chain of small born-global bio-tech firms.  
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The aims of the inductive case-study research strategy adopted for this 
study are not entirely unique. Ridder et al. (2009) aggregate the potential 
theoretical contributions of case based research as seen by other 
scholars. Table 5 below summarises various notions associated with a 
case-oriented approach by different scholars as follows: 
 
Table 5: Theoretical contribution from inductive case-study research 
Scholars Theoretical Contribution 
Eisenhardt (1989b); 
Eisenhardt & Graebner 
(2007) 
To develop concepts, theoretical constructs, conceptual frameworks, propositions, or a mid-
term range theory. Reveal an unusual phenomenon, replicate or counter the replication of 
findings in other cases, eliminate alternative explanations, elaborate emergent theory    
Flyvbjerg (2004)  
Miles & Huberman (1994) 
Sigglekow (2007  
Generate & test hypothesis 
Ground a construct empirically in a new context 
Generate new ideas to build theory  
Provide a violation of theory  
Sharpen existing theory  
Get closer to theoretical constructs and illustrate casual mechanisms   
Stake (2005)  Refine theory  
Suggest complications for further investigation  
Establish the limits of generalisation  
Vaughan (1995)  Contradict or confirm theory  
Create new hypothesis 
Add detail to the theory, model or concept  
Specify theory more fully 
Yin (2003/2009) Confirm, challenge, expand, explore, extend, generalise, modify theory 
Revise original theoretical propositions  
Build theory by making significant theoretical breakthrough  
Develop hypothesis and propositions for further enquiry  
                                                                   Source: Ridder et al., 2009, p.144 
  
The cases for this study are carefully chosen primarily for the following 
reasons: (1) to understand the world of small born-global bio-tech firms 
and (2) to contribute to theoretical concepts of dynamic capabilities view 
and the network theory. A dated but still relevant study by Eckstein 
(1975) identified five ways in which case material can be useful as 
follows: configurative idiographic studies, descriptive configurative 
studies, heuristics case studies, plausible probes and critical case studies. 
In light of this, the study was mainly interested in heuristic case-study 
types because choosing cases in this way enabled study to develop some 
theoretical concepts which were instrumental in explaining the level of 
influence business and social networks along with various elements have 
on small born-global bio-tech firms’ capacity to generate crucial scientific 
knowledge and new technology.  
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Similarly, Mitchell (1983) distinguishes heuristic case studies from 
configurative idiographic and disciplined configurative studies arguing that 
they are deliberately chosen in order to develop theory. Eckstein (1975, 
p.104) explains this point more fully: 
 
The heuristic case-study is deliberately used to stimulate the imagination towards 
discerning important general problems and possible theoretical solutions.... Such 
studies, unlike configurative idiographic ones, tie directly into theory building and 
therefore are less concerned with the overall concrete configurations that with 
potentially generalisable relations between aspects of them; they also tie into 
theory building less passively and fortuitously than does disciplined configurative 
study because the potential generalisable relations do not just turn up but are 
deliberately sort out.  
 
Indeed, after assessing the applicability of Freeman’s et al. (2010) model 
of rapid knowledge development for smaller born-global firms the 
intention was to deliberately modify the framework using evidence from 
secondary data and empirical evidence from born-global firms operating 
from the East Midlands and develop a frame of reference that adequately 
reflects their world. Developing theory in this way was described in 
literature as plausible because it is based on findings that are grounded in 
the literature (see Saunders et al., 2003; Glaser & Strauss, 1967) and in-
depth case analysis (also see Eisenhardt, 1989; Bellamy & Perri, 2009). 
The case-study method is multi discipline; historically it was used by 
clinicians to understand the “person in particular” (Runyan, 1982) and in 
education it is used to help students to understand a concept (Cohen et 
al., 2007), in law using a case law and in political science using case 
reports (Creswell, 2007). Further Creswell (2007) claims that because of 
its popularity in social science the case-study approach is familiar to social 
scientists and as such for the purpose of this study, which can be 
categorised within the discipline of business management, the research 
approach is used to construct a deeper understanding of the new types of 
business ventures and how they perceive their world. 
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According to Yin (2009, p.18) a case-study research “is an empirical 
enquiry that investigates a contemporary phenomenon in depth and 
within its real life context, especially when the boundaries between 
phenomenon and context are clearly evident”. Similarly, Robson (2002, p. 
178) defines a case-study as “a strategy for doing research which 
involves an empirical investigation of a particular phenomenon with its 
real life context using multiple sources of evidence”. Cohen et al. (2007) 
explains that a case-study is a specific instance that is frequently 
designed to illustrate a more general principle. Accordingly, Nisbet & Watt 
(1984, p.72) contend that a case-study is “the study of an instance in 
action”. As such, this study examines multiple small born-global bio-tech 
firms in networks. Cohen et al. (2007, p.253) makes a strong case for 
using case-study research and they point out that:  
Case studies can establish cause and effect and one of their strengths is that they 
observe effects in real contexts, recognising that context is a powerful determinant 
of both cause and effects  
 
It is therefore based on these attributes of a case-oriented approach that 
makes it attractive to use for the purpose this study which investigates 
the cause (collaborating/networking, trust, collaboration, prior learning & 
absorptive capacity) and the effect (innovative capabilities) of small born-
global bio-tech firms. Bellamy & Perri (2009) suggests that case based 
studies may be particularly useful, for example, in systematically tracing 
the origins and nature of social changes that occur in specific settings, 
because they are particularly sensitive to context. Yin (2003) also 
highlights the importance of context, adding that, within a case-study, the 
boundaries between phenomenon being studied and the context within 
which it is being are not clearly evident. From that perspective, the use of 
small born-global bio-tech firms in the East Midlands region as case 
studies ensures that the research problem: “The process of developing of 
innovative capabilities in biotechnology: The case of UK firms” is fully 
examined to understand how the firms perceive the world that surrounds 
them. 
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Leedy & Ormrod (2001, p.149) make an important observation and they 
comment that, case studies attempt to learn “more about a little known 
or poorly understood situation”. Indeed, not very much is known about 
the collaborative actions of small born-global bio-tech firms in the East 
Midlands region as such, this research strategy enables the reader to 
learn more about these sophisticated types of new firms. This point of 
view is supported by a number of scholars. Cohen et al. (2007, p.153) 
argue that “contexts are unique and dynamic hence case studies 
investigate and report complex dynamic and unfolding interactions of 
events and human relations and other factors in a unique setting”. Miles & 
Huberman (1994) suggest that researchers should use qualitative 
research designs when there is a clear need for a deeper understanding, 
local contextualisation, causal inference, and exposing the points of view 
of the people understudy. This is consistent with Farquhar (2012) who 
argues that using case-study research allows the researcher to gain 
particular understanding or insight into whatever they may have chosen 
to study which is usually a contemporary phenomenon.  
 
Similarly, Denscombe (2007) sees the logic behind using a case-study 
strategy and he argues that the researcher is able to gain valuable insight 
into a phenomenon that can have wider implications which could not have 
come to light when one is using a survey approach. In the same spirit, 
Bellamy & Perri (2011) agree that case-based studies help researchers to 
deal with detail, variety and complexity, and allow them to probe into the 
rich depths of social life more easily than do variable-oriented research 
designs. The multi-case-study approach was chosen for this study 
because of its ability to generate answers to the questions “why?” as well 
as the “what?” and “how?” (Farquhar, 2012) and these questions are 
outlined in chapter 1 of this study under research questions section 1.3.2 
on p.10-11.  
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Additionally, Cohen et al. (2007) claim that “case studies strive to portray 
“what it is like” to be in a particular situation to catch the close up reality 
of what Geert (1873b) described as “thick description” of participants 
lived experiences of thoughts about and feelings for a situation. Yin 
(2009) affirms that to answer the question “why” one would probably 
need to do a multiple case-study. The essential tactic and a characteristic 
of case-study research is its use of several sources of data within each 
source (Saunders et al., 2007; Yin, 2009; Farquhar, 2012). Easterby-
Smith et al. (2012) claim that case methods allow researchers to 
generate huge piles of data presenting them with the opportunity to make 
interpretations they want. Data of this nature can include both primary 
and secondary data sources. In that sense, it makes the case studies 
strategy useful to the researcher because the intention is to answer 
questions that include:  
 
•What are the main elements of the knowledge supply-chain of small 
born- global biotech firms?  
•How are the main elements of the knowledge supply-chain of small born 
global   bio-tech firms connected and to what extent do they help or 
hinder their capabilities development processes? 
•What are the specific interactions of small born-global bio-tech firms that 
lead to capability development?   
 
These questions are answered by drawing upon an array of documentary 
information and detailed within and across case analyses of small born-
global bio-tech firms. Specifically, the sources of data for this study 
consist of internal documentation, biotechnology sector reports 
(secondary) and 24 qualitative interviews. This study is of an explanatory 
as well as of a descriptive nature - the research is attempting to draw 
explanatory and descriptive inferences about the impact of networks on 
the ability of small born-global bio-tech firms to generate innovative 
capabilities.  
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The explanatory aspect of the research is aimed at explaining the 
collaborative behaviour of small born-global bio-tech firms and the level 
of influence of various elements within their knowledge supply-chain. The 
descriptive aspect of the study is aimed at describing what is happening 
in the complicated world of each firm and how these various elements are 
connected in their knowledge supply-chain. Farquhar (2012) contends 
that case-study research is suitable for descriptive, explanatory and 
exploratory types of research. This is consistent with Saunders et al. 
(2007) who agree that in studies of an explanatory and exploratory 
nature the case-study strategy is the most appropriate way of conducting 
research. Various data collection methods such as qualitative interviews, 
secondary data analysis and observations are adopted with the view to 
answer the main research problem stated as: 
 
“The process of developing innovative capabilities in biotechnology: The case of 
UK firms”           
 
Triangulation is one of a number of advantages that this study has gained 
from using a multi-case approach. Indeed, multiple data sources outlined 
above have been employed to collect data for analysis. Yin (2003) 
suggests that a single and a multiple case strategy are two techniques 
that can be used to represent either a critical, extreme or unique case 
and to establish whether the findings in one case are occurring in other 
cases respectively. Evidently, the East Midlands biotechnology sector is a 
unique situation because of its science tradition that was recognised by 
the European Commission hence its acquired status of the “science city” 
of Europe (see NSC publication, 2012). The study incorporates multiple 
cases, i.e. five small born-global bio-tech firms are investigated in order 
to generate sufficient data with a view to increase the strength of the 
conclusions that are made regarding their collaborative actions.  
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This is consistent with Farquhar (2012) who favours the use of multiples 
cases stressing that they enable the researcher to explore the 
phenomenon in a number of different instances. Furthermore, Bryman 
(2004) argues that multiple case strategies allow the researcher to access 
a range and a depth of information. Farquhar (2012) cautiously stresses 
that when using more than one case data, each case needs to meet the 
quality criteria and it should address any concerns through triangulation 
to put a case forward for the relevance of the research findings. From that 
perspective, the criteria for the research sample of this study are clearly 
outlined in section 3.4.2. For example, a firm that fits the criteria should 
exhibit the characteristics of a born-global venture (entrepreneurial, risk 
taking and ambitious) with up to 50 employees, engaging in collaborative 
activities within the East Midlands region and overseas. More so, Yin 
(2003) suggests that a multiple case strategy is preferable to a single 
case and in cases where a researcher uses a single case there is need for 
a strong justification for doing so.  
 
The researcher is aware of the inherent limits of this research approach 
including: the rationale for choosing the cases, the possible need for 
additional resources and the amount of time involved. Nonetheless, the 
benefits that accrue by using this strategy outweigh the reasons for not 
using it for this particular study. In his paper “What a case-study is for 
and what is it good for” Gerring (2004) suggests that using a case-study 
approach is effective when a researcher aims to elucidate features of a 
larger class of a similar phenomenon. Benbasat et al. (1987) express 
similar thoughts and they claim that a case methodology is clearly useful 
when a natural setting or a focus on contemporary events is needed. 
Accordingly, Bellamy & Perri (2011, p.264) affirm that “accuracy, or the 
virtue of capturing the significance of as much of the available empirical 
information as possible, and so explaining or interpreting as many aspects 
of the cases studied as possible”.  
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Furthermore, the extent to which the research findings of this study can 
be generalised is traded off for accuracy; reliability and the validity of the 
results. Yin (2009) makes a strong case regarding the generalisability of 
case-based research arguing that it is achieved through the findings being 
generalised to theoretical propositions. He called this analytical 
generalisation denoting a process where generalisation takes place from 
data to theory rather than to population.  In light of the new empirical 
evidence from case analysis and secondary data analysis, the study 
makes theoretical contributions to the dynamic capabilities concept and 
the network theory by modifying Freeman’s et al. (2010) propositions on 
their model concerning rapid knowledge development for smaller born-
global firms. Miles & Huberman (1994) observe that in analytic 
generalisation, the findings are considered of being congruent with or 
connected to prior theory.  
 
The theoretical propositions for this study are closely connected to the 
dynamic capabilities theory initially developed by Teece et al. (1997). 
Table 6 below presents more practical considerations for using multiple 
cases highlighting their benefits including: validity and accuracy 
(Farquhar, 2012). 
 
Table 6: Choice and number of cases 
Choice 
 
Advantages  Disadvantages 
Single case Depth, insight, revelatory and unique Evolving boundaries of case, 
arguments for credibility and 
contribution of findings  
 
Multiple case Stronger arguments for “validity” of 
study, evidence is often considered 
more compelling, the theory is better 
grounded, the findings are more 
accurate 
 
Less depth, possible need for 
additional resources, robust 
rationale for choice of cases e.g. 
compare and contrast  
Longitudinal case(s) Ideal for tracking changing conditions 
over a period of time 
Requires significant commitment 
and it requires a lot of resources 
 
Sources: compiled from Farquhar (2012); Eisenhardt & Graebner (2007) and Voss et al. 
(2002)  
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Given the benefits that accrue by using multiple cases the researcher is 
confident about the accuracy, reliability and validity of the conclusions 
that he makes from his inferences with the data collected from small 
born-global bio-tech firms. Yin (2009, p.61) makes a strong case for 
using multiple cases arguing that even using a “two-case” design the 
chances of doing a good case will be better than a single case design. 
Meredith (1998) claims that case-study research has two outstanding 
strengths which includes; studying the phenomenon in its natural setting 
and meaningful, relevant theory is generated from the understanding 
gained through actual practice and that the strategy enables the 
researcher to answer the questions why and how with a relatively fuller 
understanding of the nature and complexity of the complete phenomenon. 
Accordingly, this makes this strategy more appropriate to this study 
because the aim is to make a theoretical contribution in addition to filling 
a gap in the literature concerning innovative capabilities of small born-
global bio-tech firms. This is supported by Easterby-Smith et al. (2012) 
who claim that good research designs need to contribute to theory. 
Farquhar (2012) suggests that case-study research is ideal for looking at 
research questions which are closely connected to their context or 
situation. From that perspective, this makes the strategy more appealing 
for this research.  
3.4 Data collection and analysis methods  
According to Huberman & Miles (2002) “qualitative data analysis is 
essentially about detection and the tasks of defining, categorising, 
theorising, explaining, exploring and mapping are fundamental to the 
analyst’s role” (p.309). In that sense, the inductive and deductive 
designs, that are used to collect data for analysis, allow the study to 
detect and to perform in-depth analysis within and across cases (Perry, 
1998; Huberman & Miles 1994). Specifically, within and across case 
techniques are used to develop ideas and theories about the collaborative 
activities of small born-global bio-tech firms.  
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More importantly, the techniques help the research to explain the impact 
of business & social networks, inter-organisational collaboration, 
competence & goodwill trust, tacit & explicit knowledge, prior learning & 
absorptive capacity on the innovative capability development process of 
the firms under investigation. This is very crucial for the purpose of this 
study in the sense that it was able to provide some explanations to the 
main research issue which is about:  
 
“The process of developing innovative capabilities in biotechnology: The case of 
UK firms 
3.4.1 Stages of data collection 
To ensure that useful data was received in order to satisfy the objectives 
of this study it was necessary that appropriate settings were identified. As 
such, to find suitable cases the researcher chose to focus on the East 
Midlands region. The region is one the areas, in England, which has a 
large concentration of biotechnology companies (Smith and Ehret, 2013). 
This concentration of a group of firms in a single location facilitated data 
collection by providing continuous access to the founders and managers 
within the biotechnology sector.  
 
Before undertaking the main research project a pilot study was carried 
out with a view to sharpen the data collection procedures and to test the 
feasibility of conducting the proposed research. At this initial stage of the 
research a firm had to be operating in the life science sector for it to 
qualify. Its size, age or sales revenue did not matter. The preliminary 
literature review and the pilot study results performed an important role 
in formulating research questions for the main research project. This prior 
study facilitated the development of theoretical propositions though 
tentative at this stage (Huberman and Miles, 1994). The propositions 
were intend for use at the data collection stage for the main study. This is 
consistent with the views of Baxter and Jack (2008).  
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Baxter and Jack agree that when a case study proposal includes specific 
propositions the likelihood that the researcher will be able to place limits 
on the scope of the study is significantly increased as well as the 
feasibility of completing it. A similar data collection strategy was 
employed by Baxter (2000/06). In her study on the development of 
nursing students decision-making in a clinical setting Baxter used 
propositions that include: knowledge, experience, feelings of fear and 
degree of confidence. 
 
In light of this, the researcher was confident that the strategy adopted for 
this study was robust and rigorous. Thus, the propositions developed after 
conducting a pilot study helped the researcher to focus the data collection 
and to determine the direction and scope of the study.        
3.4.2 The born global nature of the selected firms 
The criteria for selecting cases were purposeful and it was based on 
theoretical sampling (Patton, 1990). The cases were chosen on the basis 
that similar results were predicted to be produced within each case – a 
process termed literal replication in Yin (2009). After establishing a 
sample selection strategy, BioCity Nottingham (BCN), Enterprise Europe 
Network (EEN), Pera Innovation Network (PIN), Loughborough Innovation 
Centre (LIC) and Medilink databases were used to identify suitable born 
global biotechnology firms. Appropriate cases were classified using the 
following criteria: (1) a biotechnology firm had to conform to a commonly 
used definition of born globals which accentuates that at least 25 percent 
of its sales had to come from outside their home market in the first three 
years of their inception (see for example Gabrielsson and Kirpalani, 2012; 
Oviatt, and McDougall, 2005b; Knight and Cavusgil, 1996), (2) The born 
global firms were also expected to use the East Midlands region as their 
home market.  
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As already mentioned the logic underpinning this classification was that 
the region has a high concentration of technology-based biotechnology 
companies. The study considered research activities at BCN, LIC, Pera 
Innovation Network and AstraZeneca’s re-organisation as the key factors 
contributing to the formation of small biotechnology companies in 
significantly large numbers, (3) The firms had to use scientific knowledge 
for new drug discovery services and technical know-how to assist their 
clients to develop new clinical processes, (4) The companies had to be 
involved in collaborative networks domestically and internationally. (5) 
Well-established biotechnology companies were excluded from the sample 
because of their tendency to develop less flexible structures.  
 
The criteria set above for selecting companies led the study to five born 
global biotech firms. Table 7 below shows that all the firms fit into the 
commonly used operationalisation model which views born globals “as 
firms less than 20 years old that internationalised on average within three 
years of founding and generate at least 25 percent of total sales from 
abroad” (Knight et al., 2004, p.649).   
 
Table 7: An overview of sampled born global biotech firms 
  
Critical 
Pharmaceuticals 
 
XenoGesis 
 
BAST 
 
Sygnature 
Discovery 
 
Haemostatix 
              
Location 
 
BCN East Midlands 
 
 
BCN East 
Midlands 
 
BCN East Midlands 
 
LIC East 
Midlands 
 
BCN East 
Midlands 
Company Age 12 3 4 10 11 
Company size 
(2013) 
 
Micro/small  Micro/small 
 
Small Micro/small Micro/small 
        No of 
Employees 
 
13 9 
 
69 6 6 
            Total 
turnover  
 
£618,315 
 
£124,962 
 
 
£6,951,533 
 
£300,681 
 
£163,616 
Overseas sales 
in year 3 
(2013) 
 
£381,348 
 
£86,642 
 
 
£2,244,018 
 
£165,884 
 
£61,742 
% Overseas 
sales 
 
61% 
 
69% 
 
 
32% 
 
55% 
 
37% 
Overseas 
partnerships 
4 in the USA and Europe  6 in the USA, 
Canada, India 
and China 
3 in  North America 
and Europe 
2 in America and 
Europe 
2 in China and 
the USA 
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3.5 Data collection procedures  
The data collection steps for this study included setting the precincts (as 
discussed in section 3.4.2 above), collecting data through qualitative 
interviews and observations, secondary documents and visual materials 
as well as establishing the protocol for recording information. Twenty four 
face-to-face interviews were carried out lasting between 105 to 150 
minutes with an average duration of 115 minutes. In each case, 4-6 
interviews were carried out to increase the reliability of the data to be 
collected for analysis (Eisenhardt, 1989; Huberman and Miles, 1994). The 
interviews were conducted with the CEOs, BDOs and senior scientists at 
the premises of the five firms. Nine additional interviews were carried out 
with experts in the main knowledge centres within the East Midlands with 
a view to verify the accounts given by the main informants. In the 
following section the study discusses in detail four types of data collection 
procedures which were utilised at the data collection stage for each firm. 
3.5.1 Qualitative interviews 
Semi-structured qualitative interviews were of particular interest to the 
wishes of the researcher as they presented him with a number of benefits 
including: opportunities to collect factual information about how the 
selected born global bio-tech firms developed scientific knowledge and 
how that knowledge was channelled towards improving their operations 
while at the same time enhancing creativity. The semi-structured 
research technique was chosen as opposed to the structured or 
unstructured research techniques because of its flexibility and adaptability 
(Easterby-Smith et al., 2012). The semi-structured interviews were 
customised to suite the context of the selected born global firms. 
Cameroon & Price (2009) explained that in a practical business research 
method semi-structured interviews are more appropriate. The research 
technique allowed the researcher to have some control over the line of 
questioning (Creswell, 2014; Mills and Birks, 2014).  
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Whereas, with the unstructured interview approach the interviewer 
introduces a broad topic and the danger is that the interviewee 
determines what to say about it (Bryman & Bell, 2011; Cameroon & Price 
2009; Burns & Burns 2008). Additionally, the semi-flexibility of the semi-
structured interview technique allowed the researcher to ask additional 
questions about the collaborative actions of small born-global bio-tech 
firms in the East Midlands assisting the study to fully explore the research 
question and the research objectives located in chapter 1 of this study.  A 
set of guiding questions were utilised in order to ensure that the 
interviews remained focused on the main area of discussion. Cameroon & 
Price (2009, p.373) commented that “it makes sense to develop an 
interview guide for semi-structured interviews”. This acts as a prompt 
ensuring that the all areas that the researcher intends to cover are fully 
examined.  
 
Furthermore, this research technique enabled the researcher to gather 
data about how the small born-global bio-tech firms developed their 
innovative capabilities and to understand the linkages of various elements 
within their knowledge supply-chain. The research technique helped the 
researcher to satisfy the second objective of this study stated as: 
 
“To explain the connectivity of the main elements of the knowledge supply-chain 
of small born-global firms and the extent to which they assist their innovative 
capability development process”. 
3.5.2 Qualitative observations 
The researcher took field notes on the activities of CEOs, Business 
development officers and senior scientists at each firm. During arranged 
visits to all the five firms the researcher recorded, in note form, their 
science-related activities e.g. lab-based collaborative programmes 
outlined on secure interactive whiteboards. The use of whiteboards was 
replicated in all the firms because they used lab equipment and facilities 
provided by BCN.  
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The researcher assumed what was described by Creswell (2014) as a 
complete observer role. The observations at the premises of the firms 
followed what Flick (2014) describes as an open-ended approach which 
permitted the researcher to ask general questions of the participants and 
it allowed them to freely provide their views. This data collection 
procedure provided the researcher with two main advantages: (1) the 
researcher had first-hand experience with the identified key participants 
in each firm and (2) the researcher was able to record information as it 
occurred.            
3.5.3 Documentation 
During the process of interviewing the key participants the researcher was 
able to gather documentation about their planned partnering activities 
e.g. newsletters and official reports published at BCN – an ‘incubator’ 
providing support and science facilities to the sampled firms. These 
documents enabled the researcher to obtain the language and words of 
participants. The researcher benefited by saving time and expenses 
associated with transcribing field data. More importantly, the documents 
represented data to which the participants had given attention. 
Additionally, secondary data materials were accessed using the websites 
of the chosen firms, Companies House and publicly available literature. 
This technique for accessing achieved material was used for all the cases.     
3.5.4 Audio-recording 
All the interviews with the key participants were audio-recorded and 
transcribed. Recorded information gave the researcher more time to 
reflect on the meanings and interpretations that the participants attached 
to networking, inter-organisational collaboration and knowledge creation. 
The researcher faced challenges associated with the interpretation of their 
statements. However, to ensure the accuracy of the presented accounts 
the participants were provided with the transcribed data to validate 
whether it represented their accounts of events.    
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3.5.5 The benefits of qualitative techniques  
As explained above the use of this qualitative technique ensured that rich 
data was collected. Mason (2002) expressed that using the interactive, 
situational and generative approach to acquire data with the more 
structured composition and uniform style of a survey interview gives the 
author the privilege to access the accounts of social actors, agents, 
individuals, or subjects as data sources. Indeed, investigating instances or 
cases of collaborative actions of small born-global bio-tech firms in their 
natural setting gave the researcher the opportunity to delve into their 
actions in more detail. This also allowed him to discover things that might 
not have become apparent through superficial research. As Burgess 
(1982, p.107) notes, conducting an in-depth interview gives the 
researcher the “opportunity to probe deeply to uncover new clues, open 
up new dimensions of a problem and to secure vivid, accurate and 
inclusive accounts that are based on personal experience”.   
 
It is also instructive to mention that in instances where clarification or 
additional information was required follow-up emails and telephone calls 
were made. The credibility of the information collected from the key 
informants was enhanced when the study reached a point of saturation 
i.e. a point where the participants were giving previously presented 
events. At that stage no further interviews were deemed necessary (Riley, 
1996) and the interviewing process was stopped. This lead to the 
commencement of data analysis.     
3.6 Inductive analysis 
The study follows an inductive analysis style with elements of deduction. 
The cases chosen for analysis consisted of CEOs/founders and their top 
management teams who are former employees of AstraZeneca or had 
vast experience of the bio-tech industry accumulated over years of 
operating in the sector and an in-depth knowledge of the pharmaceutical 
industry.  
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The next step in the analytical process was to investigate the sampled 
cases in order to identify differences, patterns and trends in relation to 
how they create knowledge in each case (Bellamy & Perri, 2009; Miles & 
Huberman, 1994). Yin (2009) suggests that using pattern matching logic 
in case-oriented studies is the most appropriate technique for case 
analysis. As such, cross case synthesis was used (Yin, 2003; Huberman & 
Miles, 1994) and a table (see table 9 on p.143) populated with qualitative 
data from individual cases showing a wide range of features on a case by 
case basis was developed (Lindstrand et al., 2011). 
 
Similar cases with identical features recognised as a typical small born-
global firm were closely scrutinised. Taking the literature review into 
perspective and the emerging themes about the processes involved in 
generating scientific knowledge for small born-global firms a causal link 
between various elements including networking, collaborating, trust, 
knowledge sharing, prior learning and absorptive capacity was formed. 
This is in line with Muller (1982) and Miller (1983) who suggest that the 
process of analytic induction starts with a tentative hypothesis to explain 
something.  The researcher’s intentions are to contribute to the concepts 
of dynamic capabilities and network theory by modifying the theoretical 
propositions on Freeman’s et al. (2010) Rapid Knowledge Development 
Model for Born-global Firms.  
 
This is achieved by tracing/analysing emerging theoretical concepts, 
trends, patterns and insights about the collaborative activities of small 
born-global bio-tech firms using within and across case analysis. As a 
result, the extent of influence of the main elements, as outlined in the 
previous paragraph, on the process of innovative capability development 
was established. Farquhar (2012) suggests that sifting through data helps 
a researcher to identify common ideas and themes that are supported 
across the interviews.  
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As such, common themes were identified in the data prompting the 
researcher to modify Freeman’s and others propositions accordingly using 
new empirical evidence from qualitative conversations and emerging 
concepts from secondary data.  Cohen et al. (2007, p.462) discusses the 
idea of “progressive focussing” understood by Parlett & Hamilton (1976) 
as a process which starts with the researcher using a wide lens to collect 
data and then through reviewing, sifting and sorting it the salient 
features, of small born-global bio-tech firms, for example, can bubble to 
the surface. In the same vein, Gerring (2005) argues that changes in the 
social world imply the dynamic nature of concepts.  
 
In other words, concepts are not static they have to be manipulated to 
take into account the world’s changing terrain and how people make 
sense of things happening around them (Weber, 1905/1949). As such, 
this study recognises the changing nature of the biotechnology sector i.e. 
the constant quest for new products to better the life of human beings 
and other species (Horsley, 2012). The debate on which strategy to use 
for analysing qualitative data has brought different perspectives from a 
number of scholars. For example, Yin (1994) claims that, where a 
researcher uses existing theory to formulate the research question and 
objectives the researcher may also use the theoretical propositions to 
help him/her to devise a framework that is needed to direct the data 
analysis process.  
 
On the contrary, Bryman (1989) sees this from a different perspective. 
Bryman argues that devising theoretical propositions before actually 
collecting the data as a way to direct and to help to analyse qualitative 
data should be disfavoured. He suggests that there is a danger that the 
researcher may make premature conclusions on the subject under 
investigation. He also maintains that the theoretical concepts developed 
in this way may predominantly be based on the views of the participants 
in the social setting.  
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Other researchers (e.g. Creswell, 2005; Huberman & Miles, 1994; Glaser 
& Strauss, 1967; Schatzman & Strauss, 1973; Saunders et al., 2003) 
highlight the benefits of an inductive approach expressing its “grounded” 
nature. In particular, Saunders et al. (2003) make three points 
highlighting that, exploring data without a descriptive framework: (1) 
allows theory to emerge for the process of data collection and analysis; 
(2) it is not necessary to commence one’s study with a defined theoretical 
framework and (3) one identifies relationships between collected data and 
then develops propositions. The scholars further express that when 
following an inductive approach it is important to have a clear research 
process.  
 
As is abundantly clear from the debate about data analysis above, it was 
confusing for the researcher to adopt one extreme of analysing data. 
Nonetheless, within this web of confusion the study borrows elements of 
both inductive and deductive data analysis to examine the activities of 
small born-global bio-tech firms. Inductive analysis is more prominent. 
The main reason for using a mixture of the two scientific paradigms was 
to enable the research to benefit from existing theory so as to develop a 
new and useful theory which satisfies his intentions in conducting the 
study. The variables modified from Freeman’s et al. (2010) original model 
of rapid knowledge development are used to analyse data from five small 
born-global bio-tech firms.  
 
The modifications to Freeman’s and others model were informed by the 
results from the “pilot” study, secondary data analysis and within case 
analysis which Cohen et al. (2007) suggest should commence earlier in 
the research. Yin (2009) accepts this way of analysing data by stating 
that a data analysis strategy based on theoretical propositions is the most 
preferred strategy in case-oriented research studies. Data collected from 
each firm were sorted and transformed into chronological order and each 
case history using thematic analysis.  
120 
 
Thematic analysis is multi-discipline; it is used in education research 
(Cohen et al., 2007), it is also used by research clinicians (see Newfield et 
al., 1991; William, 1992), and in political science (Easterby-Smith et al., 
2012). The method for analysing data was chosen because of its ability to 
focus on identifiable themes and patterns of behaviour (Aronson, 1994). 
Identifiable themes for this study are related to business & social 
networks, inter-organisational collaborations, competence & goodwill 
trust, tacit & explicit knowledge, prior learning & absorptive capacity.  
 
The study takes the stance that these concepts are the building blocks to 
the process of developing the innovative capabilities of small born-global 
bio-tech firms operating in a hyper-competitive environment driven 
among other things by the wealth of information a firm can have access 
to (Shilling, 2008). This is in line with Taylor & Bogdan (1984, p.131) who 
defined themes/concepts as units derived from patterns such as 
“conversation topics, vocabulary, recurring activities, meanings or 
feelings”. The emerging themes from qualitative conversations helped the 
researcher to piece together and form a comprehensive picture of small 
born-global bio-tech firm’s collective experience of business & social 
networks, inter-organisational collaborations, trust building, knowledge 
sharing, prior learning & absorptive capacity in networks. The cross case 
analysis was used to analyse the collaborative activities of each small 
born-global bio-tech firm (Bellamy & Perri, 2009). The first step in this 
process was to analyse each case (within case analysis).  
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The technique for analysing focussed on business & social networks and 
other variables (outlined above) as conduits for the process of innovative 
capability development of small born-global bio-tech firms. For each firm 
investigated the key variables including: business & social networks, 
competence & goodwill trust, inter-organisational collaborations, tacit & 
codified knowledge, learning & absorptive capacity contained in the 
amended conceptual framework were used to assess their impact on the 
capacity, of small born-global bio-tech firms, to generate fluid scientific 
knowledge and technical know-how. The analysis showed that the 
connection between business, social networks and trust was crucial 
because it provided the foundation to the process of knowledge-creation 
and new drug discoveries for born globals bio-tech firms. From analysing 
the cases there was strong evidence indicating that competence and 
goodwill trust are essential to the process of sharing, exchanging scientific 
knowledge and technical know-how in the form of tacit and codified 
knowledge.  
 
Thus, competence and goodwill trust in business and social networks can 
be combined into the theoretical concept of dynamic capabilities and 
network theory. Based on within case and secondary data analyses 
competence and goodwill trust are a pre-requisite for knowledge sharing 
which is essential for small born-global bio-tech firms in terms of making 
innovations. The next step was to conduct a detailed analysis of the 
investigated firms so as to identify any differences or similarities in the 
collaborative behaviours across different firms to help to explain in great 
depth the research phenomenon. Huberman & Miles (1994, p.173) 
suggest that cross case analysis helps to deepen “understanding and 
explanation”. Cross case synthesis was used (see Yin, 2003/9; Huberman 
& Miles, 1994) and it allowed the researcher to map the steps involved in 
the process of developing innovative capabilities undertaken by firms 
under investigation and their impact on generating fluid scientific 
knowledge and technical know-how which underpin innovation.  
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Yin (2009) maintains that cross-case synthesis involving at least two 
cases is likely to be easier and findings are likely to be more robust than 
using a single case. As such, the researcher was able to develop 
sophisticated descriptions and more powerful explanations (Gerring, 
2005). The cases were further probed to understand the connectivity of 
the building blocks of networks, inter-organisational collaborations, trust, 
and knowledge, prior learning and absorptive capacity as conduits for the 
innovations of small born-global firms in the East Midlands. In light of the 
preliminary literature review and cross case analysis the researcher was 
inclined to conclude that there is a strong association between these 
building blocks. For example, a CEO of a small born-global bio-tech firm 
who is a former employee of a well-established pharmaceutical company 
is likely to have business and social connections that he regularly 
interacts with to discuss, share experiences and exchange ideas about 
drug discoveries.  
 
The cross case synthesis revealed that the CEOs or science directors from 
the analysed cases have some form of links with their personal 
connections and business networks e.g. all of the participants had 
established business connections at BNC where their businesses were 
resident. Given the overwhelming evidence of similarities between the 
participants the researcher felt that there was no need to further sub-
divide the firms. Evidence from within case analysis indicates that all the 
participants have connections regionally (in the East Midlands), nationally 
(in the UK) and overseas (e.g. in America, Asia etc.). Crucially, the 
participants confirmed that their business, social relationships, 
competence and goodwill trust significantly influenced how they share 
scientific knowledge and technical know-how with their partners.  
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Empirical evidence was compared with themes emerging from recent 
literature on born globals which is fairly scant. Consequently, the 
researcher modified construct definitions to include various dimensions of 
the capabilities view (structural, relational, and cognitive) and their 
influence on a firm’s access to fluid scientific knowledge and technical 
know-how. The researcher follows Yin’s (1984) replication strategy. The 
“Knowledge and Innovative Capability Development Model” was used to 
study each case in detail. Successive cases were examined to compare 
and verify their collaborative activities (Huberman & Miles, 1994). In 
cases where information was not readily available subsequent phone calls 
and emails were made to the CEOs/founders/science directors, and the 
top management teams of the firms under the microscope. In order to 
provide a detailed account of the impact of business & social networks, 
goodwill & competence trust, inter-organisational collaboration, tacit & 
explicit knowledge, prior learning & absorptive capacity on the process of 
developing innovative capabilities for small born-global bio-tech firms the 
researcher chose to use an in-depth description of each firm. This is 
consistent with Yin (2003) who argues that single or representative cases 
can be used as examples of a larger population of cases.  
 
In line with other scholars (Mele´n & Nordman, 2009; Haslam et al., 
2011; Zheng et al., 2010) the researcher chose the firms to represent a 
larger population based on their ability to illuminate the points that his 
analysis of knowledge and the capacity of small born-global bio-tech firms 
sought to make (Lindstrand et al., 2010). He selected the firms because 
they provided a good representation of typical born-global bio-tech firms 
and they were not considered extreme cases. Because the researcher had 
conducted interviews during the “pilot” phase this, consequently gave him 
rich data to use as a platform on which to base case descriptions for the 
main study. 
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Analytic generalisation was used to examine and validate data from five 
firms and science parks (Yin, 2009; Huberman & Miles 1994/2002). 
Following that data from these firms was checked to identify any 
competing or falsifying explanations in relation to theoretical propositions 
(Kvale, 1989b). In instances where competing or falsifying explanations 
were identified propositions were reformulated to reflect the data. To 
enhance our understanding of the proposed concepts, the data were 
studied again to determine whether they relate to the reformulated 
propositions e.g. propositions such as competence, goodwill trust, prior 
learning & absorptive capacity etc.  
 
Secondary data related to these propositions are located in chapter 2 and 
transcribed data collected from qualitative interviews was kept secure. 
Engaging in the process of validation, the researcher was able to 
construct plausible explanations of the cases by developing the 
propositions and theory to such a point that all fit into the data (Yin, 
2003/2009). Thus, the final propositions consisted of business & social 
networks, competence & goodwill trust, inter-organisational 
collaborations, tacit & explicit knowledge, prior learning & absorptive 
capacity as the building blocks towards developing the innovative 
capabilities of small born-global bio-tech firms. Therefore, based on 
analytical generalisation the researcher was able to construct and develop 
new theory with regards to the innovative capabilities of small born-global 
bio-tech firms – The “Knowledge and Innovative Capability Development” 
model (see p.206).   
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3.6.1 Internal validity 
Validity is the extent to which the research findings accurately represent 
what is really happening in the situation (Collis & Hussey, 2003). In that 
sense, the researcher is confident that using within case analysis the 
findings of the study will accurately represent the world of small bio-tech 
firms in particular, the impact of business and social networks as conduits 
for acquiring scientific knowledge and developing technical know-how. 
This is consistent with Farquhar (2012); Gibbert & Ruigrok (2010) who 
collectively acknowledge that internal validity is related to the casual 
relationships between variables and results. They both claim that internal 
validity applies at both the data collection and data analysis stages. 
Furthermore, Yin (2009) suggests that internal validity is a concern for 
explanatory case studies where the researcher intends to explain why 
event X led to event Y. Indeed, this study aims to explain the connectivity 
of various elements in the knowledge supply-chain of born global biotech 
firms and their impact on how they develop innovative capabilities.  
 
Therefore, the analysis of instances of occurrences within cases and cross 
case ensures that the research findings are based on the data collected 
from small born-global bio-tech firms in the East Midlands and a detailed 
evaluation of the literature. As such, the researcher is confident with the 
findings of the study in terms of their accuracy in explaining the capacity 
of small born-global bio-tech firms to generate fluid scientific knowledge. 
Eisenhardt (1989, p.544) argues that case-study researchers can claim 
internal validity of their findings through “enfolding the literature”. In 
other words, she is expressing the notion that emerging theoretical 
concepts and developed theories from within and across case analysis 
need to be closely examined with the existing literature. Indeed, this 
suggestion is particularly important to the achievement of the research 
aims and objectives of this study, in particular, the author’s intention to 
contribute to the theoretical concepts of dynamic capabilities and network 
theory.  
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As such, it is safe to claim that the proposed “Knowledge and Innovative 
Capability Development Model” accurately represents what is happening 
in the world small born-global bio-tech firms. Collis & Hussey (2003) 
advise that research errors including: faulty research procedures and poor 
sampling can potentially undermine the validity of the research findings. 
Collis’ & Husseys’ advice was taken into consideration during the case 
selection stages and, as a result, a criterion for the representative sample 
was set to avoid these research errors. Farquhar (2012) adds that to 
increase the internal validity of the research findings great care should be 
taken in the way data about the research sample is presented; she argues 
that it should be presented in such a manner that the reader can readily 
access it.    
3.6.2 Reliability  
In addition to informing the reader about the actions of small born-global 
bio-tech firms the study makes a contribution to the theoretical concepts 
of dynamic capability theory and network theory. As such, reliability of 
the modified conceptual framework the “Knowledge and Innovation 
Capability Development Model” will be tested when the research is 
repeated (Farquhar, 2012; Collis & Hussey, 2003). Yin (2009) emphasise 
the need for the researcher to document the procedures that the initial 
researcher followed in their study. In light of this, the procedures for this 
study are clearly documented in this thesis. To dispel any suspicions 
about the transparency of the research the supervisory team were 
informed of the progress of the field work in every step during the data 
collection process. This is consistent with Yin’s advice that the general 
way of approaching the reliability problem is to operationalise as many 
steps as much as possible and to do the research as if someone is looking 
over your shoulder.     
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3.6.3 Generalisability 
The limits to the extent one can generalise the findings of case-oriented 
research design has been extensively debated in social science research 
(see Skate, 1995; Creswell, 2007; Gomm et al., 2000;  Huberman & 
Miles, 2002). Yin (2009) makes a strong case regarding the 
generalisability of case-based research arguing that the generalisability is 
achieved through the findings being generalised to theoretical 
propositions. He called this analytical generalisation denoting a process 
where generalisation takes place from data to theory rather than to 
population. Farquhar (2012) stresses that the positivist-view of statistical 
generalisation does not apply to case-study research where the primary 
goal is to study the research phenomenon in its real life context. Yin 
advocates for what he terms logic replication as opposed to logic 
sampling. From this perspective, it can be argued that the findings of this 
study in particular, the modified conceptual framework can be applied to 
other biotechnology networks/clusters e.g. to The Golden Triangle of 
Cambridge, London and Oxford reproducing similar findings to those 
achieved through analysing small born-global bio-tech firms in the East 
Midlands region.          
3.7 Operationalisation of the main concepts  
According to Bryman (2007) operationalisation entails devising measures 
of the concepts in which the researcher is interested. Knight (1997) claim 
that while measures of imprecise concepts are never completely valid or 
reliable, researchers strive to maximise these qualities. Research 
literature deals, only to a modest degree, with measurement problems 
when it comes to exploratory/qualitative research (Ghauri & Grønhaug, 
2005). However, Berg (2007) goes so far as to say that failure to define 
and operationalise concepts will spell disaster in many cases.  
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The problem is usually approached by using semi-structured questions, 
based on an interview guide – a technique which was adopted in this 
study. As the study has already explained the interview guide questions 
were developed based on the literature and the preliminary study. This 
type of study may be seen as data-driven however, without utilising the 
concepts related to born-global firms the knowledge and innovative 
capability development model will be difficult to construct. Berg (2007) 
adds that if researchers do not make clear their concepts the results they 
produce may be meaningless in terms of explanatory power or 
applicability. The scholars suggests that, “if you have not worked with the 
literature in developing  relevant meanings and measureable attributes, it 
will be impossible for you to see how eventual results fit into this extant 
body of knowledge” (p.37). From that perspective, it is essential that a 
mapping between empirical observations and concepts is undertaken. 
3.7.1 Business & social networks 
According to Solberg (1997), the more global the industry structure is the 
more important is the presence of an active and widespread network. The 
motives for forging global networks for born-global firms were 
investigated and their influence on how they develop innovative 
capabilities was sought. The business and social networks studied in this 
thesis were both business and personal contacts that the key informants 
define as crucial to how the firm acquired/acquires knowledge and 
technical know-how. These contacts were either established from their 
previous research programmes domestically or internationally. To 
evaluate the impact of these contacts on how they generate their 
scientific knowledge and technical know-how the interviewees we asked 
questions that were related to the types of linkages that existed between 
them and the network of people they identify as being important? Follow-
up questions such as how close were these relationships we also utilised?  
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3.7.2 Alliance-building  
Born-globals are entrepreneurial firms which are able to achieve 
economies of scale soon after their establishment. They reduce the 
impact of financial challenges and the liability of newness by forging 
alliances and other special types of partnerships, thus shielding the firms 
from the full impact of rapid growth (Altshuler, 2012). Small 
biotechnology firms that form partnerships with large pharmaceutical 
firms do so for their mutual benefit (Schilling, 2010). Segers (2013, p.24) 
adds that, “to varying degrees, new biotechnology firms depend on 
strategic (technology) partnerships with other organisations or large 
firms”.  
 
The interviewees were asked to explain the importance of forming 
alliances with other pharmaceutical firms, academic and research 
institutions both domestically and internationally. They were further 
probed to ascertain the basis of their success in the knowledge-intensive 
science sector. Mattsson (2011) suggest that, collaborations give rise to 
knowledge sharing and exchange in the form of analytical skills, technical 
know-how and observational learning.      
3.7.3 Trust-building 
Successful business alliances are often considered to be based on trust, 
close co-ordination of activities and constant communication (Altshuler, 
2012, Kale et al., 2000; Kanter, 1994). The process of developing trust is 
fraught with challenges and it often occurs over a long period of time 
based upon interactions between different boundary spanners and 
facilitated by organisational similarity (Gulati & Sytch, 2008). A similar 
view was presented by Parkhe (1998) who insisted that the process of 
trust development occurs over time and it takes the form of multiple 
interactions as well as reinforcing positive experiences.  
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To construct a clearer picture regarding how born-global bio-tech firms 
develop trust in their collaborative projects, the interviewees were asked 
to narrate the steps they took before commencing the process of 
exchanging scientific knowledge and technical know-how with their 
partners. The reasoning behind asking such types of questions was to 
ascertain the impact of trust, as a component of their knowledge supply-
chain, in terms of succouring the development of innovative capabilities. 
Freeman et al. (2013) maintain that for born-globals their knowledge 
development process is anchored on business relations and more so, on 
relational trust.       
3.7.4 Knowledge-creation 
Scholarship on networking universally acknowledge that firms which are 
embedded in evolving networks of inter-firm and inter-organisational 
knowledge relationships have the opportunity to ‘soak-up’ a wide range of 
specialised knowledge resulting in better performance (Powell, et al., 
1996; Malebra & Breschi, 2005, Grant, 1996). According to Chesbrough et 
al. (2006) ‘open innovation’ provides multiple learning occasions for 
young firms and it also reduces R&D costs due to the fact that a firm can 
share part of the required knowledge with other firms or research-
oriented institutions. Similarly, Kogut & Zander (1992); Malebra & 
Orsenigo (2000) acknowledge that young high-tech firms benefit from 
external knowledge networks because they enable them to bridge their 
knowledge gaps. The key discussions with the interviewees were based 
around identifying the processes involved in knowledge-creating whether 
it was explicit or tacit knowledge. Specifically, the researcher sought to 
gather data about how small firms created science-related knowledge. 
The participants were also probed about the role of trust in facilitating 
knowledge sharing outside their business. The conversations went to as 
far as to discuss conditions that the firms deemed necessary for them to 
exchange/share science knowledge. The topic on how the knowledge is 
stored and managed in the firms was also explored.     
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3.7.5 Prior-learning & absorptive capacity   
Absorptive capacity is concerned with a firm’s ability to recognise 
assimilate and to apply new knowledge productively within the firm 
(Cohen & Levinthal, 1990). Taheri & Geenhuizen (2011) maintains that 
the absorption of diversified knowledge through global networks improves 
creative activity and enhances practical adjustment of innovations by 
utilising complementary knowledge in business relationships. Concerning 
born-global bio-tech firms it is imperative that their top management use 
their local and global connections as a source of new scientific knowledge 
and technical know-how. Freeman et al. (2010) maintain that, the 
interpersonal relationships (of the born global managers through their 
earlier networks), inter-firm partnership and co-operating inter-
dependence, which lead to trust, “may be viewed as the fastest and most 
expedient conduit of tacit knowledge” (p.79). Altshuler (2012) suggests 
that tacit knowledge increases the firms’ absorptive capacity. Discussions 
with key informants were targeted at understanding the importance of 
prior-learning and the accumulated science experience of the owners and 
the top management in terms of facilitating the acquisition of useful 
information in networks.      
3.8 Measurement  
The formulated parameters in the form of concepts were designed to 
measure how small born global bio-tech firms develop their innovative 
capabilities and these are presented in table 8 on p.132. The table 
displays collected data concerning the activities of small born global firms 
that assisted their capability development processes. The data shows 
what the firms were able to achieve e.g. they were able to develop new 
drug testing combinations or new clinical products as a result of jointly 
working with other firms, research institutions, hospitals etc.  
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Table 8: Outcomes of the science activities of small born-global firms    
 
  Formulated concepts designed to measure the innovative capabilities of small born 
global biotech firms 
 
 
 
 
Innovative 
Capabilities  
 
  Business & 
Social 
Networks 
Competence & 
Goodwill trust  
Inter-
organisational 
Collaborations 
Tacit & Explicit 
Knowledge 
Prior learning 
& Absorptive 
Capacity  
 
S
m
al
l B
or
n
-g
lo
ba
l f
ir
m
s 
 
Critical 
Pharmaceuticals  
 
Strong 
academic, 
personal & 
institutional 
networks. VC 
are also part of 
the network 
 
Trust is build 
based on the 
reputation of the 
partner  
 
Engages in 
collaborative 
projects with 
other firms in 
the East 
Midlands and 
overseas. Work 
with Universities 
& scientists on 
specific projects. 
 
 
The firm sponsors 
biochemistry 
students to work 
on projects and to 
study at 
University. Data 
from projects is 
stored on a 
database. 
Students are also 
bonded    
 
Experience is 
seen as 
essential in 
order to 
understand what 
knowledge 
should be 
acquired 
 
Nano-enabled 
intranasal 
formulation of 
teriparatide for the 
treatment of 
osteoporosis as a 
result of result of 
working with an 
academic 
institution 
 
XenoGesis Ltd. 
 
Same as BAST 
Inc.  
 
Trust is built in 
escalating series 
but in cases of a 
partner whose 
cognitive 
distance is big 
that is seen as 
the basis for 
trust 
  
 
The firm work 
with scientist 
from their 
clients to bridge 
the knowledge 
gap.  
 
Same as Critical 
Pharmaceuticals  
 
Same as Critical 
Pharmaceuticals  
 
Data interpretation 
techniques 
necessary  for new 
drug testing as a 
result of working 
with other firm  
 
Haemostatix Ltd 
 
Same as Critical 
Pharmaceuticals 
& XenoGesis 
 
Trust is 
portrayed as key 
to knowledge 
exchange  
 
Same as 
XenoGesis  
 
Most of the board 
members have 
experience in 
product 
development and 
commercialisation  
 
Board members 
have vast 
experience in 
drug discoveries 
which helps to 
understand the 
needs of the 
firm   
 
 
Haemostats 
technology used 
by surgeons to 
manage 
problematic 
bleeding. Funding 
was key to the 
development of 
the technology 
Sygnature 
Discovery  
Same as 
XenoGesis & 
Critical 
Pharmaceuticals 
  
Trust is built in 
escalating series 
with partners 
Same as all the 
other 
participants  
Same as  Same as above Gold standard’ 
techniques in pain, 
metabolic and CNS 
disorders, 
inflammatory 
disease and in 
vivo 
pharmacokinetics 
BAST Inc. The firm has a 
strong network 
of 24 other 
firms. The CEO 
has personal 
connections with 
expert scientists 
& connections 
developed from 
his previous 
employment  
 
Same as Critical 
Pharmaceuticals  
Collaborations 
are seen as the 
route to new 
drug discoveries  
Same as 
XenoGesis 
Same as with all 
the other firms  
New statistical 
tools in parameter 
estimation and 
optimal design 
e.g. Risk and 
Utility Assessment 
through 
Mechanistic 
Modelling 
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Bellamy & Perri (2009, p.59) suggest that a case-study strategy “enable 
researchers to study and measure the interaction between factors, or 
variables, in producing outcomes of interest”. Indeed, by understanding 
the influence of elements that include: networks, trust, knowledge 
sharing, prior learning & absorptive capacity the researcher was able to 
analyse how the firms generate fluid scientific knowledge and acquire new 
technology. More importantly, the researcher was also able to understand 
the degree of importance small born-global bio-tech firms place on each 
factor and the strategies they adopt to ensure that they enhance their 
capacity to make crucial innovations.  
 
This provides the reader with a detailed analysis of how the formulated 
measures perform a key role in the knowledge supply-chain of the firms 
under investigation. This is consistent with Miles & Huberman (1994) who 
suggest that doing an aggregated case analysis with a core list of 
variables identified as having a strong impact cross several cases is a very 
powerful way to move from very case-specific explanations to findings 
that bridge to the discovery or re-enforcement of constructs. Maxwell 
(1984) makes a strong case for analysing data this way arguing that 
“casual explanation is a legitimate goal of qualitative research, and one 
for which qualitative methods have some unique advantages”.  
 
The strength of the ties and relationships within networks were used to 
measure social capital broadly defined as the sum of the actual and 
potential resources embedded within, available through and derived from 
the network of relationships possessed by an individual or social unit. 
Therefore, the types of connections that the CEOs/founders or science 
directors had developed from previous employment and through 
networking acted as a channel for novel information inflows (Powell & 
Grodal, 2005).  
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The end result of a process for developing innovative capabilities is the 
formation of new scientific mathematical combinations or the 
development of new clinical product. In making this assumption the 
researcher is aware that the measurement may be limited; the use of 
SPSS computer software would have generated some quantitative data to 
indicate the exact strength of the relationship between the dependent 
factor - scientific knowledge/technical know-how for example with 
independent elements within the knowledge supply-chain such as 
business & social networks, competence & goodwill trust etc. However, 
the questionnaire survey did not generate sufficient data to test the 
strength of the relationships between these elements.    
    
The structural dimension was measured by the types of actors that were 
included in a network of a born-global bio-tech firm (e.g. scientists, 
academia and research institutions) and how they were reached through 
the network given that some were located overseas (Lindstrand et al., 
2011). To measure the relational dimension of social capital the 
researcher used acceptable measures including: trust, trustworthiness, 
norms and obligations in a global network (Fukuyama, 1995; Coleman, 
1990; Putnam, 1993). The cognitive dimension was measured through 
resources that provided “shared representations, interpretations, and 
systems of meaning among parties’’ (Nahapiet & Ghoshal, 1998, p.244).  
3.9 Ethics in social science 
The issue of ethics in social science research has far-reaching 
consequences for the subject under study. Surprisingly Easter-Smith et 
al. (2012) highlight that in management research both the British 
Academy of Management and the American Academy of Management 
have been very relatively relaxed about the provision of ethical codes. 
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Pressure to have a code of ethics which every social science researcher 
should adhere to has been mounting especially from other academic 
disciplines including: medicine and psychology (see Easterby et al., 
2012). A number of scholars have attempted to define ethics. Saunders et 
al. (2003) define ethics in the context of research. The scholars agree 
that “ethics refer to the appropriateness of the behaviour in relation to 
the rights of those who become subject of your work or are affected by it” 
(p.95).  
 
In that sense, the researcher ensured that his actions did not have an 
adverse impact on small bio-tech firms he is investigating. Wells (1994, 
p.284) define ethics in terms of a “code of behaviour appropriate to 
academics and the conduct of research”. The behaviour of the researcher 
was hugely influenced by the broader social norms within the bio-tech 
industry. Zikmund (2000) contend that a social norm indicates the type of 
behaviour that a researcher has to adopt during the process of collecting 
data in the bio-tech industry e.g. respect and privacy of the research 
participants. Henn et al. (2009) point out that when we talk about ethics 
in social research the main goal is to address those issues concerned with 
the behaviour of social researchers and the negative consequences that 
their research may bring to the people they study. Well (1994) affirms 
that in reality the prevailing norms of behaviour inform a wide range of 
ethical positions for the researcher.             
3.9.1 Ethical considerations 
In Barnes (1979) ethical factors are portrayed as factors that “arise when 
we try to decide between one course of action and another not in terms of 
expediency but by reference to standards of what is morally right or 
wrong” (p.16). Saunders et al. (2003) agree that ethical concerns will 
emerge as the researcher plans to collect data i.e. planning to gain access 
to small born-global bio-tech firms, collect analyse and report about their 
collaborative activities.  
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Henn et al. (2009) suggest that ethical considerations do not focus on the 
researcher but they place the spotlight on the participants of that study 
and when designing research scholars need to ensure their protection. 
Indeed, when conducting research it is important that the research 
participants are treated in a dignified manner which Collis & Hussey 
(2003, p.39) described as common “courtesy”. Fisher (2007) stresses 
that researchers should avoid using the information they discover about 
people or organisations to harm them. Furthermore, Fisher’s suggestions 
are particularly relevant and important for this study. Necessary steps 
and measures ensured fair treatment of the participants were put in place 
in accordance with the requirements of Nottingham Trent University 
(NTU) policies concerning conducting research. In the same vein, Collis & 
Hussey (2003) affirm that in any research project it is ethical to inform 
potential participants of the purpose of the research and to obtain their 
agreement to their participation. As such appropriate documentation 
outlining data confidentiality and the participant’s consent to the interview 
was arranged and it can be found in appendices 2, 3 & 4. 
3.9.2 Confidentiality     
Information collected about the collaborative actions of small born-global 
bio-tech firms is held with the strictest confidence to safeguard the 
originators and a confidentiality form was signed. This is consistent with a 
number of scholars (see Saunders et al., 2003/2007; Bellamy & Perri, 
2009; Henn et al., 2009). It is an important step in the data collection 
process in the sense that this thesis will be published for public 
consumption. Therefore, it is crucial that firm specific information or 
product commercialisation data is not made public unless the firm or a 
bio-entrepreneur agrees to data being made available to the general 
public (Fisher, 2007). 
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3.9.3 Informed consent  
Social scientists (see Fisher, 2007; Gerring, 2005; Burns & Burns 2008; 
Henn, et al., 2009) acknowledge that regarding research ethics the issue 
of informed consent is perhaps the most important one. For any small 
born-global bio-tech firm or bio-entrepreneur wishing to participate in the 
interviewing process a consent form was designed outlining what their 
participation entails. This ensured that the participants were fully aware of 
the purpose of their participation and how the data they generate will be 
used and stored.  
 
The consent form explicitly details information about how generated data 
will be stored, presented and who will have access to it. Barrett (1995) 
makes an important statement regarding ethical considerations in 
organisational research by expressing that regardless of how robust and 
sound the chosen research approaches, methodologies, and methods are 
for any research, ethical considerations are very important and it is 
essential that the researcher investigates these implications before 
commencing the project. Saunders et al. (2003) emphasise the need to 
ensure that the promise to maintain the confidentiality and anonymity of 
the participant is kept throughout the research project. Easterby-Smith 
(2002) discusses how snowball sampling can cause serious ethical 
problems. The scholars emphasise that great care should be taken to 
maintain each participants anonymity. Indeed, the University’s guidelines 
i.e. Nottingham Trent University Code of Ethics makes it clear and 
compulsory that a research project must meet the following criteria: 
a) Integrity – the research has been carried out in a rigorous and 
professional manner  
b) Plagiarism – proper acknowledgement has been made regarding the 
origins of the data and ideas used by the researcher for the purpose 
of the research  
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c) Data Handling – the researcher has ensured that there is effective 
data record-keeping, proper storage with regard to confidentiality 
and data protection  
d) Ethical Procedures – the researcher has ensured that, in line with 
the university procedures, ethical approval is granted by the 
Research Ethics Committee. This procedure ensured that the 
research project conforms to the required codes of conduct   
 
Appropriate documentation is attached in appendices (see appendices 2, 
3 & 4, p.265-282) showing a completed ethical approval form and a 
sample of a consent form outlining steps that have been taken to protect 
the participants.       
3.9.4 Research limits 
As much as the chosen research approaches are deemed appropriate for 
this study the researcher is aware of the inherent limits of the 
methodologies. The researcher undertook a “pilot” study to inform the 
design of the actual study and that process required significant resources 
which meant that more time was devoted to data collection and 
transcribing it consequently generating huge amounts of data and some 
of it was not needed.  
 
The critics of case-oriented research (COR) design point out that the 
proponents of COR find it difficult to cope with huge volumes of data (see 
Bellamy & Perri, 2009; Henn et al., 2009). This makes the research 
strategy susceptible to the problem of producing particularistic insights 
and the relevance of its findings maybe unclear in a different setting 
(Bellamy & Perri, 2009). Henn et al. (2009) contend that this situation 
leads to a lack external validity or generalisability of the research 
findings. Similarly, Remenyi et al. (1998) argue that case-oriented 
research studies lack objectivity and rigour.  
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Bryman (2008) highlights that the main question that has been subjected 
to much debate regarding the use of case-oriented research approaches 
concern its validity and its generalisability. Henn et al. (2009) agree that 
the issue of the extent to which inferences maybe drawn from case-based 
research approaches is a contentious one and can be decisive for 
researchers of such a research design. Maybe in defence of these 
criticisms levelled against COR, by design the research approach seeks to 
understand contemporary phenomenon and in that regard the idea of 
objectivity is not something that this research is aiming to achieve 
although critical realism suggests both elements of subjectivity and 
objectivity (Farquhar, 2012).  
 
In a further attempt to counter the arguments against the COR Henn et 
al. (2009); Bellamy & Perri (2009); Bryman (2008) discuss the idea of 
trade-offs in social science research. Indeed, a shortfall in identifying the 
general law of small born-global bio-tech firms is a small price to pay in 
favour of the richness and depth of theoretical insights of these types of 
firms which can be gained through a well-designed and well-executed 
case-study. Nonetheless, the research could have benefited from the use 
of a quantitative research technique such as SPSS computer software.  
 
As the study aims to explain the relationship between innovative 
capability development and variables that include business and social 
networks, trust, inter-organisational collaborations, tacit and explicit 
knowledge, prior learning and absorptive capacity the researcher is aware 
that the use of SPSS to generate chi-square tests and frequency tables 
would have enhanced the research findings as well the accuracy and 
validity. More importantly, the researcher would have identified the level 
of impact each variable had on the process of developing innovative 
capabilities for small born-global bio-tech firms.  
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An attempt was made to generate data by distributing a questionnaire 
using survey monkey but not enough responses were collected (see 
appendix 6 for a sample of a questionnaire). Over a period of about four 
months only two responses were returned. As time was of the essence for 
this study the questionnaire technique was subsequently abandoned. 
Another reason for dispensing with the use of a questionnaire was that 
the nature of the study required the researcher to develop a deeper 
understanding of the research phenomenon and in that regard the use of 
questionnaires would not have sufficed.  
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Chapter 4 
4. Research findings 
This chapter of the thesis provides the reader with the research findings 
based on within and across case analysis. The chapter culminates with the 
proposal of a new model of knowledge and innovative capability 
development. The new model uses seven propositions to explain the 
connectivity of building blocks of networks, competence & goodwill trust, 
inter-organisational collaborations, tacit & explicit knowledge, prior 
learning & absorptive capacity in the knowledge supply-chain of small 
born-global bio-tech firms. The also explains their impact on the process 
developing innovative capabilities for these bio-tech firms.  
 
Baxter & Jack (2008) suggest a number of ways for reporting the findings 
of case-study research. The scholars suggest that findings can be 
reported by telling the reader a story, by providing a chronological report 
and by addressing each proposition. Benefits associated with remaining 
focussed and avoiding collecting large amounts of data attracted the 
researcher to tell a story about what is happening in the firms on which 
the case-study is based as well as the use of propositions as a means for 
reporting the research findings. Yin (2009) affirms that “theoretical 
propositions stemming from “how” and “why” questions can be extremely 
useful in guiding case-study analysis”. The researcher also utilises the 
principles of an analytical strategy by developing case descriptions for 
each case. The main aim is provide the reader with rich data about the 
research subjects.  
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4.1 Case findings  
This part presents detailed findings within each case. It describes the 
actions of small born-global bio-tech firms regarding how they develop 
their innovative capabilities. This is consistent with Eisenhardt (1989, 
p.540) who suggests that “within case analysis typically involve detailed 
case-study write-ups for each site”. 
 
Indeed, this part of the study narrates the actions of individual firms 
which informs the reader about what is happening in the complicated 
world of small born-global bio-tech firms (Huberman & Miles, 1994). In 
other words, the researcher is making the complicated situation of the 
research phenomenon understandable by reciting the collaborative 
actions of each bio-tech firm and by explaining how they fit in together 
according to the concepts of dynamic capabilities and the network theory. 
Scholars Gersick (1988) and Pettigrew (1988) acknowledge that although 
within case analysis is purely descriptive the research technique is crucial 
in terms of enabling the reader to gain an insight into the research 
phenomenon. More importantly, within case analysis assisted the 
researcher to cope with a large volume of data collected from the 
research sample (Eisenhardt, 1989).  
 
Further, Voss et al. (2002) suggest that following a detailed account of 
the case-study companies the next thing would be to analyse patterns of 
data within each case. In light of this section 4.3 provides a cross case 
synthesis of collected data (Yin, 2009; Huberman & Miles, 1984). In Voss 
et al. (2002) constructing an array or display of data is seen as a very 
useful way of presenting it. As such, table 9 on p.143 provides an array of 
data describing small born-global firms and science institutions. The data 
on science institutions is provided to give the reader more information 
regarding their assumed position in the process of capability development 
in terms of facilitating a platform on which small born-global bio-tech 
firms develop their innovative capabilities.  
143 
 
The main aim for doing within case analysis following a general outline of 
the activities of the sampled firms was to become intimately familiar with 
each bio-tech firm particularly all the elements that influence their 
capacity to generate fluid scientific knowledge (Stake, 2005). This 
assisted the researcher to uniquely map out the pattern of each case prior 
to generalising across the cases (Eisenhardt, 1989).    
 
Table 9: Description of Small Born-global Firms comprising the sample   
Firms    Origins Bio-tech Activity Year 
Founded 
No. of           
Interviews  
 
Critical 
Pharmaceuticals  
 
UK-based 
biotechnology 
spinout company 
from the University 
of Nottingham  
 
Involved in drug delivery technologies for the sustained 
release and nasal delivery of proteins and peptides and labile 
or insoluble small molecules. Delivers Advanced Therapeutics  
 
2002 
 
6 
 
XenoGesis Ltd 
 
UK based founded 
after the closure of 
AstraZeneca 
 
Specialises in pre-clinical drug metabolism and 
pharmacokinetics (DMPK), quantitative bio-analysis and 
expert interpretation 
 
2011 
 
6 
 
Haemostatix Ltd 
 
Spin-out firm from 
the University of 
Leicester – UK 
based 
 
Develops a pipeline of haemostats based on its new class of 
active ingredients that replace thrombin. The firm also 
commercialises its new technology platform based upon a 
specific peptide sequence that binds to fibrinogen – a protein 
essential to the formation of clots.  
 
2003 
 
3 
 
Sygnature 
Discoveries 
 
Founded in BioCity 
Nottingham  
 
Provides integrated drug discovery services. The company is 
also involved in a wide spectrum of drug discovery 
programmes and the outsourcing of discovery projects to 
contract research organisations (CROs) 
 
2004 
 
3 
 
BAST Incl. 
 
Spin-off business 
launched after the 
announcement of 
the closure of the 
AstraZeneca 
 
The pharmaceutical company is involved in a new drug 
development process known as Model-based Drug 
Development (MBDD) where investment decisions are 
supported by a simulation of the probability of success. The 
company is part of a collaborative network of twenty four 
other organisations with the East Midlands and 
internationally.  
 
 
 
2010 
 
6 
 
Science 
Institutions 
  
Networking Activity 
  
 
BioCity 
Nottingham 
(BCN) 
 
A result of 
collaboration 
activities between 
Nottingham Trent 
University, The 
University of 
Nottingham and 
EMDA 
 
UK’s largest bio science innovation centre. Operates as an 
incubator for small firms within and outside the region. 
Currently houses advanced equipment and technology in 
over 12,000m2 of bespoke laboratory and office space and it 
is also the site of a new nano-technology and micro-
technology fabrication facility for the East Midlands region 
(BioCity, 2012).     
 
2003 
 
1 
 
Medilink East 
Midlands 
 
Part of Medilink UK 
which was 
established in 1999 
operating in other 
parts of UK 
 
It is a life science industry association, whose aim is to help 
companies establish, develop and grow and connects them 
with other global players. Its network consists of more than 
4,000 contacts in over 600 organisations represents all 
aspects of the sector, including private and public 
institutions; from multinationals to high potential start-ups, 
as well as the NHS and universities. 
 
2004 
 
2 
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Case 1 – Critical Pharmaceuticals Ltd (CP) 
Year Important events  
 
2002 Critical Pharmaceuticals was established 
2004      Since CP started trading 2004 was the first year the firm secured          
 Seed funding in the region of £1.5m 
2005 CP received funding (£1.4) from Quester Capital  
2007 Lisbeth Illum was appointed as the CEO 
-Working in collaboration with scientists at the University of 
Nottingham CP announced the completion of a series of pre-
clinical studies investigating the effect of supercritical CO2 on a 
therapeutically relevant protein – human growth hormone 
(‘hGH’). 
-CP also announced the successful completion of proof of 
concept of two single shot vaccines developed using their 
NanoMix™ technology. 
2008 CP was awarded two CASE awards by the Biotechnology and 
Biological Sciences Research Council (BBSRC) 
-CP was further awarded a £33000 grant by the Bioknex 
Industrial Partnership Scheme to help the firm to assess the 
potential of drug discoveries  
-CP presented their discoveries at the Controlled Release 
Society’s Annual Conference in New York 
-Potential investors endorsed CriticalMix drug delivery 
technology and CP’s own pipeline potential 
2009 CP secured the sale of their anti-obesity nasal drug with Global 
Health Ventures Inc. (OTCBB: GHLV), a HealthCare Technology 
merchant bank 
2011 CP entered into collaboration on the development of a novel 
injectable sustained release drug delivery system with 
PolyTherics Limited which is expected to run until 2014  
2012 Critical Pharmaceuticals and the University of Nottingham jointly 
developed Nano-Enabled Nasal Spray for Osteoporosis 
-The Technology Strategy Board and the Engineering and 
Physical Sciences Research Council (EPSRC) provide grant 
funding to support the £545,000 project.  
 
Pera Innovation 
Park 
 
 
Part of a Europe 
network established 
65 years ago to help 
UK & Europe 
businesses 
 
Pera Technology helps hundreds of companies across Europe 
and beyond to harness the potential of science and 
technology to create new and valuable products and 
processes to create sustainable, valuable businesses. The 
innovation centre also provides integrated R&D services for 
firms of all sizes  
 
2008 3 
Midlands 
Enterprise 
Europe Network 
Part of Enterprise 
Europe Network 
(EEN) 
The Midlands Enterprise Europe Network is a local node 
within a network of 600 regionally based contact points 
covering the entire European Union and beyond. The 
Enterprise Europe Network is the official EC business support 
network for business cooperation and technology transfer, 
providing organisations with access to technology transfer 
for technological cooperation, research, licensing, 
manufacture and joint venture agreements. 
2008 3 
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A narrative of CP 
Critical Pharmaceuticals Ltd was formed as a spin-out company from 
Nottingham University (NU) in 2002. The bio-tech firm was established by 
two researchers in chemistry and pharmacy (BioCity, 2012). The co-
founder of the firm, who is a world-renowned scientist in the field of 
super-critical fluid processing, discovered that super-critical carbon 
dioxide (scC02) could be used to mix sensitive substances into the 
polymers. According to its CEO this was the groundwork that the firm 
needed to take-off. The firm produces polymers that are used in medical 
devices and for drug delivery on a research contract basis. The CEO 
explains that CP is now independent and it no longer receives any support 
from University of Nottingham. In 2004 the firm received seed funding 
from Mobius – a regional funding institution and it moved into new 
premises following the formation of BioCity Nottingham (BCN).  
 
As the company further developed its technology and products it attracted 
more funding from leading UK investors including: Catapult Venture 
Mangers, The Lachesis Fund, e-Synergy, East Midlands Business Angels 
and The Wellcome Trust as well as other business angel investors (Critical 
Pharmaceuticals, 2012). The company further received funding from the 
Wellcome Trust which enabled the firm to transform the delivery of ‘hGH’ 
by enabling non-invasive delivery. ‘hGH’ is a drug which treats human 
growth disorders in adults and children. For Critical Pharmaceutical 
funding performed a key part in terms of unlocking its innovations.  
 
Business & social networks 
The firm’s established business and social networks considerably 
improved its capabilities to make new innovations. For CP, BCN is seen as 
important platform which enables connections with complementary 
businesses to actually happen. According to the CP’s business 
development officer (BDO) his personal connections have also been 
valuable to its (CP’s) economic development.  
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He particularly refers to other scientists who he met at university, and 
those who he worked with in his previous employment, as sources of 
science knowledge. He explained that they are often in touch and they 
frequently exchange ideas and problem solving techniques in science. 
Moreover, the top management team (the CEO, BDO & Science Director) 
who are the key informants for this study collectively agree that CP 
access financial support, expertise, marketing, PR, and scientific 
knowledge from tenants at BCN and from their global personal and 
business networks to back-up their business operations. The BDO 
continued to explain that science knowledge and financial support are 
essential resources that are necessary to improve operational efficiency if 
one is to achieve the firm’s corporate goals.  
 
In addition to this, its head of process development confirmed that 
networks are important for CP in the sense that they enable the firm to 
access scientific capabilities that are not available internally. He stated 
that they facilitate both domestic and international links with other firms, 
academic institutions, investors and research centres. He said this 
enables CP to acquire important science-related information, knowledge 
and to secure the much-needed funding.  
 
Alliance-development  
According to Harryson et al. (2007) innovation is a learning process which 
occurs by participating in open collaboration involving a wide range of 
actors as opposed to operating as a lone ranger in a laboratory. It is 
widely accepted in the literature (see Chesbrough, 2003a, Freeman et al. 
2013, Polanyi, 1948) that innovation is based more upon personal 
interaction, emulation and joint learning among a variety of actors than 
upon the pure upstream and quite isolated technology development 
process. A look into the itineraries of the top management team validates 
that they engage in international conferences deliberately convened for 
the purpose of encouraging collaborative partnerships and learning.  
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For example, in April 2013 the CEO of CP said that he attended BIO 
International Convention in Chicago in the US, the head of process 
development disclosed that he presented case studies on the delivery of 
biological drugs at an American Association of Pharmaceutical Scientists 
National Biotechnology Conference in May 2013 and the head of Pre-
clinical and Clinical Development at CP revealed that he attended the 
Biosimilars to Biobetters conference in Stevenage, UK in May 2013. Based 
on the top management team’s participation in a wide range of 
networking activities in science-themed conferences, it is clear to see that 
CP aims to hone/sharpen its drug delivery processes by receiving 
feedback from world renowned scientists, well-established biotechnology 
firms and research institutions. This is consistent with Roudini et al. 
(2012, p.129) who insists that in global networks, “knowledge flow and 
exchange become possible through business connections and they foster 
communication between included groups, and establish a crucial channel 
for resource acquisition”.  
 
Similarly Yi et al. (2008) suggest that, integrating knowledge from diverse 
context is necessary to a firm’s ability to generate new information which 
is essential for innovation. To underscore CP’s intentions of developing 
strategic alliances the pharmaceutical company is involved in a joint 
collaborative project with PolyTherics Limited ("PolyTherics") estimated to 
be worth £700 000. The main purpose of the alliance is to allow the 
sharing of resources, assets and competences that are needed to enhance 
drug discovery activities. The science programme commenced in 2011 
and it is expected to run until 2014. PolyTherics Limited is a London 
based company which uses biomedical polymers to optimise 
pharmaceuticals, in particular biopharmaceuticals, for the treatment and 
cure of the world’s most debilitating diseases. Their expertise and 
knowledge capabilities complement Critical Pharmaceuticals’ technology of 
human injectable drugs.  
 
148 
 
According to Jordan the Head of Preclinical and Clinical Project 
Management at CP the pharmaceutical company engages in collaborative 
activities that are aimed at driving processes in drug delivery. In addition 
to the pharmaceutical company’s collaboration with PolyTherics Limited it 
works in partnership with some of the leading institutions within the East 
Midlands. These include: the University of Nottingham (UN) and 
Nottingham University Hospitals NHS Trust to develop its innovative 
formulation known as ‘teriparatide’. The CEO of CP expressed that the 
company was excited with the idea to work with internationally 
recognised clinicians and scientists at The University of Nottingham and 
Nottingham University Hospitals NHS Trust to rapidly develop a highly 
innovative formulation of ‘teriparatide’.     
 
Trust-building 
According to Granovetter (2005) close knit ties enable a strong element 
of trust which makes it possible for the exchange of vital resources to 
take place. Both the CEO and the BDO at CP emphasise that they 
exchange scientific knowledge with those partners who they trust. They 
both claim that without trust, project-based collaborations may not be 
productive. The head of process development explained that most of the 
companies they work with have people who they have met in transitional 
encounters (seminars, conferences and workshops). In transitional 
encounters where usually there is a loose agenda the BDO suggests that 
tacit knowledge can be exchanged on a small scale and he said in most 
cases this marks the beginning of the trust-building process. This 
endorses Granovetter’s (1973) dated but influential study concerning 
weak and strong ties. Granovetter argues weak network ties can be 
productive in the sense that they allow very detailed and useful 
information to flow between individuals. Furthermore, the BDO 
maintained that CP develops trust with partners based on their 
competences, reputation and he explained that the more you work with 
them the more you get to know them.  
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He elaborated on this saying that CP uses small projects as a way of 
testing the trustworthiness of its potential partners. The company’s CEO 
concurred with this expressing that CP conducts due diligence on its 
potential business partners with a view to predict or construct a picture of 
their likely behaviour based on their previous dealings. He related the 
process of trust-building with potential partners to experiments in a 
science lab where one tries different science mathematical combinations 
until he/she comes up with the right solution which provides acceptable 
results. 
 
Knowledge creation  
CP generates its knowledge by engaging in science-related research 
programmes with its trusted partners particularly, the clients who 
contract them carry out drug testing functions. Data generated in 
research programmes, that involve CP and its clients/partners, is shared 
via a central data pool which can only be accessed by authorised 
individuals. The Head of Preclinical and Clinical Project Management 
explained that, they openly share and exchange ideas, business processes 
and scientific knowledge with all the companies taking part in a specific 
science project/programme. These he said are either their clients or 
collaborating partners. He said that openly sharing science data is 
anchored on trust built over a number of years with their partners/clients.  
In their efforts to continuously generate knowledge CP’s CEO said that the 
company sponsors PhD students. This is consistent with the literature 
Lawton-Smith (2006) argues that universities perform a leading role; they 
foster a steady supply of scientific labour, which invaluable to the 
knowledge economy. Students work as understudies to experienced 
scientist at CP. To harness all the knowledge generated in such joint 
collaborations CP enters into a binding contract with the students. The 
CEO explains that the science knowledge generated by students is 
protected and it becomes part of CP’s intellectual property.  
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The intellectual property agreement they enter into with the student 
allows CP to have access and to retain the ownership of all lab-based 
experiments, outcomes, and research findings. 
 
Prior-learning & Absorptive Capacity 
The founder of CP is an academia and a world-renowned scientist in the 
field of super-critical fluid processing with 15 years of experience in the 
life science sector. According to a University website profile where the co-
founder also works as a professor, it is publicised that he is the Chair of 
Chemistry at the University. He has published over 300 papers in high-
level scientific journals. Structurally, the top management team at CP 
consists of well-experienced scientists who have international connections 
and they all share the same view about the world of science. Table 10 
below illustrates the cumulative experience of the top management team. 
 
Table 10: The top management team and the board of directors of CP 
Name  Title Background/Experience 
David Gouch Chairman Founded or co-founded 6 companies one of which, Vectura, has been 
successfully floated on AIM and moved to the main exchange in 2007. He also 
has over 30 years of experience as a senior manager, consultant, entrepreneur 
and investor and has raised, or helped to raise, close to £100m in equity 
capital and VC funds 
Gareth King PhD CEO Experienced in the development and implementation of commercial strategy 
through deal making, business development and building strong collaborations 
Terence Chadwick PhD Non-Executive Medical 
Director 
Experienced in internal medicine, endocrinology developing medicines for 
respiratory, metabolic and CNS diseases. 
Professor Steve Howdle 
PhD 
Founder and Chief 
Scientific Officer 
He is a world-renowned scientist in the field of supercritical fluid processing 
with over 15 years’ experience in the field. 
Alan Baines Financial Director He was senior partner in an internationally renowned business development 
firm  
Graham Ward Non-Executive Director Has 16 years’ experience in consulting and from 1988 to 2004. Graham was a 
Director Pricewaterhouse Coopers and Deloitte. He served as a Non-Executive 
Director with Nottingham City Hospital  
Andrew Naylor PhD Head of Process 
Development 
Andrew has over 9 years’ experience of polymer synthesis and processing in 
supercritical fluids. He manages a range of internal and external collaborative 
R&D projects 
Faron Jordan PhD Head of Preclinical and 
Clinical Project 
Management 
has several years' experience working in contract research as well as 
experience in quality assurance for a biotechnology company where he was 
responsible for GLP compliance 
Professor Lisbeth Illum 
PhD 
Scientific Advisor Lisbeth is a world-renowned scientist and entrepreneur in the field of novel 
drug delivery systems for difficult drugs, such as peptides and proteins 
 
Professor Stephen 
Shalet 
 
Consultant Endocrinologist 
 
Stephen is a world-leading expert in the treatment of children and adults with 
endocrine disorders 
Professor Martin Savage Consultant Endocrinologist Professor Savage is a world-leading expert in the treatment of children with 
endocrine disorders. 
Derek Riley Qualified Person (QP) Derek is a senior pharmaceutical executive with extensive global experience in 
pharmaceutical research and development, regulatory compliance, quality 
assurance, quality control and facilities qualification / validation 
Andrew Burgess Process Engineer Andrew is a Chemical and Bio-Process engineer who has been working in the 
field of supercritical fluids for over 10 years. 
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The CEO of CP claims that the idea to have a top management team that 
has experienced, multi-skilled scientific, clinical and commercial 
leadership team directed by a board of international standing with a broad 
base of expertise and deep knowledge in science is to enable CP to have a 
good understanding and an awareness of the capabilities that are required 
to enhance innovation and improve firm productivity. He insists that the 
firm’s top management team performs a decisive role in unlocking its 
innovation conundrum. He further elaborates that their (top 
management) years of experience in the biotechnology sector 
considerably enhanced their capacity to make important drug discoveries.  
 
Thus, a good understanding of science by key people in the business 
increased the CP’s chances of making rapid progress in developing nasal 
administered drugs. Oviatt & McDougall (1994) express similar views 
arguing that the previous experience of the management team has 
affirmative influence in enhancing a firm’s formation of capabilities. 
Admittedly, one of the advantages of a well-networked top management 
team to CP is that the bio-tech firm can potentially tap into their networks 
and make points of entry into elements of the global innovation systems.  
CP has a strong advisory board and the role of the board is mainly to get 
connected to international competency. Other possibilities for getting 
contacts include personal networks, through academia and through being 
exposed internationally at conferences. CP gets exposed a lot through EU 
projects and conference.  
Case 2 – XenoGesis Ltd 
Year Important events 
 
2011 XenoGesis was founded following the closure of AstraZeneca -   
its founder was made redundant by AstraZeneca in 2011 
2012 XenoGesis top management attend Bio-Spain 2012 – an     
international meeting on Biotechnology 
-The firm announced a positive first quarter in its first year of   
trading 
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 -XenoGesis Won the Best Start-up award at the 2012 Medilink 
Innovation Day  
 -XenoGesis enters into a strategic alliance with XenoTech a US-
based company 
2013 XenoGesis was awarded a grant for research from the 
government-backed Biomedical Catalyst Feasibility grant 
-XenoGesis attended Bio-Europe Spring’s 7th Annual 
International Partnering Conference in Barcelona  
-Dr Richard Weaver the founder of XenoGesis attends the 
International Society for the Study of Xenobiotics (ISSX) 
Workshop on The Role of Drug Metabolism in Immune-Mediated 
Drug Toxicity in Boston, USA 
-With its US strategic partner XenoGesis co-sponsored a booth 
at the exhibition in Boston, USA 
-XenoGesis introduces two new key physicochemical assays: 
kinetic solubility and logD7.4 
-Dr Iain Beattie an experienced mass spectroscopist joins 
XenoGesis team in August 2013  
 
 
A narrative of XenoGesis 
XenoGesis Limited is the brain child of Dr R Weaver who is an ex-
AstraZeneca employee. AstraZeneca the world’s fifth largest drug 
company, which develops treatments for lung and breathing problems, 
closed its research facilities in Loughborough as part of a global 
restructuring strategy. This move resulted in the loss of 1,200 jobs. The 
restructuring exercise by the giant drug company forced Dr Weaver to set 
up his own business. The scientist said that this gave him the opening to 
start-up his own business something that he has always wanted to do as 
such, the termination of his employed acted as a catalyst. He expressed 
that, “where there is a threat, there is also an opportunity”. He started his 
contract research organisation (CRO) with limited resources. He rented a 
laboratory facility at BioCity Nottingham Ltd (BCN). Despite Dr Weaver’s 
association with AstraZeneca there is no connection between his company 
and his former employer. Based at BCN – the region’s science incubator, 
XenoGesis specialises in pre-clinical drug metabolism and 
pharmacokinetics (DMPK), quantitative bio-analysis and expert 
interpretation.  
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The company’s laboratory tests have shown how the human body might 
affect the way a drug behaves. XenoGesis received rewards as recognition 
for its achievements. In July 2012 the bio-tech firm was awarded the Best 
Start-up Award at the East Midlands innovation awards ceremony hosted 
by Medilink. The pharmaceutical company operates as a CRO advising its 
clients on how to modify the chemical structure of a compound so as to 
make it more ‘drug-like’. Its founder and CEO claims that the company’s 
ability to utilise sophisticated science combinations makes its services 
attractive to global drug companies. The company signed-up several 
international clients including pharmaceutical companies from the USA 
and Europe in its first year of trading. XenoGesis has three revenue 
streams at the core of its business: (1) Pre-Clinical Drug Metabolism & 
Pharmacokinetics (DMPK / ADME) lab services, interpretation and 
recommendation, (2) Quantitative Bio analysis, (3) Expert Drug Discovery 
DMPK Consultancy.     
 
Business & social networks 
The operations manager of XenoGesis states that they have close 
relations with their strategic business partners and in most cases they are 
long-term. He maintains that close business ties are crucial to the firms’ 
continued development and growth. The founder of XenoGesis considers 
his connections which he established during his time at AstraZeneca as 
vital to the success that his company has enjoyed since its inception. At 
BCN the firm has developed a strong network consisting of former work 
colleagues who have started their bio-tech ventures, investors and 
innovation science experts. XenoGesis’ operations manager suggests that 
the firm has grown from strength to strength. In November of 2011 it 
moved to a bigger office space at BCN. Its founder and CEO explained 
that: 
I read about the support being offered following the AstraZeneca R&D 
Charnwood closure announcement and over the past year I’ve received 
fantastic advice and encouragement from the BioCity team.  
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The highly reputable address, the support infrastructure, the access to 
shared facilities such as the Biotel laboratory and being close to so many 
other innovative companies in the sector means that XenoGesis will have 
the best start and I’m really excited about its future. 
 
Thus, the founder’s structural social capital performs a decisive role in 
enabling XenoGesis to acquire financial resources, crucial scientific 
knowledge, and technical know-how. Furthermore, the CEO maintained 
that, “it is quite unusual for a new company working in this field to get off 
to such a flying start but we have the support of a strong Board of 
Directors and staff team, and several international partners”. In March of 
2012 Mobius Life Sciences Fund which is part of XenoGesis network at 
BCN announced an investment in the firm citing its fast growth as the 
main reason for investing.  
 
More importantly, Mobius funding came with help and support from 
experts at BCN which was targeted at ensuring XenoGesis’ continued 
growth and improved drug discovery activities. Support and funding are 
part of XenoGesis’s structural dimension and this is similar with the other 
4 firms sampled for this study which benefit from the support offered at 
BioCity. The Director of the Mobius Life Sciences Fund Dr Glenn Crocker 
explained more about why his organisation invested in XenoGesis:  
XenoGesis has already shown its growth capability by winning significant 
contracts and exceeding its early targets. The highly experienced and 
committed management team are focussed and passionate about what they 
do. They are ambitious but also realistic in their plans. I believe XenoGesis 
is just the kind of venture Mobius Life Sciences is looking to invest in.   
 
The achievement of funding was noted as an important breakthrough for 
XenoGesis which enabled the young firm to advance its drug development 
processes. 
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Alliance-building 
The BDO at XenoGesis believes that building strategic alliances is a very 
important strategy which enables the firm to bridge its knowledge gaps. 
The drug company works with a number of partners which include: 
XenoTech LLC, JD International Consulting, PRECOS, and Cypex. To this 
end the founder and CEO said that:  
Working in partnerships and collaborative projects increases our level of 
innovation by bridging the gap between our internal knowledge base and 
the threshold level required to discover new drugs. We also benefit in terms 
of low operational costs from our strategic partners and from those 
partners who have a good reputation we get access to their markets and 
their expertise.  
 
As a strategy for building strong alliances the firm incorporated directors 
from other firms to work in an advisory capacity directing drug discovery 
processes. XenoGesis does not only work with scientists within its locality; 
the entrepreneurial bio-tech firm aspires to develop links with reputable 
international bio-tech firm, research institutions and science labs. In the 
recent past its CEO together with the chief science officer were involved in 
conferences on biotechnology and science in London and Barcelona that 
took place in June of 2012. The conferences provided the firm with an 
opportunity to network with potential partners in the region of 80 
international experts in the field of drug metabolism. According to its 
science director this partnering exercise considerably increased the firm’s 
possibility to develop productive alliances. The widening of the XenoGesis’ 
business and social connections (structural and relational dimension) has 
enabled the firm to grow at a fast pace and to achieve scientific 
excellence and innovation.   
 
 
 
 
156 
 
Trust-building 
XenoGesis builds trust with its business partners by conducting due 
diligence. The company gathers intelligence about the level of technical 
abilities and reputation of their potential partners. In the majority of cases 
XenoGesis obtains this type of information from people who may have 
worked with their potential partners before or from their landlord - BCN. 
XenoGesis’s CEO said that, “you form a partnership with someone you 
know very well and trust based on your previous interactions with them 
or they may have been recommended to you by the people who have 
already trust”. The company’s operations manager further adds that they 
look for partners who have higher skills and are well-established or well-
respected in the bio-pharmaceutical industry. Similar to CP XenoGesis 
tests the trustworthiness of a partner by engaging in smaller projects and 
according to its operations manager they look for signs and signals which 
help to predict their likely behaviour. She explains that it is very 
important to try different combinations to ensure that you end up working 
with people who have the same scope and direction with the company.   
 
Knowledge creation 
When it comes to knowledge-sharing between XenoGesis and its various 
partners trust is seen as the main catalyst. A significant proportion of 
XenoGesis business partners consist of scientists who are known to the 
top management team. The CEO of XenoGesis said that he feels 
comfortable to share ideas and science-related data with his personal 
connections that he established during his time at AstraZeneca. The 
science director of XenoGesis expressed that the majority of the tests that 
they carry out are in the public domain (information is available to 
everyone). Together with the CEO they contribute to national and 
international scientific conferences by publishing science-related research 
papers that are accessible to other scientists. XenoGesis is also trying to 
develop its own science combinations which are specific to its business.  
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The science director said that data about their own science combinations 
remains confidential and can only be accessed by the people who have 
the right to view it.   
 
Prior-learning & absorptive capacity 
Cumulatively, XenoGesis has more than 70 years of combined experience 
in the pharmaceutical industry. The top management team consist of 
people who are educated to a PhD level and have considerable science 
experience obtained from their previous engagement with large 
pharmaceutical companies. Table 11 below illustrates their experiences in 
biotechnology. 
 
Table: 11 The XenoGesis core team 
 
 
 
 
Name Title Background/Experience 
Richard Weaver PhD Founder and 
Managing Director 
Richard has held Project leader posts with a track record of delivery at 
early and late stages of the Drug Discovery process within AstraZeneca. 
He has also held multiple prestigious global roles 
Dr. rer. nat. Manfred G. 
Ismair 
Chief Scientist Manfred Ismair is an experienced scientist in the fields of DMPK, 
molecular/cell biology and drug transport 
Dawn Parkins Operations Manager Dawn Parkins is a Regulatory Affairs Professional and Research Scientist 
with over 20 years’ experience working in commercial, academic and 
local government research institutions 
Glenn Crocker PhD Non-executive 
Director 
Glenn Crocker is also Chief Executive of BioCity Nottingham Ltd, which 
he has grown over 9 years to be the largest bioscience incubator in the 
UK. BioCity creates, develops and provides investment, facilities and 
support to early stage life science companies 
John Dixon PhD Non-Executive 
Director 
John Dixon has 36 years’ experience in Pharmaceutical R&D in several 
therapeutic areas. He was Head of Medicinal Chemistry for 20 years at 
Fisons, Vice President of Preclinical R&D in Astra Charnwood for 4 years 
and Vice President of Drug Discovery at AstraZeneca Charnwood for 9 
years 
Nigel Boughton-Smith PhD Scientific Advisor Nigel Boughton-Smith has worked in the pharmaceutical industry for 
over 35 years and has a comprehensive knowledge and expertise in 
both drug discovery and early development. As the Discovery Leader in 
multidisciplinary Global Emerging Product Teams in AstraZeneca he 
managed the progression of a portfolio of discovery projects from lead 
identification to candidate selection and contributed to the successful 
delivery of a number of candidate drugs to Phase 1, Proof of Principle 
and Proof of Concept. Nigel has led a number of teams in the in vitro 
and in vivo evaluation of chemical entities from a variety of projects and 
also in establishing robust translational biomarkers for 
pharmacodynamics and efficacy measurement in clinical trials.  
Dr. Iain Beattie   Spectroscopist  Iain has many years of experience of supporting DMPK mainly in drug 
discovery by using LC-MS/MS to detect and identify drug metabolites in 
a time frame that allows the information to influence drug design 
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The CEO of XenoGesis said that: 
One has to understand the relevance of externally acquired knowledge to 
science and experience in previous science-related assignments play an 
important part of that. Given the experience our team of experts have in 
biotechnology we are in a better position to acquire the science that is 
necessary for our service. 
 
The explanation of the role of prior-learning above also imply that in his 
company the science experiences of the top management team abetted 
the process of ‘soaking-up’ useful scientific knowledge. In the literature 
Cohen & Levinthal (1990) maintains that AC is a by-product of prior-
innovation and problem solving which is dependent upon individual ACs of 
members of an organisation. Clearly, the previous history and experience 
in life science of the top management team was crucial in terms of adding 
value to XenoGesis by assisting in assimilating useful information that 
was fundamental to its sustainable growth since its inception in 2012. In 
their study concerning the role of human capital in successful 
entrepreneurial ventures Gurău et al. (2010) observed that human capital 
available within an organisation can help the organisation to obtain 
positive business results.  
Case 3 – BAST Inc. Ltd 
Year  Important events 
 
1991 BAST Inc. first operated in Houston and Austin, Texas, USA 
As a consulting business offering population PK and PKPD 
analyses on a contract basis to pharmaceutical companies. 
-BAST was dedicated to training scientists of its clients in the 
population approach 
-Joachim Grevel the founder offered workshops on the premises 
of BAST in Austin, TX, at GlaxoWellcome in RTC, NC and in 
London, UK, at Bayer Pharma in Delaware, USA and in 
Wuppertal, Germany, and at the FDA in Maryland, USA, and at 
the Canadian FDA in Ottawa. 
-During these early years Joachim Grevel defended numerous 
applications for market authorisation at the FDA 
1997 The firm stopped trading in the US because Joachim intended to 
join AstraZeneca in the UK 
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2010 Following the closure of AstraZeneca’s Loughborough research 
site in 2011 Joachim Grevel re-established BAST Inc. using BCN 
and Loughborough Innovation centre as its bases 
2011 BAST took part in a research project on malaria vaccination 
involving international scientists  
2012 Moved from BCN to Loughborough Innovation Centre on 
permanent basis 
 -Entered a joint partnership with an accounting firm MJ Reeves 
2013  Entered into a collaboration to work with Loughborough 
University to develop new statistical tools in parameter 
estimation and optimal design, funded by grants of the European 
Union under the FP7 and IMI calls 
 -Recruited a Senior Clinical Pharmacologist   
-Recruited a senior scientist in PKPD modelling, Clinical trial 
simulation.  
-BAST is developing a state-of-the-art clinical trial simulator and 
it is inviting other companies to participate in their Advisory 
Board 
-Entered into a knowledge transfer partnership (KTP) with 
Loughborough University  
 
  
A narrative of BAST Inc. Ltd 
BAST provides strategic consulting services to pharmaceutical companies 
to assess the potential for success of projects. The probabilities of success 
and failure are derived from simulations that use mechanistic models. The 
design of experiments and clinical studies are optimised, and the 
investment risk throughout a development portfolio is quantified. The 
founder of BAST first managed a similar business under the identical 
name in Houston, Texas, from 1991 to 1998 and the company stopped 
trading in 2000. Between 2007 and 2009 the founder of BAST worked for 
Merck Serono in Geneva. His tasks and responsibilities included: providing 
technical input to project based work, coaching of junior scientists, 
modelling and simulation. This demonstrates the founders’ desire to work 
in a collaborative manner facilitating the free flow of scientific knowledge 
and technical know-how. In 2009 Dr Joachim Grevel moved to the UK 
where he briefly worked as a science consultant for a number of 
companies offering population-style data analysis.  
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Following the announced closure of AstraZeneca in 2010 he revived BAST 
in the town of Melton Mowbray in the East Midland in England. He 
assumed the role of a science director.  BAST Inc. Ltd predicts the likely 
success of studies of new drugs by analysing existing knowledge and 
data. The company also conducts silico research, either publicly or 
privately funded, in areas of oncology, autoimmunity (e.g. asthma) and 
drug delivery (nano technology). BAST Inc. Ltd offers its drug discovery 
services to a global audience on a contract basis.  
 
Business & social networks 
When BAST started operating in the East Midlands in England it occupied 
two sites namely: BCN and the science labs at Loughborough Innovation 
Centre (LIC). The Loughborough Science Park is regarded as one of the 
largest innovation centres in the UK. According to BAST’s clinical 
pharmacologist the innovation centre provides small businesses like BAST 
Incl. with access to world-leading research expertise, undergraduate and 
research students for projects and placements as well as graduates and 
postgraduates for employment.  
 
In addition to this, BCN also provides BAST with the possibility to link up 
with other pharmaceutical companies and to benefit from financial and 
expert support including research facilities it offers. BAST’s current 
structure can be described as globally dispersed. The pharmaceutical 
company works on a rhythm, which is focussed on establishing research 
collaborations with other bio-tech oriented ventures/organisations. The 
founder and science director of BAST explained that he has a number of 
personal networks that he feels have been instrumental to the 
development of his pharmaceutical company. He pointed out that his 
personal networks are wide spread.  
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In Europe he said that he established business connections in 
Switzerland, Italy, France and the UK where he was involved in a number 
of research programmes as well as in the US where BAST initially traded 
in the 90s. In Italy the pharmaceutical company is part of the Gaslini 
Network. Gaslini International is an extensive program of co-operation 
promoted by the Gerolamo Gaslini Foundation. The foundation intends to 
establish a network between the Gaslini, research organisations and 
hospitals in the Mediterranean area. Europe and America are seen as 
destinations where the firm can engage with other actors in the 
biotechnology sector to complement its drug discovery services. As part 
of BAST’s aspirations to establish international links, the pharmaceutical 
company has developed clients in multiple countries. Concerning its 
activities in terms of networking, the company is part of a collaborative 
network of twenty four other organisations operating locally (East 
Midlands) and internationally. According to its founder business networks 
have been an important part of BAST’s drug discovery process. 
 
Alliance-building 
BAST is actively seeking to develop strategic alliances with other research 
institutions (both government and private), organisations and hospitals. 
In Europe BAST engages in research programmes that are initiated by the 
Community Research and Development Information Services (CORDIS) a 
gate way to opportunities for European research and development. 
According to its founder such links are vital for scientific knowledge which 
underpins the process of drug discoveries. To underscore its founder’s 
business model, BAST established a research partnership with a Medicine 
for Malaria Venture (MMV), a not-for-profit public-private partnership 
which was established as a foundation in Switzerland. The firm was aware 
that huge amounts of resources will be required to develop modelling and 
simulation tools to assess the risk and improve decision making.  
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As such, BAST committed to contribute model-based design and decision 
support to the partnership on innovative strategies for preventing or 
treating poverty-related diseases. This demonstrates the firms’ 
commitment to engage in international activities with a view to perform a 
leading role in knowledge sharing as well as to take advantage of the 
opportunities global markets offer. This can be directly attributed to the 
founder’s experience with foreign markets given his time in Houston, 
Texas. Madsen & Servais (1997, p.569) suggest that “commitment 
decisions depend very much on experience since they are a response to 
perceived uncertainty and opportunities in the market”. According to 
Helen BAST’s senior pharmacologist the MMV’s scope of partnering was to 
involve: NGOs, Universities and other SMEs to jointly submit a project 
proposal with a view to apply for research funding from the EU 
Commission’s FP7 programme to treat malaria. Although dated but still 
relevant Wiedersheim-Paul et al. (1978) conceptualises that contract 
patterns are an important vehicle that allows for an efficient exchange of 
information and they create opportunities for knowledge transfer from 
partner firms. In the same vein, Burt (1982) and Gulati (1995) suggest 
that network research highlights the essential role inter-organisational 
ties play in terms of facilitating knowledge acquisition and its utilisation. 
To this end the Scientific Director at BAST Inc. commented: 
We share knowledge with a number of actors in the biotechnology sector 
including knowledge centres in the East Midlands such as BioCity, science 
experts from Universities, other parts of UK and Europe. The idea is to 
share best practice as well as learn from other firms how they make 
innovations      
 
Trust-building 
At BAST trust is developed in escalating series. The top management 
team at the pharmaceutical company tests the trustworthiness of their 
potential business partners by engaging them in smaller drug discovery 
projects.  
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As a contract research organisation its founder Joachim and senior 
scientists Rupert advocate for ‘open science’ where new information and 
ideas about drug discovery is honed, developed and exchanged without 
any caveats amongst the collaborating parties. Helen who is the senior 
clinical pharmacologist at BAST sums the company’s trust-building 
processes with their business partners stating that: 
In my view developing trust is a long process with a lot of little steps. 
Sometimes you chase a dead end and at times you find genuine people 
who are prepared to contribute to a lasting relationship in a meaningful way 
which eventually leads to a vital clinical outcome       
 
The process of developing trust with other firms, scientists and research-
oriented institutions in multiples countries is fraught with a wide range of 
cultural-related challenges (Lasserre, 2012). BAST’s founder is 
multilingual. He has a good command of several European languages 
which he said he uses as an effective tool in the process of 
establishing/predicting the likely behaviours of their potential 
collaborating partners. Thus, a good understanding of the values, 
assumptions and beliefs of the people one is dealing with is crucial in 
building trust and in facilitating close ties.    
 
Knowledge creation 
BAST Inc. Ltd creates knowledge in their R&D collaborations that the 
pharmaceutical company participates in. Helen explained that BAST Inc. 
Limited is in a Knowledge Transfer Partnership (KTP) with Loughborough 
University. The KTP between BAST and Loughborough University is jointly 
funded by BAST and the Technology Strategy Board. This alliance allows 
bench level collaboration using Zucker et al. (2002) description of project 
based collaborations. The structure facilitates mutual sharing of tacit 
knowledge and the collation of shared science knowledge into explicit 
knowledge.  
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This transfer and codification of knowledge at BAST was evident through 
the research publications emanating from shared work between the 
pharmaceutical company and its partners. The science director also 
explained that he presents lectures on Mechanism-based Risk Assessment 
in drug development. The lecture material includes some input (in the 
form of knowledge and ideas) from his top management team. In 2011 
the science director was part of a European consortium which was 
approved by the Drug and Disease Model Resources (DDMoRe) as one of 
the Innovative Medicines Initiative projects of the European Union. The 
science director of BAST explained that the consortium’s primary 
objective was to develop a drug–disease model library and an open-
source inter-operability framework where other scientists can have access 
to information about the use of optimal design in Pharmacometrics. The 
project comprised of 9 academic groups, 6 small and medium sized 
enterprises, and 10 pharmaceutical companies (including BAST) who are 
also members of the European Federation of Pharmaceutical Industries 
and Associations.   
 
One of the work packages for BAST and its collaborating partners was to 
develop and integrate new tools and adaptive optimal designs in 
pharmacokinetics/pharmacodynamics that employed non-linear mixed 
effect models (NLMEM). BAST’s senior pharmacologist who works within a 
project team, offering strategic advice in all aspects of Pharmacometrics 
including supporting regulatory submissions emphasised that as 
Pharmacometrics continue to increase its scope beyond population 
pharmacokinetics, design tools for more complex models and for other 
types of data, especially discrete data, will evermore be needed. She 
further stressed that joint collaborations with academics, research 
institutions and investors are very much needed in order to constantly 
generate sufficient knowledge for developing complex models for discrete 
data. Thus, knowledge creation at BAST is situational and it is contingent 
upon the structural dimension of the pharmaceutical company.  
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In that sense, BAST’s collaborative partners can influence or limit the 
pharmaceutical company’s ability to engage in productive R&D 
programmes which impact on knowledge creation, its transfer and its 
dissemination.     
 
Prior-learning and absorptive capacity 
Similar to the other four cases BAST’s top management team consist of 
well-experienced scientists and the majority of them are former 
employees of large pharmaceutical companies including AstraZeneca. 
These scientists have vast knowledge in life science. This strategy of 
forming a new venture which appears to be adopted by small global-
oriented firms was noted by Sharma & Blomstermo (2003). The scholars 
observed that because born global firms are knowledge intensive-firms 
with a very high degree of knowledge content they employ individuals 
who possess high scientific knowledge. To this end the senior 
pharmacologist explained that BAST is continuously looking to add to its 
experienced workforce. 
 
She revealed that they are expecting (as of June 2013) to be joined by a 
scientist who has diverse background and extended experience in 
applying a wide range of mathematical and computational tools to support 
decision making. The amalgamation of knowledgeable scientists was an 
important step towards developing innovative capabilities for BAST. Table 
12 on p.166 illustrates the cumulative experiences of the top 
management team that the firm assembled with a view to broaden the 
firm’s capabilities and the capacity to generate scientific knowledge from 
its project partners by ‘soaking-up’ useful data.  
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Table 12: Top management team of BAST 
Name Title Background & Experience 
Joachim Grevel, Ph.D. Founder and Scientific 
Director at BAST Inc. 
 
Former AstraZeneca employee. Consulting in Model-Based 
Drug Development (MBDD), Supervision of design and 
analysis work, Business development 
Rupert Austin, PhD Senior Scientist Ex-AstraZeneca. PK, PK/PD, PBPK modelling and simulation. 
Population data analysis 
Sheila Mburu MScs Junior Modeller  Focusses on bioinformatics, biochemistry and genetics 
Helen Walker PhD 
  
Senior Clinical 
Pharmacologist 
Experience of creating and managing a Global Team of 
senior Project Leaders during organisational change. 15 
years’ experience in Clinical Pharmacology and Drug 
Metabolism and Pharmacokinetics (DMPK) and a proven 
track record delivering within projects. 
Aaron Hayman Modelling Apprentice Good programming skills, mathematical modelling ability, 
statistics and analysing skills and interest in scientific 
research 
Garrit Jentsch PhD Senior Scientist Ex-AstraZeneca. PKPD modelling, Clinical trial simulation. 
Modeller in the Computational 
Biology Group, Discovery Sciences. 
 
According to the senior pharmacologist at BAST; bringing in experienced 
people into the top management team is crucial for the company when it 
comes to acquiring new knowledge and in enhancing the profile 
(competency) of the organisation. She further explains that experienced 
team members in their top management team have been valuable in the 
sense that they brought their contacts to the organisations that include 
investors, academics and other important government stakeholders. This 
has added to BAST’s capacity to develop essential tools for mechanistic 
models and optimal design of in vivo experiments.    
Case 4 – Sygnature Discovery Ltd    
Sygnature Discovery Limited was formed in 2004 through an MBO of the 
Synthesis department of CombiPure Ltd. Its founder/CEO has experience 
in research gained from major pharmaceutical companies including: 
AstraZeneca and OSI Pharmaceuticals; as well as in a commercial 
environment at CombiPure, where he was Managing Director and Director 
of Chemistry. The company offers integrated drug discovery solutions to 
pharmaceutical and biotechnology companies located in the USA and 
Europe. It operates within a network of expert Contract Research 
Organisations (CRO's) each specialising in their own area.  
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The company grew from five chemists to one that employs 56 medical 
chemists, vitro biologists and the majority of them have PhDs with 
considerable pharmaceutical industry drug discovery experience. This 
demonstrates that the top management team and all the employees 
share the same goals highlighting its cognitive dimension. Similar to the 
other four firms Sygnature benefited from the closure of AstraZeneca in 
2011. The firm employed experienced ex-AstraZeneca medical chemists 
to cope with the demand of services from clients in the USA and Europe.  
 
Taking the literature review into perspective, Dokko & Rosenkopf (2010) 
maintain that in addition to the knowledge and skills experienced 
individuals may have they may also bring pre-existing relationships that 
facilitates the transfer of knowledge and technical know-how. Specifically, 
the science knowledge of the company’s employees and the experience of 
the top management team made the company trustworthy to investors. 
In 2006 the firm posted a turnover of £1 million and in the same year it 
received FP6 European project funding. Three years later the firm was 
awarded a £390,000 Grant for Business Investment (GBI) award by the 
East Midlands Development Agency (EMDA) and the European Regional 
Development Fund (ERDF). The firm entered into a strategic alliance with 
Cyprotex in 2009 which was later extended in 2011 for a further 2 years. 
Cyprotex Discovery Ltd is the world’s largest specialist ADME-Tox/PK pre-
clinical discovery and it performs a leading role in developing Contract 
Research Organisations (CRO). Similar to the other four firms sampled for 
this study Sygnature Discovery’s structural dimension consists of a 
network of companies with some cognitive distance but with 
complementary foci. In the literature Nooteboom (2005) suggests that 
when absorptive capacity is aligned with organisational goals and aims it 
enhances organisational cognition. Indeed, interacting with other firms 
that may have different complementary foci at some cognitive distance 
solves what Nooteboom (2009) described as “organisational myopia”.  
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Put differently, the firm was able to bridge its knowledge gap. The main 
reason for the alliance was to expand its collaborative sales and 
marketing initiatives in order to provide a fully-integrated discovery 
chemistry/ADME-Tox/DMPK service as well as accelerate its clients’ drug 
discovery projects into development. Anthony Baxter the CEO at Cyprotex 
commented that: 
We are delighted to have extended our strategic alliance with Sygnature. 
The quality of their work and their desire to help customers achieve 
scientific success has enabled both of us to form a formidable combined 
offering in medicinal chemistry-driven integrated drug discovery and ADME-
Tox services.   
 
By using its structural and relational dimensions of social capital 
Sygnature was able to deliver innovative products and services to its 
clients as well as save significant amounts of resources in the form of 
time and financial capital. Crucially, the collaborating partners shared the 
risks associated with drug discovery. More recently, the firm entered into 
another strategic alliance with Pneumolabs (UK) Limited with a view to 
leverage its knowledge base by widening its structural dimension. The 
CEO at Pneumolabs made the following comment regarding the formation 
of a partnership between the two firms:  
Our strategic alliance combines the complementary skills of Pneumolabs, a 
“centre of excellence” for respiratory disease-focused pre-clinical research 
services, and Sygnature, a “centre of excellence” for medicinal chemistry-
driven integrated drug discovery  
 
This strategic alliance enabled both firms to share their social capital. In 
the literature social capital is defined as “the sum of the actual and 
potential resources embedded within, available through and derived from 
the network of relationships possessed by an individual or social unit” 
(Wever et al., 2005, p.1525). These types of inter-organisational 
collaborations are also evident in cases 1, 2, 3 and 5.  
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Following the partnership the company committed more resources by 
opening new purpose designed research laboratories to show its 
commitment to new drug discoveries. By committing that amount of 
resources there is sufficient evidence indicating that the firm has trust in 
its partner. This is in line with Lasserre (2012) who suggests that in global 
networks trust facilitates the exchange of vital knowledge and technical 
know-how.      
Case 5 – Haemostatix Ltd 
In 2003 a research group at Leicester University became interested in 
developing a new class of active clotting agent, or “haemostat” for the 
control of bleeding to mitigate the shortage of fresh donated platelets. 
Sarah Middleton (CEO) and Professor Alison Goodall (CSO) formed 
Haemostatix in conjunction with the University of Leicester. The 
University played a crucial supporting role in the company's early stages. 
For its relational dimension, in 2004, the company established a 
collaboration with the Scottish National Blood Transfusion Service to 
secure specialist production capability for its products. In order to 
enhance its capacity to further develop a new class of active clotting 
agent Haemostatix received start-up funding of £250,000 from The 
Lachesis University Challenge Fund and initial investment from NESTA. In 
2008 the company received further funding in the region of £1.24 million 
from a network of investors (structural dimension) that included: Spark 
Ventures, Catapult and NESTA. The CEO at NESTA, Jonathan Kestenbaum 
explained that:  
Haemostatix is a dynamic young company driving forward an innovative 
product that promises to change lives. We are excited to follow our original 
funding and look forward to working with them as the business continues to 
develop.  
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Further investments occurred in 2010 when the company received a 
Translation Award worth £409,000 from the Wellcome Trust to support 
the development of its innovative haemostat technology. The funding 
coincided with an investment of £459,000 from Spark Ventures, Catapult 
Venture Managers, NESTA, the Lachesis Fund and the University of 
Leicester as well as another new investor, Nottingham’s Mobius 
Technology Ventures. Mobius offer financial support and expert support to 
companies at BioCity that have shown potential. To further support the 
development of its innovative haemostat technology in 2011 the company 
announced that it has received an investment of £250,000 from 
Esperante. This also highlights that the firm’s structural dimension 
consists of investor companies which appear to be vital for its continued 
product development and process development.  
 
The top management’s structural and relational social capital perform a 
leading role in terms of how the company acquires financial resources and 
technical know-how necessary for the development of innovative 
haemostat technology, for example, the firm’s link with University of 
Leicester. Funding from Mobius and Nottingham City Council is meant to 
help promising start-up firms resident at BCN and it is the place where 
Haemostatix uses as its base presenting the firm with every opportunity 
to access that support and help. In the literature Kang & Park (2012) 
suggest that governments can encourage innovation and economic 
prosperity by supporting R&D projects that have the potential to generate 
social capital. When commenting about the financial support Haemostatix 
received from Mobius in 2010 Glenn Crocker, CEO of BioCity explained 
that: 
We have provided Haemostatix with a supportive business development 
environment for several years and recognise the enormous progress the 
company has made with its new product. Mobius Life Sciences Fund is 
designed to contribute to this kind of investment opportunity alongside 
major investors. 
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In addition to large investments that the company received in the last 8 
years it has a management board which consists of experienced members 
in commercialisation, science and financial investment. Its scientific 
advisory board is composed of high profile personnel from the UK and the 
EU. In that regard, the amalgamation of experienced, multi-skilled 
scientific, clinical and commercial leadership (cognitive dimension) has 
been crucial to the company’s efforts to design a cost effective alternative 
to platelet transfusion, which represents a new type of treatment that is 
safer and easier to use than the current therapy, with significant saving in 
ancillary treatments costs.  
 
To add to its already diverse management team the company is currently 
recruiting a R&D director (As of August 2012). Similarly, in the other four 
firms sampled for this study the top management comprises of 
experienced personnel demonstrating that there is sufficient evidence 
pointing to the presence of knowledge diversity (cognitive dimension) in 
all the firms under investigation. In other words, all the firms are 
benefiting from the experience and knowledge that its members they 
have accumulated from their previous roles in science related businesses 
or research programmes.  
4.2 Summary of case findings 
The findings from each case reveal some insightful data concerning the 
connectivity of various elements within the knowledge supply-chain of 
small born global bio-tech firms and how they influenced their capability 
development process. Evidently, the firms engage in multiple business 
relationships on a global scale. This business model allowed them to move 
quickly in identifying new projects and funnelling them inside the firm for 
accelerated innovation. Networks were important for all the firms at 
foundation. An extensive range of network types including interpersonal/ 
social, academic, hospital-based, industry-based, local, and international 
were mentioned across the sample.  
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Noticeably, during the first three years of life, the firms heavily relied on 
research grants, development grants and other, often personal sources of 
income.  Strikingly, the owners of the firms did not see their ventures as 
spin-offs. They argued on the basis that they independently carry out 
their operational activities without much support from their previous 
employers. Take for instance BAST and XenoGesis they were recently 
established by scientists who were forced to start their ventures after 
they were made redundant by AstraZeneca. The history of BAST was 
particularly unique in the sense that the company first operated in the 
USA in the early 1990s and it ceased to operate in 1997. The owner 
moved to the East Midlands in England to work as a consultant for 
AstraZeneca and other pharmaceutical firms. Following the closure of 
AstraZeneca’s R&D facilities in Loughborough Charnwood area he was 
made redundant and he was left with no option and BAST re-surfaced in 
2010.  
 
Three of the companies Haemostatix Ltd, Critical Pharmaceutical and 
Sygnature Discovery were founded by University professors with 
international links. What was also interesting to note is that BAST whose 
formation was different from the three firms mentioned above engages in 
knowledge transfer partnerships (KTP) with universities. Both XenoGesis 
and BAST have incorporated their former work colleagues at AstraZeneca 
into their top management teams while Haemostatix Ltd, Critical 
Pharmaceutical and Sygnature Discovery seems to be accessing human 
capital from academic institutions. This did not reveal any significant 
variations in the way all the firms designed their operational strategies. 
Specifically, their structural, relational and cognitive dimensions of social 
capital mirrored each other (see table 13 on p.174). Their innovation 
‘ecosystems’ were similar they consisted of experienced scientists, 
funding institutions, other pharmaceutical firms, academic & government 
institutions and science parks. The firms used their business and social 
contacts as sources of science knowledge.  
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Trust was the backbone to personal & inter-organisational linkages, 
knowledge-creation and its dissemination. All the firms strived to develop 
alliances with a view to collaboratively work on science-based 
programmes irrespective of the geographical location of the partner. The 
primary goal for doing this was to acquire essential resources so that they 
were not left behind given the innovation speed in biotechnology which 
according to Fontes and Videira (2012) is international in nature and is 
characterised by the presence of some global players that have a co-
ordinating function thus, being able to bring small specialised firms into 
the value chain. In a short space of time following its inception XenoGesis 
was able to enjoy a relatively high growth rate because of its global 
activities in comparison with the firms that emerged from the Universities 
measured over the same period of establishing. Irrespective of the firm 
foundings their regional innovation systems (BCN, Medilink, EEN and Pera 
Innovation) provided them with critical assets such as a strong scientific 
knowledge base and a pool of highly skilled human resources to support 
their technological entrepreneurship and to promote connections between 
the various actors (public and private).  
 
The firms displayed entrepreneurial behaviours synonymous with born 
global firms. This is observation is reflected in Freeman et al. (2013) who 
maintain that the behavioural patterns of born-globals are unique and 
highly learning-oriented. As such, the uniqueness of these entrepreneurial 
types of firms was clear to see throughout the sample. For example, the 
top management team of all the firms consisted of experienced scientists 
who had developed a web of connections worldwide. These connections 
were used as conduits to enable them to bridge their internal knowledge 
gaps and to link up the firms with other firms who have complementary 
assets. Consistent with this Ho & Wilson (2006) maintain that the 
experience of biotechnology firm founders provides for existing social 
relationships which make it easy for them to obtain the much-needed 
resources.                    
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4.3 Cross-case findings  
While more specific results can be found through within each case this 
part largely focusses on extracting patterns and trends derived from case 
findings. The principal reasons for adopting this approach were to develop 
the main propositions for this study. The main discourse is centred on the 
connectivity of various elements that include; business & social networks, 
competence & goodwill trust, inter-organisational collaborations, tacit & 
explicit knowledge, prior learning & absorptive capacity of small born-
global bio-tech firms. In discussing the connectivity of these variables the 
study traces the structural, relational & cognitive dimensions of all the 
firms as illustrated on table 13 below. With reference to the literature 
structural dimension is aligned with global network ties and their overall 
configuration (Burt, 2002; Ahuja, 2000). Relational dimension focuses on 
trust, trustworthiness, norms and obligations in a global network 
(Fukuyama, 1995; Putnam, 1993). Cognitive dimension refers to those 
resources providing ‘shared representations, interpretations, and systems 
of meaning among parties’ (Nahapiet & Ghoshal, 1998, p.244).  
    
Table 13 Structural, Relational & Cognitive dimensions 
 Critical 
Pharmaceuticals 
XenoGesis Ltd. Haemostatix Ltd BAST Inc. Sygnature 
Discovery 
 
 
Structural 
Dimension 
 
 
The acquisition  of 
scientific knowledge is 
based on the firm’s 
relationship with 
academic network and 
it’s connections with 
other firms & research 
institutions   
 
Similar to Critical 
Pharmaceuticals but 
the CEO interacts 
with his former work 
colleagues from 
AstraZeneca (global 
reach)   
 
The firm’s 
discovery activities 
are enhanced by 
venture capitalists 
(VC) and 
Technology 
Ventures such as 
Microbus   
 
Similar to XenoGesis & 
CP the firm 
collaborates with other 
small to medium size 
enterprises (SME) and 
universities 
 
Same as the 
other four firms 
and that the firm 
has strategic 
alliances with 
bioscience group 
 
Relational 
Dimension  
 
 
It is based on 
competence and 
goodwill trust and a 
long-term interaction 
with the firm’s 
academic network & 
business network 
 
Similar to CP and 
that trust is built in 
escalating series by 
trying different 
combinations 
particularly, using a 
try and error method  
 
Similar to 
XenoGesis and CP 
 
Same with the other 
four firms and that 
obligations in a global 
network of 24 other 
firms  
 
Based on 
competence & 
goodwill trust 
e.g. partnership 
with Cyprotex 
Discovery in 
2007 
 
Cognitive 
Dimension  
 
 
The firm consists of 
experienced, multi-
skilled scientific, 
clinical and 
commercial leadership 
team directed by a 
board of international 
standing with a broad 
base of expertise  
 
 
Similar to CP and 
the top management 
consists of 
experienced 
scientists in 
bioanalysis 
  
 
Similar to CP & 
BAST Incl.  
 
Same as the other 
four firms 
 
All the scientists 
have PhDs, 
post-doctoral 
experience 
gained from USA 
& Europe 
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4.4 Development of propositions  
This part of the thesis explains to the reader the connectivity of the 
formulated measures, including: business & social networks, competence 
& goodwill trust, inter-organisational collaborations, tacit & explicit 
knowledge, prior learning & absorptive capacity within the knowledge 
supply-chain of small born-global bio-tech firms. It also outlines how 
these variables influence their abilities to develop their innovative 
capabilities. The section draws upon results from cross case analysis using 
various elements within the knowledge supply-chain of born-global firms 
as the main themes. Crucially, it develops propositions which are based 
on the data obtained from each case. Secondary data is also used to 
provide some insight and to support empirical evidence. This leads to the 
construction of a new model of “Knowledge and Innovative Capability 
Development” for small born-global bio-tech firms.     
4.4.1 Business & social networks  
Business and social networks are requisite to how small born-global bio-
tech firms operate in a knowledge-intensive industry. The interaction 
between individuals, firms or organisations with varied skills, experience 
and knowledge provides synergy for small firms with limited resources by 
giving them access to a wide range of economic effects (Ho & Wilson, 
2006). Engaging in innovation ‘ecosystems’ enabled all the firms in the 
sample to access specialised input and labour, new information inflows 
and knowledge as well as access to research institutions and government 
R&D support services (Martin et al., 2011). Breschi & Malebra (2005) 
suggest that, “resource pooling, risk sharing and the formation of critical 
masses provide incentive to create a group of interlinked agents” (p.47). 
Powell et al. (1996) insists that, “when the sources of expertise are 
disparate, collaborative R&D opens an organisation's eyes to the need for 
accessing ideas and information from a variety of sources” (p.46). This 
was evident through a case by case analysis.  
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Small born-global firms link up with other firms, scientists, and research 
and academic institutions within and outside their domestic market to 
jointly develop new drugs and share technical know-how. This was 
reflected in the response given by the President at Sygnature Discovery 
when asked about why his company forge networks.  
He said that:   
Our scientists work with other scientists from other businesses, research 
institutions and strategic alliances to jointly test and develop drugs. We 
work in a highly collaborative way e.g. in our molecule synthesising 
process. We have secure data bases that we use to share data with our 
partners and clients from wherever they might be either in San Francisco or 
Santiago. We have realised that we do not have all the capabilities and we 
feel that it is important to collaborate with other companies for example, 
we collaborate with Cyprotex Discovery. They have better knowledge about 
how the drug dissolves in the body. What is important is we share 
capabilities. We feel that we have modelled our business in a “hub and 
spoke” model i.e. we are in the middle and we are networking with other 
companies.  
 
Discussing on the same topic the CEO of CP mentioned that: 
In the biotechnology sector you need various skills and knowledge, in 
addition to our in-house knowledge we collaborate internationally with 
other institutions such as universities and other companies. We have 
different levels of collaboration. We collaborate with small and large 
companies in USA and the EU. We also have intense collaborations with 
companies near to us which have expertise in areas of interest to us we 
therefore work with them to access the expertise that we do not have.  
 
His company’s head of clinical processes made similar remarks. He 
stressed that:  
Networks are very important. So personally for me it is something that I do 
a lot through conferences where I get the opportunity to meet people in the 
same field and those that I have worked with in my previous employment.  
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Networks are also important for us in terms of facilitating access to 
capabilities that we do not have here at Critical Pharmaceuticals. We link 
with other firms academic institutions and research centres. Networks are 
developed through knowing people in conferences seminars where you 
have a chance to meet people face-to-face. 
  
The science director of BAST expressed similar views saying that:  
Once a year we have an important collaboration with one company at BCN 
and there are also a lot of other collaborations with Universities e.g. with 
Loughborough University (LU). We recently received funding to collaborate 
with LU to develop a powerful science simulator. From the University we 
receive research students who will be primarily developing a new system. I 
personally have social relationships with people who I have known for a 
long time. I also engage with a number of scientists at our annual meeting 
code named PAGE. I attend seminars to brush up the ideas I have. There is 
still a network with people who have lost their jobs at AstraZeneca. Helen is 
directly involved in communicating with those people as a way of sharing 
ideas and best practice.  
 
In light of these commentaries there is sufficient data indicating that born 
global bio-tech firms develop and maintain networks with a view to 
update their knowledge bases. It is therefore, plausible to claim that 
business networks in the knowledge supply-chain of small born-global 
bio-tech firms extensively influence how they acquire expertise in 
scientific. This is consistent with Nahapiet & Ghoshal (1998) and Tsai & 
Ghoshal (1998) who suggest that social capital embedded in a firm saves 
as a conduit that facilitates positive conditions for the exchange of 
knowledge and the combination of resources to occur. When discussing 
with an expert working for a knowledge ‘hub’ the researcher got a sense 
that the business networks of small born-global bio-tech firms are an 
important source of new ideas, knowledge and business opportunities.  
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To put all this into context an innovation advisor, Rosamund Graves 
explained the role Medilink an organisation she works for saying that:  
We help firms and industry sectors access information, opportunities and 
partners on a global scale through specialist networks and business 
intelligence. On behalf of national government agencies, we deliver 
programmes to stimulate international inward investment, technology 
transfer, partnering and access to high growth global markets for UK 
companies. We provide business intelligence and contacts to help UK firms 
identify and realise international opportunities.  
 
Her statement means that her organisation provides opportunities for 
firms in the UK to forge networks/links with other companies that are 
located outside their locality. This is an important facility for bio-tech 
firms in their process of acquiring knowledge and technical know-how. As 
such, it is not misplaced judgement to infer that business and social 
networks are part of a ‘jigsaw’ puzzle that act as a foundation for small 
born-global bio-tech firms in their process of generating new information.  
 
Proposition 1: business and social networks are a catalyst for small born-global 
bio-tech firms in their process of developing innovative capabilities  
 
An interesting perspective concerning the role of networks was also given 
by Dr Thorsten of Pera Innovation Network. He outlined how they 
facilitate collaborations in the bio-tech industry in the East Midlands 
region. He explained that:   
We are in contact with a pool of science experts, research institutions, 
Universities, and various bio-tech firms within and outside the East 
Midlands. If a small firm comes to us asking for help to develop and grow 
its operations, we try to match their needs with the portfolio of companies 
that we have “we call it problem matching”. We then facilitate a network 
which is made up of three or four actors/firms and one of them has to be 
an established firm or experienced scientist or a University expert.  
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So at one given point in time we may have a number of projects that are 
on-going and these usually last for a period of three years. The bulk of 
financial support that we get comes from the EC and start-up firms usually 
receive financial support that ranges from €100 000 to €1m. 
 
The secondary data which is presented in Chapter 2 accentuates that 
social capital and network ties have a positive impact on international 
start-ups, new ventures and SMEs’ performance (Dlugoborskyte and 
Petraite, 2013; Feurest, 2010; Oviatt & McDougall, 1994; Oviatt & 
McDougall, 2005). Consistent with the remarks made by Dr Thorsten of 
Pera Innovation Network, Hughes et al. (2009) suggest that for a firm to 
gain access to knowledge and technical know-how it is essential to 
collaborate in networks and engage with a range of advisors that include: 
scientists, academia and agencies. Furthermore, this was reflected in the 
conversations with the CEO of XenoGesis Ltd, and the Science Director of 
BAST Inc. when discussing about how wide-spread their networks were. 
This is what they had to say: 
I have a good network of ex-colleagues that I used to work with at 
AstraZeneca and such connections are vital for sharing scientific knowledge 
and technical know-how. I think collaborating with other businesses and 
academia is essential in the bio-tech industry and it is important that 
businesses join to work on new discoveries. That is the way things are 
heading towards nowadays given the nature of the markets. Apart from 
using my business or social connections as conduits of scientific knowledge 
I also publish papers (CEO at XenoGesis Ltd);  
And 
I engage in networking activities both locally and internationally with firms 
and organisations in the USA, and Asia for example. I personally have some 
contacts in America where my business started way back in 1998 as a 
model based on a drug development firm (Science director at BAST Inc. 
Ltd).  
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Sally Barker an innovation expert at Medilink East Midlands expounded 
more on this by outlining how the knowledge centre creates networking 
opportunities for bio-tech firms that are located in the East Midlands 
saying:   
One of the things that we encourage small and established firms in the East 
Midlands to do is to develop links with international organisations. The 
Animal corridor from the USA will be visiting the East Midlands in March this 
year to attend one of our networking conferences. We also had an alliance 
with bio-masters who specialise in cats and dogs. Some people came over 
from USA. We also promote international trade and I think international 
links are also important as they give organisations/firms a chance to 
acquire new knowledge. People exchange knowledge, ideas and best 
practice (Innovation Expert at Medilink).     
 
The conversations with Sally Barker, the CEO of XenoGesis and the 
science director at BAST substantially underscore the essence of business 
and social networks. What is vividly projected here is a sense that in the 
globalised markets of the biotechnology sector going it alone is no longer 
the best option. This is true for small firms due to fact that it is so difficult 
for them to possess all of the necessary capabilities. Discussing on the 
same topic concerning business and social networks Gareth King PhD the 
CEO of XenoGesis explained that: 
The way business is conducted in the biotechnology industry has 
significantly changed when we started most of the knowledge was 
generated mainly in-house. Cross-function in biology seems to the way 
forward even for the world class companies such as AstraZeneca they are 
outsourcing R&D services so as to get the expertise from outside for 
continuous development and innovation. They have more links with 
academia and I think that has been very productive. Therefore, I see 
collaborations as essential for growth and innovation especially in biology 
and chemistry  
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The business and social networks of small born-global firms are a conduit 
through which they can access scientific knowledge and technical know-
how for growth, innovation and development. Lasserre (2012) maintains 
that firms can benefit in globalised networks by accessing and taking 
advantage of geographical clusters of knowledge creation and 
development. Consistent with this the head of process development at 
XenoGesis said that: 
We use companies worldwide; we have worked with a number of 
companies in Demark and USA. I would say we have a global dimension to 
our operations. We travel worldwide e.g. attending seminars in the USA, in 
Europe. We engage with global networks to access knowledge sets that we 
feel are important for our business.   
 
Considering how Critical pharmaceuticals, XenoGesis, BAST Inc. Ltd, 
Haemostatix and Sygnature Discovery conduct their business operations it 
suffices to infer that small born-global bio-tech firms use networks to 
generate knowledge in order to leverage their internal science capabilities 
with a view to make new drug discoveries. Thus, giving them greater 
flexibility needed to survive in a hypercompetitive business environment 
(Su, 2013; Andersson, 2011; Lasserre, 2012; Hisrich 2012). Furthermore, 
Schilling (2010) maintains that, “as firms forge collective relationships 
they weave a network path between them that act as a conduit for 
information and other resources” (p.158).  
 
Funding institutions were a noteworthy feature that was identified by 
small born-global bio-tech firm as one of the most important links within 
the supply-chain which enables a project/programme to take off. Mobius 
Life Sciences - an investment arm of BioCity Nottingham (BCN) work 
alongside Nottingham City Council (NCC) to provide financial support 
“seed investments” in high potential life science businesses. Crocker 
(2012) explains this more fully stating that the investment arm has a 
team of investors who are highly experienced and well-networked.  
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Based on Crocker’s remarks one gets a sense that financial support for 
bio-tech firms considerably boosts their ability make new drugs and it 
adds value to their businesses which ultimately enhances their capacity to 
innovate. The CEO at Haemostatix said this:  
While business networks facilitate the flow of novel information, financial 
investments are a “shot in the arm” in that they also provide a company 
with the opportunity to develop innovative technology. In our case we were 
presented with the opportunity to develop an innovative haemostat 
technology through a funding from Wellcome Trust CEO at Haemostatix   
          
The CEO of Haemostatix meant that business links that include funding 
institutions are the bedrock for small firms seeking to make crucial 
innovations. The funding structures seen at the Golden Triangle, Silicon 
Valley, and Boston metropolitan area are being replicated in the East 
Midlands. This is consistent with the concept underpinning the Cambridge 
phenomenon. The Cambridge Cluster Report of 2004 reports that between 
1993 and 2003 the cluster acted as a magnet attracting supportive 
infrastructure comprising of a number of key players such as venture 
capitalists firms, banks, marketing experts and patent agents.    
4.4.2 Competence & goodwill trust  
A causal link was established between trust inter-organisational 
collaborations and knowledge-sharing in bio-tech firms. Across the 
research sample there is sufficient evidence pointing to the fact that 
exchanging ideas about science was anchored on trust. The study 
identified trust as the main backbone of the knowledge supply-chain of 
small born-global bio-tech firms connecting business & social networks 
with inter-organisational collaborations and knowledge-sharing. This 
ultimately led to the development of innovative capabilities in the form of 
scientific knowledge and technical know-how.  
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Discussions with key informants across the research sample yielded that 
small bio-tech firms build trust with their collaborating partners based on 
their partner’s technical prowess (competence trust) and good intentions 
(goodwill trust) within the life science sector. The study uses Blomqvist’s 
(1997) definition of trust expressed as an “actor's expectation of the 
other party's competence, goodwill and behaviour” (p.3). Consistent with 
Blomqvist’s conceptualisation of trust Gubbins & MacCurtain (2008) insist 
that to trust an individual’s ability is to trust in his or her skills and 
competences to do the job. Discussing within this context there was 
strong emphasis, from the informants, on the fact that they will trust a 
collaborating partner when they know that they are very capable and 
skilled in a specific area of science more so, if their capabilities 
complement internal knowledge gaps. Richard Weaver the CEO of 
XenoGesis said this concerning trust-building in a network:  
We build trust by first conducting due diligence (i.e. we do a search on their 
level of technical capabilities, their reputation which we get from people 
who have worked with them before). In other words we look for partners 
who have higher skills and are well established/known in the industry. This 
is all done in a trial and error method.  
 
Paul Clewlow of Sygnature Discovery explains trust-building from a 
slightly different angle: 
Our clients and business partners build trust basing it on our competence 
and reputation. Getting acknowledged by colleagues at BioCity and 
overseas because of the quality of the work that we do is very important in 
this business and that’s all part of establishing credibility. 
 
The interpretations from these remarks are supported in the literature 
(see Blomqvist, 1997; Şengün, 2009) and they validate the relevance of 
competence (technical capabilities, skills and know-how) in the 
biotechnology sector.  
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More importantly, their meanings (Paul’s and Richard’s remarks on p.90) 
imply that trust is a necessary antecedent and a base in professional 
relationships within a business context. Networking with organisations 
that have better skills levels was an important factor in building trust in 
the biotechnology sector. Business partners were expected to have 
technological knowledge and competences. The reputation of a partner 
(moral responsibility and positive intentions towards the other) was also a 
vital factor that influenced the decision to accept a potentially vulnerable 
position - risk inherent by partnering. In the literature Welter (2012, 
p.194) claims that “trust is seen to assist in lowering the transaction costs 
of commercial actions and the risks inherent in entrepreneurship”. In the 
majority of the firms trust was built in escalating series using a “trial and 
error” method. To this end Helen Walker a senior pharmacologist at BAST 
stated that,  
In establishing strong business connections, we start with smaller drug 
delivery projects and if those are delivered we then escalate the 
collaboration to another level where we engage in more joint projects. 
 
The President of Sygnature Discovery Paul Clewlow maintained that: 
It takes time. Trust with a client is very important and it is done in little 
steps at a time. We ensure that we deliver to our clients promises that we 
have made from the day we entered into a collaborative project. We also 
ensure that information is made available to the client when the client 
needs it. We also build rapport with them. The science is really important to 
what we do but we also have to develop personal relationships especially 
with our clients in Santiago or San Francisco for example. 
 
Clearly, in the biotechnology sector trust is built in escalating series; 
different combinations involving collaborations that start with smaller 
projects with a view to establish the commitment of a potential partner 
were used.  
 
185 
 
Once trust was established the collaboration was validated and the 
channel through which scientific knowledge and technical know-how are 
exchanged was established. In a discussion with a senior scientist at 
XenoGesis on the same topic he clearly stressed that: 
There has to be utmost trust in a relationship and there has to be a benefit 
for both partners and that will lead to knowledge-sharing. If that is non-
existent that relationship will not last. 
 
And Paul Clewlow said this: 
Social networks are important as they lead to trust and strong business 
relationships. I think it is important that those relationships become the 
backbone to business relationship as well as using our scientists to talk with 
scientists from other firms through encouraging them to attend 
collaboration seminars that way they get to know what is happening in 
terms of scientific developments. And I guess at the end of the day the 
pharmaceutical industry is changing and the business model seems to 
indicate that collaboration is essential. 
 
As the study has already referred to the fact that trust is a major pillar in 
the knowledge supply-chain of small born-global bio-tech firms; the 
remarks above and on p.186 capture this. They denote that productive 
business relationships are directly anchored on trust. This is consistent 
with the social exchange theory. The theory hypothesises that 
information, advice; social support and recognition are important means 
of building trust created through repeated interactions and reciprocity 
(Pretty & Ward, 2001; Inkpen & Tsang, 2005; Blau 1964, Whitener et al., 
1998). In addition to the meaning of the social exchange theory, when 
asked about how Sygnature Discoveries Ltd develops trust with its 
partners the company’s president specified that: 
I guess our partners also do a due diligence to assess whether we fit into 
what they are looking for.  
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With our alliances we are well connected actually, before establishing this 
connection we first test the partners trustworthiness through engaging in 
small projects and we take it step by step until we are fully convinced that 
a stronger partnership can be established. Competence and reputation play 
a key role in building new networks.     
 
In light of this, it cannot be misplaced judgement to suggest that building 
trust requires small born-global bio-tech firms to have access to a wide 
scope of information because different types of information including 
relational-emotional, socio-economic and tacit-explicit extensively impact 
on the trust they experience. Trust between firms in the same locality was 
naturally developed. However, with organisations and institutions outside 
their locality there was more of “trial and error” requiring a lot of 
information search. Notably, due diligence was done mainly to test the 
trustworthiness of a potential business partner in particular, their 
intentions. This is related to the goodwill dimension of trust.  
 
The process of testing a partners’ trustworthiness through small projects 
was targeted at identifying positive or negative signs and signals which 
Blomqvist (1997) claims are visible and easier to evaluate when the 
relationship is developing. Testing a partner’s intentions earlier on in a 
collaborative relationship was a vital step for small born-global firms. 
More importantly, the stage was critical to how they forged productive 
working relationships in newly established networks. Responding to the 
question on trust-building in newly developed networks usually 
established in a global context the CEO of XenoGesis stressed that:  
It is very important to try different combinations to ensure that you end up 
working with people who share the same values with you, approach 
business in a similar way you do and their views mirror yours.     
 
In this case it was the CEO’s envisaged strategy that his organisation 
should develop trust with their partners based on the soundness of their 
strategy and vision.  
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In the relevant literature (see Mishra 1996; Sydow 1998) the 
competences of an organisation are seen as a basic and profound source 
of trust in asymmetric technology partnerships. Blomqvist, (1999) 
suggests that competence trust may be born out of a firm’s technical 
capabilities, financial resource base and partnering competences.  
Thus, the study proposes that: 
 
Proposition 2: For small born-global firms competence and goodwill trust are 
major pillars that reduce friction and perceived risks allowing the free flow of 
fluid scientific knowledge and technical know-how through established or newly 
developed business partners.       
 
The most common form of trust that was evident in the research sample 
was the sense of benevolence meaning that the scientific knowledge and 
technical know-how developed together with partners will be protected 
within the trusted group/network (Hoy & Tschannen, 1999). The firms 
relied on the goodwill of their partners to act in the best interest of both 
parties. In on-going relationships future behaviour was not specified but 
there was a mutual attitude of goodwill. As illustrated on the Knowledge 
and Innovative Capability Development Model figure 8 under section 4.5 
on p.206 trust was the basis on which inter-organisational collaborations 
stemmed from in the capability development process of small born-global 
bio-tech firms. More importantly, trust was a pre-requisite to knowledge 
sharing and the exchange of technical know-how.       
4.4.3 Inter-organisational collaborations  
Data collected from sampled firms confirms that there is a connection 
between inter-organisational collaboration, trust & new drug discoveries. 
A detailed case by case analysis specifies that the main reason why small 
born-global bio-tech firms collaborate with other firms/research 
institutions is to acquire new information and science-related ideas in 
order to enhance their innovative capabilities (drug discovery).  
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Basile (2010) explains that innovation “is a complex and interactive 
process that involves a variety of actors” (p.3). In a conversation with the 
head of process development at Critical Pharmaceuticals on the subject of 
working with other organisations to improve firm-based capabilities he 
said that: 
We work with research institutions such as Sheffield University and 
companies worldwide. We have worked with companies in Demark and 
USA. I would say we have a global dimension. We travel worldwide e.g. 
attending seminars in the USA, and in Europe seeking for partners with 
complementary capabilities.   
 
The biotechnology sector is a science-driven industry in which scientific 
knowledge is both complex and ever-expanding in search of new 
discoveries. The industry is characterised by widely dispersed sources of 
expertise. In such business environments, Powell et al. (1996) suggest 
that the locus of innovation is usually found in networks of learning as 
opposed to going it alone. Consistent with the statement made by his 
head of process development the CEO of Critical Pharmaceuticals said 
that: 
In the bio-tech industry you need various skills and knowledge, in addition 
to your in-house knowledge. We collaborate with other institutions that 
include universities, other companies - large or small both locally and 
internationally and along with that we have different levels of collaboration. 
We collaborate with companies in the USA, EU. We also have intense 
collaborations with companies near to us who have expertise in areas of 
interest we therefore work with them to access the expertise that we do not 
have.  
 
Paul Clewlow of Sygnature Discovery expressed similar views saying: 
We work with people who have better knowledge than ours in areas that 
complement what we do. We have realised that we do not have all the 
expertise. We work with companies that have the part of the ‘jigsaw’ that 
we do not have and that benefits all of us in terms of reciprocity 
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Scholarship on inter-organisational collaborations universally 
acknowledges that firms should look further than their own boundaries to 
acquire strategic resources (see Subramanian & Soh 2010; De Weaver, 
2005; Feldman, et al., 2002). In the East Midlands where not much is 
reported about inter-organisational collaborations as compared to well-
established networks such as the Golden Triangle of Cambridge, London 
and Oxford, Silicon Valley and Boston Metropolitan Area there are “hot 
spots” where science-related activities are happening in significant 
proportions. For example, in the ‘Science City of Nottingham’ joint 
research projects between scientists, academics and life science firms 
irrespective of their location are actively encouraged by knowledge 
centres that include BCN, Pera Innovation Network and Medilink. From 
that point of view, one gets a sense that the traditional model of large 
pharmaceutical companies where all research activities were carried-out 
under one roof by large pharmaceutical companies is slowly fading into 
the horizon. This is giving rise to the emergence of well-networked 
organisations that work in collaborative programmes. The managing 
director of BCN Toby Reid observed that:  
The large Pharma used to employ a large number of scientists under one 
roof; that structure is fragmenting which means that small organisations 
are being formed.  
 
Helen Walker of BAST echoed similar sentiments and she explains that:  
The pharmaceutical industry is changing in a way that has never been seen 
for a long while. The ‘Big Pharma’ model is transforming and this 
restructuring is leaving a huge number of scientists with no work which is 
causing them to start their own businesses and collaborating with other 
organisations has become very much part of that of their operational 
strategy.  
The remarks by Toby Reid and Helen Walker demonstrate that the 
traditionally auspicious ‘Big Pharma’ model in the pharmaceutical industry 
is evolving.  
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Large pharmaceutical companies are re-configuring their business models 
to achieve operational efficiency. The preferred option appears to be out-
sourcing science-related R&D as opposed to conducting the research in-
house. In the East Midlands the majority of these firms are based in 
network centres that include BCN and LIC. This marks the genesis of a 
significant move towards project-based programmes. The outcome of this 
is that there will be more and more collaborations between small and 
large organisations. As such, smaller firms whose structural designs are 
known to be adaptive and flexible will perform a more active role. The 
head of process development at Critical Pharmaceuticals Andrew Naylor 
explained that: 
If you avoid science-based collaborations in the biotechnology industry 
which is nowadays littered with small but extensively innovative firms you 
will not get anywhere. In a business such ours you need to share expertise 
in order to innovate and develop the business. I personally keep contact 
with people who I previously worked with in projects with a view to keep on 
sharing knowledge because technology is ever-changing therefore, we need 
to be upfront. I also see academic collaborations as very important because 
they produce new ideas and knowledge.  
 
Richard Weaver of XenoGesis expressed similar views when he 
commented that:  
To be creative in science one has to collaborate on a number of levels with 
multiple actors. Talking from my personal experience acquired in science I 
believe that to be innovate you have to work with people who have some 
expertise in other science-related fields so that you can learn from them 
and that can only be good for your business growth and development 
 
Other studies (see Gabrielsson & Kirpalani, 2012; Cannone et al., 2012; 
Stuart et al., 2007; Zucker et al., 1998) have report a growing trend in 
the biotechnology sector where small firms are being contracted to do the 
research for other pharmaceutical companies.  
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Kang & Park (2012, p.70) report that “while the new biotechnology firm 
specialises in specific types of knowledge, products and applications large 
established firms have expertise in the commercialisation of new 
inventions that involve large scale production, marketing and distribution, 
and regulatory processes”. In the same context Gareth King - the CEO of 
Critical Pharmaceuticals emphasised that:  
We acquire financial support to back up our products, expertise, marketing, 
PR, scientific knowledge and these are things that we do not have in-house 
and they are needed to enable us to achieve our goals. The only way to 
achieve this is through linking up with people who have been there and 
done it and are well established in the market.  
 
There is a strong hint in the remarks above informing the study of the 
significance of inter-organisational collaborations in terms of: (1) bridging 
the knowledge gap of small born-global bio-tech firms; (2) enabling them 
access to markets; (3) providing them with financial back-up and (4) 
getting help from science experts who have vast experience. Consistent 
with this, Schilling (2010) stresses that, small pharmaceutical firms form 
partnerships with other pharmaceutical firms for their mutual benefit. For 
example, large pharmaceutical companies gain access to the drug 
discoveries of the small pharmaceutical firms and likewise the small 
pharmaceuticals firms gain access to the capital resources, manufacturing 
& distribution capabilities of large pharmaceutical companies. BAST Inc. 
Ltd seeks to establish working relationships with firms that can enable 
them to develop useful science tools. Its science director stated that:  
We are interested in collaborating with a computer firm to jointly develop 
simulation mathematical combinations. This cross fertilisation is important 
in the sense that it enables us to develop what we intended to produce 
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Discussing on the same subject regarding alliance-building the CEO of 
XenoGesis explained that: 
We have developed a good working relationship with XenoTech a company 
which is located America. They are our distributor in the US. We know that 
they have credibility through their peer reviewed journals and we also 
visited their premises as part of developing trust. We discovered that 
XenoTech have life science expertise and they are mature than us and they 
have been going since 1984 and they have developed a strong base in 
science which we are now using for distribution purposes.   
 
The remarks made by the science director of BAST and the CEOs of 
XenoGesis and CP above indicate that small bio-tech firms seek to 
collaborate with companies that complement firm-based capabilities. In 
the East Midlands this trend is on the rise. For example, Nottingham Trent 
University, Nottingham University and University of Leicester (UoL) are 
jointly working with small bio-tech firms to share expertise, resources and 
human capital with a view to develop life-saving drugs and clinical 
equipment. Critical Pharmaceuticals work closely with academia to 
develop a highly innovative formulation of teriparatide. The UoL 
performed a crucial role in supporting Haemostatix Ltd during its early 
stages of development. The firm received support in the form of clinical 
laboratories as well as opening up links with other institutions and 
organisations. As a result of Haemostatix Ltd’s links with the UoL it 
received start-up funding of £250,000 from The Lachesis University 
Challenge Fund and an initial investment from NESTA. The founder of 
Haemostatix expressed her profound gratitude in 2006 when her 
organisation received support from Quester, “Quester has worked with 
the company (Haemostatix Ltd) since 2002 and we are pleased to have 
their financial support and strategic input to take the business forward”. 
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Proposition 3: Inter-organisational collaborations are an important 
developmental step within the knowledge supply-chain of small born-global firms 
and they influence their process of developing innovative capabilities  
 
It is however important to reiterate that inter-organisational 
collaborations have the potential to produce desirable outcomes for all the 
parties only when trust has been established first. The majority of the 
firms participating in the study are contract research organisations 
(CROs) implying that they work with other firms or for other firms to 
develop drugs. Their collaborating partners are not only located within 
their vicinity but they are global dispersed which means that trust (in the 
form of competence and goodwill) becomes important. In that sense, one 
can envisage a strong association between trust and inter-organisational 
collaborations. Small born-global bio-tech firms collaborated with 
organisations they believed to have expertise and experience. The idea 
was to limit the chances of failure given their lack of resources. Carrying 
on with the discussion concerning inter-organisational collaborations and 
trust the president of Sygnature Discovery Paul Clewlow was asked to 
explain the importance of a potential partner’s expertise in science and 
benevolence in trust-building and this is what he had to say: 
We develop trust with potential partners based on their science and 
technical capabilities. We also receive advice from BioCity, Medilink and 
UKTI about potential partners and I guess it is part of due diligence. You 
need to confident that they will respond in a positive way and their attitude 
is congruent with your expectations.   
 
Paul’s version of a potential business partner’s capability also hints that a 
firm intending to enter into partnerships with another firm that is not 
known to them they use BCN, Medilink a knowledge network centre and a 
government advisory body on trade and investment (UKTI) as 
intermediaries.  
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These network facilitators provided small born-global bio-tech firms with 
information about potential partners’ scientific capabilities and technical 
know-how more so, for those which are geographically distant. In addition 
to this, the network centres also supported other firms from oversees 
intending to relocate their operations to the East Midlands. Rosamund 
Graves an innovations manager at Medilink East Midlands explained this 
situation more fully when asked about the role her organisation performs 
in facilitating inter-organisational collaborations, she said that:  
We would facilitate for companies that intend to relocate to the East 
Midlands by providing them with the necessary information. We support 
both domestic and international organisations and recently we had a 
company that came from India intending to establish in the East Midlands. 
In that case we supported them by providing them with information to 
enable them to achieve their goal. 
 
In the literature Bachmann & Inkpen (2011) accept that in cases where 
face-to-face interaction with a potential partner is not possible or 
desirable a third party may operate as a guarantor. Tony Reid the 
managing director of BCN elaborated on this by explaining that for their 
tenants they: 
Guarantee a certain level of competence and quality of a potential partner 
but after that they take a step back and let people work and learn on their 
own.  
 
Over a period of time a strong bond was gradually developed by engaging 
in smaller research projects between collaborating firms regardless of 
their geographical location. When the relationship got stronger the level 
of trust was increased accordingly thereby, facilitating the free flow and 
exchange of scientific capabilities as well as technical know-how. In the 
literature high levels of trust are associated with a decrease in perceived 
risk and they are cast as being fundamental to the formation of strong 
relationships.  
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Thus, strong relationships are a precursor to trusting that a business 
partner will act in the interest of both parties. Evidently, some form of 
connection existed between firms which used a pre-existing business 
network such as BCN as their base but for partners outside their locality 
the “trial and error” method taking the form of smaller projects was used 
as the main method of assessing the trustworthiness of prospective 
partners. As such the study’s 4th proposition is that: 
 
Proposition 4: Small born-global bio-tech firms build trust with their 
prospective partners in escalating series basing it on their partner observations 
through inter-organisational collaborative projects      
4.4.4 Tacit & explicit knowledge 
The process of acquiring knowledge is a very complex exercise which 
involves participating in generating, storing and disseminating it in a way 
that benefits all the players involved (Powell & Grodal, 2005). There were 
sufficient clues indicating that small born-global bio-tech firms work in 
collaborative projects with a view to ensure that they continue to receive 
crucial scientific knowledge. The science director of BAST Ltd Inc. Joachim 
Grevel commented that: 
The idea of working in joint projects is essential in science as it gives small 
less established firms access to vital knowledge. I think the idea of 
intellectual capital is important for both established organisations and small 
start-up firms like ours. It is basically an understanding that we share ideas 
and collaborate in projects and generate IP in joint programmes.  
 
Consistent with this, Andrew Naylor the head of process development at 
Critical Pharmaceuticals explained that: 
We create knowledge by engaging in science-related research programmes 
with our partners. We are currently working with a Danish company on a 
drug discovery programme. All the data from experiments becomes our 
joint intellectual property.  
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We also sponsor PhD students who we enter into contractual agreements 
which enables us access to their research output and any experiments 
(results) they may produce as part of their research. So that is roughly how 
we generate knowledge.          
 
Andrew Naylor’s remarks are supported by his CEO Gareth King who 
explains how they generate knowledge at length saying: 
We have some structure take for instance when we work with a business 
partner who has expertise in a certain area we come to some form of 
agreement in order to protect IP. We all sit down and we choose leaders 
from each side and these people work together and they have to work out 
what is needed. They come up with a plan for the project; they update us 
with what is required for that project to progress. Once a project is 
underway it is monitored all the way to final delivery. We usually encourage 
the leaders to produce a document explaining how the project is 
progressing so that we have an idea of what capabilities are needed for it to 
fulfil its purpose. We ask them to produce a report to evaluate the project 
i.e. what has been achieved etc. All the data that is generated from this is 
kept securely in a database which we both have access to. 
 
Helen Walker the senior pharmacologist made similar remarks explaining 
that:  
We participate in a Knowledge Transfer Partnership (KTP) programme. The 
programme helps us to create and share knowledge. In our case we jointly 
create knowledge with students who undertake projects which BAST 
mentors. This is how it works a student who is identified as having potential 
is recruited to work with a mentor. Now one of the key requirements of that 
partnership is to produce a report of their work and we also expected them 
to keep a lab log book. That way we are confident that all the data they 
generate from that partnership is retained in the business. Basically, we 
keep a trail of their work. Actually, it is good practice in science to keep a 
trail of your work. 
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Commenting on the same subject regarding knowledge creation Richard 
Weaver of XenoGesis said that: 
We receive knowledge through published data and from people who we 
have had some dealings with them. 
 
Paul Clewlow of Sygnature Discovery remarked that: 
We send our scientists for training in Universities with a view that they will 
be able to acquire knowledge which would be useful for our drug discovery 
service. Crucially, we keep all the data from tests stored in our secure 
databases which are only accessed by authorised parties. 
 
The remarks made by the key informants, above and on p.202-204, 
signify that small bio-tech firms create science knowledge by participating 
in science-related projects and programmes, and through working with 
academic institutions. Taking a closer look at these commentaries one 
gets a genuine feeling that small born-global bio-tech firms create 
knowledge using a wide range of sources. These encompass joint 
research projects with other firms which are known to them, through 
knowledge transfer partnership programmes and by sponsoring 
undergraduate students.  
 
This is consistent with the literature for example; De Weaver et al. (2005, 
p.1525) broadly define social capital “as the sum of actual and potential 
resources embedded within, available through and derived from the 
network of relationships possessed by an individual or social unit”. 
Bourdieu’s (1986), Coleman’s (1990), and Putman’s (1995) 
conceptualisation of social capital assumes various dimensions which are 
reflected in the statements made by the interviewees. Bourdieu (1986, 
p.248) defines social capital as “the aggregate of the actual or potential 
resources which are linked to possessing of a durable network of more or 
less institutionalised relationships of mutual acquaintance or recognition”. 
Coleman (1990) defines social capital by its function.  
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Coleman argues that social capital consist of some form of social structure 
that facilitates certain actions by actors within it. Putnam (1995) appears 
to treat social capital as a single dimension. Putnam defines it as “the 
networks, norms, and trust that enable participants to act together to 
effectively pursue shared objectives” (1995, p21). Taking into account the 
literature and the remarks from the key informants the study proposes 
that: 
 
Proposition 5: Tacit and explicit knowledge created in collaborative projects 
performs a leading role in facilitating a small born-global bio-tech firm’s ability to 
improve its capacity to innovate.      
     
Furthermore, across the entire sample there was sufficient data indicating 
that ideas and knowledge created in science-related projects/programmes 
are codified and retained in the firm for future developments. This was 
realistically explained in a discussion with the CEO of Critical 
Pharmaceuticals concerning how his firm managed data accrued from 
collaborative projects. This is what he said: 
From a scientific perspective for a lot of the key projects we trap the 
knowledge that people have used in a project and we have project 
management systems to make sure that we capture all the knowledge e.g. 
by monitoring projects, gantt charts and project reports. 
 
Managing scientific information this way was not only unique to Critical 
Pharmaceuticals. All the firms echoed the same sentiments. They also 
revealed that knowledge management was a crucial part of their drug 
discovery process. For example, the science director of BAST Ltd Inc. 
stressed that: 
We are part of a collaborative network and I agree that knowledge exists in 
people’s minds but I also think that it should be codified and stored in 
databases for all the members in the network to access it and hopefully 
make essential innovations. 
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As a matter of fact, we are part of consortia of 24 other firms and we are 
developing a common sharing repository where everyone with interest will 
have access to this data and we hope to have the system up and running in 
about 5 years.   
 
The findings are consistent with a number of scholars (see Daud & Yusoff, 
2010; Hughes et al., 2009; Nonaka et al. 2000) who discuss the concept 
of knowledge externalisation. Knowledge externalisation allows knowledge 
that exists in the head of the knower to be codified into rules, 
specifications and formulas that can be used and become the basis of new 
knowledge. All the firms that participated in the discussions regarding 
developing innovative capabilities in the biotechnology sector placed great 
value on both tacit and explicit knowledge acquired from their trusted 
partners.  
 
The findings from across cases also show that knowledge created in 
collaborative projects was regarded as essential to the development of 
new scientific combinations and formulas needed for testing new drug 
discoveries and compounds. Conversations with the key informants also 
yielded that their firms go beyond their immediate environment in search 
of a new context and a new world-view. This is consistent with Todtling et 
al. (2009) who suggest that sector based innovations are not bound by 
geographical location. They often have international or even global reach. 
Global networking in search of new insights was a dominant characteristic 
in the majority of the firms that took part in the survey. In the literature 
Nonaka et al. (2000) point out that the process of creating knowledge is a 
continuous one and it transcends beyond one’s immediate environment. 
The interaction between individuals or a group of firms is vital in terms of 
facilitating knowledge transfer.  
 
 
200 
 
Small born-global bio-tech firms work in collaborative projects with other 
scientists, research institutions and other firms with an objective to 
stimulate its transfer. Porter et al. (2005) point to the amalgamation of 
intellectual capital of clinical researchers and research academics as key 
to the success of the commercial world of biotechnology in the Boston 
metropolitan area. Similarly, Todtling et al. (2009, p.67) claim that, 
“universities are regarded as key knowledge sources of firms for more 
advanced innovations”. This bears striking resemblance to the methods 
used by firms in the East Midlands region to create science knowledge. 
There is evidence of the existence of strong ties and relational-like trust in 
the sampled firms that are located at BCN, the region’s science centre. 
Based on their shared values and common beliefs vested in BCN the firms 
naturally formed business connections and the intentions of all the firms 
were predictable. Boschma (2005); Asheim & Gartler (2005) make similar 
observations and they highlight the fact that interactions that occur in an 
institutional context facilitate the transfer of tacit and explicit knowledge. 
Through strong ties and relational-like trust, knowledge was freely 
exchanged. Discussions with the participants yielded two main forms of 
knowledge sharing in the biotechnology sector.  
 
The idea to complement each other’s innovative capabilities was one form 
of knowledge-sharing that was clear. The strategy was evident across all 
the sampled cases. The collaboration between Critical Pharmaceuticals 
and PolyTherics is an example of complementary knowledge assets. 
Critical Pharmaceuticals specialises in injectable products and PolyTherics 
Limited are innovators in precision improvement of proteins and peptides. 
In that sense, their expertise and knowledge capabilities complement 
Critical Pharmaceuticals’ technology of human injectable drugs. The 
second form of knowledge sharing was in the mould of process re-
configuration. It is however important to mention that the process of 
transferring knowledge occurred after the establishment of the intentions 
of the partnering firm(s) or institution(s).  
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BAST Ltd as a contract research organisation (CRO) exchanged knowledge 
with its collaborating partners by re-arranging science apparatus in such a 
way that enhanced new drug discoveries. When responding to the 
question about how his firm’s collaborative partners utilise the knowledge 
acquired in collaborative drug discovery projects the science director 
explained that:   
We use the information that we share with them to enhance their 
innovations and to accelerate their business processes. Basically, our ideas 
would change the next developments that they have which helps them to 
reduce costs and even sharpen their innovations and the way they put their 
resources together e.g. their operations and product development 
strategies  
                 
In the first form of knowledge transfer where both parties provide 
valuable input to the project, there was high commitment to create tacit 
and explicit knowledge. The firms developed relational capacities pooling 
together the skills of specialised participants who ultimately played a 
leading role in the overall flow of information and resources in the 
network. The exchange and transfer of specialised scientific knowledge 
and skills between the firms engaged in collaborative projects or in the 
wider network at BCN had a significant impact on how they increased 
their capacity to innovate. This highlights the fact that tacit and explicit 
knowledge are important elements that have an impact in the knowledge 
supply-chain of small born-global bio-tech firms. Nonaka & Takeuchi 
(1995) suggest that the creation of new knowledge is predominantly 
characterised by the interaction between two main forms of knowledge 
i.e. tacit and explicit knowledge.  
4.4.5 Prior learning & absorptive capacity 
Small born-global bio-tech firms operate in a constantly changing 
business environment which has become global as a result of the liberal 
trade structures governing trade today. This requires constant resource 
re-configurations to sustain their economic development.  
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In that sense, prior-learning and the cumulative science experiences of 
bio-entrepreneurs is a catalyst that facilitates the economic development 
of their bio-tech ventures by assisting in the process of acquiring useful 
scientific knowledge from multiple knowledge sources. The head of 
process development at XenoGesis explained this more fully when asked 
about the importance of prior learning in terms of understanding the 
specific knowledge that is useful for their science in business and social 
networks that span beyond their proximity. This is how he puts it: 
Understanding what is required is important in terms of acquiring useful 
knowledge/principles that are necessary in science experiments. 
 
The same sentiments were echoed by Ben Nichols the CEO of 
Haemostatix who explained that:  
Experience in science plays an important role when it comes to selecting 
the right type of knowledge that is needed to develop new technology.  
 
The Richard Weaver the CEO of XenoGesis contributed to this by stating 
that:  
It is important to have some understanding of science in order to acquire 
useful information. More importantly, it is crucial that one adopts a 
methodical or rational way with a view to acquire essential data. In other 
words, you will be separating wheat from chuff. Here at XenoGesis we are 
constantly looking for relevant data and in that regard science experience 
comes into play. It would be difficult to know our knowledge gaps if we did 
not have the necessary science experience. 
 
The science director of BAST Joachim Grevel commented that: 
We work in projects on a global basis. In that sense, personal experience 
becomes very important in locating what is essential for our business. Take 
for instance I attend various conferences throughout the year where more 
than 5000 pieces of information are generated therefore understanding 
what is necessary you have a better chance of acquiring. In that sense 
when you attend such conferences you will be able to realise useful data. 
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The commentaries on p.202 demonstrate that BAST’s and XenoGesis’s 
ability to exploit and assimilate external knowledge was crucial to their 
process of developing innovative capabilities. In the literature Cohen & 
Levinthal (1990) argue that a firm’s ability to evaluate and utilise 
information is heavily influenced by prior-related knowledge. Within case 
analysis indicated that for all the sampled firms their management 
structure was composed of individuals who had vast experience in science 
and have worked for large bio-pharmaceutical firms. As such, their wealth 
of experience was vital in terms of understanding the knowledge gap in 
their firms. To get a different perspective on this the topic about prior-
learning and absorptive capacity was presented to an innovation expert at 
Sally Barker Medilink as a point of discussion and she commented that: 
Working with other organisations to share knowledge and ideas is great, 
but what is important is that one has to have some knowledge about the 
knowledge that will help his/her business to take that one step forward.  
 
Helen Walker of BAST commented that: 
Absorbing information is one thing what is important is that when you go 
back to your company you have a good understanding about how you are 
going to use the information. Therefore, to productively apply the 
knowledge to your science there is no doubt that you have to have vast 
experience in science.   
  
All of the comments above and on p.202 reveal to greater extent that the 
personal experience and prior-learning of key individuals in a firm have 
considerable influence on how bio-tech firms select useful knowledge that 
complement their specific knowledge gap. Clearly, working with other 
firms or science institutions whose complementary foci is at some 
cognitive distance results in the accumulation of vast amounts of 
information but recognising what a firm needs increases its innovative 
capacity. Indeed, working in collaboration accelerates the firm’s process 
improvement.  
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Taking the literature review in Chapter 2 into perspective, Schilling (2010) 
suggests that a firm’s prior-related experience shapes its ability to 
recognise the value of new information and its ability to utilise that 
information effectively. Thus the study proposes that:   
 
Proposition 6: The experiences of small born-global bio-tech firms are essential 
to their ability to recognise, assimilate and apply knowledge from their business 
and social relationships in a way that enhances their capacity to innovate       
  
It is instructive to inform the reader that the concept of learning has not 
been fully explored here because it is beyond the remit of this study. 
Although the concept has been discussed in a limited fashion it has been 
an important part of the process of understanding its role in the 
development process of innovative capabilities. Following an in-depth 
account of various elements within the knowledge supply-chain of small 
born-global bio-tech firms the study proposes a refined conceptual 
framework of knowledge and innovative capability development. 
4.5 A model of knowledge and innovative capability development 
This section of the thesis provides the reader with a diagrammatic 
representation of the variables/factors, along with a detailed explanation 
of the improved “Knowledge and Innovative Capability Development 
Model” following an in-depth explanation of the key concepts contained in 
the model. Before the study clarifies the connectivity of various elements 
within the knowledge supply-chain of the small born global biotech firms; 
it is deemed necessary that the reader is informed about the role theories 
occupy and perform in social science. The formation of theories in social 
science is fundamental to how researchers explain what they are trying to 
talk about (Gerring, 2005). Precisely, theories are instrumental in social 
science as they help researchers to make connections between the world 
people live in and how they interpret it (Gerring, 2001).  
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Concepts can be seen as occupying a central role in social science. In that 
sense, the concepts contained in the improved model on figure 8 p.206 
are essential to what this study intends to convey to the reader. Bellamy 
& Perri (2009, p.90) point out that regardless of one’s research 
philosophy developing an adequate conceptual framework provides a 
roadmap that guides how the study explores the social world and for 
those working with variables and correlations they are able to “establish 
valid measures and apply them reliably”. Building on the instrumental 
work by Freeman et al. (2010) regarding how smaller firms rapidly 
develop new knowledge by forging business networks, this study uses 
their ideas as a foundation on which it develops a new improved 
framework. The modified concepts on the new framework are based on 
empirical evidence and existing literature. Developing a frame of 
reference in this manner makes the theories developed in this study 
credible and acceptable (Bellamy & Perri, 2009).  
 
Furthermore, Saunders et al. (2007) concur with this view and they insist 
that developing a strong theory involves a process that delves into 
underlying processes with a view to understanding the systematic reasons 
for an occurrence or non-occurrence. Taking a cue from Saunders and 
others the study proposes the “Knowledge and Innovative Capability 
Development Model” – an improved version of Freeman’s et al. (2010) 
model. Figure 8 on p.206 neatly illustrates the proposed conceptual 
framework for this study. 
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Figure 8: Knowledge and Innovative Capability Development Model 
 
  
  
 
 
 
 
 
 
Source: Modified from Freeman et al. 2010 “A Process Model of Rapid Knowledge 
Development: The Smaller Born-global firm” and author’s ideas 
 
The “Knowledge and Innovative Capability Development Model” builds on 
earlier theories concerned with knowledge development (see Lane et al., 
2006; Elfring & Hulsink, 2003; Freeman et al., 2010). The model shows 
that elements/variables that include: business & social networks, 
competence & goodwill trust, inter-organisational collaborations, tacit & 
explicit knowledge, prior learning & absorptive capacity have a strong 
connection. The connectivity of these variables has a positive or negative 
influence on how small born-global firms develop their capacity to 
innovate. Small born-global bio-tech firms operate in a very complex and 
sophisticated business environment which is ever changing. Therefore, it 
is imperative that firms formulate strategies that enable them to continue 
to produce innovative life-saving products.  
 
The primary aim should be to enhance their innovative capabilities to 
enable them to make crucial innovations (Powell & Grodal, 2005). The 
firms used in this sample are all resident at BioCity implying that they 
exist in a network which is established where they have developed strong 
business and social ties. They also demonstrated an entrepreneurial flair 
by venturing into the global markets in search of global partners.  
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As denoted on figure 8 p.206, the establishment of business and social 
networks described as innovation networks by Powell & Grodal (2005) 
both locally and globally, is the key building block within the knowledge 
supply-chain of small born-global bio-tech firms. Elfring & Hulsink (2003) 
make an important observation about entrepreneurial firms. Elfring and 
Hulsink claim that networks (business & social) meaningfully contribute to 
the venturing process of small but entrepreneurial firms. They present 
them with access to knowledge and unique capabilities that underpin 
innovation.  
 
At their local network (BCN) and the wider East Midlands region the firms 
were aware of the competences and the intentions of their potential 
collaborative partners thus, trust was built at a very early stage. This 
allowed rapid knowledge transfer and the exchange of technical know-
how. As trust-like relationships existed in established it led to intensified 
inter-organisational collaborations. Established networks made it possible 
for small born global bio-tech firms to develop new networks – networks 
of networks (see Cooke, 2003; Davis, 1970; Wall, 2009). In newly 
developed networks, trust was very loose or in the majority of cases it did 
not exist at all. Therefore, for R&D institutions, firms or scientists located 
in foreign markets inter-organisational collaborations in the form of 
smaller projects were used in a “trial and error” method to test the 
trustworthiness of the prospective partner in newly established networks. 
In the process of developing innovative capabilities small born-global bio-
tech firms embarked on a number of different, often unsuccessful, 
configurations and techniques before finding the right combination that 
worked well for the firm (Lichtenthaler & Lichtenthaler, 2009).  
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Schilling (2010) explains this process of experimentation and learning 
more clearly asserting that this stage in the knowledge supply-chain is 
vital in the sense that it allows the firm to build a base of knowledge 
about how key components behave, what alternatives are more likely to 
be successful than others, what types of projects the firm is most 
successful at, and so on. The can disclose that small bio-tech firms were 
forced to adopt the experimentation approach because of the dynamic 
nature of the biotechnology sector i.e. its heavy reliance on highly fluid 
scientific knowledge and technology to make new drug discoveries and 
the speed at which these types of firms form and disintegrate required 
high levels of trust (Maxwell & Lévesque, 2011; Welter 2012). This, 
therefore, strongly suggests that trust is ever-more critical for the 
transient and the high speed environment of the small born-global bio-
tech firms as the basis for knowledge sharing (Freeman et al., 2010). As 
such, trust was built in escalating series because of the risks associated 
with developing new partnerships. Sitkin & Pablo (1992) discuss about 
risk perception referring to the assessment of the risk inherent to a 
situation.  
 
In all of the five small born-global firms the assessment of the risks 
associated with knowledge-sharing with new partners was done in a 
carefully orchestrated logical step-by-step approach as described above. 
Once trust was built, whether in established or newly developed business 
and social networks, it paved the way for effective knowledge-sharing. Hill 
(1990) suggests that it is highly likely that a firm will engage in 
knowledge transfer with partners that have demonstrated their 
trustworthiness and co-operative ability in their other relations. Indeed, 
the process of knowledge-sharing is embedded in pre-existing business 
and social connections. Hutchings & Michailova (2006) suggest that 
sharing of knowledge, depends on the pre-existence of insider 
relationships and a disposition towards co-operative interdependence.  
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It is widely accepted that small firms with limited resources have a 
tendency to soak-up as much information as is possible with the hope 
that something magical will happen (Simba, 2013). The proposed model 
accentuates that for small born-global firms prior-learning a good 
understanding of the complementary resources needed for the firm to 
develop new life-saving drugs or technical products is essential. 
Otherwise, engaging in collaborative projects will count to nothing in the 
way of innovations. The underlying assumptions of the model are that by 
acquiring new scientific knowledge and technical know-how the firm 
enhances its innovative capabilities that will support the development of 
new products and services in the life science industry.  
4.6 Discussion of findings 
This study offers an interesting contribution to the discussion about how 
small born-global firms develop their innovative capabilities. The study 
accentuates that, following the re-structuring of the life science industry 
which has seen large pharmaceuticals such as AstraZeneca and Lund in 
Sweden closing down their R&D facilities to concentrate on external 
collaborations, small born-global bio-tech firms appear to taking a leading 
role in science-related R&D activities. This is well-represented in the 
extant literature (see for example: Karra et al., 2008; Gurau et al., 2010; 
Rafols et al., 2012; Taks, 2012)  
 
Small born-global firms are taking advantage of the advancement in 
information technology and the harmonisation of global markets by 
engaging in global networks (Eurofound, 2012; Dlugoborskyte & Petraite, 
2013). Consequently, networks have become a key part of their 
knowledge supply-chain. In biotechnology, there is a strong association 
between the performance of firms and innovative regions. It is generally 
accepted that small firms do not possess all the resources that are 
necessary for R&D and sustained economic growth (Freeman et al. 2013; 
Gabrielsson & Kirpalani, 2012; Eurofound, 2012).  
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As such, they rely on their business and social connections and they 
locate their businesses in regions where they have an opportunity to 
explore and exploit pooled resources (Kocak & Abimbola, 2009). 
Arguably, the development of new products in life science is very much 
driven by a firm’s ability to build strategic alliances mentioned in Harryson 
et al. (2007) as part of a total knowledge creation process. Alliance-
building is an integral feature of networking. Therefore, a good insight 
into processes of alliance-building, knowledge-creation and the network 
perspective is fundamental to our comprehension of corporate technology 
and innovation management processes of small born global bio-tech 
firms.  
 
It is universally agreed that the science-related industries are knowledge 
intensive (see Travinsky, 2012; Tanev, 2012; Cavusgil & Knight, 2009; 
Gabrielsson et al., 2008). Small firms in this field have limited options and 
engaging in collaborative R&D activities seems to the most viable 
approach to take as opposed to going it alone. The study discusses 
various interconnected elements that dominate their knowledge supply-
chain and how they influence innovation. The study infers that, it is 
imperative that small born global firms strengthen their internal 
capabilities by recruiting experienced scientists and participate intensively 
in globalised R&D programmes. Their innovation ‘ecosystems’ should 
include key performers in science such as university scientists, 
established pharmaceutical firms, science parks and government 
sponsored trade advisors. This will allow them to move expeditiously and 
identify research programmes/projects that will help them to accelerate 
firm-based innovations. Nonetheless, in this euphoria to speed up drug 
discoveries small born global bio-tech firms should be very cautious of the 
risks associated with an excessive focus on exploitation. The danger is 
that, they may end up diverting resources away from exploration which 
might adversely impact on their ability to innovate.  
211 
 
Accordingly, too much focus on exploration can seriously weaken a firm’s 
ability to appropriate and capitalise on the innovation (March, 1991; 
1999; Levinthal & March, 1993). When discussing about innovation it is 
reasonable for one to think about the concepts of dynamic capabilities and 
networking because the theories have direct implications on how small 
born global bio-tech firms develop their innovative capabilities. The 
dynamic capabilities theory explains how organisational and strategic 
routines designed by firms enable them to achieve new resource 
configurations. The theory explicates a firm’s ability to integrate, re-
configure and to acquire new ideas, information and knowledge. Clearly, 
the dynamic capabilities theory is anchored on a firm’s knowledge-based 
processes which are instrumental to knowledge-creation, knowledge-
integration, and knowledge-configuration. 
 
The network theory draws one’s attention to the fact that firms can 
overcome their resources shortages by accessing external resources such 
as knowledge and international opportunities. International network 
relationships mitigate risks associated with newness and inexperience. At 
the network level firms have a chance to form partnerships, business 
networks, personal networks, and to participate in clusters. This 
demonstrates that both dynamic and network theories are interwoven 
into the innovation management processes of born global firms.  
 
The dissection of small born global bio-tech firms in this study joins 
together ideas of both international business and entrepreneurship 
theories. Avoiding being too defensive about the design of this study; it 
was inevitable to adopt a series of theories in order to comprehend the 
behaviour and decision rationale of born global firms (Su, 2013; Cavusgil 
& Knight, 2009) especially in the literature where the study touches upon 
a variety of concepts.  
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As such, the main theories which are helpful in building the epistemology 
of small born global bio-tech firms for this study include: dynamic 
capabilities theory, organisational learning, knowledge management, 
innovation, and network theories (Dlugoborskyte & Petraite, 2013).                         
4.7 Potential hazards 
It will be naïve on the part of the researcher to ignore the issues small 
born-global bio-tech firms have to contend with in the process of 
acquiring scientific knowledge and technical capabilities. Firms may 
choose not to collaborate or to engage in research programmes with 
others for a variety of reasons. A firm may possess all the capabilities 
needed to develop a clinical product in-house (Schilling, 2010) meaning 
there will be no need to search for partners. Alternatively, after assessing 
a number of firms using the “trial and error” method a company may 
conclude that there is no other firm whose skills or resources complement 
theirs or there may be no partner willing to collaborate and it could decide 
to go solo.  
 
The study can reveal that one of the main issues that arose in inter-
organisational collaborations was to do with intellectual property risks. 
During the data collection phase the researcher had an opportunity to 
discuss with a scientist at a University in Nottingham. The scientist 
expressed concern about participating in the interview for fear of 
divulging sensitive information about her business strategy. She was 
actually a victim of patent violation – her compounds (scientific 
combinations) for testing new drugs were used without her permission by 
a supposedly business partner from a country in the Far East. Similarly, 
Lasserre (2012) reports that, “the protection of intellectual property rights 
(IPR) is a source of concern and sometimes an impediment to global 
collaborations” (p.298). Other firms may choose to go solo in order to 
have full control over the project’s development and its returns (Lin & 
Chen 2002; Schilling, 2010).  
213 
 
New inventions occur as a result of complex linkages between a number 
of actors in a concentrated area and this brings about the problem of 
critical mass constraint noted by Lasserre (2012) as existing in situations 
where, in order to perform one activity efficiently and effectively, a firm 
has to mobilise resources using its external links. Admittedly, the 
scientists, bio-entrepreneurs and technologists who participated in this 
study are not lone inventors, they thrive by networking. They aim to 
benefit from the complementarities of personal and business networks in 
their field through horizontal integration and in related domains through 
vertical integration. They also require state-of-the-art science equipment 
for their inventions to materialise. Anything below that threshold of 
resources causes difficulties in the majority of research projects. As such, 
critical masses for small born global bio-tech firms are unavoidable. What 
is crucial though is for them to be flexibly, adaptable and learn rapidly in 
order to avoid the constraints associated with critical mass.     
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Chapter 5 
5. Conclusion 
This chapter of the research project provides a summary of the highlights 
of the study. It provides a set of conclusions that are based on the main 
findings of the research. The main aim of the project was to explain the 
connectivity of various elements within the knowledge supply-chain of 
born global bio-tech firms and how they influence their strategic plan for 
generating scientific knowledge and technical know-how. The findings 
establish that the relationship between business and social networks and 
other elements/variables that include: business & social networks, 
competence & goodwill trust, inter-organisational collaborations, tacit & 
explicit knowledge, prior learning & absorptive capacity of small born-
global bio-tech firms is decisive to their innovation development process. 
All the elements mentioned above indicated that they have a considerable 
impact on the process of how small born-global firms develop their 
innovative capabilities. This satisfies the second research objective of this 
study which was aimed at explaining the connectivity of various elements 
within the knowledge supply-chain of small born-global firms.           
 
The proposed model of Knowledge and Innovative Capability Development 
is constructed from a detailed case-by-case analysis, across case and the 
existing literature together with evidence from a “pilot” study. The 
concepts contained in the new model endorse the importance of 
horizontal networks and the links between firms, research institutions and 
academics which have complementary technologies and science within the 
knowledge supply-chain of small born-global bio-tech firms. The most 
significant contribution of the study is concerned with theory-building. The 
newly formulated theory of innovative capability development contributes 
to a better understanding of two theories namely: dynamic capabilities 
and network theories.  
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The network approach focuses on specific, well-selected relationships in 
the innovation process with specific actors within an innovation 
‘ecosystem’ described by Booth (2009, p.705) as a ‘brave new world’. It 
stresses the motives for engaging in co-operations such as technological 
complementarities or access to resources and specific knowledge, and it 
emphasises on the connection between trust and social capital (scientific 
knowledge) as vital to the development of networks. The connectivity and 
collaboration between various actors within the East Midlands network 
shows that they performed a leading role in ensuring continued 
development of knowledge and technical know-how by providing expert 
advice, financial support and infrastructure to bio-tech firms. The 
principles of dynamic capabilities theory are borrowed to explain how 
organisational and strategic routines designed by small born global firms 
enabled them to achieve new resource configurations. The theory helped 
to explicate how these entrepreneurial firms integrate, re-configure and to 
acquire new ideas, information and knowledge.   
 
From that perspective, the construction of a new conceptual framework 
satisfies the third research objective which was aimed at making a 
theoretical contribution to dynamic capabilities and network theories. The 
study also demonstrates that the structural, relational and cognitive 
dimensions of small born-global bio-tech firms are important in providing 
the firm with business partners that have complementary capabilities 
allowing them to jointly develop new innovative products. Entrepreneurial 
firms such as born-global firms are known for their resource deficiencies 
especially, financial resources. In that respect, the study safely discloses 
that within the structural dimension of these firms venture capitalists (VC) 
execute a crucial role as they provide the much-needed financial support 
which makes it possible for a proposed research project(s) to progress to 
the next level.  
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The study also concludes that in order for small born-global firms to 
receive and share tacit and explicit knowledge some form of trust 
between the collaborating parties has to be established. Particularly, 
competence trust i.e. trust which is based on the scientific and technical 
capabilities of the prospective partner and goodwill trust referring to the 
intentions of the prospective partner were identified as critical to inter-
organisational collaborations that occur in the biotechnology sector. The 
collaborations in this sector predominantly involved small born-global bio-
tech firms, bio-pharmaceutical companies, research institutions, and 
academia.  
 
The key criteria for collaborating were based on the extent to which the 
partner complements the existing knowledge base.  More importantly, the 
research highlights the fact that trust, in the collaborative projects of bio-
tech firms, is built in escalating series. Established science networks are 
an exception. In science parks such as BCN relational-like trust already 
exists among resident firms. However, in newly developed networks trust 
exists very loosely or does not exist at all. With newly developed 
relationships the study can infer that the “trial and error” method was 
evoked. The process starts with a firm engaging in smaller projects aimed 
at testing the trustworthiness of a prospective partner and this is likely to 
lead to more collaborations.  
 
This observation is consistent with Shilling (2008) who argues that 
experimenting by linking up with different partners during the stage of 
establishing a partnership is necessary for high tech firms because 
collaborating is not without risks. The exchange of crucial scientific 
knowledge and technical know-how was found to occur only when trust 
has been established between the collaborating parties.  
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The study also concludes that prior-learning and the absorptive capacity 
of small born-global bio-tech firms performed a leading role in their 
knowledge acquisition process. It was insightful to note that within the 
knowledge supply-chain of small born-global bio-tech firms previous 
learning and the sector based-experiences of the CEOs, bio-entrepreneurs 
or science directors were crucial in terms of absorbing specific capabilities 
or for selecting the ‘right’ partner with specific skills or knowledge that 
complements the firm’s internal capabilities. Cohen & Levinthal (1990) 
emphasises on the importance of understanding what is needed for the 
firm to enhance its innovative capacity. Without prior-learning it is difficult 
for a firm to acquire knowledge or skills that complements its firm-based 
capabilities. It was fascinating to find that the once secretive science 
sector is moving at an alarming pace towards the concept of open science 
(Owen-Smith & Powell, 2004). The explanations above regarding how 
various elements interacting within the knowledge supply-chain of small 
born global firms fit in together satisfies the first research objective of this 
study. The first objective about understands how various elements that 
interact within the knowledge supply-chain of born-global bio-tech firms 
relate to their capability development  
 
Successes in producing innovative products and services documented 
elsewhere e.g. Silicon Valley, the Golden Triangle of Cambridge, London 
and Oxford and the Boston Metropolitan Area have initiated this huge 
wave skewed towards inter-organisational collaborations. Regarding the 
increase in the number of biotechnology firms the study concludes that 
the current restructuring phase in the pharmaceutical and biotechnology 
sector is the main contributing factor. Rafols et al., (2012) made similar 
observations and they reported that this is a fast-developing trend which 
has seen the disintegration of the “Big Pharma” model in favour of 
outsourcing R&D activities to small bio-tech firms in highly concentrated 
innovative regions usually populated with entrepreneurial firms.  
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Findings from a case by case analysis revealed that born global bio-tech 
firms participate in networks. Specifically, they engage in science 
research programmes that involve international scientists in which 
existing firm-specific information is recycled and added to new 
information. Innovations are honed and sharpened resulting in the 
development of innovative products which have made a marked 
difference to human and animal life. The study also highlights that 
although collaborating with other organisations brings a wide range of 
economic effects there are challenges that small born-global bio-tech 
have to deal with to achieve their corporate goals. These have been 
identified as: intellectual property violation, communication problems, 
cultural related issues, government policies and political influence.  
 
Irrespective of the afore-mentioned challenges associated with 
collaborating, the reader is informed about the fascinating developments 
that are taking place in the life science industry particularly in the bio-
tech sector where entrepreneurial firms are engaging in science-related 
collaborative programmes. The study shows that the concept of working 
in collaboration is on an upward trend in the bio-tech industry following 
the restructuring that is taking place industry wide. The study can 
disclose that the East Midlands region is very active in science-related 
collaborations. Going way back to the 1960s the region was already 
encouraging innovation networks which resulted in the development of a 
world known pain killer ibuprofen and lately the MRI scan to better the 
lives of human beings.  
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These findings are useful to a wide range of stakeholders that include: the 
government, the EU Commission, other researcher and bio-tech firms. 
They help them to evaluate whether their networking strategies are 
enhancing product and process innovations in the biotechnology sector. 
Finally, this research has shown that the process of developing innovative 
capabilities for small born-global firms requires them to develop 
productive relationships with other organisations. Their business and 
social networks should include both domestic and global partners to 
increase their propensity to generate new scientific knowledge and 
technical know-how. The learning experiences of bio-entrepreneurs who 
are responsible for formulating the strategies for their firms are crucial in 
terms of choosing the right combination of resources that complement 
their operations.  
 
Conclusively, the study demonstrates that firms which operate in the bio-
tech sector should aim to adjust their resource mix in order to enhance 
their innovative capabilities as they underpin their ability to make 
innovations. When doing so, they have to pay particular attention to 
various elements that include: trust, knowledge management and 
absorptive capacity within their knowledge supply as they significantly 
influence their capacity to develop their innovative capabilities.   
5.1 Research contribution 
The contribution of this study is in three folds. Firstly, the study highlights 
the experiences of small born-global bio-tech firms in the East Midlands 
within their knowledge supply-chain. It explains various elements that 
influence their capacity to generate scientific and technical know-how. 
Smith et al. (2012) suggest that, the East Midlands region possesses an 
important local concentration of pharmaceutical (R&D) activities. On that 
account, this study has enlightened the reader about the actions of bio-
tech firms which appear to be leading the way in science-related R&D 
programmes within the region.  
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Secondly, the study makes a theoretical contribution by modifying 
Freeman’s et al. (2010) influential conceptual model of rapid knowledge 
development for smaller born-global firms. The modified model can be 
used to explain the innovation management processes of both small and 
large organisations. Thirdly, the study is valuable to a number of 
stakeholders. It informs other researchers about the activities of small 
born-global bio-tech firms and it helps science institutions, policy-makers 
including: the UK government, the EU Commission to assess whether 
their strategies are enabling small firms to make new discoveries in the 
biotechnology industry given the amount of investment in the sector 
which is in the region of £5.5bn (HM Government, 2010).  
 
The idea to reach a wide range of audiences was rather nicely summed up 
by Todtling et al. (2009) who understood innovation systems model as 
encompassing the business sector, the science sector, and policy actors. 
This is consistent with Easterby-Smith et al. (2012) who argue in favour 
of research that contributes to a field of study in different ways. The 
scholars insist that, “theoretical contribution is most important, and it 
may be supplemented by each of the others” (p.237).  
5.2 Newness 
The achievements of this research are new in the way they employ the 
preliminary research findings, case-by-case, cross case analysis, and 
secondary data to formulate a new conceptual framework which 
contributes to the understanding of the concept of dynamic capabilities 
and network theory. While other instruments exist with capabilities similar 
to the Knowledge and Innovative Capabilities Model very few have been 
developed to be utilised in the life science sector. This research was 
particularly new in demonstrating the connectivity and the influence of 
various elements within the knowledge supply-chain of small born-global 
bio-tech firms.  
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5.3 Limitations of the thesis 
While this study has provided valuable insights into the social world of 
small born-global bio-tech firms global markets are much more complex 
and sophisticated. Science-related projects/programmes that have a 
global dimension involve more than eight participants, decision-making in 
that context is fraught with many more variables and challenges that 
influence the process of developing innovative capabilities, and the focus 
on bio-tech firms in the East Midlands region mimic the demands of a 
study of this magnitude at the feasibility stage.  
 
Therefore, it merits investigations that use of research methodologies 
which involve quantitative measures in order to provide even more 
accurate insights into the extent to which various elements and elements 
mitigate in the knowledge supply-chain of born-global firms.      
5.4 Barriers to collaboration 
The study also highlights some barriers that hinder the process of 
capability development in complex global networks. The issue of 
appropriation of intellectual property was a serious factor which affected 
the process of exchanging technical know-how and scientific knowledge. 
The global networks of born-global bio-tech firms involve multiple parties 
from different countries. Therefore, during fieldwork all the participants 
emphasised that trust and commitment were the most important factors 
that influenced the productivity of a relationship in the way of resource 
sharing. To overcome the dilemma of trust firms evoked the “trial and 
error” method i.e. conducting due diligence on their prospective partners. 
What was clear in the conversations with the key informants was that; in 
established networks trust occurred at a very early stage in a relationship 
but in newly developed relationships it was developed in escalating series. 
This is consistent with what Schilling (2008) called a process of 
experimentation when formulating an alliance.    
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5.5 Recommendations 
Political institutions and government policy-makers play a leading role in 
shaping firm development patterns in market-oriented economies, 
especially, in uncertain economic times. A flexible, dynamic and 
innovative bio-tech sector significantly improves the lives of human 
beings and animals. In the recent past the world has witnessed the 
private sector taking a leading position in the society in creating wealth 
and jobs for example (Halkier et al., 2010).  
 
This apparent transformation from government to governance requires 
extensive and on-going interaction and partnership between public and 
private actors as opposed to imposing government ideologies by 
exercising authority. This state of affairs is needed for small born-global 
bio-tech firms to realise their potential especially in the life science sector 
where life-saving drugs and clinical products can make a difference to the 
lives of the general public worldwide. To achieve this desirable state it is 
necessary to develop a platform on which a wide range of resources can 
be exchanged in order to influence the direction of socio-economic 
activities.  
 
The ability to perform this role effectively depends not only on political 
and financial resources - for example, but it also depends on the 
decentralisation of policy-making and revenue-generating powers. In that 
sense, the study recommends that the central government should 
reconsider its strategy of centralising policy-making and devolve those 
powers to local authorities. This will enable local institutions that facilitate 
networking such BCN, Medilink, Business Link etc. to respond quickly to 
the needs of small but entrepreneurial firms and at the same time 
encouraging their economic growth and development.  
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5.6 Future research direction  
This study explains the innovative capability development process of small 
born-global bio-tech firms. The traditionally held view that large Bio-
pharmaceuticals are the most dominant force in global markets might well 
be evolving. As such, the advent of small born-global bio-tech firms on 
the global stage in substantial numbers (Kermani & Bonacossa, 2003) 
worldwide reflects an emerging business model with the potential to 
perhaps become the most dominant in harsh economic times in which 
large organisations are feeling the strain.  
 
In that regard, the born-global phenomenon requires great attention 
because it heralds the emergence of a new phase in international 
exchange systems whereby regardless of the size of a business, any 
company can perform an important role in global markets. For future 
research, the study recommends research which focus on how small born-
global bio-tech firms learn to cope with the complexity of global markets 
given their cultural diversity. This will help us to deepen our 
understanding of how born-global firms organise the exchange of ideas, 
technologies, people and information in global networks.  
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Appendix 1: Interview guide questions 
 
 
 
     
Nottingham Business School      
Division of Management   
 
Discussion about Born-Global Firms – East Midlands, England 
Semi-structured questions – Interview guide questions  
I would start by saying thank you for agreeing to participate in the 
discussion about small born-global bio-tech firms. In particular, their 
collaborative activities with other firms, research institutions, regional 
incubators and research centres which can be found within the East 
Midlands and overseas  
1. Before we go into great depth about how your firm develops its 
capabilities in order to improve its drug discovery abilities or technical 
know-how for the development of new clinical apparatus, would you tell 
me a bit about your firm’s business activities? Do you operate in both the 
domestic and international markets?   
2. The process of developing scientific knowledge in the bio-tech sector 
requires to a greater extent fluid scientific information inflow into a firm 
and that has been seen, from an academic perspective, as vital for new 
drug discovery and new product development. Can you explain to me the 
extent to which you use your personal or business networks to acquire 
this type of information and how wide spread are these connections? And 
how risky is sharing information with your business partners? 
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3. Are you part of an established business network? In the future do you 
see your firm developing new partnerships as a way of enhancing your 
knowledge base i.e. enhancing your ability to develop new scientific 
knowledge and technical know-how for the development of new clinical 
products and services? 
4. To what extent does trust influence how you share and exchange ideas 
with your business partners? Could you tell me a bit more about how you 
develop this trust in both existing and potential i.e. newly developed 
partnerships? 
5. Is your firm engaged in inter-firm collaborations, if so which ones? In 
other words you are working with other firms within the East Midlands or 
overseas to jointly discover new drugs or to jointly develop new clinical 
products. 
6. Going back to the question of trust and inter-firm collaborations at 
which stage would you say trust occurs when collaborating with other 
firms or research agents in your established networks or newly developed 
networks? As a follow up question to that what would you say comes first, 
is it inter-firm collaborations or trusting your business partners? What 
might be the reasons for developing trust in these two different ways?  
7. How do you build trust in your collaborative networks? Do you trust a 
firm/business because of the competences (i.e. based their skills & 
knowledge bases and reputation? 
8. How important are social networks in your efforts to develop new 
scientific knowledge and technological know-how?   
9. Working in collaborative networks is a very risky strategy how one can 
minimise the risk involved e.g. minimising the risk of having your ideas 
represented by your partners as theirs. 
10. What risks do you envisage when collaborating with other firms that 
are in the same line of business or different line of business?  
11. How do you learn in networks? Is it through observing others or 
through coaching?  
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12. When working in collaborative projects with external parties the issue 
of who owns the new development becomes very important. How do you 
ensure that a joint discovery or the joint development of clinical 
equipment remains jointly owned? 
13. Tacit knowledge exists in the head of the knower. In your personal 
and business networks how do you ensure that this knowledge is 
exchanged and captured in your firm? 
14. That leads us to the question of knowledge acquisition. When working 
with people who have better skills, better knowledge bases and 
technological know-how how do you select useful information?, because 
there is this danger that you end up acquiring vast amounts of knowledge 
that you may never use. How important is prior learning in the process of 
assimilating knowledge that your social and business networks make 
available to you?   
15. Do you do a trial and error method to see which combinations of 
business partners might work for you? And how important is this 
experimentation stage in building a resource base for your firm?  
16. In the last 5 years can you recall any discoveries or clinical 
services/apparatus that you have developed that you can attribute to 
your collaborative actions locally and internationally? 
17. What is your opinion about working in collaboration in the bio-tech 
sector?                      
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Appendix 2: Ethical approval form  
NOTTINGHAM TRENT UNIVERSITY 
COLLEGE OF BUSINESS, LAW AND SOCIAL SCIENCES 
BLSS/College REC Form 
APPLICATION FORM FOR ETHICAL APPROVAL OF A RESEARCH 
PROJECT 
For use by members of academic staff and doctoral students 
Who should use this form? 
You should use this form if you are a member of academic staff or a research degree student 
(including the DBA or ProfD). If you are a student on a taught masters or undergraduate 
programme, you should use Form BLSS/School REC 
 
Can I begin work before the project is ethically approved? 
NO primary data collection can begin until a favourable ethical opinion is received from the College 
Research Ethics Committee or from an external REC, or, alternatively, you have established that 
your project does not need ethical approval. Collecting primary data in the absence of ethical 
approval, or in the face of an adverse ethical opinion, may constitute a disciplinary offence.  
 
If, after receiving ethical approval, you change your project such that the information provided in 
this form no longer holds, the approval will automatically become void, and you should re-apply 
for ethical approval. 
 
Is there any help available to complete this form? 
Yes. Guidance on filling in this form can be found in Guidance Note BLSS/Ethics 01. This document 
can be found in the ethics section of the University’s Research Intranet. 
 
In this site, you will also find documents dealing with specific issues in research ethics, and also 
some examples of participant information sheets and consent forms. 
 
Further advice is available through the BLSS Graduate School Office. Please email Sandra. Odell 
 
 
 
Please make sure that you complete the Declaration at the end of the form. Doctoral 
students must ask their Director of Studies to countersign the form before it is 
submitted.   
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1. Information about the project 
Title of Project: An Investigation how small born-global bio-tech firms in the 
East Midlands, UK develop their innovative capabilities: A multi-case 
approach 
Name of Principal Investigator (PI): Amon Simba 
Names of co-investigators (CIs) (If any of the CIs are not employed at NTU, please give 
the name of their organisation) 
None 
How many additional research staff will be employed on the project? None  
Please give their names (if known) and their organisational affiliation: N/A 
Project start date: 1st of April 2010 
Estimated end date of the project:1st of April 2014 
Who is funding the project? Myself 
Has funding been confirmed? N/A 
(For research degree students only) Have you applied for and received project approval? 
Approval applied for – Approved 
If so, please give date of approval: January 2012 
(For research degree students only) please provide  the name of your Director of Studies 
Dr. Francis Neshamba 
Which learned society’s code of ethical practice is most relevant to your project? (for 
example, the Social Research Association, the British Psychological Society, the Socio-legal 
Studies Association) 
Social Research Association 
2. Does this project need ethical approval?     
 
Does the project involve collecting and/or analysing primary or 
unpublished data from, or about, living human beings? 
Yes No 
  
No 
Does it involve collecting or analysing primary or unpublished 
data about people who have recently died, other than data that 
are already in the public domain? 
    
No 
Does it involve collecting or analysing primary or unpublished 
data about or from organisations or agencies of any kind, other 
than data that are already in the public domain 
 
Yes 
 
Does it involve research with non-human vertebrates in their 
natural settings or behavioural work involving invertebrate 
species not covered by the Animals Scientific Procedures Act 
(1986).1 
  
No 
                                   
1 The Animals Scientific Procedures Act (1986) was amended in 1993. As a result the common octopus 
(Octopus vulgaris), as an invertebrate species, is now covered by the act. 
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If the answer to all the above questions is NO, you do not need to submit your project for ethical 
approval. You should sign the Declaration at the end of the form, and keep a copy for your own 
records. Doctoral students must ask their Director of Studies to countersign the declaration, and 
they should keep a copy, too. 
 
If the answer to any of the above questions is Yes, please proceed to Section 3 below 
3. Does the project require Criminal Records Bureau checks? 
Please refer to Guidance Note BLSS/Ethics 06.  
 Yes No 
  
Does the project involve direct contact by any member of the 
research team with children or young people under 18 years of 
age? 
  
No 
Does the project involve direct contact by any member of the 
research team with adults with learning difficulties; adults who 
are infirm or physically disabled; adults who are resident in social 
care or medical establishments; or adults in the custody of the 
criminal justice system? 
  
No 
Has a CRB check been stipulated as a condition of access to any 
source of data required for the project 
 No 
 
If you have answered Yes to any of these questions, please explain the nature of the contact 
required by the project, and the circumstances in which it will be made. 
4. Is this project liable to scrutiny by external ethical review 
arrangements? 
 
Has a favourable ethical opinion been given for this project by an 
NHS or social care research ethics committee, or by any other 
external research ethics committee? 
Yes No 
  
No 
Will this project be submitted for ethical approval to an NHS or 
social care committee or any other external research ethics 
committee? 
  
No 
 
If the answer to either of these questions is YES, please sign the declaration at the end of the 
form, and send a copy to the Research Office. Doctoral students must ask their Director of Studies 
to countersign the form before submitting it.  
 
Note - if you are applying to an NHS or Social Care REC, you are advised to consult Guidance Note 
BLSS/ Ethics 03 
 
If the answer to both these questions is NO, please proceed to Section 5. 
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5. About the project 
If the information required below is provided in a succinct form in a previous document, such as 
your application for external funding or for approval of a PhD project you may submit this 
document (or preferably the relevant section from it) either in whole or partial answer to the 
questions below. 
What are the aims and objectives of the project? 
 
The main aim of this research study is to investigate how entrepreneurs in the 
biotechnology sector make innovations through strategic alliances. It explores how the 
learning and strategic alliance of bio-entrepreneurs influence their capability 
development by taking advantage of regional knowledge networks. It also examines how 
they manage knowledge both within the firm and that which is acquired from their 
external connections in order to ensure continuous innovation and sustainable business 
development. 
To explore the extent to which bio-entrepreneurs/bio-tech firms within the East Midlands 
region in Britain use knowledge networks to generate knowledge and share ideas.  
To examine the learning processes of bio-entrepreneurs and bio-tech firms in a network 
or a cluster in the UK.  
To investigate how external resources such as knowledge, acquired from knowledge 
networks is vital for business and new product development. 
To understand the importance of knowledge management systems and how these 
systems can ensure continuous product development    
 
Briefly describe the principal methods, the sources of data or evidence to be used and the number 
and type of research participants who will be recruited to the project 
In order to investigate the dynamic impact of knowledge networks and clusters on the innovative 
capabilities of bio-entrepreneurs, bio-tech firms are drawn from the East Midlands region. A semi-
structured questionnaire is used to collect qualitative data from 10 bio-tech firms and a structured 
questionnaire is employed to collect quantitative data from 150 bio-tech firms to be targeted as 
part of the survey. Seminars and conferences on networking will be attended to observe activities 
in the bio-technology sector.       
 
What research instrument(s) will be used to collect data? 
A semi-structured questionnaire is used to guide face-to-face interviews and the interviews are 
recorded using a voice recorder. Additionally, a structured questionnaire is used in a survey to 
collect data for analysis using SPSS.  
   
If you are using an externally validated scale, please specify 
 
If you are not using an externally validated scale, please attach a copy of the research instrument 
you will use to collect data (for example, a measurement scale, questionnaire, interview schedule, 
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observation protocol for ethnographic work, or, in the case, of unstructured data collection, a topic 
list). 
6. Confidentiality, security and retention of research data 
 
Are there any reasons why you cannot guarantee the full security and 
confidentiality of any personal or confidential data collected for the 
project? 
Yes No 
  
No 
Is there a significant possibility that any of your participants, or people 
associated with them, could be directly or indirectly identified in the 
outputs from this project?  
  
No 
Is there a significant possibility that confidential information could be 
traced back to a specific organisation or agency as a result of the way 
you write up the results of the project?  
  
No 
Will any members of the project team retain any personal or confidential 
data at the end of the project, other than in fully anonymised form?  
  
No 
 
If the answer to all these questions is No, please explain briefly how you will ensure the 
confidentiality and security of your research data, both during and after the project 
 
The tapes and transcripts of interviews discussions will be handled only by me, in line with 
data protection principles and the approved research protocol. Hard copies of research 
notes will be kept in locked filing cabinets, and electronic files are kept on password 
protected computers which are not accessible to any other university staff. Participants will 
be assigned pseudonyms and will not be otherwise named or identified in any publication 
arising from this project. All possible care will be exercised to ensure that participants and 
the organisation they work for cannot be identified by the way I write up my findings.  
 
At the end of the study, in line with usual practice, all the transcripts will be deposited in 
the archive of research material maintained by the Business School. The transcripts will be 
fully anonymised before they are archived. Once the transcripts have been deposited in 
the Business School archive, the tape of the interviews will be destroyed and the relevant 
files erased from my computer. 
 
If the answer to any of these questions is YES, please explain: 
why it is necessary for the research to be conducted in the way you propose, such that the 
usual standards of confidentiality and security cannot be respected 
what steps will you take to maximise confidentiality and security, within the constraints 
imposed by the research design 
what steps you will take to ensure that participants understand and consent to the 
implications of these constraints?  
 
7. Informed consent 
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Please see Guidance Note BLSS/Ethics 02 for examples of model participant information sheets 
and participant consent forms, together with advice on how to use them 
 Yes No 
Will all participants be fully informed why the project is being conducted 
and what their participation will involve, and will this information be given 
before the project begins? 
 
Yes 
 
Will every participant be asked to give written consent to participating in 
the project, before it begins? 
 
Yes 
 
Will all participants be fully informed about what data will be collected, 
and what will be done with these data during and after the project? 
 
Yes 
 
Will explicit consent be sought for audio, video or photographic recording 
of participants? 
 
Yes 
 
Will every participant understand what rights they have not to take part, 
and/or to withdraw themselves and their data from the project if they do 
take part. Will they also understand that they do not need to give you 
reasons for exercising these rights and that there will be no repercussions 
as a result? 
 
 
Yes 
 
If the project involves deceiving, or covert observation of, participants, 
will you debrief them at the earliest possible opportunity? 
 
 
 
No  
 
If the answer to all the above questions is YES, please explain briefly how you will 
implement your answers. You are advised to attach copies of your participant information 
sheet and consent form as evidence of your plans.  
All participants will be approached prior to commencement of the fieldwork and given a 
participant information sheet explaining the purpose of the study, what their participation 
will involve and their rights with respect to non-participation and if they subsequently 
decide not to participate. They will be asked to sign a written consent form and their 
permission will be sought to tape record the interviews. No deception or covert observation 
of the participants is anticipated. Please see Appendices 1, 2 and 3 for copies of the 
participant information sheet and consent form for this project. 
 
If the answer to any of the above questions is NO, please explain: 
why it is academically necessary for the project to be conducted in a way that will not 
allow all  participants the opportunity to exercise fully-informed consent 
and how you propose to address the ethical issues arising from the absence of 
transparency.  
 
You are advised to attach copies of your participant information sheet and consent form as 
evidence of your plans. 
 
 
8. Risk of harm 
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(If there is any possibility that the project involves significant risks to researchers, you are advised 
to consult Guidance Note BLSS/Ethics 04 on the assessment and management of risk, and to 
submit a risk assessment form to the relevant authority). 
Is there any significant risk that your project may lead to: Yes No 
Physical harm to participants or researchers?   
No 
Significant psychological or emotional distress to participants    
No 
Harm to the reputation of participants, or their employers, or of any 
other persons or organisations? 
 
 
 
 
No 
 
If the answer to any of these questions is YES, please explain: 
the nature of the risks involved, and why it is academically necessary for the project to 
incur them 
how you propose to mitigate them 
the arrangements by which you will ensure that participants understand and consent to 
these risks 
any arrangements you will make to refer participants to sources of help, if they are 
seriously distressed or harmed as a result of taking part in the project 
your arrangements for recording and reporting any adverse consequences of the research                                               
N/A 
9. Risk of disclosure of harm or potential harm  
If the project is likely to involve work with children, or the discovery of physical or mental abuse of 
children, you should consult the Nottingham Trent University Policy on Child Protection (available 
in the BLSS Ethics Toolkit) before completing this section of the form. 
 
Is there a significant risk that the project will lead participants to 
disclose evidence of previous criminal offences, or their intention to 
commit criminal offences? 
Yes No 
  
No 
Is there a significant risk that the project will lead participants to 
disclose evidence that children or vulnerable adults are being 
harmed, or are at risk of harm? 
  
No 
Is there a significant risk that the project will lead participants to 
disclose evidence of serious risk of other types of harm? 
  
No 
 
If the answer to either question is YES, please explain: 
why it is academically necessary for these risks to be incurred  
what actions you would take, if such disclosures were to occur 
whether you will take advice before taking these actions, and from whom 
what information you will give participants about the possible consequences of disclosing 
information about criminal or serious risk of harm 
 
 
 
10. Payment of participants 
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Do you intend to offer participants cash payments or any other kind of 
inducements or compensation for taking part in your project?   
Yes No 
  
No 
Is there any significant possibility that such inducements will cause 
participants to consent to risks that they might not otherwise find 
acceptable? 
  
No 
Is there any significant possibility that the prospect of payment or 
other rewards will systematically skew the data provided by 
participants in any way? 
  
No 
Will you inform participants that accepting compensation or 
inducements does not negate their right to withdraw from the project? 
  
No 
 
If the answer to any of these questions is YES, please explain: 
 
the nature of the inducements or the amount of the payments that will be offered 
the reasons why it is necessary to offer them  
why you consider that they are ethically and methodologically acceptable 
 
11. Capacity to give valid consent 
Please note that, from October 2007, research involving people who are mentally 
incapacitated and cannot give valid consent must be cleared through the NHS research 
ethics procedures, not through a University REC 
Do you propose to recruit any participants from the following groups? 
 
Yes No 
Children under 18 years of age   
No 
People with learning difficulties 
 
  
No 
People with communication difficulties, including difficulties arising 
from limited facility with the English language 
  
No 
Very elderly or infirm people   
No 
People with mental health problems or other medical problems that 
may impair their cognitive abilities 
 
  
No 
Any other people who may not be able fully to understand the nature 
of the research and the implications for them of participating in it 
  
No 
 
 
 
If you have answered YES to any of these questions, please explain how you will ensure 
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that the interests and wishes of participants (and in the case of children, the wishes of 
their parents or guardians) are understood and taken into account 
12. Is participation genuinely voluntary? 
Are you proposing to recruit participants from the following groups? Yes No 
Employees or students of NTU or of organisation(s) that are formal 
collaborators in the project 
  
No 
Employees recruited through other business, voluntary or public sector 
organisations 
  
No 
Pupils or students recruited through educational institutions   
No 
Clients recruited through voluntary or public services 
 
  
No 
People living in residential communities or institutions 
 
  
No 
People who are in-patients in a hospital or other medical establishment   
No 
People recruited by virtue of their employment in the police or  armed 
services 
  
No 
People being detained or sanctioned in the criminal justice system   
No 
Other people who may not feel empowered to refuse to participate in 
the research 
  
No 
 
If you have answered YES to any of these questions, please explain how your participants 
will be recruited, and what steps you will take to ensure that their participation in this 
project is genuinely voluntary 
13. Online and Internet Research 
If you intend to conduct any part of your project online, please consult Guidance Note BLSS/Ethics 
05 before completing this section 
 
Will any part of your project involve collecting data by means of 
electronic media, such as the internet or email? 
Yes No 
 
Yes 
 
Is there a significant possibility that the project will encourage children 
under 18 to access inappropriate websites, or correspond with people 
who pose risk of harm? 
  
No 
Is there a significant possibility that the project will cause participants 
to become distressed or harmed, in ways that may not be apparent to 
the researcher(s)  
  
No 
Will the project incur any other risks that arise specifically from the use 
of electronic media? 
  
No 
 
If the answer to any of these questions is YES, please explain: 
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why you propose to use electronic media 
how you propose to address the risks associated with online/internet research, especially 
those flagged above (if relevant) 
 
Please ensure, too, that your answers to other questions in this form address these 
questions in ways that are relevant to online research.  
 
The questionnaire to be used for collecting quantitative data will be made available via 
suverymonkey.com an online market research facilitator. The main reason for using this 
method of collecting data is to ensure that I reach out to a wider range of my research 
sample at limited costs and it will allow me to collect the key variable that are of interest 
to this study. Data collected from participants is sent to a secure online storage which can 
be accessed using a unique password and this is reflected on the company’s security 
statement: Passwords and credit card information are always sent over secure, encrypted 
SSL connections and when a user accesses secured areas of our site, Secure Sockets Layer 
(SSL) technology protects user information using both server authentication and data 
encryption, ensuring that user data is safe, secure, and available only to authorised 
persons.   
14. Other ethical risks 
 
Are there any other ethical issues or risks of harm raised by your 
project that have not been covered by previous questions? 
Yes No 
 No 
If you have answered YES, please explain: 
the nature of these issues and risks 
why you need to incur them, 
and how you propose to deal with them 
  
 
15 Research with non-human vertebrates in their natural settings or 
behavioural work involving invertebrate species not covered by the Animals 
Scientific Procedures Act (1986).2 
 
Will any part of your project involve the study of animals in their natural 
habitat? 
Yes No 
  
No 
Will your project involve the recording of behaviour of animals in a non-
natural setting that is outside of the control of the researcher? 
  
No 
Will your field work involve any direct intervention other than recording 
the behaviour of the animals available for observation? 
  
No 
Is the species you plan to research endangered, locally rare or part of 
sensitive ecosystem protected by legislation? 
  
No 
Is there any significant possibility that the welfare of the target species or   
                                   
2 The Animals Scientific Procedures Act (1986) was amended in 1993. As a result the common octopus 
(Octopus vulgaris), as an invertebrate species, is now covered by the act. 
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those sharing the local environment/habitat will be detrimentally 
affected? 
No 
Is there any significant possibility that the habitat of the animals will be 
damaged by the project, such that their health and survival will be 
endangered? 
  
No 
Will project work involve intervention work in a non-natural setting in 
relation to invertebrate species other than Octopus vulgaris? 
  
No 
 
If you have answered Yes to any of these questions, please explain: 
the reasons for conducting the project in the way you propose, and the academic benefits 
that will flow from it 
the nature of the risks to the animals and their habitat 
how you propose to mitigate these risks 
Principal Investigator’s Declaration 
Please tick all the boxes relevant to your project, and sign this form. Doctoral students must ask 
their Director of Studies to countersign it before it is submitted. 
I believe that this project does not require the approval of a research ethics 
committee. I have completed Sections 1-2 and kept a copy for my own records 
 
I request that this project is exempt from review by the College Research 
Ethics Committee, because it will be, or has been, reviewed by an external 
REC. I have completed Sections 1-4 and attach/will attach a copy of the 
favourable ethical review issued by the external REC 
 
Please give the name of the external REC here 
 
 
 
 
I request a statement of ethical approval from the College of BLSS Research 
Ethics Committee, and confirm that I have answered all relevant questions in 
this form honestly  
 
√ 
I confirm that I will carry out the project in the ways described above, and that 
I will request a fresh ethical approval if the project subsequently changes in 
ways that materially affect the information I have given in this form 
 
√ 
I confirm that I have read and agree to abide by the code of research ethics 
issued by the relevant national learned society, and that I have ensured that all 
members of my research team (if any) also do so  
 
√ 
I confirm that I have read and agree to abide by the University’s Research 
Governance Framework, and that I have ensured that those members of my 
research team (if any) who are employees of Nottingham Trent University also 
do so 
 
√ 
 
 
Signed:  (Doctoral student) 
Date: 20/12/2011 
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I have read this form, and confirm that it covers all the ethical issues raised by this project fully 
and frankly. I also confirm that these issues have been discussed with the candidate, and will 
continue to be reviewed in the course of supervision. 
 
Countersigned:  Dr Francis Neshamba   (Director of Studies) 
Date: 18/12/2011 
 
Note: If you are submitting this form by email, you should type your name in the signature space: 
an email attachment sent from your university inbox will be assumed to have been virtually signed 
by you. 
 
If you are a doctoral student and are submitting this form by email, please attach an email from 
your DoS confirming that they are prepared to make the declaration above and to countersign this 
form:  this email will be taken as a virtual countersignature 
 
For office use only 
Date form initially received: 
Initial assessment in office 
(1)    Risk assessment required  Yes  No 
(2)    CRB check required  Yes  No 
(3 )   Exempted on grounds that will be submitted to an external REC Yes  No 
Name of external REC:_______________________________________________ 
Copy of external ethical clearance received  (date):  
(4)   Committee Reviewer(s)  
Review 1: 
Date: 
Review 2: 
Date: 
(5)   Decision (Consultation with Chair) 
Approve    Yes  No 
Approve with conditions (specify) Yes  No 
Date of letter to applicant: 
(6)   Date of receipt of resubmission: 
(7)   Date sent to reviewers: 
(8)   Decision (Consultation with Chair) 
Approve    Yes  No 
Approve with conditions (specify) Yes  No 
Date of letter to applicant 
(9)    Date referred to CREC: 
(10)   Tabled  at CREC  (date): 
(11)   Decision 
Approve    Yes  No 
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Approve with conditions (specify) Yes  No 
Date of letter to applicant: 
(12)   Date of receipt of resubmission: 
(13)   Decision 
Approve    Yes  No 
Approve with conditions (specify) Yes  No 
Date of letter to applicant: 
(14)   Final decision recorded 
Date: 
Signature (Chair of CREC):  
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Appendix 3: Introductory letter  
 
 
 
 
Amon Simba (Post graduate researcher) 
 Nottingham Business School 
 Division of Management 
Burton Street, 8th Floor, Newton Building, Nottingham, NG14BU 
 Tel: 0115 848 500 ext. 85822 
 Email: amon.simba@ntu.ac.uk 
 
The Chief Executive Officer 
XenoGesis Ltd. 
BioCity Nottingham 
Pennyfoot Street, Nottingham, UK 
NG1 1GF 
 
1 May, 2012 
 
Dear Dr Weaver 
 
Bio-tech Collaborations in the East Midlands 
 
I am currently researching about the above, in order to investigate this 
topical and important issue in science. I am a post graduate researcher in 
the Business School at Nottingham Trent.  
 
You have experience that would be of value to this research and I would 
very much like to know your views on how you bio-tech firms generate 
scientific knowledge and technical know-how. I have currently undertaken 
2 interviews with other small bio-tech firms within the East Midlands 
region and my target is to do 5 interviews. I started the interviews in 
November of 2011 and they are on-going until June 2012. An outline of 
the interview structure is attached, although it is not my intention to 
follow this slavishly.  
 
I am aware of the need to treat my findings with the utmost 
confidentiality. No source, individual or organisation, will be identified or 
comment attributed without the express permission of the originator. The 
intended outputs of the research will be presented in my thesis and 
research papers of which I will send a copy directly to you and all the 
other participants. I hope you are able to help me and should be grateful 
if you would return the attached consent form.  
I will contact you on receipt to confirm arrangements for me to visit you 
for the interview. If you prefer to contact me with a suitable time and 
venue convenient for you please let me know by phone or email.  
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In the meantime if require any further information please do not hesitate 
to get in touch. 
       
Yours sincerely  
 
Amon Simba  
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Appendix 4: Consent form 
 
Data Protection Act 1998 
Consent Form for company data to be used for research 
 
Project name:  
 
Biotechnology collaborative activities in the East Midlands 
 
Name of project leader: 
 
Amon Simba 
Contact details: 
 
Nottingham Business School, 8th Floor, Newton Building, 
Burton Street, NG14BU, email: amon.simba@ntu.ac.uk, 
tel: 0115 848 500 ext. 85822 
 
Scope of the project: 
 
 
The data are used for the purpose of a PhD project, and 
research publications  
Any other details: 
 
 
N/A 
 
 
Name of the data 
subject:  
 
XenoGesis Ltd 
Contact details for the 
data subject: 
 
 
Richard Weaver, Chief Executive Officer, XenoGesis Ltd  
The main data to be used for this research is about your collaborative activities 
within and outside the East Midlands region. I will also use data from your company 
website and published material at BioCity about your networking activities. I have 
attached a transcribed copy of the conversation/interview that I did with you 
regarding this subject for you to verify the contents. All the data used for the purpose 
of this research will be kept secure according to the guidelines of research ethics as 
stipulated by the Research Ethics Committee at Nottingham Trent University, 
College of Business, Law and Social Sciences. Thank you  
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Please complete the following: 
 
I consent to data about my company, as outlined above, to be used for the research 
project detailed above. 
 
Signature: R. Weaver (PhD)  
Date: 10.07.2013  
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Appendix 5: Evidence of email communications 
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Appendix 6: Example of a questionnaire 
 
 
 
    Nottingham Business 
                                                                         Division of Management 
 
 
2011/12 International Survey of biotechnology firms 
 
 
 
 
 
 
 
 
 
 
 
 
 
           Please direct any questions about the survey to: 
                                      Amon Simba  
 Postgraduate Researcher 
 Division of Management  
 Nottingham Business School 
 Burton Street, Nottingham 
 NG1 4BU 
 Tel: 0115 848 500 ext. 85822 
 Email: amon.simba@ntu.ac.uk  
   
 
 
This questionnaire is designed to be answered by a variety of 
UK and Europe based bio-tech firms. Please answer as many 
questions as you can. Estimates are acceptable answers to 
factual questions. 
Data will be held securely and confidentially in accordance with 
the Nottingham Trent University Data Protection Policy; no 
individual firms will be identified, and only aggregated findings 
will be made public. Data will be used for academic research 
and to inform bio-tech firms and to help policy-makers 
including the UK government and the EU Commission. 
YOUR CONTRIBUTION TO THE LIFE-SAVING BUSINESS SECTOR IS 
VERY VALUABLE 
FOR EVERY COMPLETED QUESTIONNAIRE A CONTRIBUTION WILL 
BE MADE TO CANCER RESEARCH UK 
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 BIOTECHNOLOGY SECTOR & BUSINESS 
STRATEGY 
  
Q1. In which market category or categories would you say your firm/business 
operates in? Please select all that applies  
  
 Medical technology markets, used to define companies included in the medical 
technology and diagnostics sector 
 Medical biotechnological markets, pharmaceutical companies that develop or 
manufacture medical biotechnology products 
Industrial biotechnology markets, companies that are developing, manufacturing and 
marketing industrial products and services based on biotechnology   
 
Q2. Please indicate the extent to which you disagree or agree with the following 
statements with regards to overseas markets: Please circle      your responses  
 
  
 
Q3. Do you have international business partners that can be classified in any of the 
following categories?   
Please select all that applies.  
  Private research lab    
  
  University/Hospital 
 
  Government Lab 
 
  Established biopharmaceutical companies 
 
Our firm has operations in more than one country 1 2 3 4 5 
Our firm is part of a network of other firms in the UK and overseas 1 2 3 4 5 
Our goal for networking with other firm(s) overseas is to take advantage 
of the overseas markets 
1 2 3 4 5 
We source new technology inside the UK and overseas 1 2 3 4 5 
We seek new ideas from overseas to enable us to continuously 
produce new products 
1 2 3 4 5 
Some markets are attractive in terms of opportunities to maximise profit 
returns 
1 2 3 4 5 
We seek lower costs 1 2 3 4 5 
We go  to overseas markets as a way of avoiding local competition 1 2 3 4 5 
Our business has developed significantly as a result of venturing into 
foreign markets 
1 2 3 4 5 
With our overseas partners we have jointly developed innovative 
products  
1 2 3 4 5 
We are benefiting more from our overseas business partners 1 2 3 4 5 
We seek scientific knowledge which is not available in our business 1 2 3 4 5 
Strongl
y Agree  
A
g
re
e 
  
Neither 
Agree 
nor 
Disagree  
D
is
ag
re
  
 
 
Strongly 
Disagree  
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  Other bio-tech firms 
 
  Other, Please specify  
 
 
 
Q4. Reasons for networking with a foreign partner or foreign partners  
Using a scale of LOW to HIGH IMPORTANCE rate the following reasons, of forming 
business networks or corporative arrangements with a foreign partner, according to how they 
influence your decision of doing so 
 
 
 
 
Importance 
Low                                  High  
    1          2            3            4           
5 
Research and development R&D       
Regulatory affairs      
Production/manufacturing      
Access international markets/distribution 
channels 
     
Access to capital (venture capitalists, EU funding, 
government funding etc.)  
     
Access to intellectual property (IP) from 
international partner   
     
Access others’ knowledge and skills       
Other, please specify 
 
     
  
Q5. Please rate each of the following strategies on your firm’s global performance 
since your firm entered the overseas markets through a networking  
knowledge development strategies on the 
international scene  
 
Importance 
Low                                           
High   
    1          2            3            4           
5 
Captured and used knowledge obtained from 
other industry 
sources including: partner’s industry 
associations, competitors, clients and foreign 
suppliers 
 
 
 
 
 
 
 
 
 
 
 
 
Captured and used knowledge obtained from 
public research institutions including 
government laboratories through foreign partner    
     
Developed new knowledge through collaborative 
arrangements with foreign partners 
     
Used and updated databases of scientific 
information   
     
Developed firm policies and practices for 
knowledge/intellectual property protection 
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Developed/encouraged staff 
education/upgrading 
     
International Business Strategies  
Increased firm size through international joint 
ventures 
     
Began new research & development projects      
Allowed us to expand into foreign markets       
Entered product trials/adapted products or 
processes for 
increased market penetration  
     
Other, Please specify      
Q6. In the last 5 to 10 years was your firm involved in biotechnology related 
cooperative/collaborative arrangements with other foreign firms, academic 
institutions, research centres or hospitals? In the table below, select collaboration/co-
operation arrangements by each partner type and their geographic location:  
  
 
 
Country/ 
Region  
 
 
 
Partner Type 
Biotechnology 
firm 
Non-
biotechnology 
firm 
Academic 
Institution/Hospital 
Incubators/Research 
centres/knowledge 
centres 
Other, 
Please 
specify 
 
USA 
     
 
Europe 
     
 
Asia 
     
 
Other, 
Please 
specify 
 
 
     
 
  
 
 
Q7. Do you think there is anything unique about developing science technology with 
an overseas business partner? 
 
 
If yes would you say the capabilities are…………… 
Please select all that applies 
Unique (they cannot be found anywhere in my home markets)  
 
Novel (new) 
Yes No 
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Difficult to imitate (they cannot be easily copied)  
 
Significantly improve your product innovation 
 
Significantly improve business processes  
 
Q8. In the last 5 to 10 years has your firm introduced any new or significantly changed 
bio-tech products?   
 
Yes           No  
 
 
If you answered yes to the above question please continue to question 8a and b  
 
(a) Were any of these new products new to your overseas market(s) as well as to your 
firm? 
   
Yes            No 
           
(State NO if all new products were essentially similar to those already available from 
competitors)  
 
(b) Relative to your firm’s objective of taking advantage of your business networks in 
the overseas markets please rate your performance in the following:  
 
Please circle      your responses   
 
 
 
Speed of product innovation and project 
completion  
Poor 
 
 
1 
OK 
 
 
2 
Average 
 
 
3 
Good 
 
 
4 
Very 
Good 
 
5 
Market Share achieved as a result of 
overseas networking  
1 2 3 4 5 
Sales of your innovative products/services 
achieved as a result of your overseas 
partnership(s) 
 
1 
 
2 
 
3 
 
4 
 
5 
Return on investment (i.e. investment in 
terms of time, human capital or financial 
capital) 
 
1 
 
2 
 
3 
 
4 
 
5 
 
Profitability of the new markets 
 
1 
 
2 
 
3 
 
4 
 
5 
 
Q9. Access to international talent i.e. highly skilled staff and deep talent pool 
Please rate the level of importance of the following in relation to your internationalisation 
strategy 
 
 Very 
Important 
Important Somewhat 
Important 
Not 
Important 
No 
Opinion 
Skilled new 
graduates with 
world class 
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technical training 
Pool of 
experienced 
entrepreneurs  
     
Access to bio-
tech executives  
 
     
Scientific experts 
 
     
Experienced 
investors (i.e. 
venture 
capitalists, angels 
or private equity  
     
 
 
 
Q10. Knowledge management strategies adopted for the international venture 
 
         Please select all that applies to your business 
                                    
 We protect knowledge using intellectual property protection law  
We enter into confidentiality agreements with our international partners 
 
We code knowledge into processed information and store it in a secure database 
 
Give people access rights to specific company information/data   
 
We create good working conditions that encourage knowledgeable individuals  
 to stay in my company for longer both domestically and internationally 
 
 
Q11. What is your role in the business? Please select all that applies 
 
  Business Owner (bio-entrepreneur) 
 
  Co-owner  
   
  Scientist  
 
  Business Development Manager 
 
  Academic consultant 
 
  Other, please specify 
 
 
 
Q12. How old would you say your firm is?  
 
  0-5 years 
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  5-10 years 
 
  10-15 years 
 
  15 years + 
 
 
Q13. Which of the following would you say is your home market? 
 
  United Kingdom 
 
  EU (European Union) 
 
  Asia-Pacific 
 
  USA  
 
  Other, please specify 
 
         
 
Thank You! 
Thank you very much for your time in completing this survey which I hope will enhance the 
development of life-saving products and services. 
Please note that your information will be completely anonymous and shown only in 
aggregated form. For your participation I will send you a report of the combined 
results and findings.  
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Part B: Personal Development 
Research articles extracted from the thesis  
Paper 1 
Simba, A., (2013). A new model of knowledge and innovative capability development for 
small born-global bio-tech firms: Evidence from the East Midlands, UK. The International 
Journal of Entrepreneurship and Innovation Management, Special Issue on: "Inter-Firm 
Cooperation and Innovation, Inderscience. In Press  
 
Paper 2 
Simba, A., (2013). The impact of global R&D networks on the innovative capabilities of born-
global biotech firms: A multi-case approach. The International Journal of Entrepreneurship and 
Small Business, Vol.20, No.3, pp.342–362  
 
Research articles under review 
 
Paper 3 
Simba, A., (2013). The learning experiences and the absorptive capacity of bio-
entrepreneurs: A case of the East Midlands Region, UK. International Journal of Business 
Administration 
 
Paper 4 (paper not included in this thesis) 
Simba, A., and Ndlovu, T., (2014). The entrepreneurial marketing 
management and commercialisation arrangements of born global bio-
enterprises: The case of UK companies. Paper submitted to International 
Business Review    
 
 
Conference Proceedings  
 
Paper 4 
Simba, A, Wang, J, & Neshamba, F, (2011). The impact of knowledge networks and clusters 
on the Innovative capabilities of bio-entrepreneurs, in the United Kingdom, The article was 
presented in Nov 2011 at the Octagon Conference in Sheffield (ISBE) 
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A new model of knowledge and innovative capability development 
for small born-global bio-tech firms: Evidence from the East 
Midlands, UK 
 
Amon Simba¹ 
Abstract 
In the last two decades, the rapid transformation in information and communication 
technologies together with the adoption of more liberal structures governing trade as well 
as the modularisation of production and services has resulted in the proliferation of small 
born-global bio-tech firms. The firms have an international flair and they rapidly globalise 
their operations. Their strategic intent is to develop unique innovative capabilities through 
networking. In science-based industries such as the biotechnology sector the ability to 
innovate can only occur if a firm is able to both generate and integrate knowledge from 
inside and outside its boundaries. In that respect, this article employs a multi-case approach 
to construct a frame of reference for developing innovative capabilities that complement 
firm-based competences. The main focus is on small born-global bio-tech firms in the East 
Midlands region of the United Kingdom. The newly developed framework is invaluable to 
researchers, small born-global bio-tech and large bio-pharmaceutical firms. More so, it 
contributes to the concepts of dynamic capabilities and networking.  
 
Keywords 
Born-global, networks, knowledge, internationalisation, absorptive capacity, inter-
organisational collaborations, innovation ecosystems 
 
Introduction 
Born-global bio-tech firms are entrepreneurial enterprises which develop complex 
international resource configurations (Karra et al., 2008). Scholars universally agree that 
when a firm ventures beyond its immediate vicinity, it is exposed to unique resource 
combinations (Schumpeter, 1950; Oviatt & McDougall, 1994; Cooke, 2001; Owen-Smith & 
Powell, 2004; Johnson & Vahlne, 2009). Born-global bio-tech firms exhibit characteristics of 
traditional entrepreneurial firms. For example, they are proactive and, innovative and they 
take risks but in an exceedingly complex fashion involving significant degrees of uncertainty 
synonymous with global markets (Burns, 2012). As we strive to understand how these new 
types of international ventures complement their firm-based competences fresh and more 
nuanced theories are needed. From that perspective, the article proposes a theoretical 
framework for born-global bio-tech firms illustrating the complex processes and 
mechanisms in their knowledge supply-chain. Empirical evidence from multiple cases of bio-
tech firms, in the East Midlands region of the United Kingdom, is used to construct a new 
model of “Knowledge and Innovative Capability Development”. The model is anchored on the 
ideas of Freeman et al. (2010). An understanding of how born-global bio-tech firms view 
their social world helps us to interpret and comprehend the meanings they attach to their 
lived world (Pittaway, 2000; Saunders et al., 2007).  
 
¹Nottingham Business School  
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A definition of Born-global bio-tech firms  
Born-globals are defined in a number of different ways. For example, Oviatt & McDougall 
(1994) define them as international ventures that seek to derive competitive advantage from 
the use of resources and the sale of outputs in multiple countries. Other scholars (see 
Knight & Cavusgil, 1996; Knight, 2001) use a variety of measures as criteria for defining 
these international ventures such as: the vision and strategy to become global, time of 
internationalisation and overseas sales volumes. Considering the different labels used to 
define born-globals a distinguishing feature in all their definitions is that, they adopt a global 
strategy evidenced by their structural dimension which encompasses various actors in 
multiple countries (Oviatt & McDougall, 1994). Regardless, of this distinctive feature there 
still is no universal agreement to a single definition of born-globals. In all the confusion and 
misconceptions regarding the definition of born-global firms, the author is of the view that 
researchers should base their definitions on observable traits. Particularly, behaviours that 
are embedded in the design of the ventures should form the basis of how we define them. 
For example; they should be based on three prominent multi-dimensional constructs of 
social capital identified in the literature as structural, relational and cognitive dimensions. 
Structural dimension is related to global network ties and their overall configuration (Burt, 
2002; Ahuja, 2000). Relational dimension focuses on trust, trustworthiness, norms and 
obligations in a global network (Fukuyama, 1995; Putnam, 1993). Cognitive dimension refers 
to those resources providing ‘shared representations, interpretations, and systems of 
meaning among parties’ (Nahapiet & Ghoshal, 1998, p.244). From that perspective, it suffices 
to define born-globals as small bio-tech firms which have an international flair and rapidly 
globalise their operations without any preceding long-term domestic or internationalisation 
period.       
 
Theoretical Background 
Scholarship on the internationalisation of small firms is littered with various models aimed at 
explaining their internationalisation processes. From early on Johnson & Vahlne (1977) 
developed the inspirational Uppsala internationalisation model (U-model) and it became a 
widely used model in business management. The model was based on the assumption that 
an enterprise develops in foreign markets by adopting a process which evolves incrementally 
in stages ‘progressing like rings in the water’ Bhowmick (2004, p.760). Put in a different way, 
the enterprise passes from one stage to another as it acquires more and more international 
experience as well as deepening its resource commitments. Other management scholars 
(e.g. Rogers, 1962) have developed the Innovation Diffusion Model (I-model) which focusses 
on internationalisation as innovation for the firms. These two models (U and I) became the 
bedrock of stages theory that explained the incremental internationalisation process of small 
firms. According to Anderson (1993, p.212) ‘both the U and I models can be properly 
regarded as behaviourally oriented’. Arguably, the gradual process of internationalisation, as 
denoted on the U and I models, can be seen as a risk-averse strategy adopted by firms as an 
entry mode into foreign markets. Moving forward in 1997 Teece, Pisano, and Shuen 
proposed the dynamic capabilities theory, they defined the theory as “the ability to 
integrate, build, and reconfigure internal and external competences to address rapidly-
changing environments”. The dynamic capabilities view is based on the notion that externally 
acquired dynamic capabilities attempt to bridge a firm’s capability gaps by adopting a process 
approach: and by acting as a buffer between firm resources and the changing business 
environment (Teece et al., 1997). According to Helfat & Peteraf (2003) dynamic resources 
help a firm to adjust its resource mix thereby enhancing its innovative capabilities which 
underpins its ability to make new innovations.  
297 
 
More recently, Freeman et al., (2010) proposed an inspirational model for rapid knowledge 
development for smaller born-global firms. Their model, similar to the dynamic capabilities 
concept extends the resource-based view (RBV) and network theory specifying the level of 
interaction required for the development of the new knowledge process to occur in rapidly 
internationalising smaller born-global firms. Freeman and others instrumental model is 
illustrated in the figure below. 
 
Figure 1: A Model of Rapid Knowledge Development: The Smaller Born-global Firm 
 
   
               Sources: Freeman, Hutching and Lazaris, 2010, p.76 
 
Building on the ideas by Freeman et al. (2010) the new theory of “Knowledge and Innovative 
Capability Development” for small born-global bio-tech firms is developed as a result of 
inference from new empirical evidence and secondary data. The new model is anchored on 
the model of rapid knowledge development for the smaller born-global firm. Adjustments to 
Freeman and others inspirational model are made so that the new framework adequately 
explains the process of acquiring innovative capabilities specific to small born-global bio-tech 
firms.  
 
The intention is not to undermine the categorisation of the concepts contained in the model 
of rapid knowledge development for smaller born-global firms but rather, to adapt it so that 
it suites the emerging phenomenon in the bio-tech sector. Learning from Gerring’s 2001; 
Turnbull’s (1987); Anderson’s (1983) and Bhowmick’s (2004) critical analyses of the stages 
models it is a plausible thing to adjust a theory to meet the specific needs of the research 
phenomenon. The scholars suggest that contextual range i.e. the scope, reach and stretch of 
a concept determines whether it needs to be adjusted to accommodate and to maximise its 
performance. Indeed, when examining specific units of a phenomenon e.g. born-global bio-
tech firms being examined for this study, their contextual range can be a decisive factor in 
terms of the extent to which the new conceptual framework can be generalised (Gerring, 
2001; Santori, 1970). This is consistent with the views of Yin (2009, 2003) who argues for 
analytical generalisation of case-oriented research strategy. Yin suggests that; analytical 
generalisation denotes a process where generalisation takes place from data to theory rather 
than to population.  
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Approach 
To inform the process of theory-building the author uses a multi-case approach (Yin, 2009). 
The main focus is on small born-global bio-tech firms in the East Midlands region of the 
United Kingdom. Yin (2003) and Stake (1995) advise that to avoid pursuing a study that has 
too many objectives, it is necessary to determine your case(s). From that perspective, the 
author uses a technique known as case-binding which includes: using time and place 
(Creswell, 2003); time and activity (Stake, 1995); and by definition and context (Huberman 
& Miles, 1994). Baxter & Susan (2008, p.546) support the use of a case-binding technique 
claiming that, ‘binding the case will ensure that your study remains reasonable in scope’. 
Data is collected from a systematically selected sample of five biotechnology firms identified 
as having an international flair. Expert opinion is also sought from three key science research 
institutions in the East Midlands region of the United Kingdom that were identified as 
“champions of innovation”. The main reason for using the multi-case research approach for 
this study is to allow the author to examine the research subject(s) more closely so that 
rich data is collected. This ensures the validity and the reliability of the new conceptual 
framework (Bellamy & Perri, 2011). More so, it demonstrates that the new concepts on the 
model of knowledge and innovative capability development are grounded within and across 
cases of small born-global bio-tech firms. Results achieved in this way can be taken to be 
reliable (see Gerring, 2005; Huberman & Miles, 1994; Yin, 2009). Baxter & Susan (2008) 
affirm that a multiple case-study (Yin, 2003) or a collective case-study (Stake, 1995) allows a 
researcher to analyse data within and across settings. Crucially, the author preferred this 
method of research in particular because the evidence it generates is considered to be 
robust and reliable (see Huberman & Miles, 1994).   
 
Methodology   
Cases used in this study have been carefully chosen primarily for the following reasons: (1) 
to understand the world of small born-global bio-tech firms and (2) to contribute to 
theoretical concepts of dynamic capabilities and networking. The seemingly dated but still 
influential work by Eckstein (1975) identified five ways in which case material can be useful 
as follows: configurative idiographic studies, descriptive configurative studies, heuristics case 
studies, plausible probes and critical case studies. In light of this, the author is mainly 
interested in heuristic case-study types because choosing cases using this way enabled him 
to develop some theoretical concepts which are useful in explaining the capability 
development process of small born-global bio-tech firms. 
Data Collection 
The author interviewed senior managers who were responsible for spearheading their firm’s 
operational strategies. In the majority of cases the founders were also the CEOs/science 
directors of the visited firms and had vast experience in the biotechnology sector either 
from their previous posts or through years of operating as key players in the sector. For a 
period of about six to eight months commencing from November 2011 to June 2012, a total 
of about eleven face-to-face qualitative discussions were conducted ranging from 35 minutes 
to 45 minutes in length with an average duration of about 40 mins. Table 1 on p.5 provides 
an array of data describing the small born-global bio-tech firms that were visited during the 
data collection stage. 
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Table 1: Description of Small Born-global Firms comprising the sample  
 
 
To achieve internal validity the author adhered to an interview guide. In cases where 
interesting lines of enquiry emerged follow-up questions were asked to explore the subject 
further. The interview guide included questions about the influence of various factors within 
the knowledge supply-chain of small born-global bio-tech firms identified as: business & 
social networks, inter-organisational collaborations, competence & goodwill trust, tacit & 
explicit knowledge, prior learning & absorptive capacity. The questions also focused on their 
personal experiences in business and social networks and how they developed trust in those 
relationships. The schedule guide also included questions that were aimed at getting the 
interviewees to explain the perceived risks of their operational strategies. 
Analysis 
The study follows an inductive analysis style with elements of deduction. The cases chosen 
for analysis consist of CEOs/founders who are former employees of AstraZeneca or have 
vast experience in the bio-tech industry accumulated over years of operating in the sector. 
The next step in the analytical process was to investigate the sampled cases in order to 
identify patterns and trends in relation to how they generate knowledge in each case 
(Bellamy & Perri, 2009; Miles & Huberman, 1994). Yin (2009) suggests that using pattern-
matching logic in case-oriented studies is the most appropriate technique for case analysis. 
Similar cases with identical features seen as typical born-globals were closely scrutinised. 
Taking into perspective the emerging themes, regarding the processes of generating 
scientific knowledge for small born-global firms, a causal link between various factors 
including networking, collaborating, trust, knowledge sharing, prior learning and absorptive 
capacity was formed.  
 
Firms 
    
Origins 
 
Bio-tech Activity 
Year 
Founded 
No. of           
Interviews  
 
Critical 
Pharmaceuticals 
 
UK-based 
biotechnology 
spinout company 
from the University 
of Nottingham 
 
Involved in drug delivery technologies for the sustained 
release and nasal delivery of proteins and peptides and 
labile or insoluble small molecules. Delivers Advanced 
Therapeutics 
 
2002 
 
4 
 
XenoGesis Ltd 
 
UK based founded 
after the closure of 
AstraZeneca 
 
Specialises in pre-clinical drug metabolism and 
pharmacokinetics (DMPK), quantitative bioanalysis and 
expert interpretation 
 
2012 
 
3 
 
Haemostatix Ltd 
 
Spin-out firm from 
the University of 
Leicester – UK 
based 
 
Develops a pipeline of haemostats based on its new class of 
active ingredients that replace thrombin. The firm also 
commercialises its new technology platform based upon a 
specific peptide sequence that binds to fibrinogen – a 
protein essential to the formation of clots.  
 
2003 
 
4 
 
Sygnature 
Discoveries 
 
Founded in BioCity 
Nottingham  
 
Provides integrated drug discovery services. The company 
is also involved in a wide spectrum of drug discovery 
programmes and the outsourcing of discovery projects to 
contract research organisations (CROs) 
 
2004 
 
4 
 
BAST Incl. 
 
Spin-off business 
launched after the 
announcement of 
the closure of the 
AstraZeneca 
 
The pharmaceutical company is involved in a new drug 
development process known as Model-based Drug 
Development (MBDD) where investment decisions are 
supported by a simulation of the probability of success. The 
company is part of a collaborative network of twenty four 
other organisations with the East Midlands and 
internationally.  
 
 
2010 
 
3 
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This way of analysing data is consistent with other scholars’. For example, Muller (1982) and 
Miller (1983) suggest that the process of analytic induction starts with a tentative hypothesis 
to explain something. Data collected from each firm was sorted and transformed into a 
chronological order and using thematic analysis in each case history (see Table 2 below). 
Thematic analysis is multi-discipline; it is used in education research (Cohen et al., 2007), by 
research clinicians (see Newfield et al., 1991; William, 1992), and in political science 
(Easterby-Smith et al., 2012). Identifiable themes for this study are related to business & 
social networks, inter-organisational collaborations, competence & goodwill trust, tacit & 
explicit knowledge, prior learning & absorptive capacity.  
 
The study takes the stance that these concepts are the building blocks to the process of 
developing the innovative capabilities of small born-global bio-tech firms operating in a 
hypercompetitive environment driven, among other things; by the wealth of information a 
firm can have access to (Shilling, 2008). The emerging themes from qualitative conversations 
enabled the author to piece together and form a comprehensive picture of small born-global 
bio-tech firm’s collective experience of business & social networks, inter-organisational 
collaborations, trust building, knowledge sharing, prior learning & absorptive capacity in 
networks. This is in line with Taylor & Bogdan (1984, p.131) who define themes/concepts as 
units derived from patterns such as ‘conversation topics, vocabulary, recurring activities, 
meanings or feelings’. 
 
Table 2: The Outcomes of the global activities of small born-global firms    
 
   
Building blocks essential for developing innovative capabilities 
 
 
 
 
 
Innovative 
Capabilities  
 
   
Business & 
Social 
Networks 
 
Competence & 
Goodwill trust  
 
Inter-
organisational 
Collaborations 
 
Tacit & Explicit 
Knowledge 
 
Prior learning 
& Absorptive 
Capacity  
 
Sm
al
l B
or
n-
gl
ob
al
 fi
rm
s 
 
Critical 
Pharmaceuticals  
 
 
 
 
 
 
Strong academic, 
personal & 
institutional 
networks. VC are 
also part of the 
network 
 
Trust is build 
based on the 
reputation of the 
partner  
 
 
 
 
 
 
Engages in 
collaborative 
projects with 
other firms in the 
East Midlands and 
overseas. Work 
with Universities 
& scientists on 
specific projects. 
 
 
The firm sponsors 
biochemistry 
students to work 
on projects and to 
study at University. 
Data from projects 
is stored on a 
database. Students 
are also bonded    
 
Experience is 
seen as essential 
in order to 
understand what 
knowledge should 
be acquired 
 
Nano-enabled 
intranasal 
formulation of 
teriparatide for the 
treatment of 
osteoporosis as a 
result of result of 
working with an 
academic institution 
 
XenoGesis Ltd. 
 
Same as BAST 
Inc.  
 
Trust is built in 
escalating series 
but in cases of a 
partner whose 
cognitive distance 
is big that is seen 
as the basis for 
trust 
  
 
The firm work 
with scientist 
from their clients 
to bridge the 
knowledge gap.  
 
Same as Critical 
Pharmaceuticals  
 
Same as Critical 
Pharmaceuticals  
 
Data interpretation 
techniques 
necessary  for new 
drug testing as a 
result of working 
with other firm  
 
Haemostatix Ltd 
 
Same as Critical 
Pharmaceuticals 
& XenoGesis 
 
Trust is 
portrayed as key 
to knowledge 
exchange  
 
Same as 
XenoGesis  
 
Most of the board 
members have 
experience in 
product 
development and 
commercialisation  
 
Board members 
have vast 
experience in 
drug discoveries 
which helps to 
understand the 
needs of the firm   
 
 
Haemostats 
technology used by 
surgeons to manage 
problematic 
bleeding. Funding 
was key to the 
development of the 
technology 
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Sygnature 
Discovery  
 
Same as 
XenoGesis & 
Critical 
Pharmaceuticals 
  
 
Trust is built in 
escalating series 
with partners 
 
Same as all the 
other participants  
 
Same as  
 
Same as above 
 
Gold standard’ 
techniques in pain, 
metabolic and CNS 
disorders, 
inflammatory 
disease and in vivo 
pharmacokinetics 
 
BAST Inc. 
 
The firm has a 
strong network 
of 24 other firms. 
The CEO has 
personal 
connections with 
expert scientists 
& connections 
developed from 
his previous 
employment  
 
 
Same as Critical 
Pharmaceuticals  
 
Collaborations 
are seen as the 
route to new 
drug discoveries  
 
Same as XenoGesis 
 
Same as with all 
the other firms  
 
New statistical 
tools in parameter 
estimation and 
optimal design e.g. 
Risk and Utility 
Assessment 
through Mechanistic 
Modelling 
Findings 
Innovative Capabilities’ Knowledge Supply-chain  
This part explains the impact of the building blocks, including: business & social networks, 
competence & goodwill trust, inter-organisational collaborations, tacit & explicit knowledge, 
prior learning & absorptive capacity, on the abilities of small born-global bio-tech firms to 
build their innovative capabilities. It draws upon results from within and cross case analysis 
using the various factors, which mitigate the knowledge supply-chain of born-global firms, as 
the main themes. It also outlines the authors’ propositions based on the information 
obtained from within and across cases. Secondary data analysis is also used to provide some 
insight and to support empirical evidence. This leads to the development of a model of 
“Knowledge and Innovative Capability Development” for small born-global bio-tech firms.     
 
Business & Social Networks  
For small born-global bio-tech firms business and social networks are essential to their 
success. The interaction between individuals, firms or organisations with varied skills, 
experience and knowledge provides synergy for small firms with limited resources. They 
provide them with access to a wide range of economic effects (Ho & Wilson, 2006) 
including: access to specialised input and labour, novel information inflows and knowledge as 
well as access to research institutions and government R&D support services (Martin et al., 
2011). Breschi & Malebra (2005, p.47) suggest that, “resource pooling, risk sharing and the 
formation of critical masses provide incentives to create a group of inter-linked agents”. 
Powell et al. (1996, p.46) affirms that, ‘when the sources of expertise are disparate, 
collaborative R&D opens an organisation's eyes to the need for accessing ideas and 
information from a variety of sources’. This was evident when the author conducted a case 
by case examination of their networking activities. He found that small born-global firms link 
up with other firms, scientists, research and academic institutions within and outside their 
vicinity to jointly develop new drugs and share technical know-how. This was reflected in 
the response given by the President at Sygnature Discovery when asked about whether his 
company engages in networking. He commented that:   
 
Our scientists work with other scientists from other businesses, research institutions and strategic alliances to jointly 
test and develop drugs. We work in a highly collaborative way e.g. in our molecule synthesising process. We have 
secure data bases that we use to share data with our partners and clients from wherever they might be either in San 
Francisco or Santiago. We have realised that we do not have all the capabilities and we feel that it is important to 
collaborate with other companies for example, we collaborate with Cyprotex Discovery. They have better knowledge 
about how the drug dissolves in the body. What is important is we share capabilities.  
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We feel that we have modelled our business in a ‘hub and spoke’ model i.e. we are in the middle and we are 
networking with other companies.  
 
In light of this evidence, indicating that bio-tech firms in the East Midlands region in the 
United Kingdom are forging global networks to enhance their capability development, the 
author can confidently conclude that the business and social networks in the knowledge 
supply-chain of small born-global bio-tech firms significantly influence how they acquire 
scientific knowledge and technical know-how. Accordingly, Nahapiet & Ghoshal (1998) and 
Tsai & Ghoshal (1998) suggest that social capital embedded in a firm saves as a conduit that 
facilitates and enables positive conditions for the exchange of knowledge and the 
combination of resources to occur. When discussing with an expert working in a knowledge 
‘hub’ the author was fully convinced that the business and social networks of small born-
global bio-tech firms play a decisive role in how they develop their innovative capabilities. 
The innovation advisor, Rosamund Graves, commented that:  
 
We help firms and industry sectors access information, opportunities and partners on a global scale through specialist 
networks and business intelligence. On behalf of national government agencies, we deliver programmes to stimulate 
international inward investment, technology transfer, partnering and access to high growth global markets for UK 
companies. We provide business intelligence and contacts to help UK firms identify and realise international 
opportunities.  
 
Her statement endorses that forging networks within and outside a firm’s local industry 
milieu plays a key role in the process of acquiring knowledge and technical know-how. In 
that regard, it is plausible to claim that business and social networks are part of the jigsaw 
puzzle needed to complete the process of generating novel information for small born-
global bio-tech firms.  
 
Proposition 1: business and social networks act as a catalyst for small born-global bio-tech firms 
in their process of developing innovative capabilities  
 
Social capital and network ties have a positive impact on international start-ups, new 
ventures and SMEs’ performance (Johanson & Vahlne, 2003; Oviatt & McDougall, 1994; 
Oviatt & McDougall, 2005). Furthermore, Hughes et al. (2009) stress that for a firm to gain 
access to knowledge and technical know-how it is essential to collaborate in networks and 
engage with a range of advisors that include: scientists, academia and agencies. This was 
echoed in the conversations with the CEO at XenoGesis Ltd, and the Science Director at 
BAST Inc. Ltd. When discussing about how wide-spread their networks are the CEO, and 
the Science Director of the firms mentioned above explained that: 
 
I have a good network of ex-colleagues that I used to work with at AstraZeneca and such connections are vital for 
sharing scientific knowledge and technical know-how. I think collaborating with other businesses and academia is 
essential in the bio-tech industry and it is important that businesses join to work on new discoveries. That is the way 
things are heading towards nowadays given the nature of the markets. Apart from using my business or social 
connections as conduits of scientific knowledge I also publish papers. CEO at XenoGesis Ltd;  
 
And,  
 
I engage in networking activities both locally and internationally with firms and organisations in the USA, Asia for 
example. I personally have some contacts in America where my business started way back in 1998 as a model based on 
a drug development firm. Science director at BAST Inc. Ltd  
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Their responses boldly underline the essence of business and social networks. Indeed, the 
evidence is strong and this indicates that in the globalised markets of the biotechnology 
sector, going it alone is no longer the best option because it is so difficult for small firms to 
possess all the necessary capabilities. Lasserre (2012) argues that firms can benefit in 
globalised networks by accessing and taking advantage of geographical clusters of knowledge 
creation and development. In that sense, business and social networks of small born-global 
firms can be seen as channels through which they can access scientific knowledge and 
technical know-how. Considering the suggestions from the CEO of XenoGesis, and the 
Science Director at BAST Inc. Ltd quoted above it is plausible to conclude that small born-
global bio-tech firms use networks to generate knowledge so as to leverage their internal 
science capabilities with a view to discovering new drugs. Thus, giving them greater flexibility 
needed to survive in a hypercompetitive business environment (Shilling, 2008; Lasserre, 
2012; Hisrich 2012). Shilling (2008, p.158) further affirms that ‘as firms forge collective 
relationships they weave a network path between them that act as a conduit for information 
and other resources’.  
 
Funding institutions are also a key player in the networks of small born-global firms. Mobius 
Life Sciences - an investment arm of BioCity Nottingham (BCN) work alongside Nottingham 
City Council (NCC) to provide financial support ‘seed investments’ in high potential life 
science businesses. Crocker (2012) explains that the investment arm has a highly 
experienced and well networked team. This gives the author strong belief that financial 
support for bio-tech firms significantly boosts their limited resources and it adds value to 
their businesses which ultimately enhances their capacity to innovate. The CEO at 
Haemostatix said this:  
 
While business networks facilitate the flow of novel information, financial investments are a ‘shot in the arm’ in that 
they also provide a company with the opportunity to develop innovative technology. In our case we were presented 
with the opportunity to develop an innovative haemostat technology.  
          
This shows that business links that include funding institutions are the bedrock for small 
firms seeking to make crucial innovations. What is happening in the East Midlands has 
striking resemblance to networking activities documented elsewhere e.g. in the Golden 
Triangle of Cambridge, London and Oxford, the Silicon Valley and the Boston metropolitan 
area. The Cambridge Cluster Report of 2004 reports that over the last decade the cluster 
has acted as a magnet attracting supportive infrastructure comprising of number of key 
players such as: venture capitalists firms, banks, marketing experts and patent agents.  
     
Competence & Goodwill Trust 
Strong relationships that allow the free flow of information to occur were found to exist 
between parties involved in a well-established network and trust was the most important 
component of that process. Results from within and across cases show that small bio-tech 
firms trust their collaborating partners based on their technical prowess (competence trust) 
and good intentions (goodwill trust) within the life science sector. In this study, the author 
uses Blomqvist’s (1997, p.3) definition of trust expressed as an ‘actor's expectation of the 
other party's competence, goodwill and behaviour’.  
 
 
 
 
 
304 
 
Consistent with Blomqvist’s definition, Gubbins & MacCurtain (2008) claim that to trust an 
individual’s ability is to trust in his or her skill and competencies to do the job. Evidently, all 
the participants in this study indicated that trust is established when they know that their 
collaborating partner is skilled and very capable. Especially, in a specific area of science which 
complements their knowledge gaps. In a discussion with the CEO at XenoGesis about how 
trust is developed in networks he expressed that:  
 
We build trust by first conducting due diligence (i.e. we do a search on their level of technical capabilities, their 
reputation which we get from people who have worked with them before). In other words we look for partners who 
have higher skills and are well established/known in the industry. This is all done in a trial and error method.  
 
The interpretation from this statement, which is supported in the literature (see Blomqvist, 
1997; Sengun, 2009), demonstrates the relevance of competence (technical capabilities, skills 
and know-how) in the biotechnology sector and it shows that it is a necessary antecedent 
and basis for trust in professional relationships within a business context. Networking with 
organisations that have better skills levels is an important factor in building trust in the bio-
tech sector particularly, in instances where potential partners are assumed to have 
technological knowledge and competences (Blomqvist, 1997).   
 
Furthermore, the statement highlights that the reputation of a partner, including: moral 
responsibility and positive intentions towards the other, was an important factor that 
influenced his firms’ decision to accept a potentially vulnerable position (risk inherent by 
partnering). Welter (2012, p.194) claims that ‘trust is seen to assist in lowering the 
transaction costs of commercial actions and the risks inherent in entrepreneurship’. In the 
majority of the firms in the sample, trust was built in escalating series using a ‘trial and error’ 
method. This discovery contributes to the social exchange theory (Pretty & Ward, 2001; 
Inkpen & Tsang, 2005; Whitener et al., 1998) which suggests that information, advice, social 
support and recognition are important means of building trust created through repeated 
interactions and reciprocity.  
 
 
In addition to the main meaning of the social exchange theory, when asked about how trust 
was built in his firm the President at Sygnature Discoveries stressed that:  
 
Our partners I guess they also do a due diligence to assess whether we fit into what they are looking for. With our 
alliances we are well connected actually, before establishing this connection we first test the partners trustworthiness 
through engaging in small projects and we take it step by step until we are fully convinced that a stronger partnership 
can be established. Competence and reputation play a key role in building new networks.    
     
This is further evidence suggesting that in order to build trust a wide scope of information is 
necessary for small born-global bio-tech firms because different types of information 
including relational-emotional, socio-economic and tacit-explicit significantly impact on the 
trust experienced. With all the firms in the sample, trust was naturally developed within 
their business community at BCN but with organisations and institutions outside their 
locality there was more of ‘trial and error’ requiring a lot of information search. The 
process of due diligence was done mainly to test the trustworthiness of a potential business 
partner in particular, their intentions which is related to the goodwill dimension of trust. 
The process of testing a partners’ trustworthiness through small projects was targeted at 
identifying positive or negative signs and signals which Blomqvist (1997) claims are visible 
and easier to evaluate when the relationship is developing. This was found to be a vital 
activity for small born-global firms and it was critical to how they developed innovative 
capabilities in newly established networks.  
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Responding to the same question on trust building in newly formed networks which they 
develop in a global context, the CEO at XenoGesis stressed that: ‘it is very important to try 
different combinations to ensure that we end up working with people who share the same 
values as us’. In this case it was the CEO’s envisaged strategy that his organisation should 
develop trust with its partners based on the soundness of their strategy and vision. In the 
relevant literature (Mishra 1996; Sydow 1998) the competences of an organisation are seen 
as a basic and profound source of trust in asymmetric technological partnerships. Blomqvist, 
(1999) suggests that competence trust may be born out of a firm’s technical capabilities, 
financial resource-base and partnering competences. Thus, the author proposes that: 
 
Proposition 2: For small born-global firms competence and goodwill trust are major factors that 
reduce friction and perceived risks allowing the free flow of fluid scientific knowledge and technical 
know-how through established or newly developed business partners.       
 
The most common form of trust that was evident in the research sample was the sense of 
benevolence; meaning that scientific knowledge and technical know-how developed with 
partners were protected within the trusted group/network (Hoy & Tschannen, 1999). The 
firms relied on the goodwill of their partners to act in the best interest of both parties. In 
on-going relationships future behaviour was not specified but there was a mutual attitude of 
goodwill. As illustrated in the “Knowledge and Innovative Capability Development Model” on 
p.17, trust was the basis on which inter-organisational collaborations stemmed from in the 
capability development process of small born-global bio-tech firms. More importantly, trust 
was a pre-requisite to knowledge sharing and the exchange of technical know-how.        
Inter-organisational Collaborations  
Data collected from sampled firms demonstrates that there was a strong relationship 
between collaboration and innovation. Through conducting a detailed case by case analysis it 
was found that the main reason why small born-global bio-tech firms collaborate with other 
firms/research institutions was to learn from them in order to enhance their innovative 
capabilities. Zucker et al. (1998) posit that learning underpins organisational innovation and 
according to Basile (2010, p.3) innovation ‘is a complex and interactive process that involves 
a variety of actors’. In the biotechnology sector where scientific knowledge is both complex 
and ever-expanding in search of new discoveries the sources of expertise are widely 
dispersed. In such sectors, Powell et al. (1996) postulates that the locus of innovation is 
usually found in networks of learning as opposed to going it alone. The CEO at Critical 
Pharmaceuticals revealed that: 
 
In the bio-tech industry you need various skills and knowledge, in addition to our in-house knowledge we collaborate 
with other institutions such as universities, other companies - large or small both locally and internationally and along 
with that we have different levels of collaboration. We collaborate with companies in the USA, EU. We also have 
intense collaborations with companies near to us who have expertise in areas of interest we therefore work with them 
to access the expertise that we do not have.  
 
This evidence powerfully demonstrates that small born-global bio-tech firms maintain a 
broad scope of interactions with a wide range of actors in the bio-technology sector with a 
view to complement their knowledge bases. Scholarship on inter-organisational networks 
argues that firms should look further than their own boundaries to acquire strategic 
resources (Subramanian & Soh 2010; Feldman, et al., 2002). The traditional model of large 
pharmaceutical companies where all research activities were done in-house is slowly fading 
into the horizon.  
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The managing director at BioCity Nottingham (BCN) observed that: ‘The large Pharma used 
to employ a large number of scientists under one roof and that structure is fragmenting 
giving rise to the formation of smaller research-based organisations’. The re-structuring 
exercise happening at AstraZeneca and Boots in the East Midlands and at Lund in Sweden 
typifies this. The pharmaceutical giants are undergoing a strategic shift towards outsourcing 
their R&D activities to small bio-tech firms. This heralds a significant move towards more 
collaboration between organisations in the biotechnology sector where smaller firms such 
as those investigated for this study are taking the centre stage. Large pharmaceuticals 
continue to provide marketing, commercial capabilities and financial resources. Similar 
studies (see Stuart et al., 2007; Zucker et al., 1998) have reported a growing trend, in the 
biotechnology, sector where small firms are being contracted to do the research for large 
pharmaceutical companies. More recently, Kang & Park (2012, p.70) reported that ‘while the 
new biotechnology firm specialises in specific types of knowledge, products and applications 
large established firms have expertise in the commercialisation of new inventions that 
involve large scale production, marketing and distribution, and regulatory processes’. The 
CEO at Critical Pharmaceuticals expressed that:  
 
We acquire financial support to back up our products, expertise, marketing, PR, scientific knowledge and these are 
things that we do not have in house and they are needed to achieve our goals. The only way to achieve this is through 
linking up with people who have been there and done it and are well established in the market.  
 
This highlights the significance of inter-organisational collaborations in terms of: (1) bridging 
the knowledge gap of small born-global bio-tech firms; (2) enabling them access to markets; 
(3) providing them with financial back-up and (4) getting help from science experts who 
have vast experience in life science.  
 
In support of these findings, Schilling (2008) makes similar observations and she postulates 
that, small biotechnology firms form partnerships with large pharmaceutical firms for their 
mutual benefit: pharmaceutical firms gain access to the drug discoveries of the 
biotechnology companies and likewise small bio-tech firms gain access to the capital 
resources, manufacturing & distribution capabilities of these large pharmaceutical firms. The 
author discovered a growing trend of these mergers and consolidations. For example, 
Critical Pharmaceuticals worked closely with academia to develop a highly innovative 
formulation of teriparatide. The University of Leicester (UoL) played a crucial role in 
supporting Haemostatix Ltd during its early stages of development. The firm received 
support in the form of clinical laboratories as well as opening up links with other institutions 
and organisations. As a result of Haemostatix Ltd’s links with the UoL, it received start-up 
funding of £250,000 from The Lachesis University Challenge Fund and an initial investment 
from NESTA. The founder of Haemostatix expressed her profound gratitude in 2006 when 
her organisation received support from Quester, ‘Quester has worked with us 
(Haemostatix Ltd) since 2002 and we are pleased to have their financial support and 
strategic input to take the business forward’. 
 
Proposition 3: Inter-organisational collaborations are an important step in the knowledge supply-
chain of small born-global firms and they influence their process of developing innovative capabilities  
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However much seemingly important inter-organisational collaborations are; the study 
discovered that trust played a significant role in allowing the exchange and transfer of 
knowledge between collaborating partners to occur. It was found that for small born-global 
bio-tech firms with global foci; their inter-organisational collaborations were based on 
competence and goodwill trust. Şengün & Önder (2011, p.796) claim that, ‘trust in 
competence refers to the perceptions of the trustor concerning the trustee’s technical, 
cognitive and communicative competences’. At the inter-organisational exchange level small 
born-global firms collaborated with organisations they believed to have expertise and 
experience. This enabled them to successfully develop or test drug combinations. When the 
president at Sygnature Discovery was asked about the importance of firm-based 
competencies and goodwill in trust building this is what he had to say: 
 
We build trust with potential partners based on their science and technical capabilities. We also receive advice from 
BioCity, Medilink and UKTI about potential partners and I guess it is part of due diligence. 
 
The above statement also brings to light the fact that firms intending to enter into 
partnerships with other firms can use a third party to gather information about their 
scientific capabilities and technical know-how, more so, for those which are geographically 
distant. In all the firms that took part in the interviews this was important as their intentions 
were to work with global partners. When seeking global partners these firms relied on the 
advice they received from BCN, Medilink East Midlands, UK Trade and Investment (UKTI), 
and from their established connections. The innovations manager at Medilink explained this 
more fully when asked about the role her organisation plays in facilitating inter-
organisational collaborations. She stated that:  
 
We would facilitate for companies that intend to relocate to the East Midlands by providing them with the necessary 
information. We support both domestic and international organisations and recently we had a company that came 
from India intending to establish in the East Midlands. In that case we supported them by providing them with 
information to enable them to achieve their goal. 
 
 
Bachmann & Inkpen (2011) agree that in cases where face-to-face interactions with a 
potential partner are not possible a third party may operate as a guarantor. The managing 
director at BCN echoed these sentiments explaining that for their tenants they ‘guarantee a 
certain level of competence and quality of a potential partner but after that they take a step 
back and let people work and learn on their own’. A strong bond was gradually developed 
between collaborating firms, whether local or foreign, over a period of time through a ‘trial 
and error’ method. When the relationship got stronger the level of trust was increased 
accordingly thereby allowing the free flow and exchange of scientific capabilities as well as 
technical know-how. In the literature regarding trust, high levels of trust are associated with 
a decrease in perceived risk and they are cast as being fundamental to the formation of 
strong relationships. Thus, strong relationships are a precursor to trusting that a business 
partner will act in the best interest of both parties (Şengün & Önder, 2011). Evidently, some 
form of connection existed between firms which used a pre-existing business network such 
as BCN as their base but for partners outside their locality a ‘trial and error’ method taking 
the form of smaller projects was the main method of assessing the trustworthiness of 
prospective partners. As such the author’s fourth proposition is that: 
 
Proposition 4: Small born-global bio-tech firms build trust with their prospective partners in 
escalating series basing it on their partner observations from inter-organisational collaborative 
projects 
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Tacit & Explicit Knowledge 
The process of acquiring knowledge is a very complex process which involves participating 
in generating and disseminating it in a way that benefits all the people involved (Powell & 
Grodal, 2005). There was cogent evidence indicating that small born-global bio-tech firms 
aim to develop stronger ties with local and international partners in order to ensure that 
they continue to receive crucial scientific knowledge. Ideas and knowledge generated from 
science-related projects involving sampled firms were codified and retained in the firm for 
future developments. This was reflected in the discussion with the CEO at Critical 
Pharmaceuticals regarding how his firm managed data accumulated from collaborative 
projects. To this end, he explained that: 
 
From a scientific perspective for a lot of the key projects we trap the knowledge that people have used in a project and 
we have project management systems to make sure that we capture all the knowledge e.g. by monitoring projects, 
gantt charts and project reports. 
 
Managing scientific information this way was not only unique to Critical Pharmaceuticals. All 
the firms echoed the same sentiments. They also revealed that knowledge management was 
a crucial part of their drug discovery process. The findings are consistent with a number of 
scholars (see Daud & Yusoff, 2010; Hughes et al., 2009; Nonaka et al. 2000) who discuss the 
concept of knowledge externalisation. They postulate that externalisation allows knowledge 
that exists in the head of the knower to be codified into rules, specifications and formulas 
that can be used and become the basis of new knowledge. All the firms that participated in 
the discussions regarding developing innovative capabilities in the biotechnology sector 
placed great value on both tacit and explicit knowledge they acquired from their trusted 
partners. The firms went beyond their immediate environment in search of a new context 
and a new world-view. Todtling et al. (2009) suggest that sector-based innovations are not 
bound by geographical location; they often have international or even global reach. Global 
networking in search of new insights was a dominant characteristic in the majority of the 
firms that took part in the survey. Nonaka et al. (2000) point out that the process of 
creating knowledge is a continuous one and it transcends beyond one’s immediate 
environment. In a discussion with the CEO at Critical Pharmaceuticals he acknowledged that 
since his firm started to operate 15 years ago he has witnessed a significant transformation 
in the way his business now generates new knowledge. He emphasised that: 
 
The way we do business in the bio-tech industry has changed; when I started at Critical Pharmaceuticals most of the 
knowledge was only in-house. We now have access to a lot of external resources and nowadays there is a huge push 
towards accessing knowledge from outside for non-core areas. I would say the industry has changed somewhat it is 
now more open and there are a lot of collaborations with academics and research institutions and I think that has been 
good for the industry. 
  
From that perspective, the interaction between individuals or a group of firms is vital in 
terms of facilitating knowledge transfer. As tacit knowledge exists in the head of the knower 
(Hughes et al., 2009), small born-global bio-tech firms work in collaborative projects with 
scientists, research institutions and other firms with a view to stimulate its transfer. Porter 
et al. (2005) point to the amalgamation of intellectual capital of clinical researchers and 
research academics as key to the success of the commercial world of biotechnology in the 
Boston metropolitan area. Similarly, Todtling et al. (2009, p.67) claim that, ‘universities are 
regarded as key knowledge sources of firms for more advanced innovations’. This bears 
striking resemblance with the patterns of knowledge development emerging from the East 
Midlands region in the UK. There is cogent evidence of the existence of strong ties and 
relational-like trust in the sampled firms that are located at BCN, the region’s science ‘hub’.  
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Based on their shared values and common beliefs invested at BCN the firms naturally 
formed business connections and the intentions of all the firms were predictable. Boschma 
(2005); Asheim & Gartler (2005) make similar observations and they highlight that 
interactions that occur in an institutional context facilitate the transfer of tacit and explicit 
knowledge. Through strong ties and relational-like trust, knowledge was freely exchanged. 
Discussions with the participants yielded two main forms of knowledge-sharing in the 
biotechnology sector. One form of knowledge-sharing that was clear was the idea of 
complementing each other’s core competences. The strategy was evident across all the 
sampled cases. The collaboration between Critical Pharmaceuticals and PolyTherics is an 
example of complementary knowledge assets. Critical Pharmaceuticals specialises in 
injectable products and PolyTherics Limited are innovators in precision improvement of 
proteins and peptides. In that sense, their expertise and knowledge capabilities 
complemented Critical Pharmaceuticals’ technology of human injectable drugs. The second 
form of knowledge-sharing was in the mould process re-configuration. It is, however, 
important to note that in both forms of knowledge-sharing the process of transferring 
knowledge occurred after the establishment of the intentions of the partnering firm(s) or 
institution(s). BAST Ltd as a contract research organisation (CRO) exchanged knowledge 
with its collaborating partners by re-arranging science apparatus in such a way that it 
enhances new drug discoveries. When responding to the question about how his firm’s 
collaborative partners utilise the knowledge acquired in collaborative drug discovery 
projects the science director at BAST Ltd explained that:   
 
We use the information that we share with them to enhance their innovations and to accelerate their business 
processes. Basically, our ideas would change the next developments that they have which helps them to reduce costs 
and even sharpen their innovations and the way they put their resources together e.g. their operations and product 
development strategies.  
 
                 
With the first form of knowledge-sharing where both parties provide valuable input to the 
project, there was high commitment to generate both tacit and explicit knowledge. The 
firms developed relational capacities pooling together the skills of specialised participants 
who ultimately played an important role in the overall flow of information and resources in 
the network. The exchange and transfer of specialised scientific knowledge and skills 
between the firms engaged in collaborative projects or in the wider network at BCN had a 
significant impact on how they build their innovative capabilities. This brings to light the fact 
that both tacit and explicit knowledge are important factors that have an impact on the 
knowledge supply-chain of small born-global bio-tech firms. Nonaka & Takeuchi (1995) 
suggest that the creation of new knowledge is predominantly characterised by the 
interaction between two main forms of knowledge i.e. tacit and explicit knowledge. Thus, 
the author proposes that: 
 
Proposition 5: Tacit and explicit knowledge generated in the collaborative projects of small born-
global bio-tech firms influence how they develop their innovative capabilities 
 
Prior Learning & Absorptive Capacity 
Building on earlier studies by Cohen & Levinthal (1990); Jansen et al. (2005) on prior 
learning and absorptive capacity evidence from qualitative conversations with the 
founders/science directors of small born-global bio-tech firms suggests that their experience 
in science was crucial in the process of assimilating useful scientific knowledge.  
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Small born-global bio-tech firms gather science-related information from a wide range of 
sources and the science knowledge levels of their management teams played a crucial role 
during the process of acquiring information which was specific to their needs. The CEO at 
XenoGesis explained this more fully when asked about the importance of prior learning in 
terms of understanding the specific knowledge that is useful for their science in business and 
social networks that span beyond their proximity. This is how he put it: 
 
One has to understand the relevance of the acquired knowledge to science and experience in that respect plays an 
important role. Given the experience our team of experts have in bio-tech we are in a better position to acquire the 
science that is necessary for our service.  
 
The same sentiments were echoed by the CEO at Haemostatix he explained that:  
 
Experience in science plays an important role when it comes to selecting the right type of knowledge that is needed to 
develop new technology.  
 
This demonstrates that their ability to recognise and assimilate external knowledge was 
crucial to their process of developing innovative capabilities. Cohen & Levinthal (1990) argue 
that a firm’s ability to evaluate and utilise information is heavily influenced by prior related 
knowledge. Within case analysis revealed that for all the sampled firms, their management 
structure was composed of individuals who had vast experience in science and had worked 
for large bio-pharmaceutical firms. As such, their wealth of experience was vital in terms of 
understanding the knowledge gap in their firms. To get a different perspective on this the 
topic about prior learning and absorptive capacity was presented to an innovation expert at 
Medilink East Midlands as a point of discussion and she commented that: 
 
Working with other organisations to share knowledge and ideas is great, but what is important is that one has to have 
some understanding about the knowledge that will help his/her business to take that one step forward.  
 
In all of the above statements, made by the participants, there is clear evidence that 
experience and prior learning have a significant impact on how a firm selects useful 
knowledge to complement its knowledge gap. Evidently, working with other firms or science 
institutions whose complementary foci is at some cognitive distance results in the 
accumulation of vast amounts of information but recognising what a firm needs significantly 
increases its capacity to innovative. Indeed, working in collaboration accelerates the firm’s 
process and product improvements. Schilling (2008) suggests that a firm’s prior related 
experience shapes its ability to recognise the value of new information and its ability to 
utilise that information effectively. Thus the author proposes that:   
 
Proposition 6: The experiences of small born-global bio-tech firms are essential to their ability to 
recognise, assimilate and apply knowledge from their business and social relationships in a way that 
enhances their capacity to innovate   
      
It is also important to inform the reader that the concept of learning has not been fully 
explored here because it is beyond the remit of this study. Although the concept has been 
discussed in a limited fashion it has been an important part of the process of understanding 
its role in the development process of innovative capabilities small born-global bio-tech 
firms. Following an in-depth account of various factors within the knowledge supply-chain of 
these entrepreneurial ventures the author proposes a refined conceptual framework of 
knowledge and innovative capability development. 
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A Model of Knowledge and Innovative Capability Development 
The formation of theories in social science is fundamental to how we explain what we are 
trying to talk about (Gerring, 2005). Precisely, theories are instrumental in social science as 
they help us to make connections between the world people live in and how they interpret 
it (Gerring, 2001). Bellamy & Perri (2009, p.90) point out that regardless of one’s research 
philosophy developing an adequate conceptual framework provides a roadmap that guides 
how the researcher explores the social world and for those working with variables and 
correlations they are able to ‘establish valid measures and apply them reliably’. Building on 
the inspirational work of Freeman et al. (2010) regarding how smaller firms rapidly develop 
new knowledge in their internationalisation process; this study proposes a new improved 
framework for small born-global bio-tech firms. Using existing literature, empirical evidence 
from within and across cases the study proposes the “Knowledge and Innovative Capability 
Development Model”. Sigglekow (2007) affirms that using rich data acquired through closely 
examining instances of occurrences in cases can inspire new ideas in theory construction. In 
the same vein, Eisenhardt & Graebner (2007) express that the output of case-oriented 
research designs take various forms including: a new concept, theoretical construct, 
conceptual framework, propositions, and in other cases a mid-range theory. Similarly, 
Ridder et al., (2009) agree that case studies have the potential to uncover unusual 
phenomena and of repeating or countering the replication of findings of other cases which 
eliminates alternative explanations and elaborates the emerging theory. From these 
perspectives the author presents Figure 2 below which neatly illustrates the proposed 
conceptual framework as a result of new evidence.  
 
Figure 2: Knowledge and Innovative Capability Development Model 
 
 
Small born-global bio-tech firms operate in a very complex and sophisticated business sector 
which is exceedingly dynamic. Therefore, it is imperative that they formulate strategies to 
enable them to continue to produce innovative life-saving products. The primary aim should 
be to enhance their innovative capabilities which enable them to make crucial innovations 
(Powell & Grodal, 2005).  The firms used in this sample were all resident at BCN implying 
that they exist in a network which is already established where they have developed strong 
business and social ties. They demonstrated an entrepreneurial flair by venturing into the 
global markets in search of global partners. As denoted in figure 2 above, the establishment 
of business and social networks, described as innovation networks by Powell & Grodal 
(2005), is the key building block within the knowledge supply-chain of small born-global bio-
tech firms.  
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Elfring & Hulsink (2003) make an important observation about entrepreneurial firms by 
suggesting that networks (business & social) contribute significantly to the venturing process 
of entrepreneurial small firms by presenting them with access to knowledge and unique 
capabilities. In their local network at BCN and the wider East Midlands region the firms 
were aware of the competences and the intentions of their potential collaborative partners 
thus, trust was built at a very early stage. This quickened the process of knowledge transfer 
as well as the exchange of technical know-how. So, established networks are credited with 
building trust which leads to inter-organisational collaborations. Established networks also 
led to newly-formed business and social networks (see Davis, 1970; Wall, 2009).  In newly 
developed networks, trust was quite superficial and in some cases non-existent. Therefore, 
for R&D institutions, firms or scientists located in foreign markets inter-organisational 
collaborations in the form of smaller projects were used as ‘trial and error’ conduits to test 
the trustworthiness of the prospective partner. Indeed, in their process of developing 
innovative capabilities small born-global bio-tech firms embarked on a number of different, 
often unsuccessful, configurations and techniques before finding the right combination that 
worked well for them (Lichtenthaler & Lichtenthaler, 2009). Schilling (2008) explains this 
process of experimentation and learning more clearly asserting that this stage in the 
knowledge supply-chain is vital in the sense that it allows the firm to build a base of 
knowledge about how key components behave, what alternatives are more likely to be 
successful than others, and what types of projects the firm is most successful in.  
 
Small bio-tech firms were forced to adopt the experimentation approach because of the 
dynamic nature of the biotechnology sector i.e. its heavy reliance on highly fluid scientific 
knowledge and technology to make new drug discoveries and the speed with which these 
types of firms form and disintegrate required high levels of trust (Maxwell & Lévesque, 2011; 
Welter 2012). This strongly suggests that trust is ever-more critical for the transient and 
the high speed environment of the small born-global bio-tech firms as the basis for 
knowledge sharing (Freeman et al., 2010). As such, trust was built in escalating series 
because of the risks associated with developing new partnerships. Sitkin & Pablo (1992) 
discuss risk perception by referring to the assessment of the risk inherent to a situation. In 
all of the five small born-global firms the assessment of the risks associated with knowledge-
sharing with new partners was done in a carefully orchestrated logical step-by-step 
approach. Once trust was built, whether in established or newly developed business and 
social networks, it paved the way for effective knowledge-sharing. Similarly, Hill (1990) 
claims that, it is highly likely that a firm will engage in knowledge transfer with partners who 
have demonstrated their trustworthiness and co-operative abilities in their other relations.  
 
The process of knowledge-sharing is embedded in pre-existing business and social 
connections. Hutchings & Michailova (2006) suggest that sharing knowledge depends on the 
pre-existence of insider relationships and a disposition towards co-operative 
interdependence. Scholarship on entrepreneurship generally agree that small firms with 
limited resources have a tendency to soak as much information as is possible with the hope 
that something magical will materialise. The proposed model suggests that for small born-
global firms prior understanding of the complementary resources needed for the firm to 
develop new life-saving drugs or technical products is essential otherwise engaging in 
collaborative projects will count to nothing in the way of innovations. The underlying 
assumptions of the model are that, by acquiring new scientific knowledge and technical 
know-how the firm enhances its innovative capabilities that underpin the development of 
new products and services in the life science industry.  
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Furthermore, the process of generating innovative capabilities is directly anchored on the 
greater connectivity and enhanced collaborations in the life science’s innovation 
‘ecosystems’ described by Booth (2009, p.705) as a ‘brave new world’. Indeed, the 
connectivity and collaboration between various actors within the East Midlands network 
performed a key part in the process of ensuring continued development of scientific 
knowledge and technical know-how by providing financial support and infrastructure. BCN 
provided the firms specialised premises with state of the art lab equipment while NCC and 
Mobius provided seed funding to promising ventures. A similar observation was made by 
Laine et al. (2008), the scholars maintain that, at the core of innovation ‘ecosystems’ are 
firms and enterprises which are involved in innovative collaborations with academic 
institutions and investors. A convincing argument regarding the logic behind facilitating the 
development of innovation ‘ecosystems’ similar to those appearing in the East Midlands 
region, was made by Hautamäki (2007). Hautamäki argues that the ‘ecosystems’ approach 
places great emphasis on close co-operation and a culture of creativity which refers to 
adventurism, entrepreneurship and innovativeness.  
 
The evidence is clear in the East Midlands region suggesting that born-global bio-tech firms 
are involved in local innovation ‘ecosystems’ that considerably influence the movement of 
knowledge within their knowledge supply-chain. Adner (2006) insists that an innovation 
‘ecosystem’ facilitates integration risks of having the solution adopted across the value-chain. 
This is consistent with Bramwell et al. (2012) conceptualisation of an innovation ‘ecosystem’ 
approach. The scholars see it as a sophisticated way of holistically looking at mechanisms 
that interact within an economic system. Crucially, for policy makers such innovation 
systems will ‘enable them to pay close attention to the collaborative, inter-dependent nature 
of the innovation processes and to identify the best means of stimulating productive 
networks and relationships within and across disciplines and sectors of comparative 
advantage’ (Bramwell et al., 2012, p.49). Additionally, Wolfe et al. (2011a) describes the 
regional knowledge ‘ecosystem’ approach insisting that it leverages regional infrastructures 
with a view to stimulate/support regional innovation processes through the collaborations of 
multiple partners that include: research and academic institutions, investors, other firms and 
investors. Wolfe and others description of regional knowledge ‘ecosystems’ has a striking 
resemblance with the innovation ‘ecosystems’ within the East Midlands region that are 
supporting the process of generating innovative capabilities denoted on figure 2 p.17.  
 
Discussions 
Rationale for stretching the model 
Freeman et al. (2010) invite other scholars to carry out more research to develop further 
their model of rapid knowledge development for smaller born-global firms. This stretches its 
reach. In particular, they recommend the need for further studies to refine their conceptual 
framework and its applicability to the internationalisation processes of smaller born-global 
firms, and the network perspectives. As such, the advent of bio-tech firms with an 
international flair necessitates the modification of their model to accurately capture the 
specific world of this new phenomenon. The firms build their innovative capabilities by 
participating in evolving global R&D networks (Simba, 2012) hence; the need to develop a 
conceptual framework that adequately captures the changing terrain. As Swain (2012, p.12) 
noted, ‘The Big Pharma model is undergoing a painful evolution, moving from competition to 
collaboration, from one-size-fits-all to more tailored approaches, and a longer-term view of 
basic research’.  During the restructuring phase occurring in Europe and America (Rafols et 
al., 2012); scientists are taking centre stage in global R&D activities.  
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They are forming science-based firms (small born-global bio-tech firms) which are 
exceedingly productive (Simba, 2012). Evidence in the literature, from within and cross cases 
demonstrates that the business and social connections of the scientists which were 
developed during their previous employment have become part of the structural dimension 
of their new ventures. According to Munos (2009) the business and social connections of 
these scientists are used as channels for scientific knowledge, technical know-how and 
market-related intelligence. Their cognitive dimension consists of experienced scientists 
implying that they have vast knowledge in science. As such, Freeman’s et al. (2010) model 
was stretched to accommodate this new empirical evidence. By doing so, the newly 
constructed model of knowledge and innovative capability development significantly 
contributes to the understanding of the concepts of dynamic capabilities and networking 
theories that already exist (e.g. Rogers, 1962; Johnson & Vahlne, 1977; Teece et al. 1997; 
Freeman et al., 2010).      
 
Conclusion  
The new propositions and a revised model presented in this paper increase the 
performance of Freeman’s et al. (2010) model of rapid knowledge development for smaller 
born-global firms. The new model develops new and alternative understanding of the new 
types of bio-tech firms developing in the biotechnology industry which are conceived with 
global foci. The study reveals the importance of horizontal networks and the interplay 
between firms, research institutions and academics that have complementary technologies 
and science within the knowledge supply-chain of small born-global bio-tech firms (Shilling, 
2008). The author believes that the newly formulated theory of innovative capability 
development contributes to the understanding of the network approach which focusses on 
specific, well-selected relationships in the innovation process with specific actors within the 
same innovation milieu and beyond (Cooke, 2003; Breschi & Malerba, 2005). The study also 
demonstrates that for small born-global firms to receive and share tacit and explicit 
knowledge some form of trust between the collaborating parties has to be established. In 
that sense, competence trust i.e. trust which is based on the scientific and technical 
capabilities of the prospective partner and goodwill trust referring to the intentions of the 
prospective partner were identified as critical to inter-organisational collaborations that 
occur in the biotechnology sector.  
 
The study also brings to light that trust, in the collaborative projects of bio-tech firms, is 
built in escalating series. In established science centres relational-like trust naturally exist 
among resident firms. But, in newly developed networks trust exists casually or does not 
exist at all. With newly developed relationships the study found that the ‘trial and error’ 
method was evoked. The process was observed as starting with firms engaging in smaller 
projects aimed at testing the trustworthiness of a prospective partner. This potentially led 
to more collaboration(s). This observation is consistent with Shilling (2008) who claims that 
experimenting by linking up with different partners during the stage of establishing a 
partnership is necessary for high-tech firms as collaborating is not without risks. Within the 
knowledge supply-chain of small born-global bio-tech firms the previous learning and sector-
based experiences of the CEOs, bio-entrepreneurs or science directors are crucial in terms 
of absorbing specific capabilities or choosing the right partner with specific skills or 
knowledge that complements their firm’s internal capabilities. As much as the research 
approach adopted for this study is presumed appropriate the author is aware of its inherent 
limits. For example, using computer software SPSS which generates quantitative data would 
add to the validity of the proposed concepts.  
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The study is limited to five participants from the East Midlands region in the United 
Kingdom. Nonetheless, the output which is “Knowledge and Innovative Capability Development 
Model” illuminates the salient mechanisms and process that mitigate the knowledge supply-
chain of small born-global bio-tech firms. Finally, the author makes two important 
recommendations. He recommends studies that test the extent to which independent 
variables such as: business, social networks, competence, goodwill trust, prior learning and 
absorptive capacity influence the innovative capability development process of small born-
global bio-tech firms. The traditionally held view that large bio-pharmaceuticals are the most 
dominant force in global markets might well be evolving. The advent of small born-global 
bio-tech firms on the global stage in substantial numbers, worldwide, reflects an emerging 
business model with the potential to perhaps become the most dominant in the harsh 
economic times in which large organisations are feeling the strain. In that regard, the born-
global phenomenon requires great attention because it heralds the emergence of a new 
phase in international exchange systems whereby regardless of the size of a business, it can 
play an important role in global markets. From that perspective, he also recommends future 
studies that investigate how small born-global bio-tech firms learn to cope with the 
complexity of global markets given their cultural diverse nature. This will help us to deepen 
our understanding of how born-global firms organise the exchange of ideas, technologies, 
people and information in global networks.   
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The role of global R&D networks in generating social capital for born-global bio-tech firms: 
A multi-case approach 
 Amon Simbaa  
Abstract 
The traditionally auspicious ‘Big Pharma’ business model in the pharmaceutical industry is 
rapidly evolving. Large pharmaceutical companies are re-configuring their business models to 
achieve operational efficiency. The preferred option appears to be out-sourcing science-
related R&D as opposed to conducting the research in-house. This has marked the ‘birth’ of 
born-global bio-tech firms which operate as contract research organisations. The firms are 
owner-managed by entrepreneurial scientists who generate social capital in the form of 
scientific knowledge and technical know-how by participating in multifarious global R&D 
networks. In that sense, this empirical study utilises multiple cases of born-global bio-tech 
firms sampled from the East Midlands in the United Kingdom to investigate how various 
mechanisms in their knowledge supply-chain (global networks), including complex business 
and social relationships, shape their social capital generating strategies. By doing so, the 
study contributes to the concept of dynamic capabilities and networking. The study is also 
invaluable to a number of stakeholders including: large & small firms, other researchers, and 
policy makers.   
Keywords: Born global, Global R&D Networks, Innovative Capabilities, Trust, Knowledge, Inter-organisational 
Collaborations, Social Capital 
1. Introduction 
The life science industry is currently undergoing substantial transformation whereby large 
bio-pharmaceutical companies are streamlining their R&D facilities in favour of out-sourcing 
the services (Rafols et al., 2012). As a consequence of this unfolding strategic move a new 
form of entrepreneurial ventures identified in the literature as born-global firms have 
proliferated (see Knight & Cavusgil, 1996; Oviatt & McDougall, 1994; Mathews & Zander, 
2007, Gabrielsson & Kirpalani, 2004). Outside the Golden Triangle of Cambridge, London 
and Oxford in the United Kingdom, there is enthralling evidence from the East Midlands 
region showing an exponential rise of small firms in the biotechnology sector that are 
conceived with an international flair. The firms engage in complex global networks of 
innovation. Kalantaridis & Vassilev (2008) suggest that this is made possible by the liberal 
global structures governing trade today. As such, born-global bio-tech firms have designed 
their business operations in a way that boosts their capacity to generate fluid scientific 
knowledge and technical know-how (Shilling, 2008; Lasserre, 2012).  In this article the term 
social capital which means, ‘the sum of the actual and potential resources embedded within, 
available through and derived from the network of relationships possessed by an individual 
or social unit’ (de Wever et al., 2005, p.1525) is used to refer to scientific knowledge and 
technical know-how.  
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The structural dimension of born-global bio-tech firms includes global academic networks 
and research labs, other firms, and international science parks (Lindstrand et al., 2011; 
Todtling et al., 2009). There is a near universal acknowledgement that the business and 
social connections of born-global firms perform a fundamental role as conduits for their 
capability development (see Freeman et al., 2010; Sharma & Blomstermo, 2003; Karra et al., 
2008). From that perspective, the ability to be innovative in the science intensive 
biotechnology sector can only occur if a firm is able to both generate and integrate 
knowledge from inside and outside its proximity (Powell & Grodal, 2005). While it is often 
assumed that business networks yield innovation (Owen-Smith & Powell, 2004) more 
research still needs to be carried out to understand the various mechanisms that manifest in 
the knowledge supply-chain of born-global bio-tech firms. More importantly, how these 
mechanisms shape the processes involved in generating scientific knowledge and technical 
know-how. As such, this article investigates the role of global networks which are part of 
the knowledge supply-chain of born-global bio-tech firms. A look into the knowledge supply-
chain of these international ventures will exact a better understanding of the complexity of 
global networks and their strategic effect or fit.   
 
2. Literature Review 
 
2.1 The Characteristics of Born-global Bio-tech Firms 
 
The term born-global is used in this study to describe small bio-tech firms, trading in the 
biotechnology industry, which engage in global R&D activities i.e. they take part in science-
related projects on a global scale (Simba, 2012). This rather new and emerging strategy of 
acquiring innovative capabilities is gaining momentum in the biotechnology sector. 
Scholarship on firm internationalisation attributes this developing operational strategy to the 
availability of advanced information systems and technology, efficient means of 
transportation, and the liberalisation of world markets (Shelling, 2008; Lasserre 2007/2012; 
Ferreira et al., 2010; Kalantaridis & Vassilev, 2008). The liberalisation of global trade markets 
significantly gives rise to the formation of entrepreneurial firms with an international flair. 
Early studies (see Schumpeter 1934’s theory of innovation) closely associate entrepreneurial 
behaviour with innovation. In Anderson (2000); Mathews & Zander (2007) innovative and 
entrepreneurial firms were described as business ventures that have the vision and the 
flexibility needed to identify and exploit the benefits offered by existing and new overseas 
markets. Hisrich (2012) affirms that global markets offer entrepreneurial firms new market 
opportunities. The extant literature on international entrepreneurship (see Oviatt & 
McDougall, 1994; Li & Ferreira, 2006) characterises born-global firms as enterprises which 
take risks, innovate and have the vision to anticipate economic events. This is necessary 
because in science-intensive industries, technology and firm-based capabilities evolve at a 
fast pace. According to Gurău et al. (2010, p.452) ‘Rapid change, increased competition, 
faster life cycles, globalisation, new process models, breakthrough technologies – all 
contribute to the complexity of the organisational and business context of modern 
biopharmaceutical firms’. In that context, born-global bio-tech firms operating in these 
constantly evolving market conditions, escapades that involve risk such as networking across 
the globe can be crucial for bridging the knowledge and capabilities gap (Ferreira et al., 2010) 
or in enabling new resource combinations (Schumpeter, 1950). 
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2.2 The Global R&D Networks of Born-global Bio-tech Firms  
Networks are defined as a set of nodes (persons or organisations) linked by a set of social 
or friendship connections of a specific type (Cooke, 2001; Breschi & Malebra, 2005). They 
are distinct from hierarchical or market relationships in their reliance on reciprocity, 
collaboration, complementary independence and orientation towards mutual gain. Thus, the 
global R&D networks of born-global firms provide them with four key benefits that include: 
proximity to markets, access to geographical clusters of knowledge creation and 
development, learning and access to low cost and good quality scientists and engineers 
(Lasserre, 2012). More so, Breschi & Malebra (2005, p.47) claim that, ‘resource pooling, risk 
sharing and the formation of critical masses provide an incentive to create a group of inter-
linked agents’. Adding to the growing discourse on business relationships, a recent study by 
Johnson & Vahlne (2009) provides two core arguments. Firstly, the study suggests that 
markets are networks of relationships where firms are connected to each other in different 
formats including complex and visible patterns. This perspective is critical in understanding 
the collaborative activities of entrepreneurial firms or born-global bio-tech firms. Secondly, 
the study draws attention to the fact that relationships developed at an organisational level 
facilitate learning and the potential to develop trust. This is crucial for the resource-
impecunious born-global bio-tech firms which rely, to a greater extent, on strategic alliances 
to jointly develop new science technology and life-saving drugs. The social exchange theory 
accentuates the differences between business relationships that have a positive connection 
and the ones that have a negative one. In a business-like relationship where the connection 
is positive the flow and exchange of information is bi-directional whereas in those 
relationships with a negative connection information flows in one direction (Cooke, 2003; 
Ahuja, 2000).  
Innovation has always been the backbone and underlying strength of the pharmaceutical 
industry. The core concept of networking in business is that the co-ordination of activities 
between the parties involved in a business-like relationship has to take place within a wider 
network context (Anderson et al., 1994; Ahuja, 2000; Owen-Smith & Powell, 2004). 
Accordingly, in well-established business networks, within the knowledge supply value-chain 
of born-global bio-tech firms, strong business connections are developed which enable 
learning through social exchange overtime (Anderson et al., 1994). Stanek (2004) emphasises 
that a network can often be superior for a stand-alone firm due to its greater knowledge 
diversity and a pool of talent found within. Freeman & Cavusgil (2007) claim that strong 
camaraderie is found to exist between born-global firms and their foreign partners and it is 
frequently based on long standing past associations of the senior management team.  
 
2.3 Innovation and R&D Capacity 
 
According to Khanna (2012, p.1088) ‘innovation has always been the backbone and 
underlying strength of the pharmaceutical industry’. A strong R&D base, within a network, 
can provide the ideas and products for future development (Cooke, 2001). Certainly, for 
born-global bio-tech firms global R&D networks are vital sources of new ideas and 
technology. According to the UK’s Department for Technology and Innovation (2004) the 
term innovation refers to product or process development while R&D is mainly concerned 
with the development of new knowledge. Drucker (1985, p.8) conceptualises knowledge in 
the form of science and technology as ‘superstars of entrepreneurship’ and Tushman & 
Anderson (1997) claim that, successful innovation is the output of an R&D process.  
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Like Drucker (1985) and Tushman & Anderson (1997) the author takes the views that 
global networks accelerate firm-based innovations. Su et al. (2009, p.312) suggest that, ‘a 
firm’s R&D capability reflects its ability to generate new scientific discoveries and 
technological breakthroughs’. Shilling (2008) echoes similar sentiments suggesting that, a 
firm’s R&D capability demonstrates its drive to generate new scientific discoveries and 
technological breakthroughs. After undertaking a study involving five high-tech firms 
Danneels (2002) found that a firm’s R&D is sturdily linked to product innovation.  
 
2.3 Social Capital and Born-global Bio-tech Firms 
 
Social capital refers to the long-standing aspect of human relationships (Bridge & O’Neill, 
2013) and it has been a focus of interest by many scholars from a wide-range of disciplines. 
The term social capital can be traced back to the early 19th century specifically, to the work 
by Hanifan in 1916. In the last quarter of the century the concept was advanced by Bourdieu 
(1986), Coleman (1990), and Putman (1995). Their conceptualisation of social capital 
assumes various dimensions and their work does not produce a uniform understanding of 
social capital which can be confusing (Bridge & O’Neill, 2013). For instance, Bourdieu (1986, 
p.248) defines social capital as ‘the aggregate of the actual or potential resources which are 
linked to possessing of a durable network of more or less institutionalised relationships of 
mutual acquaintance or recognition’. Coleman (1990) defines social capital by its function. 
Coleman argues that social capital consist of some form of social structure that facilitates 
certain actions by actors within it. Putman (1995) appears to treat social capital as a single 
dimension. Putman defines it as ‘the networks, norms, and trust that enable participants to 
act together to effectively pursue shared objectives’ (1995, p21).  
 
From these various perceptions of social capital, one can identify its relevance to 
entrepreneurship and business. For example, MacMillan et al. (1985) examined new ventures 
and observed that as the new venture evolves it becomes apparent that ‘who you know’ is 
as important as ‘what you know’. Crucially, MacMillan and others found that for 
entrepreneurs to develop support it is important that they develop rapport with their 
network contacts. Consistent with MacMillan and other’s observation and recognising the 
importance of entrepreneurial behaviour of what they called ‘know who’ Peterson and 
Rondstadt (1986, p.11) proposed a formula: ‘Entrepreneurial Success = New Venture Idea + 
Entrepreneurial Know-how + Entrepreneurial Know-who’. Thus, the social and business 
connections of born-global bio-tech firms in global R&D networks are an essential part of 
their ability to be innovative, to economically grow and develop in global markets.   
                         
3. Methodology 
 
3.1 Research Goal 
 
The study investigates the role of global R&D networks, in the knowledge supply-chain of 
born-global bio-tech firms especially, their effect on the firms’ process of generating social 
capital. To satisfy the research issue the study utilises multiple cases. The participants 
include CEOs and science directors from five bio-tech firms identified as born-globals. The 
sample predominantly consists of firms which use the East Midlands region in the United 
Kingdom as their home market. The interviews took place between November 2011 and 
June 2012. Multiple steps were taken to identify sample cases.  
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First the author checked the BioCity Nottingham (BCN) web site, a regional ‘incubator’ to 
identify cases of firms that are active in drug discovery and global R&D projects. This is 
consistent with Flyvbjerg (2013 in Denzin & Colin, 2013, p.169) who suggests that, ‘the 
decisive factor in defining a study as a case-study is the choice of an individual unit and the 
setting of its boundaries’. In other words, its ‘casing’ to use Ragin’s (1992) felicitous term. 
The procedure generated about 20 East Midlands based bio-tech firms which were 
subsequently narrowed down to five based on their ability to illuminate various aspects of 
the research phenomenon. The case-study method is multi-discipline; historically it was used 
by clinicians to understand the ‘person in particular’ (Runyan, 1982) and in education it is 
used to help students to understand a concept (Cohen et al., 2007), in law using a case law 
and in political science using case reports (Creswell, 2007). Furthermore, Creswell (2007) 
claims that because of its popularity in social science the case-study approach is familiar to 
social scientists.  
 
In that sense, for the purpose of this study, which can be categorised within the discipline of 
business management, the research approach is used to extend our understanding of the 
role of global networks in generating social capital for born-global bio-tech firms. This is 
consistent with Yin (2009, p.18) who defines a case-study research as, ‘an empirical enquiry 
that investigates a contemporary phenomenon in depth and within its real life context, 
especially when the boundaries between phenomenon and context are clearly evident’. 
Cohen et al. (2007, p.253) makes a strong case in support of researchers who assume a 
case-oriented approach by insisting that, ‘case studies can establish cause and effect and one 
of their strengths is that they observe effects in real contexts, recognising that context is a 
powerful determinant of both cause and effects’. It is therefore based on these attributes of 
a case-oriented approach that attracted the author to use the research strategy for the 
purpose this study which investigates the cause (global networks) and the effect (social 
capital) of born-global bio-tech firms.      
4. Case Findings 
This section provides detailed findings within each case. It describes the actions of born-
global bio-tech firms regarding how they generate their social capital. This is consistent with 
Eisenhardt (1989, p.540) who suggests that, ‘within case analysis, typically involve detailed 
case-study write-ups for each site’. Crucially, it helps to describe what is happening in the 
complicated world of born-global bio-tech firms (Huberman & Miles, 1994). Scholars 
Gersick (1988) and Pettigrew (1988) agree that although within case analysis is purely 
descriptive the research technique is crucial in terms of enabling the reader to gain an 
insight into the research phenomenon. The main aim for doing within case analysis was to 
become intimately familiar with each bio-tech firm (Stake, 2005). Particularly, with all the 
factors that influence their capacity to generate social capital. This assisted the author to 
uniquely map out the pattern of each case prior to generalising across the cases (Eisenhardt, 
1989). Table1 on p.6 provides an array of data describing born-global bio-tech firms and 
science parks. The data on science parks is provided to give the reader more information 
regarding their role in facilitating a geographic concentration of a critical mass of inter-
connected companies and R&D science institutions (Engel & del-Palacio, 2009).     
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Table 1 Description of Born-global Biotech Firms comprising the sample 
 
Case 1 – Critical Pharmaceuticals Ltd (CP)  
Critical Pharmaceuticals Ltd is a spinout company from University of Nottingham (UoN) 
which was formed in 2002 by two researchers in chemistry and pharmacy (BCN, 2011). The 
firm received seed funding and it moved into new premises following the formation of BCN 
in 2003. As the company further developed its technology and products it attracted more 
funding from leading UK investors including: Catapult Venture Mangers, The Lachesis Fund, 
e-Synergy, East Midlands Business Angels and The Well-come Trust. The funding CP 
received from Wellcome Trust enabled the firm to transform the delivery of hGH a drug 
which treats human growth disorders in adults and children. For Critical Pharmaceutical, 
funding was a catalyst used to unlock its innovations.  
 
 
Firms 
   
 Origins 
 
Bio-tech Activity 
Year 
Founded 
No. of           
Interviews  
 
Critical 
Pharmaceutica
ls 
 
UK-based biotechnology 
spinout company from 
the University of 
Nottingham 
 
Involved in drug delivery technologies for the sustained release and nasal 
delivery of proteins and peptides and labile or insoluble small molecules. 
Delivers Advanced Therapeutics 
 
2002 
 
4 
 
XenoGesis 
Ltd 
 
UK based founded after 
the closure of 
AstraZeneca 
 
Specialises in pre-clinical drug metabolism and pharmacokinetics (DMPK), 
quantitative bio-analysis and expert interpretation 
 
2012 
 
3 
 
Haemostatix 
Ltd 
 
Spin-out firm from the 
University of Leicester – 
UK based 
 
Develops a pipeline of haemostats based on its new class of active 
ingredients that replace thrombin. The firm also commercialises its new 
technology platform based upon a specific peptide sequence that binds to 
fibrinogen – a protein essential to the formation of clots.  
 
2003 
 
4 
 
 
Sygnature 
Discoveries 
 
 
Founded in BioCity 
Nottingham  
 
 
Provides integrated drug discovery services. The company is also involved 
in a wide spectrum of drug discovery programmes and the outsourcing of 
discovery projects to contract research organisations (CROs) 
 
 
2004 
 
 
4 
 
BAST Incl. 
 
Spin-off business 
launched after the 
announcement of the 
closure of the 
AstraZeneca 
 
The pharmaceutical company is involved in a new drug development 
process known as Model-based Drug Development (MBDD) where 
investment decisions are supported by a simulation of the probability of 
success. The company is part of a collaborative network of twenty four 
other organisations with the East Midlands and internationally.  
 
 
2010 
 
3 
 
Science 
Institutions 
  
Networking Activity 
  
 
BioCity 
Nottingham 
(BCN) 
 
A result of collaboration 
activities between 
Nottingham Trent 
University, The 
University of Nottingham 
and EMDA 
 
UK’s largest bio science innovation centre. Operates as an incubator for 
small firms within and outside the region. Currently houses advanced 
equipment and technology in over 12,000m2 of bespoke laboratory and 
office space and it is also the site of a new Nano-technology and micro-
technology fabrication facility for the East Midlands region (BioCity, 2012).     
 
2003 
 
1 
 
Medilink East 
Midlands 
 
Part of Medilink UK 
which was established in 
1999 operating in other 
parts of UK 
 
It is a life science industry association, whose aim is to help companies 
establish, develop and grow and connects them with other global players. 
Its network consists of more than 4,000 contacts in over 600 organisations 
represents all aspects of the sector, including private and public institutions; 
from multinationals to high potential start-ups, as well as the NHS and 
universities. 
 
2004 
 
2 
 
Pera 
Innovation 
Park 
 
 
 
Part of a Europe network 
established 65 years ago 
to help UK & Europe 
businesses 
 
 
Pera Technology helps hundreds of companies across Europe and beyond 
to harness the potential of science and technology to create new and 
valuable products and processes to create sustainable, valuable businesses. 
The innovation centre also provides integrated R&D services for firms of all 
sizes  
 
 
2008 
 
3 
Midlands 
Enterprise 
Europe 
Network 
Part of Enterprise Europe 
Network (EEN) 
The Midlands Enterprise Europe Network is a local node within a network 
of 600 regionally based contact points covering the entire European Union 
and beyond. The Enterprise Europe Network is the official EC business 
support network for business cooperation and technology transfer, 
providing organisations with access to technology transfer for technological 
cooperation, research, licensing, manufacture and joint venture agreements. 
2008 3 
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The structural dimension i.e. CP’s global business connections presented the firm with an 
opportunity to leverage its resource deficiencies. This was reflected in a conversation with 
the firm’s CEO when discussing the resources that his firm acquired from its collaborative 
networks he said that:  
 
We acquire technical and financial support from our business partners scattered throughout the world to 
back-up our internal expertise, marketing, PR, science knowledge that may be limited in-house yet we 
needed it to achieve our goals.  
 
This evidence is strong and it indicates that the firm has a wide range of business 
connections on a global scale including funding institutions, academia, other firms and 
research institutions which it uses to generate social capital. XenoGesis, Haemostatix, 
Sygnature and BAST have crafted similar structures with a view to generate social capital. 
This is consistent with Granovetter (2005).  Granovetter suggests that in close-knit ties 
there is a strong element of trust which makes it possible for the exchange of new ideas and 
knowledge. The CEO of CP commented that:  
 
You should have trust with the people who you have business-like relationships so as to allow the free 
movement of knowledge and information to happen.  
 
The management team at CP consists of well-experienced scientists of international stature 
and they all share the same view about the world of science. In that respect, global 
networks can be seen as an essential component of the jigsaw puzzle needed by small bio-
tech firms in their process of developing innovative capabilities. Similarly, Yi et al. (2008) 
contend that integrating knowledge from diverse contexts is a pivotal part to a firm’s ability 
to generate fluid information. This view was reflected by the CEO of CP when announcing 
the firm’s collaborative project with UoN. This is what he had to say:  
 
We are excited about working with internationally-recognised clinicians and scientists at The University of 
Nottingham and Nottingham University Hospitals NHS Trust to rapidly develop this highly innovative 
formulation of teriparatide.  
 
His sentiments were also echoed by a research fellow at the UoN who expressed 
excitement at the prospect of collaborating with CP. He observed that, it was going to 
enable the UoN to jointly develop world leading research as well as share scientific 
knowledge and technical know-how. This highlights that the concept of working in 
collaborative projects is gaining prominence in the biotechnology sector. Scientists are of 
the opinion that collaborative projects are necessary for developing complementary assets 
(Shilling, 2008). The author found this form of co-operation to be crucial for CP in terms of 
generating fluid scientific knowledge. These collaborative projects also enabled CP to bridge 
its knowledge gaps. This observation is consistent with Helfat & Peteraf (2003) who agree 
that external resources help a firm adjust its resource mix. Undeniably, interacting with 
other firms or organisations with diverse skills (cognitive distance) provide synergy for firms 
with insufficient resources. In science-based industries the extent to which knowledge is 
spread, described as knowledge diversity in Nooteboom (2009), increases the innovative 
capabilities of small firms. More importantly, it significantly improves their business 
processes and also influences their ability to make crucial innovations.  
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When asked about the importance of working with firms within and outside their vicinity 
the CEO of CP explained that: 
 
In the biotechnology sector you need various skills and knowledge. In addition to our in-house knowledge 
we collaborate with other institutions such as universities and other companies both locally and 
internationally. We have different levels of collaboration. We collaborate with small and large companies 
in the USA and the EU. We also have intense collaborations with companies near to us who have 
expertise in areas of interest to us we therefore work with them to access the expertise that we do not 
have.  
This is compelling evidence indicating that CP is involved in global R&D networks. Its 
knowledge/market value-chain includes both domestic and international actors. From that 
perspective, the author can confidently claim that strategic alliances between businesses 
and research centres worldwide are the cornerstone to innovation given the globalised 
nature of the markets today. Lasserre (2012, p.293) concurs with this presupposition and 
he emphasises that, ‘every process of globalisation implies some process of technological 
transfer’. Irrefutably, the statement made by the CEO of CP quoted above endorses this. 
Likewise, Teece (1986) supports this point of view by affirming that small firms can form 
alliances with big firms to tap into the larger firm’s greater capital resources, distribution 
and marketing capabilities, or credibility. Similarly, Roudini et al. (2012, p.129) claim that 
in global networks, ‘knowledge flow and exchange become possible through marketing 
connections and they foster communication between included groups, and establish a 
crucial channel for resource acquisition’. The firm’s management team also performed a 
decisive role in unlocking its innovation conundrum. The team’s years of experience in 
the biotechnology sector significantly enhanced the firm’s capacity to make important 
drug discoveries. Thus, a good understanding of science by key people in the business 
increased the firm’s chances of making rapid progress in developing nasal administered 
drugs. Oviatt & McDougall (1994) express similar views by claiming that the previous 
experience of the management team has affirmative influence in enhancing a firm’s 
formation of capabilities.   
Case 2 – XenoGesis Ltd 
XenoGesis is a company that was formed in 2012 following the closure of AstraZeneca’s 
R&D facilities in Loughborough in the East Midlands, UK. For its cognitive dimension, its 
management team is composed of scientists who are former employees of AstraZeneca and 
have vast experience in life science. Its founder who is also its CEO is a former Associate 
Principal Scientist in drug metabolism & pharmacokinetics (DMPK) at AstraZeneca. He has 
been involved in about 60 different projects during his time at the pharmaceutical giant and 
has delivered new medicines. Experience in science-based firms is a valuable asset that can 
be crucial to the performance of a firm. XenoGesis specialises in data-driven iterative drug 
design PK/PD study planning and interpretation, dosing regimen recommendations, toxic 
kinetic support and drug transport (XenoGesis, 2012). The founder of the firm considers his 
connections which were established during his time at AstraZeneca as central to the success 
that his company has enjoyed since its inception. Thus, the founder’s structural social capital 
played a pivotal role in enabling XenoGesis to acquire crucial scientific knowledge, technical 
know-how and financial resources. The company’s CEO commented that:  
 
It is quite unusual for a new company working in this field to get off to such a flying start but we have the 
support of a strong Board of Directors and staff team, and several international partners. 
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In March 2012 Mobius Life Sciences Fund announced an investment in XenoGesis citing its 
fast growth as the main reason for investing. More importantly, Mobius funding comes with 
help and support from experts at BCN targeted at ensuring a firm’s continued growth and 
creativity. Expert support and funding were very much part of XenoGesis structural 
dimension. This is similar with the other 4 firms sampled for this study which all benefited 
from the support offered at BCN. The Director of the Mobius Life Sciences Fund Dr Glenn 
Crocker (2012) explained more about why his organisation invested in XenoGesis:  
 
XenoGesis has already shown its growth capability by winning significant contracts and exceeding its early 
targets. The highly experienced and committed management team are focussed and passionate about 
what they do. They are ambitious but also realistic in their plans. I believe XenoGesis is just the kind of 
venture Mobius Life Sciences is looking to invest in.       
The firm has grown from strength to strength and in June last year (2012) it moved to a 
bigger office space at BCN. This was attributed to the firm’s economic growth at the 
beginning of 2012. To demonstrate its entrepreneurial flair synonymous with born-global 
firms, the enterprise collaborates with other players in the biotechnology sector within its 
vicinity and on a global scale. In the recent past, its CEO was involved in conferences on 
biotechnology and science in London and Barcelona that took place in June of 2012. The 
conferences provided the firm with the opportunity to network with potential partners 
from 80 international experts in the field of drug metabolism presenting the firm with a 
chance to build its knowledge base. The widening of the firm’s business and social 
connections (structural, relational and cognitive dimensions) has enabled it to grow at a fast 
pace and achieve scientific excellence and innovation. The CEO at Critical Pharmaceuticals 
uses conferences as a source of new technical know-how and fluid scientific knowledge. 
Case 3 – Haemostatix Ltd 
In 2003, a research group at the University of Leicester (UoL) became interested in 
developing a new class of active clotting agent, or ‘haemostat’ for the control of bleeding to 
mitigate the shortage of fresh donated platelets. Consequently, Sarah Middleton (CEO) and 
Professor Alison Goodall (CSO) formed Haemostatix in conjunction with the UoL. The 
University played a crucial supporting role in the company's early stages. For its relational 
dimension, in 2004 the company established a collaboration with the Scottish National 
Blood Transfusion Service to secure specialist production capabilities for its products. To 
enhance its capacity to further develop a new class of active clotting agent Haemostatix 
received start-up funding of £250,000 from The Lachesis University Challenge Fund and 
initial investment from NESTA. In 2008, the company received further funding in the region 
of £1.24 million from a network of investors (structural dimension) that included: Spark 
Ventures, Catapult and NESTA. The CEO of NESTA, Jonathan Kestenbaum explained that:  
 
Haemostatix is a dynamic young company driving forward an innovative product that promises to change 
lives. We are excited to follow our original funding and look forward to working with them as the business 
continues to develop.  
 
To further support the development of its innovative haemostat technology in 2011 the 
company received an investment of £250,000 from Esperante, an American company. This 
evidently shows that the firm’s structural dimension consists of investor companies which 
not only supports, but appears to be vital to; it’s continued product and process 
development. Locally, funding from Mobius and the Nottingham City Council (NCC) is 
aimed at assisting promising start-up firms located at BCN.  
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As such, Haemostatix uses BCN as its base presenting the firm with an opportunity to 
access support and help offered at the region’s science ‘incubator’. Kang & Park (2012) 
suggest that governments can encourage innovation and economic prosperity by supporting 
R&D projects that have the potential to generate social capital. When commenting about 
the financial support Haemostatix received from Mobius in 2010, Glenn Crocker CEO of 
Mobius explained that: 
 
We have provided Haemostatix with a supportive business development environment for several years 
and recognise the enormous progress the company has made with its new product. Mobius Life Sciences 
Fund is designed to contribute to this kind of investment opportunity alongside major investors. 
In addition to large investments that the company received in the last 8 years, it has a 
management board which consists of experienced members in commercialisation, science 
and financial investment. Its scientific advisory board is composed of high profile personnel 
from the UK and the EU. The company’s efforts to design a cost effective alternative to 
platelet transfusion was anchored on the amalgamation of experienced, multi-skilled 
scientific, clinical and commercial leadership. Similarly, in the other four firms sampled for 
this study, their management structure consists of experienced personnel demonstrating 
that there is strong evidence pointing to the presence of knowledge diversity in all the firms 
that were investigated. In other words, all the firms are benefiting from the experience and 
knowledge its members have amassed from their previous roles in science-related 
businesses and global-oriented research groups over the years.  
Case 4 – Sygnature Discovery Ltd   
Sygnature Discovery Limited was formed in 2004 through an MBO of the Synthesis 
department of CombiPure Ltd. Its founder/CEO has experience in research gained from 
major pharmaceutical companies such as; AstraZeneca, OSI Pharmaceuticals and at 
CombiPure, where he was Managing Director and Director of Chemistry. The company 
offers integrated drug discovery solutions to pharmaceutical and biotechnology companies 
located in the USA and Europe. It operates in a global network of expert Contract Research 
Organisations (CROs) each specialising in their own area. The company grew from five 
chemists in 2004 to one that now employs 56 medical chemists, vitro biologists and the 
majority of them have PhDs with significant pharmaceutical industry drug discovery 
experience. This implicitly shows that the management team and all the employees share the 
same goals highlighting its cognitive dimension. Similar to the other four firms Sygnature 
benefited from the closure of AstraZeneca’s Loughborough R&D site in 2011. The firm 
employed experienced former AstraZeneca medical chemists to deal with the demand of 
services from their clients in the USA and Europe. Scholars Dokko & Rosenkopf (2010) 
suggest that in addition to the knowledge and skills experienced individuals may have they 
also bring pre-existing relationships that facilitate the transfer of knowledge and technical 
know-how. Specifically, the science knowledge of its employees and the experiences of the 
management team made the firm trustworthy to investors and potential partners. The 
president of the firm explained that: 
 
Our clients and business partners build trust basing it on our competence and reputation. Getting 
acknowledged by colleagues, clients at BioCity Nottingham and overseas because of the quality of the 
work that you do is very important in this business and that’s all part of establishing credibility. 
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In 2006, the firm posted a turnover of £1 million and in the same year it received FP6 
European project funding. Three years later the firm received a £390,000 Grant for Business 
Investment (GBI) awarded by the East Midlands Development Agency (EMDA) and the 
European Regional Development Fund (ERDF). The firm entered into a strategic alliance 
with Cyprotex in 2009 which was later extended in 2011 for a further 2 years. Cyprotex 
Discovery Ltd is the world’s largest specialist ADME-Tox/PK pre-clinical discovery and it 
plays a major role in developing CROs. Similar to the other four firms sampled for this 
study, Sygnature Discovery’s structural dimension consists of a network of companies with 
some cognitive distance but with complementary foci. Nooteboom (2006) suggests that 
when absorptive capacity is aligned with organisational goals and aims, it enhances 
organisational cognition. Indeed, interacting with other firms that may have different 
complementary foci at some cognitive distance solves what Nooteboom (2009) described as 
‘organisational myopia’. Put differently, the firm was able to bridge its knowledge and 
capabilities gaps. The main reason for the alliance was to expand its collaborative sales and 
marketing initiatives to provide a fully-integrated discovery chemistry/ADME-Tox/DMPK 
service as well as accelerate its clients’ drug discovery projects into development. Anthony 
Baxter the CEO of Cyprotex commented that: 
We are delighted to have extended our strategic alliance with Sygnature. The quality of their work and 
their desire to help customers achieve scientific success has enabled both of us to form a formidable 
combined offering in medicinal chemistry-driven integrated drug discovery and ADME-Tox services.   
By using its structural and relational dimensions of social capital Sygnature was able to 
deliver innovative products and services to its clients/partners while saving significant 
amounts of resources in the form of time and financial capital. Crucially, the collaborating 
partners shared the risks associated with drug discovery. More recently, the firm entered 
into another strategic alliance with Pneumolabs (UK) Limited with a view to leverage its 
knowledge base by widening its structural dimension. The CEO at Pneumolabs made the 
following comment regarding the formation of a partnership between the two firms:  
Our strategic alliance combines the complementary skills of Pneumolabs, a ‘centre of excellence’ for 
respiratory disease-focused pre-clinical research services, and Sygnature, a ‘centre of excellence’ for 
medicinal chemistry-driven integrated drug discovery  
Sygnature Discovery’s alliance with Pneumolabs enabled both firms to share their social 
capital. This form of inter-organisational collaboration was also evident in cases 1, 2, 3 and 5. 
Following the partnership, the company committed more resources by opening new 
purpose-designed research laboratories to show its commitment to new drug discoveries. 
By committing such amount of resources, there is concrete evidence disclosing that the firm 
had developed trust with its partner.   
Case 5 – BAST Inc. Ltd 
The founder of BAST first managed a similar business under an identical name in Houston, 
Texas, from 1991 to 1998 and the company stopped trading in 2000. Between 2007 and 
2009 he worked for Merck Serono in Geneva. His tasks and responsibilities included: 
providing technical input to project-based work, coaching junior scientists, modelling and 
simulation. The founder’s desire to work in a collaborative way enabling the free flow of 
scientific knowledge and technical know-how has always been abundantly clear. In 2010, he 
moved to the UK where he worked as a science consultant for a number of companies 
offering population-style data analysis. Following the closure of AstraZeneca’s Loughborough 
R&D site he revived BAST Ltd Incl. where he has assumed the role of a science director.  
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The firm conducts silico research, either publicly or privately funded, in areas of oncology, 
autoimmunity (e.g. asthma) and drug delivery (Nano technology). BAST provides its drug 
discovery services to a global audience. For its structural dimension, the firm occupies 
science labs at BCN and Loughborough Science Park. This underscores the company's 
efforts to develop social capital through networking with other firms, scientists and research 
institutions. Similar to the other four cases, the firm’s management team is composed of 
well-experienced scientists. The majority of them are former employees of large 
pharmaceutical companies such as AstraZeneca. This pattern of forming new ventures by 
small entrepreneurial firms was noted by Sharma & Blomstermo (2003). Sharma & 
Blomstermo observed that because born-globals are knowledge-intensive firms with an 
exceedingly high degree of knowledge content they employ individuals who possess high 
scientific knowledge.  
 
The amalgamation of knowledgeable scientists was an important step for the firm towards 
developing innovative capabilities. The firm assembled scientists who are multi-skilled and 
vastly experienced in science which further underlines its cognitive dimension. To develop 
its social capital, the firm was committed to engaging with potential partners on a global 
scale e.g. its management intends to form a consortium which includes: NGOs, Universities 
and other SMEs with a view to submit a project proposal for funding from the EU 
Commission’s FP6 programme. Wiedersheim-Paul et al. (1978) stress the importance of 
contact patterns explaining that they allow an efficient exchange of information as well as 
creating opportunities for knowledge transfer from partner firms. Furthermore, Burt (1992) 
and Gulati (1995) suggest that network research highlights the essential role inter-
organisational ties perform in terms of facilitating knowledge acquisition and its utilisation. 
The Scientific Director at BAST Inc. said that: 
We share knowledge with a number of actors in the biotechnology sector including knowledge centres in 
the East Midlands such as BioCity, science experts from Universities, other parts of UK and Europe. The 
idea is to share best practice as well as learn from other firms how they make innovations  
The firm was aware that huge amounts of resources will be required to develop social 
capital and it committed to contribute model-based design and decision support to 
collaborative projects on innovative strategies for the prevention or treatment of poverty-
related diseases. Its commitment to engage in international activities further demonstrates 
its desire to perform a key role in knowledge-sharing while taking advantage of the 
opportunities global markets offer. This strategic position can be directly attributed to the 
founder’s experience with foreign markets given his time in Houston, Texas. Consistent 
with this observation, Madsen & Servais (1997, p.569) postulate that ‘commitment decisions 
depend very much on experience, since they are a response to perceived uncertainty and 
opportunities in the market’. The main decisions about the strategic direction of BAST Ltd 
Incl. are predominantly done by its founder/science director. Europe and America are seen 
as destinations where the firm can engage with other actors in the biotechnology sector 
who complement its drug discovery services. Because its founder is multi-lingual, BAST Ltd 
Inc. was in a much stronger position to collaborate with other global-oriented firms or 
institutions.  
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Cross Case Findings 
While more specific results can be found within each case, in this section the author is 
interested in extracting patterns and trends from field research to figure out various factors 
and mechanisms that are traceable in the knowledge supply-chain of small born-global 
biotech firms. Precisely, the primary goal is to develop a clear picture regarding the complex 
business-like relationships in the global networks of born-global biotech firms. The author 
sketches the structural, relational and cognitive dimensions as well as presents 
commonalities across all the firms (see table 2 below). The founders of all the firms are 
scientists who are exceedingly experienced in life science. Shane & Khurana (2001) observed 
that a founder’s previous career experience is an important attribute that mitigates the 
problems associated with the liability of newness when establishing a new international 
venture. Ho & Wilson (2006) affirm that the experiences of the founders of biotechnology 
firms provide for existing social relationships which make it less complicated for them to 
obtain often scarce science-related resources. Evidence from cross-case analysis using 
structural, relational and cognitive dimensions (see table 2 below), reveal that all the 
founders had vast experience in the biotechnology sector which enabled them to acquire 
threshold capabilities essential for innovation and firm development in the biotechnology 
sector. Their influence played a significant part in crafting a global strategy that was pivotal in 
terms of acquiring knowledge and technical know-how for their firms. Cross-case analyses 
also show that funding institutions have become a strong part of the networks of born-
global biotech firms.  
Table 2 Structural, Relational & Cognitive dimensions of born-global bio-tech firms 
  
Critical Pharmaceuticals 
 
XenoGesis Ltd. 
 
Haemostatix Ltd 
 
BAST Inc. 
 
Sygnature 
Discovery 
 
 
Structural 
Dimension 
 
 
The acquisition  of scientific 
knowledge is based on the 
firm’s relationship with 
academic network and it’s 
connections with other 
firms & research institutions   
 
Similar to Critical 
Pharmaceuticals but the 
CEO interacts with his 
former work colleagues 
from AstraZeneca (global 
reach)   
 
The firm’s discovery 
activities are enhanced 
by venture capitalists 
(VC) and Technology 
Ventures such as 
Microbus   
 
Similar to XenoGesis & CP 
the firm collaborates with 
other small to medium size 
enterprises (SME) and 
universities 
 
Same as the other 
four firms and that 
the firm has strategic 
alliances with 
bioscience group 
 
Relational 
Dimension  
 
 
It is based on competence 
and goodwill trust and a 
long-term interaction with 
the firm’s academic 
network & business 
network 
 
Similar to CP and that 
trust is built in escalating 
series trying different 
using try and error 
method  
 
Similar to XenoGesis 
and CP 
 
Same with the other four 
firms and that obligations in 
a global network of 24 
other firms  
 
Based on 
competence & 
goodwill trust e.g. 
partnership with 
Cyprotex Discovery 
in 2007 
 
Cognitive 
Dimension  
 
 
The firm consists of 
experienced, multi-skilled 
scientific, clinical and 
commercial leadership team 
directed by a board of 
international standing with a 
broad base of expertise  
 
 
Similar to CP and the top 
management consists of 
experienced scientists in 
bio-analysis 
  
 
Similar to CP & BAST 
Incl.  
 
Same as the other four 
firms 
 
All the scientists 
have PhDs, post-
doctoral experience 
gained from USA & 
Europe 
 
The scientific competence and the benevolence of a firm was the basis on which 
partnerships were developed (see table 2, above). Evidently, the competence level in terms 
of the science base or depth of a firm was seen as a barometer to gauge the extent to which 
a firm can be trusted. Trust in competency refers to the perceptions of the trustor 
concerning the trustee’s technical, cognitive and communicative competences (Şengün & 
Önder, 2011; and Nooteboom 2009).  
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Blomqvist (1997) and Ganesan (1994) express similar views claiming that competence trust 
is based on a high probability that agreed strategic objectives will be successfully 
accomplished. This they suggest increases the reliability and the predictability of global 
partners in a relationship. Good reputation along with firm-based competences were 
perceived to be crucial in terms of developing trust given the risks inherent in sharing 
important scientific combinations that are essential for drug development and testing. 
Conclusion  
The article has highlighted the fact that participating in global R&D networks including 
international research labs are necessary deeds that facilitate the process of capability 
development in the knowledge intensive bio-tech sector. Following the author’s analysis of 
born-global biotech firms he found that they usually have limited resources and to mitigate 
their inadequacies they engage in collaborative activities with other firms within and beyond 
their vicinity. This led the research to conclude that global R&D networks have a huge 
impact on how they generate social capital. Precisely, knowledge diversity, trust and 
strategic alliances were the main variables, within their knowledge supply-chain, which had a 
significant bearing on how scientific knowledge and technical know-how was generated.  
In the East Midlands region in the United Kingdom, science parks perform a strategic role in 
forging the global R&D networks of born-global bio-tech firms. The firms are given the 
opportunity to establish, grow and develop by establishing strategic alliances, and creating 
specialist forums for joint problem solving. They are also offered specialised support and 
given a chance to participate in science-related debates with a view to hone their new ideas 
and innovations. Debate forums in the East Midlands often feature international participants 
who have a wealth of experience in life science. The study also infers that the structural, 
relational and cognitive dimensions of born-global biotech firms are central in providing 
them with business partners that have complementary assets and it allows them to jointly 
develop new ideas and science knowledge. Entrepreneurial firms such as born-global firms 
are known for their financial resource deficiencies and as the study reveals within their 
structural dimension venture capitalists (VC) are increasingly performing a decisive role. 
They are providing the much-needed financial support which makes it possible for a 
proposed research project(s) to progress to the next level. The author recommends future 
studies that investigate the specific types of networks which are developed on a global scale.  
Specifically, the number of actors that can participate in a network or cluster at a given time, 
the period it takes to establish a global R&D network and its life span? The author believes 
that such studies can potentially add to our understanding regarding the impact of global 
R&D networks of born-global firms in today’s science markets that appear to have 
converged into a single global trading place. 
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Prior-learning, cumulative science experiences and the absorptive capacity of bio-
entrepreneurs: A case of the East Midlands Region, England 
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Abstract 
In the modern healthcare and medical sectors corporate bio-pharmaceutical firms continue 
to scale down their in-house research and development (R&D) activities in favour of 
outsourcing the services to bio-tech ventures. These small but, entrepreneurial research-
oriented organisations have increased dramatically. They are predominantly owned by bio-
entrepreneurs who are extensively experienced scientists. Innovation ‘ecosystems’ 
consisting of global business and social networks are a common feature of science-based 
industries. As such, entrepreneurial ventures operating in this transient business 
environment have to consistently source new knowledge from their innovation ‘ecosystems’ 
to complement their knowledge deficiencies. In that context, the paper sets out to 
investigate five bio-tech ventures in the East Midlands region in England. It particularly 
recites the role performed by prior-learning and the cumulative science experiences of bio-
entrepreneurs in recognising, assimilating and productively applying science-related 
knowledge acquired from their innovation ‘ecosystems’ to argument firm-based 
competences.     
 
Keywords: innovation ecosystems, bio-entrepreneurs, prior-learning, cumulative scientific experience, absorptive capacity 
Introduction   
Innovation ‘ecosystems’, in the science intensive healthcare and medical sectors, are the 
main source of economic effects that include knowledge and technical know-how (Ho & 
Wilson, 2006). Research labs, academic institutions, science parks, small and large 
organisations co-exist within the maze and they purposefully interact with each other. 
Collectively, they work towards supporting technology development and the free flow of 
information (Bramwell et al., 2012). In such complex systems of multiple relationships, 
significant amounts of science-related data are generated. This has huge implications for bio-
entrepreneurs in the sense, that they have to effectively utilise their history and experience 
(antecedent influences) in science in order to identify and acquire useful knowledge that can 
facilitate the development of their bio-tech ventures. Burns (2012) elaborates on the 
antecedent influences of entrepreneurs highlighting that they are shaped by their business 
and social connections, culture, previous employment, and educational attainment.  
Noticeably, bio-tech ventures operate in a constantly changing business environment which 
has become global as a result of the liberal trade structures governing trade today 
(Kalantaridis & Vassilev, 2008). This requires constant resource re-configurations to sustain 
their economic development. In that sense, this study takes the view that, prior-learning and 
the cumulative science experiences of bio-entrepreneurs can be a catalyst that facilitates the 
economic development of their bio-tech ventures by assisting in the process of acquiring 
useful scientific knowledge from their innovation ‘ecosystems’.  
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Extant literature has paid much attention to the concept of inter-organisational learning 
largely focussing at the organisational level (see Dutta & Crossan 2005; Lumpkin & 
Lichtenstein 2005; Senge, 1990; Hibbert et al., 2010). There is a dearth of studies that 
specifically examine the role of prior-learning and industry specific experiences of bio-
entrepreneurs yet, a significant proportion of them imprint what Burns (2012) describes as 
‘entrepreneurial DNA’ in their bio-tech ventures. In other words, they communicate their 
personality through the way they manage/run their bio-tech ventures and it merits a closer 
examination of their role to their economic development. Considering the operational 
structures within small entrepreneurial firms, there is sufficient evidence to signify that their 
bio-entrepreneurs are actively involved in formulating their business strategies (see Gurău, 
et al., 2010; Burns, 2012; Bessant & Tidd 2011; Stokes & Wilson, 2006). From that 
perspective, there is logic in suggesting that their personality traits are replicated in their 
firms (Allen, 2012). In Storey (1994) seventeen multivariate studies were reviewed to 
examine the effects of antecedent influences on the development of entrepreneurial 
ventures. Storey’s study inferred that there is a strong association between an 
entrepreneur’s educational attainment (prior-learning) and the development of their 
venture. Kuratko (2013) contends that as entrepreneurs react to a diverse, multi-faceted, 
and imposing array of activities, events and developments they considerably influence the 
development of their ventures. Bessant & Tidd (2011) insist that the competences of owner-
managers strongly influence the scope and the direction of their ventures. This opens up the 
debate regarding the wisdom to analyse entrepreneurs and their ventures as separate 
entities.  
 
In light of Kuratko’s, Bessant’s and Tidd’s views it makes it so difficult to examine 
entrepreneurs and their ventures as independent units. As such, in seeking to contribute to 
the entrepreneurial learning literature and the concept of absorptive capacity (AC), this 
paper recites the experiences of bio-entrepreneurs and their ability to ‘soak-up’ new 
science-related knowledge in their innovation ‘ecosystems’. Particularly, it sets forth an 
empirical account of the role performed by their prior-learning and science-related 
experience in recognising, assimilating and productively applying new scientific knowledge in 
their bio-tech ventures. This answers the call of studies that focus their analysis of 
entrepreneurial learning at individual entrepreneurs (see Krueger 2007; Cope 2005; Corbett 
2005). In Crossan et al. (1999) new insights and ideas are seen as a by-product of individual 
learning which, when proven successful are eventually embedded into the organisation. 
Scholarship on learning universally agrees that learning takes place at individual level (see 
Rothaermel and Hess, 2007; Lichtenthaler & Lichtenthaler 2009; Cohen and Levinthal, 1990) 
and from that point of view; it even makes more sense to commence the analysis of the 
concept of absorptive by reciting the ACs of individual entrepreneurs. Equally, a number of 
recent studies have directed their efforts towards the field of entrepreneurial learning 
primarily focussing on individual learning and AC (see for example, Fogg, 2012; Smith, 2011; 
Zhang & Hamilton, 2010; Gold & Thorpe, 2008).   
 
Background Literature  
Process and substantive learning characteristics show the distinction between the concept 
of learning in collaboration and learning through innovation ‘ecosystems’. In technology-
based industries, collaborative relationships make it possible for knowledge to be exchanged 
between individuals, firms, academic institutions, and other non-profit research 
organisations (Oliver, 2010). Indisputably, entrepreneurship is a concept embedded in cycles 
of continuous learning described as ‘double-loop learning’ in Burns (2012, p.477).  
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Kim (1993) conceptualises effective learning as a revolving wheel of learning. Based on Kim’s 
account of effective learning, the science experience accumulated by bio-entrepreneurs from 
previous science-related assignments/projects within their innovation ‘ecosystems’ can be 
viewed through the lens of a revolving wheel of learning. Smilor (1997) maintains that, 
entrepreneurs learn by replicating the actions of other entrepreneurs. 
 
Bio-entrepreneurial Learning & Experience  
Effective entrepreneurs are exceptional learners (Smilor, 1997). Learning as concept is a 
very broad topic and it is by no means fully explored in this study. It is partially covered in 
this paper to inform the debate on entrepreneurial learning and AC. In Huczynski & 
Buchanan (2007, p.107) learning is described as the ‘process of acquiring knowledge through 
experience which leads to an enduring change in behaviour’. From that perspective, the 
most effective strategies for recognising new scientific knowledge for bio-entrepreneurs are 
informed, to a large extent, by their prior-learning and experience in life science (Simba, 
2013). Similarly, King & Lakhani (2011) agree that there is an association between individual 
learning and the stock of prior-related knowledge one holds. Continuing in the same vein, 
Huczynski & Buchanan (2007) discuss procedural and declarative learning. The scholars 
express that procedural learning or ‘know how’ is concerned with one’s ability to carry out 
skilled actions. They also insist that declarative learning or ‘know that’ is one’s ability to 
store factual knowledge. Concerning the unit of analysis for this research – bio-
entrepreneurs/owner-managers, it is not a misplaced judgement to view their vast 
knowledge acquired from previous science-related events within the frame of declarative 
learning.   
 
Furthermore, Kolb (1984, p.26) expounds the underlying principles of experimental learning 
stating that ‘ideas are not fixed and immutable elements of thoughts but, are formed and re-
formed through experience’. Scholarship on entrepreneurial learning collectively 
acknowledge that experimental learning is a process which attempts to explain how 
entrepreneurs acquire knowledge and enact new behaviours in recognising and acting on 
opportunities as well as organising and managing their ventures (see Petkova, 2008; 
Cobbett, 2007; Toiviainen, 2003; Cope, 2005). Deakins & Freel (1998) and Sarasvathy 
(2001) collectively claim that the majority of learning that occurs within an entrepreneurial 
context takes the form of an experiment. Schilling (2010) discusses experimentation that 
takes place in innovation ‘ecosystems’. She maintains that the process of experimenting is an 
important step in the development process of science-based firms as it enables them to test 
what works and what doesn’t. Similarly, Petkova (2008) presents a model of entrepreneurial 
learning from performance errors with a view to extend the psychology models of error-based 
learning. Petkova’s (2008, p.4) model proposes that entrepreneurs,’ ‘prior knowledge and 
cognitive biases can perform a significant role at each stage of the learning process and may 
determine whether the processes of error-detection and error-correction that leads to 
learning will actually occur’. Schilling’s and Petkova’s propositions have huge implications for 
bio-tech ventures as they are directly intertwined in their mental modes of learning 
particularly, their bio-entrepreneurs. Using Kolb’s (1984) view of learning by trying different 
configurations until one finds a combination that works, Cobbett (2005) makes a convincing 
argument. He argues that ‘cognitive mechanisms’ or the mental processes through which 
entrepreneurs acquire, store, transform, and use information are the output of individual 
learning.  
 
 
342 
 
Absorptive Capacity  
A comprehensive understanding of the concept of AC at a firm level is essential to how this 
study explains the significance of learning by individual entrepreneurs in their innovation 
‘ecosystems’. According to Cohen & Levinthal (1990) AC is the ability of a firm to recognise, 
assimilate and apply external knowledge. In Zahra & George (2002) a clear distinction 
between potential and realised AC was made. Potential AC was related to knowledge 
acquisition and assimilation capabilities and realised AC was associated with knowledge 
transformation and exploitation. Lichtenthaler & Lichtenthaler (2009) conceptualises AC as 
the ability to explore external knowledge. King & Lakhani (2011, p.2) introduce the notion 
of ‘adoption capacity’ which means the ability of a firm to adopt ideas from external 
connections. This is consistent with Cope (2005, p.481) who maintains that individuals 
transform (using cognitive properties) their experiences (situative) into new knowledge.  
 
Furthermore, Lichtenthaler & Lichtenthaler (2009) claim that new knowledge acquired from 
outside the firm (in innovation ‘ecosystems’) becomes useful when it is integrated with 
internal knowledge bases. A recent study by Jones et al. (2010) presents the idea of 
generative learning in global networks stressing that it is a critical step that informs the 
accumulation of specific and useful knowledge. Tidd & Bessant (2011) contend that AC is 
about accumulated learning and the embedding of capabilities. Crucially, in Cope & Down 
(2010, p.4) a strong link is constructed ‘between the outcomes of learning (information, 
knowledge, expertise) that impact on the entrepreneur's cognitive frameworks and the 
participative process by which these socio-cognitive resources are acquired’. The dated but 
inspirational works by a number of scholars (see Estes, 1970; Ellis, 1965; Bower & Hilgard, 
1981) highlight that an individual’s learning is cumulative and that learning performance is 
enhanced when the primary goal of learning (to understand the new knowledge to be 
acquired) is related to what the individual already know. Cohen & Levinthal (1990) also 
make a crucial point suggesting that AC is a by-product of prior-innovation and problem 
solving which is dependent on individual ACs of members of an organisation.  
 
When individual ACs of members in a firm and the firm’s ability to value, assimilate and 
commercially utilise new external knowledge are combined Lane et al. (2006) and Kim 
(1993) collectively agree that the duality modifies mental modes. In other words, the 
dualism modifies assumptions about the lived world. This is a fundamental point to make in 
the sense that, for global-oriented bio-tech ventures their bio-entrepreneur’s/owner-
manager’s prior-learning and science-related experience can modify their cognitive biases 
which plays a decisive role in their economic development given that they source scientific 
knowledge in multiple countries. Indeed, sourcing knowledge from established or newly 
developed business or social networks (innovation ‘ecosystems’) domestically and in other 
countries  consequently lead to a point of ‘knowledge saturation’ hence sifting, sorting and 
decoding useful information requires prior-learning and industry-specific experience.  
          
Research Approach 
The study adopts a case-oriented research approach (COR). Ragin (1992) claims that 
researchers who employ a COR approach do so partly, because their studies are exclusively 
qualitative and that the methods are more suitable with small research samples. In light of 
this, this study utilises five cases of bio-tech ventures located in the East Midlands region in 
England primarily focussing on their bio-entrepreneurs. The logic for using multiple cases 
was to establish whether the findings from one case can be replicated across the entire 
research sample.  
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This enabled the study to make plausible concluding statements concerning the role 
performed by prior-learning and the cumulative science experiences of bio-entrepreneurs in 
acquiring useful scientific knowledge in innovation ‘ecosystems’ to  develop their bio-tech 
ventures. Taking a cue from Saunders et al. (2012) view on choosing a research sample; 
cases of bio-entrepreneurs were systematically selected on the basis that similar results 
were predicted to be produced from each case. In Yin (2009); Huberman & Miles (1994) the 
procedure for selecting cases is termed literal replication. Cases for this study were designed 
to corroborate each other and to achieve this, a systematic sampling technique was deemed 
appropriate.  
 
A trade-off was made between systematic sampling and stratified random, cluster, and multi-
stage sampling techniques. Stratified random, cluster and multi-stage sampling techniques 
turn to follow a sophisticated research design which generates a number of data sub-sets; 
making it so complex to explain a research phenomenon (Saunders et al., 2012). As such, 
the study preferred to use a systematic sampling technique for selecting a representative 
sample because of its features that include: (i) accuracy and easy to access the research 
sample; (ii) low costs; (iii) its suitability to the scope and size of the study; (iv) its ability to 
allow the study to choose bio-entrepreneurs from the same geographical concentration 
making it feasible to conduct face-to-face interviews; (v) its ability to facilitate the 
explanation of the role performed by prior-learning and the cumulative science experiences 
of bio-entrepreneurs in recognising, assimilating and productively applying science-related 
knowledge to argument firm-based competences. The criteria for selecting the research 
sample are presented under the data collection and analysis section. 
  
To ensure construct validity, internal validity, external validity and reliability of the findings the 
study adopted ideas from Yin’s (2003/2009); Farquhar’s (2012); Stake’s (2005) and Voss et 
al. (2002). During the data collection phase interviews and documentary evidence were used 
for construct validity. At the data analysis stage casual links (Huberman & Miles, 1994), 
between prior-learning, the cumulative experiences and the ACs of bio-entrepreneurs, were 
established as well as the identification of patterns across the bio-entrepreneurs with a view 
to enhance the internal validity of the findings within each case. The basis for designing the 
study with multiple bio-entrepreneurs was to achieve external validity using the replication 
logic. Pattern matching in case-oriented studies is the most appropriate technique for case 
analysis (Farquhar, 2012; Yin, 2009). Data collected from the participants was transcribed and 
sent back for them to confirm whether it is an accurate representation of their account of 
events. The desired effect was to increase the reliability of the data collected for analysis. Yin 
(1998) insists that researchers who follow these strategies tremendously increase the 
quality of their case-oriented studies and they help to overcome traditional criticisms of the 
weakness of case study research.    
            
Data Collection and Analysis 
The unit of analysis for this study are bio-entrepreneurs/founders of small bio-tech ventures. 
They were chosen based on their academic attainment, competence in science, life science 
experiences and their ability to ‘soak-up’ useful knowledge for their bio-tech ventures. The 
bio-entrepreneurs were also expected to be part of an innovation ‘ecosystem’. Semi-
structured interview questions were employed as a guide during discussions. The open-
ended questions allowed the bio-entrepreneurs to tell a story about their experience in life 
science and achievements. The qualitative discussions with the bio-entrepreneurs lasted on 
average 20 minutes.  
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In addition to the interviews with them their publicly available career profiles were utilised 
to gather existing information about their accolades and educational attainment. Company 
and University websites were also used as another source of this type of data. The process 
of analysing data commenced during its collection phase. The empirical study constructs 
detailed profiles for each case. The logic for compiling detailed profiles for each case was to 
gain intimate knowledge of each of the individual cases as well as to understand each case on 
its terms (Huberman & Miles, 1994). Taking Bazeley’s (2013) advice that studies which 
solidly relies on coding techniques such as NVivo run the danger of being superficial as such, 
this study prefers to maintain the perspective of the cases by profiling each case.  
 
Additionally, Yin (2009) maintains that case descriptions and profiles summaries serve a 
much wider range of analytical purpose. Consistent with Yin, this study focusses on a 
representative sample from a large population of bio-entrepreneurs in the East Midlands in 
England. Bazeley (2013) insists that, in small-sample studies or for studies with a methodical 
or substantive focus on particular cases the preparation of a profile for each case is the 
most useful early step for both within-case and cross-case analysis. An important point 
relating to the strategy for data analysis adopted for this study is made by Stake (2005), he 
stresses that a case study can be both an analysis process and a product of analysis. In that 
sense, data analysis for this study is done inductively by using a case-by-case and across case 
analysis. The study also draws upon theories that exist in the literature in its analysis – 
pointing to elements of a deductive approach. Aronson (1994, p.3) supports this way of 
analysing data by suggesting that, ‘when the literature is interwoven with the findings, the 
story that the interviewer constructs is one that stands with merit’. Perry (1998) makes a 
convincing argument for adopting the duality insisting that, a study which is purely inductive 
potentially prevents a researcher from enjoying the use of existing theory while one which 
purely deductive restricts a researcher from developing new and useful theory.  
   
Case Findings 
This part of the study presents the research findings. It establishes the critical role 
performed by prior-learning and the accumulate science experiences of bio-
entrepreneurs/owner-managers to their venture development. In presenting the findings 
within each case, the study also draws upon secondary data which enables it to make strong 
inferences (Gerring, 2005, Huberman & Miles, 1994).   
 
Case A 
Bio-tech venture A’s bio-entrepreneur holds a PhD. He is a former global leader of 
Pharmacometrics at a large pharmaceutical company which was based in the East Midlands 
region in England and he has also worked in both Switzerland and Italy. In 2010 he formed a 
new bio-tech venture in England. Before establishing the new venture he started and 
managed a similar business model in America from 1991 to 1998. The knowledge and 
experience he gained from his American venture were instrumental to his comprehension 
of the sequence of processes and procedures that were fundamental in crafting a sustainable 
business venture in the life science sector in England. The bio-entrepreneur revealed that his 
company is part of a consortium of 24 other firms and research institutions in multiple 
countries. He also disclosed that at his previous employment he was involved in global 
science-related programmes.  
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The bio-entrepreneur acknowledged the role of declarative learning or ‘know that’ in 
choosing a learning partner, described by Huczynski & Buchanan (2007) as one’s ability to 
store factual knowledge and this is what he said: 
 
Choosing a business partner is like choosing your partner for life. I learned early in the US, that 
you want to keep your business and social connections throughout the life cycle of your business.  
 
This statement concerning the bio-entrepreneur’s take on choosing a learning partner 
implies that the knowledge and experience he acquired from his previous business in the US 
was very useful in helping his venture to identify/locate a business partner with a ‘strategic 
fit’ – meaning the extent to which a potential business partner is prepared to achieve the 
proposed operational objectives. In the literature, Corbett (2005) forcefully argue that the 
‘cognitive mechanisms’ or the mental processes through which entrepreneurs acquire, 
store, transform, and use information are the output of individual learning. The bio-
entrepreneur was further probed about the degree of influence his learning, expertise and 
experience in science gained over the years has on his decision-making in the business. He 
categorically stressed that: 
 
I think I use experience; it is really about developing a way of doing things and some of it is 
intuition - i.e. seeing things that are not connected and link them together to spark new product 
development. Some of this is also down to skills and knowledge. You could also say that a person 
who is successful uses intuition based on their learning and experience.   
     
The evidence is convincing and it points to the fact that the bio-entrepreneur’s knowledge, 
skills and intuition are a by-product of his science experience, personality and learning. More 
importantly, using his experience from his previous associations established during his time 
with a large pharmaceutical company the bio-entrepreneur was able to develop technical 
capabilities in the form of statistical software (SAS, S+, R, and Matlab) and design modelling 
software (NONMEM, WinBugs, Monolix, WinNonlin, Berkeley Madonna). His mathematical 
science combinations enabled him to add value to business processes within his venture 
which significantly assisted new drug discoveries. Crucially, using his knowledge in science, 
he designed formulas for drug development and testing. This facilitated the development and 
growth of his venture as well as recognition of his capabilities by other bio-enterprises 
involved in developing clinical equipment and drug discoveries. The bio-entrepreneur 
accepts that his experience in life science acquired from his role as a global leader of 
Pharmacometrics in his previous employment was instrumental to how he designed the 
mathematical science tools for use in his bio-tech venture to test new drug discoveries.  
   
Case B  
The founder/bio-entrepreneur of bio-tech venture B, similar to venture A’s the bio-
entrepreneur holds a PhD in medicinal chemistry and is educated to a post-doctorate level. 
In addition to his academic credentials, he has 14 years of experience in life science gained 
from his previous role at the world’s fifth largest pharmaceutical company. His publicly 
available profile describes him as an expert in drug discovery who has led various drug 
development projects for his former employers. He concedes that, some 
experiments/projects that he was involved in were not successful and he suggests that it was 
part of the learning processes. This is consistent with Schilling’s (2010) and Petkova’s (2008) 
views regarding learning through experimenting and entrepreneurial performance errors.  
Indeed, recalling a procedure that worked or did not work in the past is essential in drug 
discovery and development.  
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Clearly, learning from past performances was an important part of the process of developing 
his entrepreneurial capabilities to discover and exploit opportunities. According to his 
profile the founder has a record of delivering drug discovery processes for the world’s fifth 
largest pharmaceutical company. From that perspective, it is plausible to suggest that his 
science experiences were decisive to the economic development of his bio-tech venture. To 
this end the bio-entrepreneur expressed that: 
 
One has to understand the relevance of externally acquired knowledge to science and experience 
in previous science-related assignments play an important part of that. Given the experience our 
team of experts have in biotechnology we are in a better position to acquire the science that is 
necessary for our service. 
 
The explanation of the role of prior-learning above also hints that in his company the 
science experiences of his top management team abetted the process of ‘soaking-up’ useful 
scientific knowledge. In the literature Cohen & Levinthal (1990) affirms that AC is a by-
product of prior-innovation and problem solving which is dependent upon individual ACs of 
members of an organisation. In that sense, it is adequate to infer that one’s previous history 
and experience in life science can add value to their bio-tech venture by assisting in 
assimilating useful information that can be fundamental to a firm’s sustainable growth and 
development. Gurău et al. (2010) echo similar sentiments in their study concerning the role 
of human capital in successful entrepreneurial ventures. In their study the scholars 
concluded that the human capital available within an organisation can help the organisation 
to obtain positive business results. In the same vein, Murray (2004) found that in a firm 
where the founder was both the CEO and CSO, he rolled out the critical path to be 
followed as a blueprint in the process of acquiring essential technical capabilities to assist his 
venture to make new drug discoveries. This has a striking resemblance with the bio-
entrepreneur in bio-tech venture A who directs science projects using his experience 
acquired from leading international science-related R&D projects.  
 
Case C  
The bio-entrepreneur of bio-tech venture C is a co-founder of the business. The bio-tech 
venture was formed in 2002. His record shows that he is an academia and a world-
renowned scientist in the field of super-critical fluid processing with 15 years of experience 
in the life science sector. According to a University website profile for staff, it was publicised 
that the bio-entrepreneur is a professor and he is also a Chair of Chemistry at the 
University. He is also said to have published over 300 papers in high-level scientific journals. 
His record further documents that in the past decade, his research focused on the 
pharmaceutical formulation of drugs using super-critical fluids with ten patents filed. The 
record also discloses that he received a number of awards between 2001 and 2006 from the 
science community as recognition for his science ingenuity. Based on his antecedent 
influences, he was able to realise that super-critical carbon dioxide (scC02) could be used to 
mix sensitive substances into the polymers. This was the groundwork that his business 
needed to take-off. The bio-tech venture also grew by forging strategic alliances with other 
businesses which had complementary assets and those that had advanced technical know-
how with a view to augment its internal capabilities. The bio-entrepreneur explains that the 
learning partners for his bio-tech venture were developed based on his past associations 
with them and the knowledge that the relationships will generate the required capabilities.  
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His philosophy of selecting learning partners is reinforced  in the extant literature (see 
Petkova, 2008; Lane et al. 2006; Estes, 1970; Bower & Hilgard, 1981) which universally 
acknowledges that an individual’s learning is cumulative and that learning performance is 
enhanced when the primary goal of learning is related to what the individual already knows.  
When commenting on the success of the bio-entrepreneur’s firm a venture capitalist (VC) 
who provides growth funding to entrepreneurial ventures explained that:  
 
By combining world-class research with knowledge of the real needs of the pharmaceutical 
sector, the firm has made rapid progress.  
 
In that respect, the study can infer that knowing what is required to complement firm-based 
competences is an important developmental step for bio-tech ventures which operate in the 
life science sector and it earns support in the form of financial capital from private investors.  
More importantly, it facilitates the process of acquiring new knowledge especially, for bio-
tech ventures whose bio-entrepreneurs source for new scientific knowledge from multiple 
countries. 
 
Case D  
The founder and CEO of bio-tech venture D is a medical chemist with 23 years’ experience 
in the pharmaceutical industry. His record shows that he holds a PhD in synthetic organic 
chemistry and he took a post-doctoral research position at a University before starting his 
own venture in 2004. He has experience in science-related research projects which was 
acquired during his time at the world’s fifth largest pharmaceutical company as well as in a 
commercial environment. In the past the bio-entrepreneur explains that he was involved in a 
wide range of drug discovery programmes. He states that the programmes ranged from lead 
generation libraries, hit-to-lead campaigns, all the way to successful lead optimisation 
projects and candidate drug selection. This highlights the idea of generative learning which is 
achieved through engaging in research projects that include a wide range of participants 
from multiple countries. Such innovation ‘ecosystems’ allow new product ideas to be 
generated, debated and honed. According to his bio-tech venture’s website, in 2011, the 
bio-entrepreneur won the Science and Technology Entrepreneur of the Year Award as 
recognition for his significant personal contribution to the success of the company he 
established and runs. This endorses the view that bio-entrepreneurs emboss their ‘DNA’ in 
their ventures and they perform a major role in making their strategic choices using their 
cognitive biases. Over a period of 8 years, the bio-entrepreneur expressed that he has 
added to the growth of his bio-tech venture by developing science testing tools to enhance 
drug discovery and testing for their clients.  
 
To underscore the importance of entrepreneurial learning at an individual level, the bio-
entrepreneur explained that he is also involved in a European funded collaborative research 
programme which is aimed at speeding up the discovery of new drugs. He states that 
participants of the programme range from scientists working for large pharmaceutical 
companies to bio-entrepreneurs who manage bio-enterprises as well as academic 
researchers. As his company focuses on the delivery of integrated drug discovery taking 
part, in a drug discovery programme which involves international participants, can 
considerably enhance his cognitive biases which underpin his ability to acquire useful 
scientific knowledge which is essential for drug discovery and testing in his venture. 
Innovation ‘ecosystems’ in science-based industries are designed to aid the discovery of new 
products and are characterised by an array of experiments (Bramwell et al., 2012).  
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In the literature (Cobbett, 2007; Petkova, 2008; Schilling, 2010; Cope & Down, 2010) the 
process of experimenting is viewed as an essential developmental step for entrepreneurial 
ventures in the sense that it allows entrepreneurs to test what works and what doesn’t. 
Commenting on the opportunity to acquire new drug development processes that are 
necessary for his bio-tech venture the bio-entrepreneur explained that: 
 
The really exciting aspect of this project is the opportunity to discover novel drugs through the 
collaboration of seven international pharmaceutical companies and an open call to academics 
and industry across Europe.   
 
Learning through innovation ‘ecosystems’, described as a participative learning process by 
Cope & Down (2010) makes it possible for individuals to exchange scientific knowledge and 
technical know-how and it helps to bridge any knowledge shortages that might exist in a 
firm. This seems to be fairly consistent with Gordon & Jack’s (2010) findings. In their study 
regarding higher education institutions’ engagement with SMEs to develop social capital the 
scholars conclude that, a learning environment (innovation ecosystem) provide SMEs and 
their owners the opportunity to create social capital which has a positive impact on firm 
development.   
    
Case E  
According to her personal profile the bio-entrepreneur/founder of bio-tech venture E 
started her academic life as a bio-chemist. After finishing an undergraduate degree in 
biology, her curriculum vitae discloses that she went on to complete a PhD in bio-chemistry 
and then started to work with a group of immunologists at a Royal Free Hospital (RFH). She 
acknowledges that the experience gained from working with other immunologists at the 
RFH was fundamental to her decision to set up a hybridoma laboratory which was funded by 
a Technology Group. The bio-entrepreneur also explains that she was involved in a leading 
edge research developing monoclonals with potential commercial applications. Strikingly, her 
involvement with immunologists and research to develop monoclonals significantly influenced 
her decision to jointly establish a bio-tech venture.  
 
Another point to make is that, her innovation ‘ecosystems’ were central to the 
development of the bio-tech venture because they formed part of her knowledge supply-
chain. More importantly, her science background enabled her to contribute to the 
development of a new technology targeted at overcoming a number of deficiencies with 
platelet transfusion making the therapy more widely and easily available. Her passion to 
continue making new discoveries can be seen in the way she contributed to the 
development of the platelet transfusion technology which was pivotal to the economic 
prosperity of their venture. This is in line with Burns (2012) who takes the view that 
entrepreneurs engrave their ‘entrepreneurial DNA’ in their ventures. In that respect, the 
bio-entrepreneur explains that, ‘for both of them the motivation is to develop the product 
and to see it work’. This may also imply that in making new technological developments for 
their bio-tech venture the bio-entrepreneur and her co-founder ensure that the new 
technology works by directing all their efforts in the form prior-learning and cumulative 
science experiences towards its success. According to a University website where she is 
employed as a Professor the bio-entrepreneur is currently not involved in teaching at the 
institution but, she is engaged in research. This emphasises her desire to continue learning 
which is vital to the process of ‘soaking-up’ useful scientific knowledge and for updating her 
cognitive biases.  
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The bio-entrepreneur explains that the process of setting up their bio-tech venture involved 
her increasing her knowledge of business – finding out ‘the rules of the game’. Her 
statement is well-represented in the literature. Simba (2013) posits that bio-entrepreneurs 
engage in a ‘trial and error’ method until they find the right knowledge combinations that 
complement their internal knowledge bases. Schilling (2010) stresses that experimenting is 
an important step in the development process of science-based firms as it enables a firm to 
test what works and what doesn’t.     
    
Cross Case Findings 
This part provides a cross-case synthesis (Yin, 2009) with a view to build a common 
narrative (Bazeley, 2013; Huberman & Miles, 1994) about the prior-learning and the 
cumulative experience of the founders of the bio-tech ventures. More importantly, the idea 
is to identify whether there are any relationships in their antecedent influences that assist 
them to ‘soak-up’ useful scientific knowledge necessary for development of their bio-tech 
ventures. Table 1 below illustrates the similarities and differences across the cases.   
 
  
Table 1: A cross-case analysis of bio-entrepreneurs  
 
  
Bio-entrepreneur in 
case A  
 
Bio-entrepreneur 
in case B 
 
Bio-entrepreneur 
in case C 
 
Bio-entrepreneur 
in case D 
 
Bio-entrepreneur 
in case E 
 
Structural 
Dimension 
 
Strong global academic 
network and industrial-
related business and 
social connections. 
Participated in science-
related projects.    
 
Same as bio-
entrepreneur in 
case A 
 
Same as bio-
entrepreneur in 
case A but with a 
strong academia and 
he is a well-known 
science professor   
 
Same as bio-
entrepreneur in 
case A. He also 
participates in 
international drug 
discovery 
programmes 
 
Same as bio-
entrepreneur in 
case A. The venture 
also relies on VCs 
for funding to 
develop it 
technology  
 
Relational 
Dimension 
 
 
Trust is based on 
shared representations  
and interpretations of 
science  
 
Same as bio-
entrepreneur in 
case A 
 
Same as bio-
entrepreneur in 
case A 
 
Same as bio-
entrepreneur in 
case A 
 
Trust is based on 
shared 
representations  
and interpretations 
of science 
 
Cognitive 
Dimension 
 
 
The top management 
team consists of 
experienced scientists 
in drug discovery 
projects with the bio-
entrepreneur 
spearheading the 
operational strategies 
of the venture 
 
Same as bio-
entrepreneur in 
case A 
 
Same as bio-
entrepreneur in 
case A, but with a 
skew towards 
academia. Also his 
venture sponsors 
PhD research 
students  
 
Same as bio-
entrepreneur in 
case A 
 
She is a co-founder 
of the venture. 
Their team consist 
of scientists and 
members with 
commercial 
experience 
 
Prior-Learning 
 
Started a similar 
company in America 
between 1991&1998. 
He holds a PhD 
qualification in 
Chemistry  
 
Held various roles – 
leading science-
related R&D 
projects globally. 
Hold a PhD 
 
He has published 
over 300 science 
papers 
demonstrating that 
he is a researcher. 
Also he is a 
renowned world 
scientist  
 
 
 
Same bio-
entrepreneur in 
case B 
 
Laboratory and 
hospital research 
related experience. 
She also holds a 
PhD 
Cumulative 
Science 
Experience  
He has over 20 years 
of science experience  
Has 14 years 
science-related 
experience 
Has 15 years of 
experience in 
science 
He has 23 years’ 
experience in the 
pharmaceutical 
industry 
She has 16 years’ 
experience in 
biochemistry, 
molecular biology 
and medicine 
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The role of prior-learning & the cumulative science experience on the ability recognise, assimilate and apply new 
knowledge productively in the venture   
 
Developed 
firm-based 
competences 
Recalling his 
experience and prior-
learning in innovation 
‘ecosystems’ The bio-
entrepreneur designed 
Mathematical science 
tools for mechanistic 
modelling (R-sim & U-
per). Used to test and 
predict performance of 
a diagnostic test   
Similar to bio-
entrepreneur in 
cases A & D he was 
instrumental in 
developing drug 
discovery and 
testing tools for this 
venture 
The bio-
entrepreneur 
realised, through his 
learning and science 
experience, that 
super-critical 
carbon dioxide 
(scC02) could be 
used to mix 
sensitive substances 
into the polymers 
Using his cognitive 
biases the bio-
entrepreneur was 
instrumental in 
developing new 
drug discovery and 
testing tools.  
Recalling their 
cumulative science 
experience with a 
co-founder the bio-
entrepreneurs 
developed a new 
technology that 
controls bleeding by 
binding to the blood 
protein, fibrinogen. 
The new type of 
treatment is seen as 
safer and easier to 
use  
 
Synthesising data from the primary and secondary sources the study is able to construct a 
clearer picture regarding the role performed by prior-learning and the cumulative science 
experience of bio-entrepreneurs. In addition to the two factors (prior-learning and 
cumulative science experience) the process of combining information to determine their 
importance also considers the structural, relational and the cognitive dimensions which are 
related to how bio-entrepreneurs accumulated social capital through innovation 
‘ecosystems’ which was indispensable for their bio-tech ventures.  
 
In order to measure the impact of the antecedence influences of bio-entrepreneurs in 
recognising useful information for the venture the last variable on Table1 above explains the 
specific outcomes of individual learning. Strikingly, out of five bio-entrepreneurs one of 
them, i.e. (20%) of the research sample, was a female who jointly runs the venture with 
another female co-founder. This demonstrates evidence of women who are also involved in 
scientific entrepreneurship. It is also intriguing to note that all the bio-entrepreneurs in the 
sample have a strong academic background in chemistry and pharmaceuticals and they have 
previously worked, at the very least, for a large pharmaceutical company before starting 
their own ventures. They also have more than 14 years’ experience in life science. Murray 
(2004) maintains that the inventor’s (the equivalence of a bio-entrepreneur) role in their 
ventures is determined by a wide range of factors including: personal preferences, career 
stage, and professional norms.  
 
Similarly, Burns (2012) comments that entrepreneurs influence the strategic direction of 
their ventures and they aim to engrave their ‘DNA’ in the venture. Science-related projects 
in innovation ‘ecosystems’ are characterised by experimentation with a view to make new 
discoveries and as such, all the bio-entrepreneurs, at some point, before establishing their 
bio-tech ventures participated in science-related projects which enriched their cognition of 
science. More importantly, they were able to experiment with different configurations until 
they discovered an effective one. Consequently, they were able to update their cognitive 
biases. This learning process was observed to be critical for their bio-tech ventures 
especially in informing the process of designing essential mathematical science combinations 
and chemical compounds necessary for new drug discoveries and for testing them. This 
observation is consistent with Gurau et al. (2010). The scholars insist that the strategic 
roadmap of new bio-tech firms requires competent directors for better performance and 
development.  
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A closer look across the profiles of all the bio-entrepreneurs further reveals that they are 
well-educated scientists with expertise in the bio-pharmaceutical technology and product 
development. It is also fascinating to note that 75% of the bio-entrepreneurs run their bio-
tech ventures along with their academic commitments. Perhaps this explains their drive to 
continuously engage in drug discovery activities of learning with a view to constantly 
updating their cognitive biases and to sustain the development of their bio-tech venture. In 
that sense, it is safe for the study to suggest that the main fulcrum of a bio-tech venture is 
its bio-entrepreneur. Therefore, when analysing the AC of such small owner-managed 
ventures it is sensible to commence such an analysis at the individual level particularly, on 
the bio-entrepreneurs because of their degree of influence in their direction and scope. 
Similarly, Gurau et al. (2010) observe that, mainstream bio-pharmaceutical enterprises are 
developed by successful scientists who aim to transform their innovations in commercial 
applications.  Furthermore, Sony & Iman (2005) observed that there is a strong correlation 
between entrepreneurial competences consisting of industry specific skills, opportunity 
spotting skills and technical skills and the growth of a venture. Indeed, this was evidently 
clear from all the bio-entrepreneurs who were under the spotlight for the purpose of this 
study. In ensuring that the human capital within their bio-tech ventures contribute to 
internal knowledge bases all the bio-entrepreneurs linked-up with experienced scientists 
who became part of their top management team. Equally, their structural dimension which 
consisted of their business and social connections established from their previous 
employment and their research groups were critical to their continued learning because 
they formed part of their innovation ‘ecosystems’ which facilitated the flow of scientific 
knowledge. 
 
Conclusion 
The research examined bio-entrepreneurs with a view to develop explanations about how 
their prior-learning and the cumulative science experience influence their ability to ‘soak-up’ 
useful scientific knowledge for their ventures. In that context, the profiling of each bio-
entrepreneur and pattern matching cross the entire research sample enabled the study to 
conclude that prior-learning and the cumulative science experience of the bio-entrepreneur 
leads to enhanced AC. Indeed, as a consequence of their individual learning, bio-
entrepreneurs were able to acquire, store, transform and use information from their 
innovation ‘ecosystems’ productively in their bio-tech ventures. Equally, by utilising their 
skills in science and competences developed from previous science-related 
projects/assignments the bio-entrepreneurs were able to update their cognitive biases which 
greatly assisted them in recognising and assimilating the right combination of resources 
necessary for designing or crafting new science technology for the economic development 
of their ventures. Furthermore, their antecedent influences shaped their decision-making 
process within their ventures including the process of selecting a learning partner and for 
formulating their operational strategies. The study discloses that bio-entrepreneurs who 
participated in the study are intimately attached to their bio-tech ventures and they have a 
strong desire to commercialise their discoveries. As such, it is plausible to infer that the 
study adopted a sensible approach in its endeavour to contribute to the concept of AC by 
placing the spotlight on the bio-entrepreneurs because of their huge influence on the 
direction and the scope of their bio-tech ventures. In that sense, in seeking to contribute to 
the literature on entrepreneurial learning and the concepts of AC there is logic in examining 
entrepreneurs and their ventures as inter-connected units.      
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A look into the career of the bio-entrepreneurs of the bio-tech ventures samples for this 
study demonstrates that all of them are well-educated in science. In addition to that, the 
study also discloses that the structural dimension of the bio-tech ventures consists of 
learning networks (innovation ‘ecosystems’) populated with scientists from multiple 
countries. In that web of connections the study infers that the most effective strategies for 
recognising useful scientific knowledge for bio-entrepreneurs are informed, to a large 
extent, by their ability to store factual knowledge about life science. More importantly, their 
ability to relate to new scientific knowledge which can be productively applied to their 
business processes with a view to complement/augment existing knowledge bases was 
meaningfully enhanced. Furthermore, the study discloses that in addition to rolling out the 
roadmap of their bio-tech ventures their cognitive dimension i.e. the top management team 
consisted of experienced scientists who also added value to their internal knowledge base 
thereby enhancing their AC. This underscores the essence of individual absorptive capacities 
to firm development.   
 
As much as the study considers the chosen research approach for research to be 
appropriate however, there are inherent limits such as the generalisation of the research 
findings. In defence of the case-oriented research strategy adopted for this study the 
primary aim was not to generalise the findings to a large population but, to achieve what Yin 
(2009); Huberman & Miles (1994) describes as analytical generalisation. In terms of 
recommendations for future studies the research suggests a longitudinal variable-oriented 
research (VOR) study which utilises SPSS computer software to measure the impact factor 
of prior-learning and the industry specific experience over a predetermined period on the 
abilities of a bio-entrepreneur to ‘soak-up’ useful knowledge for their bio-tech ventures.             
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Abstract  
Objectives: The research aims to investigate the impact of knowledge networks on the innovative 
capabilities of bio-tech firms in the East Midlands region.  
 
Prior Work: In knowledge intensive sectors where the business environment is always changing 
there is a growing trend whereby firms are adopting a new open science paradigm of cooperation and 
collaboration (Garayannis and Wang, 2008). The interaction between firms or organisations with 
varied skills, experience and knowledge provides synergy for firms with limited resources by giving 
them access to a wide range of economic effects (Ho and Wilson, 2006) including: access to 
specialised input and labour, novel information inflows and knowledge as well as access to research 
institutions and government R&D support services (Martin et al., 2011). Therefore, understanding the 
impact of knowledge networks and clusters becomes essential to the success of local innovative and 
multinational bio-tech firms. On that account, effective knowledge sharing is the most important target 
to seek for innovative bio-tech firms (Powell and Grodal, 2005).  
 
Approach: Primary data was collected through semi-structured interviews in the East Midlands region 
of the United Kingdom. Six interviews were conducted with bio-tech firms and knowledge network 
centres. The research sample composed of three influential knowledge network centres and three 
bio-tech firms involved in collaborative activities. Additionally, secondary literature sources were used 
to develop an understanding of and insight into previous research on dynamic capabilities and 
networking (Saunders et al., 2003).  
 
Results: The paper argues that the innovative capabilities of bio-tech firms in a changing business 
environment are affected by the interaction of heterogeneous actors with different knowledge, 
competences and specialisation, with relationships ranging from formal to informal and from 
competitive to cooperative. In the East Midlands region, knowledge centres have played an important 
role in forging the knowledge network of bio-tech start-ups. Small bio-tech firms are given the 
opportunity to establish, grow and develop which is achieved by creating specialist forums for problem 
solving, specific help and debate. BioCity the region’s most successful incubator use incubation as a 
means for bio-enterprise and capability development. The technology incubator fosters the growth of 
new technology based ventures by helping them to close the gaps in the innovation process and 
correct market failures. In sum the knowledge network centres in the region are acting as new bio-
tech firms’ “nurseries”, “accelerators of innovation” and “greenhouses”.  
 
Implications: The findings have practical implications for bio-tech firms, regional knowledge network 
centres and policy makers. Crucially, the findings enable these key stakeholders to evaluate whether 
their current networking strategies or support schemes are enhancing R&D activities and product 
innovations.  
 
Value: The importance of regional knowledge networks as bases for innovative capabilities for bio-
tech firms is emphasised. Additionally, it highlights that for regional economic strategies, projects and 
frameworks for innovation to be effective policy makers have to rebuild knowledge bases and 
integrate them with government R&D centres. 
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Introduction 
The advent of small bio-tech firms in the bio-tech sector significantly contributes to a wide range of 
economic effects including regional development, job creation, knowledge transfer and technological 
transfers (Ho and Wilson, 2006). Bio-tech firms have high expectations of growth and development 
due to economic return from everyday applications as well as the exponential industry growth which is 
evidenced by the number of biotechnology companies, an increase in the number of approved 
products as a result of biotechnology processes, market capitalisation and revenues (Kermani and 
Bonacossa, 2003).  The bio-tech industry is one that is knowledge based and it is dominated by small 
firms that usually have connections with innovation centres (Ho and Wilson, 2006). Nowadays 
knowledge creation processes are composite, meaning that they combine many interacting pieces of 
knowledge coming from different sectors.   
 
The knowledge intensive bio-tech industry heavily relies on continuous innovation. The ability to be 
innovative can only occur if an organisation is able to generate and integrate knowledge from both 
inside the organisation or through the formation of strategic alliances with other firms (Owen-Smith 
and Powell, 2004; Powell, 2009; Zheng, et al., 2010; Zeller, 2011). There is a growing trend in the 
biotechnology sector where bio-tech firms work in collaborative projects sharing scientific knowledge 
and ideas in order to develop novel products (Vrande et al., 2008; Chesbrough, 2006). There are two 
“predominant approaches to innovation research” (Su et al., 2008, p.310). One approach suggests 
that the firm’s internal capabilities are the main drivers of innovation while the resource based 
approach emphasises that a firm’s innovative capacity is boasted through working in strategic 
alliances.  
 
The paper mainly explores how the dynamic knowledge networks have impact on the innovative 
capabilities of bio-entrepreneurs in the East Midlands region of the United Kingdom. In particular, it 
examines how bio-entrepreneurs leverage their core competences with knowledge acquired from their 
knowledge networks for innovation and business development. We argue that the innovative 
capabilities of bio-tech firms in a changing business environment are affected by the interaction of 
heterogeneous actors with different knowledge, competences and specialisation, with relationships 
ranging from formal to informal and from competitive to cooperative (Malerba, 2005).    
 
The paper is structured into six distinctive sections as follows. The second section critically reviews 
the concept of capability development and its multifaceted dimensions stressing the impact of 
knowledge networks on the innovative capabilities of bio-tech firms. Following a thorough literature 
review the section also outlines the theory construction process and proposes a conceptual 
framework. The third section outlines a detailed methodology of the empirical study. The fourth 
section provides an account of how bio-tech firms view the idea of collaboration. The fifth section 
builds on empirical evidence and it discusses in detail the special characteristics of collaborative 
activities in the East Midlands bio-tech sector. Additionally, comparisons are made with world class 
clusters such as Silicon Valley, Cambridge and Boston bio-tech clusters. This section also makes 
suggestions about how the key stakeholders in a network such as the bio-tech firms, the government 
and the EU can facilitate regional economic development as well assess whether their strategies are 
achieving the intended corporate goals. The last section concludes that collaborative activities are 
necessary for bio-tech firms to build innovative capabilities in order to respond to changing market 
conditions. For future research the section recommends an empirical study of the business incubation 
process of small bio-tech firms in their early development stages.            
 
Literature Review 
Autio et al. (2010, p. 18) define capabilities as “a combination or sequence of processes and its 
enabling resource commitments that have the potential to reliably achieve outputs congruent with 
organizational goals”. The horizontal and vertical integration of firms in the bio-tech industry presents 
bio-tech firms with the opportunity to enhance their innovative capabilities (Visser, 2009). In other 
words, bio-entrepreneurs are able to improve their technical capabilities significantly as a result of 
interacting with other bio-tech firms who are superior in specific knowledge areas. Maskell (2001) 
suggests that where firms in the same line of business compete with each other, the innovative 
capabilities of the individuals are enhanced as a result of three specific conditions including 
spatial/physical proximity – a densely populated area of related economic activity and cognitive 
proximity in terms of domains and mental models.  
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Industrial clusters are the cornerstone for the regional and economic development, which makes it 
imperative for policy makers and central authorities to craft strategies that facilitate R&D activities and 
regional innovations to enable firms operating in the bio-tech sector, often hailed as the new wealth 
creator, to improve their business and thinking processes (Ho and Wilson, 2006). McDonald et al. 
(2007) concluded that established clusters with deep networks are desirable and that there is need to 
craft effective strategies and policies to preserve existing networks and facilitate further collaborations 
in order to give firms and bio-entrepreneurs involved an opportunity to improve their innovative 
capabilities. Nooteboom (2005) describes diversity in the context of clustering and networking and 
expresses that it is associated with a number of agents, people or firms who are involved in a process 
of learning or innovation by interaction. Diversity is linked to the different knowledge bases and skills 
that agents/people/firms bring into a relationship, which denotes the notion of cognitive distance 
(Nooteboom, 1992, 1999).  
 
The Dynamic Capabilities View 
The dynamic capabilities view builds on the resource-based view, which sees a firm as a bundle of 
static resources (McKelvie and Davidsson, 2009). According to Grant (1991), the resource-based 
view is based on the idea that rival firms possess varied resource repositories. Following the 
realisation of the static nature of the resource based view, scholars have emphasised the dynamic 
capabilities view since the late 1990s (Teece at al., 1997; Narayanan et al., 2009; and Dixon et al., 
2010). The dynamic capabilities based view sees a firm as a constant belt of novel information 
inflows.  It highlights a firm’s ability to adopt a flexible business model, which allows it to react to 
uncertainty and disruptive technology. McKelvie and Davidsson (2009, p. 36) argue that, “Dynamic 
capabilities can be seen as those processes where resources are acquired, integrated, transformed 
or reconfigured to generate new value-creating firm-based activities”. Autio et al. (2010) interpret 
dynamic capabilities as a firm’s capacity to deploy strategic resources and improve business 
processes with purpose in order to achieve its goals. Accordingly, Nelson and Winter (1982) and 
Winter (2003) contend that dynamic capabilities can be seen as routines or repetitive patterns that are 
project based involving multiple firms. From these analyses, there is evidence of a growing body of 
researchers who agree that dynamic capabilities have an impact on a firm’s capacity to innovate 
(Wheeler, 2002; Teece, 2007; Narayanan et al., 2009; and George et al, 2009). Additionally, Visser 
(2009) indicates a strong relationship between diverse knowledge networks and innovative 
capabilities.    
 
Easterby-Smith et al. (2009) suggest that dynamic capabilities are a response to the need for change 
or new opportunities. Their observation is very useful for bio-tech firms who are faced with changing 
market conditions which require constant knowledge generation and business re-engineering. Dixon 
et al. (2010) posits that for a firm to be able to respond to changing market changes, there is need to 
make fundamental transformations in its organisational processes, the allocation of resources and 
operations. The crucial part of dynamic capabilities for bio-tech firms is their ability to facilitate the 
allocation and utilisation of its resources strategically in order to make crucial innovations (Teece et 
al., 1997; Nooteboom, 2009). These resources can take various forms of economic effects including 
human capital, technological capital, knowledge-based capital, and tangible-asset-based capital 
(Easterby-Smith et al., 2009). Since the introduction of the dynamic capabilities theory by Teece, 
Pisano and Shuen in 1997, many scholars emphasised the operational (zero level) and the dynamic 
nature of capabilities (Eisenhardt and Martin, 2000 and Winter, 2002/05) and heterogeneous learning 
of firms (Cobbett, 2007). Building on these topologies, Ambrosini et al. (2009) proposes three levels of 
capability development including incremental, renewing, and regenerative capabilities. Notably, the 
strategy of regenerative dynamic capabilities (Easterby-Smith et al., 2009) is important because of its 
ability to completely overhaul existing business processes and adapt to new business processes that 
open new channels for novel information inflows. It is assumed that “organisations can have several 
different kinds of dynamic capabilities such as idea generation capabilities, market disruptiveness 
capabilities, new product development capabilities, marketing capabilities or new process 
development capabilities” (Easterby-Smith et al., 2009, p. 4).  
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Furthermore, Teece (2007, p. 1319) suggests that “the capacity to sense and shape opportunities and 
threats, to seize opportunities, and to maintain competitiveness through enhancing, combining, 
protecting, and, when necessary, reconfiguring the business enterprise’s intangible and tangible 
assets”.  In the context of bio-tech industry in which constant novel information inflows are crucial 
towards making innovations, it is important to reconstruct existing business processes to position the 
firm strategically on course to achieve its corporate strategy. The literature on organisational 
management (Mullins, 2006 and Torrington et al., 2005) emphases on the need for top management 
to take the lead in shaping business processes and gearing the business towards its strategic goals. 
Similarly, developing dynamic capabilities requires a lot of input from bio-entrepreneurs in providing a 
vision for purpose aimed at shaping the types of capabilities to be sought after. Martin et al., (2011) 
examine the process of dynamic capability development in a large pharmaceutical firm.  Narayanan et 
al., (2009) found that senior managers play a major role in the development of capabilities by 
imprinting an organisation with their specific cognitive orientation and then orchestrating the multi-
level organisational routines necessary for actualisation of a capability. More importantly, their 
inspirational study identified key underlying processes and mechanisms that are pertinent to bio-tech 
firms in terms of capability development and these processes were identified as research and 
development (R&D) strategies, knowledge transfer processes, and knowledge exploring mechanisms. 
This highlights the impact of dynamic capabilities on the innovative capabilities of bio-entrepreneurs 
or bio-tech firms and the capacity to make innovations.                 
      
The Impact of Network Dynamics    
Networks are defined as a set of nodes (persons, organisations) linked by a set of social, friendship of 
a specific type (Cooke, 2001; Breschi and Malebra, 2005). They are distinct from hierarchical or 
market relationships in their reliance on reciprocity, collaboration, complementary independence and 
orientation towards mutual gain. Breschi and Malebra (2005, p. 47) suggests that, “resource pooling, 
risk sharing and the formation of critical masses provide incentive to create a group of interlinked 
agents”. Accordingly, Nooteboom (2009) focuses on network structure and network ties while Suire 
and Vicente (2009) examines networks from the perspective of social interactions under mimetic 
pressures. Nooteboom (2009) suggests that according to the novel architectural principles or basic 
logistics or design logistics, the expectation is that a volatile structure emerges at the early stages of 
exploration and experimentation of novel combinations of elements from pre-existing practices. He 
also noticed the volume of traffic such as frequent exit and entry of actors to allow for frequent and 
fast re-configuration of ties, a dense structure to allow for the hedging of relational bets that such 
volatility requires and the availability of high shared absorptive capacity (Lichtenthaler and 
Lichtenthaler, 2009). 
 
Dense networks can be seen as being supportive of the casual discussions that may include novel 
information or reputation systems, which are crucial for governance especially in face-to-face 
uncertainty and fluid knowledge with consequent limits to governance by contract or hierarchy.   At 
optimal cognitive distance, direct ties are sought and indirect ties play a vital role by providing the 
crucial links between nodes/actors/bio-entrepreneurs for governance and for crossing cognitive 
distance that is too large to deal with within a single firm. Nooteboom (2009) contends that 
participants with high betweenness centrality offer bridging of structural holes in ties with distant 
clusters as sources for new knowledge. Given these cluster dimensions, it is within reason to claim 
that firms that venture beyond their immediate surroundings for partnerships place themselves in a 
better position to acquire new knowledge. Regarding the strength of ties in a network, Nooteboom 
(2009) suggests that the main dominant characteristics should be wide scope (i.e. large complexity) in 
order to deal with a wide range of uncertainties (a common occurrence in knowledge based 
industries).  This uncertainty can be concerned with both technical and commercial knowledge, 
network structures and membership, reputation concerning both competence and intentional reliability 
of potential partners (Owen-Smith and Powell, 2004; Breschi and Malebra, 2005). In such types of 
networks, high frequency of interaction is expected as a result of fast changing conditions, a great 
deal of trust building to compensate for difficulties of contract and monitoring on the basis of shared 
ethics, empathy and identification (Nooteboom, 2009). In the constantly changing market conditions, 
especially those of the bio-tech sector, ties between actors in a network should not be static but 
should offer some flexibility and avoid the dependency syndrome (Cooke, 2001).  
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In the literature on economic geography the idea of social interactions under mimetic pressures has 
gained momentum (Suire and Vicente, 2009; and Orle´an, 2006). The rationale of the concept is that 
interactions are always sequential. This assumption is vital due to the fact that it creates a situation 
whereby actors/bio-tech firm can observe the decisions of others in the network and to some extent, 
access “the black box of decision externalities leading to cumulative processes” (Suire and Vicente, 
2009, p. 24). Suire and Vicente (2009) identified two key elements as: (1) uncertainty and legitimacy 
and (2) accessibility to and the exchange of knowledge.  
 
With uncertainty and legitimacy, when agents are faced with uncertainty in their decision making unit, 
the expectation would be to try to learn from others in the network and make an informed decision 
based on “observational learning” (Suire and Vicente, 2009, p. 24). A herding behaviour model 
developed by Bikhchandani et al. (1992, 1998) highlight the fact that heterogeneous learning is a key 
criterion of sequential interactions.  Legitimacy arises as a direct result of uncertainty oriented mimetic 
interactions. Suire and Vicente (2009) extends the concept of cognitive distance  where start-up firms 
in a network learn from agents who are more experienced, have expertise, reputation and “can 
influence the trajectories of collective choices in the early stages of or during the clustering process” 
(Suire and Vicente, 2009, p. 24). Hedstrom (1998) posits that legitimacy can be seen as a strong 
source of rational imitative behaviour. In the bio-tech industry where collaborations between start-up 
firms and established bio-pharmaceutical firms appear to be prevalent, it would seem rational to 
imitate and follow the lead of those with experience and expertise.     
 
The second drive for agents in a network is accessibility to and the exchange of knowledge explains 
the convergence in decision making through sequential and mimetic processes. In knowledge 
intensive industries such as the bio-tech industry, networks are seen as necessary as a source for 
novel information inflows as firms in a network usually have varied skills, knowledge, expertise and 
capabilities. Vicente and Suire (2007) suggest that the wider the connection of firms in a cluster, the 
more chances a firm has of accessing complementary bits of knowledge stemming from cognitively 
distant firms. This perspective is essential in understanding how firms access knowledge and engage 
in knowledge sharing activities with members of the network that are either in the same line of 
business (horizontal integration) or those who are not in the same line business (vertical integration) 
but have processes that can been be useful to the firm.   
 
The Impact of Cognitive Distance  
A firm’s ability to generate new knowledge and ideas is directly linked to its ambition of developing 
strategic alliances in a given geographic area or even beyond in order to supplement its internal 
research and development (R&D) capacity. Su et al., (2009, p. 312) indicate that, “A firm’s R&D 
capability reflects its ability to generate new scientific discoveries and technological breakthroughs”.  
The successful clusters such as the Cambridge cluster, Silicon Valley and the Boston metropolitan 
area are well known for their innovative capabilities and their push towards inter-organisational 
corporations and the sharing of ideas in those close knit communities (DTI, 2004). Powell and Grodal 
(2005) suggest that diversity is an essential condition which is facilitated by firms coming together and 
sharing capabilities, specialities, ideas and best practice. 
 
The concept of cognitive distance emanates from a social constructivist view of knowledge, which 
advances the idea of perception, interpretation, understanding and value judgment. It entails mental 
constructions on the basis of mental categories that are developed in interaction with the physical and 
social world (Pittaway, 2000). At organisational level cognitive structures constitute absorptive 
capacity which relates to the idea of exploring knowledge (Lichtenthaler and Lichtenthaler, 2009). 
Accordingly, Nooteboom (2005) suggests that when absorptive capacity is aligned with organisational 
goals and aims not only does it enable organisational cognition, but also constrains what gives rise to 
organisational myopia that can only be compensated by interacting with other firms which may have a 
different complementary foci at some cognitive distance. Therefore, it is within reason to claim that 
external relationships give the organisation a new purpose for inter-firm collaboration the need for a 
firm to make a trade-off between its identity in terms of clear focus and the wide scope of its core 
competences (Johnson et al., 2006). In the context of cluster dynamics the analysis of optimal 
cognitive distance has huge implication for innovation and the period an alliance is likely to last 
(Wuyts et al., 2005).  
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According to Nooteboom (2005) cognitive distance between firms can be reduced in proportion to the 
life time of an alliance, particularly in cases where the alliance is restricted to a group of firms. 
Strategic alliances are usually developed between firms that share the same values and have high 
levels of trust. In those circumstances there is the danger of dependency syndrome which leads to 
reduced innovation activities (Cooke, 2001). Crucially, Nooteboom (2005) identified variables that 
have impact on the absorptive capacity of firms including: educational facilities, research and 
development (R&D) in firms, government R&D activities and the transfer of outcomes to firms. There 
are also other variables that include knowledge diversity and cognitive distance in the network, the life 
time of an alliance and external linkages such as international links can be seen as catalysts to 
innovation as they supply novel information inflows. This underlines the impact of cognitive distance 
and knowledge diversity on the innovative capabilities of a firm. The extant literature on cluster 
development emphasises on the social benefits of collaboration in science based industries, (Pittaway 
2000; and Neergaard et al., 2005). Nonetheless, more research needs to be done to understand the 
dynamic impact of networks on the innovative capabilities of bio-entrepreneurs. 
 
Conceptual Framework 
By the time we become aware that Porter’s model of clusters and competitive advantage could be 
relevant to capability development in knowledge networks we had a 
sizeable store of data that we had absorbed making it relatively easy 
to assess the applicability of the model. Our awareness that Porter’s 
model was an appropriate means for explaining the phenomena we 
were investigating emerged through the research process as we 
collected, sifted, sorted and analysed data (Irvine and Gaffikin, 
2006).  We refined the model so that it becomes a more suitable 
description of our data.  The process of developing theory diagram 
neatly illustrates how the data and our understanding of Porter’s 
model informed both our perceptions and comprehension of the 
impact of knowledge networks on the innovative capabilities of bio-
tech firms. This led to the development of a robust innovative 
capabilities model to capture the key themes.  
 
  
The proposed conceptual framework recognises that the 
innovative capabilities of bio-tech firms in volatile markets 
are affected by the interaction of heterogeneous actors 
with different knowledge, competences and 
specialisation, with relationships that may range from 
formal to informal and from competitive to cooperative 
(Malerba, 2005). In the same vein, our model which is 
adapted from Porter’s model of clusters and competitive 
advantage is a development from static models, 
regarding the effects of different network architectures on 
organisational performance, to dynamics of networks. It 
emphasises the dynamic capabilities view. In particular, it 
is based on the notion that dynamic capabilities attempt 
to bridge capability gaps by adopting a process approach: 
and by acting as a buffer between firm resources and the 
changing business environment. Dynamic resources help 
a firm adjust its resource mix thereby enhancing its 
innovative capabilities which underpins its ability to make 
innovations (Helfat and Peteraf, 2003). So, while the RBV 
emphasises resource choice or the selection of appropriate resources, dynamic capabilities 
emphasise resource development and renewal facilitated through collaborative activities. Indeed, 
interacting with other firms or organisations with varied skills (cognitive distance) provide synergy for 
firms, with limited resources or knowledge gaps, by providing access to a wide range of economic 
effects (Ho and Wilson, 2006), which include: the access to specialised input and labour, novel 
information inflows and knowledge, access to research institutions and government R&D support 
services. In science-based industries knowledge diversity can potentially lead to increased innovative 
capabilities and improved business processes which impacts on a firm’s ability to make innovations.                         
 
361 
 
Research Methods 
A qualitative multiple case study approach  is used to study the extent to which knowledge diversity 
and cognitive distance can have an impact on how bio-entrepreneurs develop their innovative 
capabilities in order to improve their business process as well as to respond to changing business 
conditions. According to Robson (2002, p. 178), a case study is “a strategy for doing research which 
involves an empirical investigation of a particular phenomenon with its real life context using multiple 
sources of evidence”. The approach allowed us to study how bio-tech firms build their innovative 
capabilities. We chose to use the East Midlands region as a case study for the following reasons.  
Firstly, the region is home to leading pharmaceutical companies including Boots Plc. and 
AstraZeneca, the world’s seventh largest biopharmaceutical company. Secondly, the region has seen 
the establishment of very successful incubators such as BioCity as a means for bio-enterprise 
development. Thirdly, the UK government and the European Union have spearheaded the 
development of network centres including Enterprise Europe Network Midlands (EEN), Medilink and 
the Pera Innovation Centres in the region. Furthermore, the region has world class scientific research 
institutions including Nottingham University, Nottingham Trent University, Leicester University and 
Loughborough University. The paper interviewed a good sample composed of three bio-tech firms 
with links to research centres and academic institutions and three knowledge network centres from 
November 2010 to May 2011. A sample provide a good alternative, Fink (1995, p.1) posits that, “a 
sample is a portion or subset of a larger group called population. The population is a universe to be 
sampled; a good representative sample is a miniature version of the population”.  
 
Semi-structured interviews were used to collect primary data. Qualitative research frequently entails 
the reconstruction of events by asking selected participants to think back over how they developed 
innovative capabilities as a way to respond to the constantly changing market conditions. To ensure 
that the same topics were fully exhausted in all the interviews, we used an interview guide with open-
ended questions giving the interviewees the opportunity to tell a full story. The interview guide was 
based on our previous literature review. In that regard, the first part of data collection process can be 
described as deductive due to the fact that we began with a conceptual framework. By sticking to our 
interview guide, our aim was to achieve the validity of the data collected. However, when interesting 
lines of enquiry were brought up by the participant during the interview process, we asked them some 
follow up questions. We were aware of the danger of diverting from the main themes of our study, so 
our interview guide included questions that sought to gather information were mainly about the 
economic effects of knowledge networks. To ensure the accuracy of data collected, the interviewees 
were given the transcripts to validate the data (Bryman and Bell, 2011).  
 
To analyse the data collected from bio-tech firms and bio-entrepreneurs, we used the principles of 
thematic analysis which is commonly used by research clinicians (Newfield et al., 1990, 1991; William, 
1992). The method for analysing data was chosen because of its ability to focus on identifiable 
themes and patterns of behaviour (Aronson, 1994). Identifiable themes for this study are related to 
collaborative activities, cognitive distance, innovative capabilities, knowledge diversity, knowledge 
exchange and acquisition which were derived from interviews with bio-tech firms and knowledge 
network centres. According to Taylor and Bogdan, (1989, p.131) themes are defined as units derived 
from patterns such as “conversation topics, vocabulary, recurring activities, meanings or feelings”. 
The emerging themes from our interviews helped us to piece together and form a comprehensive 
picture of bio-tech firm’s collective experience of knowledge networks.  
 
In addition to field research, secondary literature is also used in the paper. The literature sources are 
used to develop a good understanding of and insight into previous research which can be divided into 
three categories that include: primary, secondary and tertiary sources (Saunders et al., 2003). The 
primary literature sources represent the flow of information from original sources such as government 
white papers on cluster development and organisational reports as well as information scripts from 
networking seminars. Published materials in books and journals about innovative capabilities, 
cognitive distance, knowledge diversity and regional cluster dynamics are sources that provided 
secondary literature for this study. Tertiary sources also known as search tools were used to locate 
primary and secondary literature and these include: abstracts, indexes as well as encyclopaedias and 
bibliographies. By reading related literature we were able to come up with key themes. In doing so, 
we gained valuable information about the economic effects of knowledge networks of bio-tech firms in 
the East Midlands region which allowed us to make inferences from the interviews. According to 
Aronson (1994, p. 3), “When the literature is interwoven with the findings, the story that the 
interviewer constructs is one that stands with merit”.  
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Research Findings: Patterns of Knowledge Networks and Innovative Capabilities of Bio-tech 
Firms 
 
Collaboration and Innovative Capabilities 
Working in projects has become a very popular strategy in the bio-tech sector. To provide an in-depth 
account of how firms in the East Midlands are obtaining economic growth in their collaborative 
networks, we chose bio-tech firms in their early development stages and established knowledge 
network centres to represent the entire population. In line with prior studies that focussed on social 
benefits of networking (Pittaway, 2000;  Owen-Smith and Powell, 2004), we selected bio-tech firms 
and knowledge network centres to represent the entire population based on their abilities to illuminate 
the various economic effects associated with the  growth of bio-tech firms.  
 
Our findings show that bio-entrepreneurs and bio-tech firms in the East Midlands region link up with 
other firms, institutions and knowledge networks to work on new product development initiatives and it 
is in those collaborative projects that valuable scientific knowledge and clinical products development 
ideas are shared and exchanged. This was reflected in the response given by Firm C and Firm E 
when asked about how their firms developed intellectual capital. Their responses were as follows: 
 
 “I think the idea of intellectual capital is important for both established organisations and small start-
up firms and the idea of collaboration is key as it gives less established firms access to essential 
knowledge. It is basically an understanding that we share ideas, collaborate in projects and generate 
joint programmes and IP”. (Firm C). 
 
 “The only thing I would say is that my business has changed, when I started the business most of the 
knowledge was only in-house. We now have access to a lot of external resources and nowadays 
there is a huge push towards accessing knowledge from outside for non-core areas. I would say the 
industry has changed somewhat. It is now more open and there are a lot of collaborations with 
academics and research institutions and I think that has been good to the industry. Cross function in 
biology seems to the way forward even for the world class companies such as AstraZeneca, which is 
outsourcing so as to get the expertise from outside for continuous development and innovation. They 
have more links with academia and I think that has been very productive. Therefore, I see 
collaborations as essential for growth and innovation especially in biology and chemistry”. (Firm E). 
 
In light of this evidence indicating that by forging knowledge networks, bio-tech firms can equip 
themselves with strategic resources needed to make new innovations, we were in a much stronger 
position to conclude that engaging in collaborations in the bio-tech sector is an important step to take 
as it has a positive impact on the innovative capabilities of the actors in the collaboration. Powell et al. 
(1996, p.46) made similar observations and affirmed that, “when the sources of expertise are 
disparate, collaborative R&D opens an organisation's eyes to the need for accessing ideas and 
information from a variety of sources, to exploit the research findings in a commercial context”. 
Crucially, by engaging in collaborative activities, bio-tech firms place themselves in a good position to 
withstand changing market conditions. When the bio-entrepreneur in Firm B was asked about why he 
engages in collaborative activities he stated that; 
 
“I go nationally and internationally as I am interested in the new technology in the bio-tech so the best 
way to gather that technology is to have links internationally”. (Firm B) 
 
However, many of these seemingly bold steps towards capability development, bio-tech firms need to 
have prior knowledge of what is to be absorbed especially in areas that were referred by Firm E as 
“non-core areas”. Otherwise, their collaborative strategy will not yield a positive outcome for their 
business. It would be naive for us to ignore the barriers that may hinder knowledge exchange, transfer 
and the learning process in collaborative networks. When asked about whether his business shares 
knowledge freely in a network, the bio-entrepreneur in Firm E categorically stated that; 
 
“We are not totally open but we are to people who fund us and those who collaborate with us on 
specific projects therefore people who are our partners will have full access to all the knowledge 
available for that specific project”. (Firm E) 
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The statement highlights that some bio-tech firms in the East Midlands region are conservative; they 
are still secretive about their business operations which defeats the purpose of collaboration. These 
firms pick and choose their partners based on trust and their expected economic returns in an 
alliance. The “whats in it for me” attitude can hinder the process of knowledge sharing. This implies 
that acquiring innovative capabilities via networking depend on the depth and width of relationships 
and the strength of ties between actors in a geographical proximity. It is often assumed that strong 
ties in social networks usually yield high flow of information due to shared common values, aims, trust 
and the use of a common language for communication (Melkas and Harmaakorpi, 2008). Weak ties 
have been described, by a number of authors (Granovetter, 2005; Burt 2004; Zaheer and Bell, 2005), 
as productive for innovation to flourish because they are credited with allowing the flow of quality 
information or data directly to individuals in seemingly weak ties as opposed to strong ties. At optimal 
cognitive distance, direct ties are sought and indirect ties play a vital role by providing the crucial links 
between nodes/actors/bio-entrepreneurs for governance and for crossing cognitive distance that is 
too large to deal with within a single firm (Nooteboom, 2009; Visser, 2009).       
 
Knowledge Diversity and Innovative Capabilities 
Our interviews also indicate that having access to the knowledge from a wide range of organisations 
either in the same line of business or related business is a catalyst for capability development for bio-
tech firms. Firms that venture beyond their immediate geographical proximity in search of novel 
information inflows offer their businesses better opportunities to acquire the much needed innovative 
capabilities including specialised skills, new ideas, human capital, financial capital and knowledge 
necessary to respond to the dynamic business conditions. In the interview with the project manager in 
Knowledge Centre B established in the East Midlands region, he made it clear that the knowledge 
centre provides access to global knowledge and markets; 
 
“We help firms and industry sectors access information, opportunities and partners on a global 
scale through specialist networks and business intelligence. On behalf of national government 
agencies, we deliver programmes to stimulate international inward investment, technology 
transfer, partnering and access to high growth global markets for UK companies. We provide 
business intelligence and contacts to help UK firms identify and realise international 
opportunities”.      
 
Contacts outside the local industry milieu are crucial to the process of acquiring rich novel information 
inflows which underpins the generation of scientific knowledge for bio-tech firms. Furthermore, the 
same sentiments were echoed in our interview with the manager in Knowledge Network A. When 
asked about the impact of knowledge diversity on the innovative capabilities of bio-tech firms she 
explained that:  
 
“One of the things that we encourage small and established firms in the East Midlands to do is 
to develop links with international organisations. The Animal corridor from the USA will be 
visiting the East Midlands in March this year to attend one of our networking conferences. We 
also had an alliance with bio-masters who specialise in cats and dogs. Some people came over 
from USA. We also promote international trade and I think international links are also important 
as they give organisations/firms a chance to acquire new knowledge. People exchange 
knowledge, ideas and best practice”.   
 
This indicates that regional resources and collective networks are decisive for firms in their early 
development stages and for those intending to improve their business logistics and design. Indeed, in 
the face of globalisation, bio-tech firms are tied in evolving international networks and clusters which 
facilitates the continuous renewal of a firm’s knowledge resources. Thus, the capacity for bio-tech 
firms to dramatically reshape their business logistics and the business design is significantly 
improved.     
 
Cognitive Distance and Innovative Capabilities  
Nelson’s and Winter’s (1982) evolutionary perspective on innovation stresses heterogeneity or variety 
as a vital source for innovation. Cognitive distance is the difference between the cognitive foci of 
firms, with two main dimensions of technological knowledge, competences and moral principles of 
internal governance (Nooteboom, 2009; and Narayanan et al., 2009). Stuart (1998) contends that the 
most valuable alliances are those between firms with similar technological foci or those operating in 
the same markets.  
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As our interviewee said: 
 
“I work with any organisation in clinical development and in that process I gain ideas and 
knowledge as a result of their varied business processes”. 
 
Tanriverdi and Vankatraman (2005) posit that in alliances where partners have related skills and 
knowledge their learning is significantly enhanced. Indeed, the level of knowledge transfer and 
sharing is very high in cross boarder collaborations which assist firms in developing essential 
innovative capabilities. The increasingly complex nature of technology in the bio-tech sector has led to 
the emergence of this trend of inter-firm relationships aimed at primarily outsourcing new knowledge 
from complementary technological sources and absorbing it into the firm’s technological portfolio 
(Agata and Santangelo, 1994). The same view was offered by Nooteboom (2009) who expressed that 
participants with high betweenness centrality offer bridging of structural holes in ties with distant 
clusters as a source for new knowledge. Interestingly, our interviews indicate that in the East 
Midlands region bio-tech firms with knowledge gaps are placed into projects with both indigenous and 
international specialists or experts in small groups of five to six nodes known as “science projects” 
monitored by a project manager in a knowledge network centre or a government designated 
innovation zone or by office representatives from the Euro zone.  The idea is to coach, nurture, guide 
and support firms that have limited resources. At one given time we found that there could be ten to 
fifteen projects running concurrently. The project manager in Knowledge Network A and the office 
representative in Knowledge Network C explained that; 
 
 “We facilitate collaborations in the bio-tech industry in the East Midlands region. We are in contact 
with science experts, research institutions, universities, and various bio-tech firms within the East 
Midlands and internationally. If a small firm come to us asking for help to develop and grow its 
operations, we try to match their needs with the portfolio of companies that we have “we call it 
problem matching”. We then facilitate a network which is made up three or four actors/firms and one 
of them would be an established firm or experienced scientist or academic expert”. (Knowledge 
Network A) 
 
 “EEN is part of the bio-tech sector group which brings together numerous business profiles in the bio-
sector industry regionally and internationally. The sector group discusses possible partnerships that 
could be made”. (Knowledge Network C) 
 
This indicates a direct link between the knowledge distances and the geographical proximity of actors 
in a network or cluster with innovation. In particular, the findings show that a firm’s ability to generate 
new knowledge and ideas is directly linked to its ambition to develop alliances with experienced 
actors in a given geographic area or even beyond in order to supplement its internal research and 
development (R&D) capacity which is also evident in our secondary literature.  
   
Discussion 
The process of capability development in the bio-tech firms within the East Midlands region highlight 
some striking similarities with well-established networks including Silicon Valley, Cambridge and the 
Boston biotechnology cluster. Network formation in the East Midlands region exhibits some special 
and unique characteristics in terms of how firms develop networks within the region which are vital for 
acquiring essential innovative capabilities. The 
East Midlands region bio-tech sector which is 
part of the M1 corridor including Sheffield and 
Leeds sectors, knowledge network centres 
create industry milieu by linking small start-up 
firms with the established local and international 
organisations and academic research institutions. 
The patterns of knowledge networks diagram 
neatly illustrates the interplay of the key actors 
involved in the special networks of biotech firms.  
Crucial scientific knowledge is shared in those 
collaborative projects enabling small firms to 
improve their business logistics and designs and that has proved to be vital for corporate and regional 
economic growth.  
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This unique type of networking is designed by knowledge centres with the view to equip firms with the 
right resources mix in order to respond to changing market conditions and create a strong regional 
economy which secures the region’s long term vitality. The region’s strategy for facilitating 
collaborative projects as a way to solve scientific puzzles has proved to have a positive impact on 
small firms in their early development stages. These results are similar to those achieved by world 
renowned clusters including Silicon Valley, Cambridge clusters and Boston bio-tech cluster. All of the 
firms within their geographical proximity have access to shared resources; innovations are honed and 
developed in the network.  
 
Concerning the economics of regional development we cannot overlook the fact that the UK 
government and the EU need to take a leading role by developing effective inter-firm collaboration 
strategies to boost economic growth. This will help to dispel the stigma sometimes attached with 
knowledge sharing. During our data collection process potential interviewees turned down our 
interview requests fearing that they may be making available, to their competitors, vital information 
about their new innovations. Policy makers should take the initiative to rebuild existing knowledge 
bases and integrate them with government R&D centres. By facilitating collaborative activities they 
place themselves in a strong position to monitor the outcomes of R&D projects. This also helps both 
the policy makers and organisations in regional networks to assess whether their goals of economic 
growth associated with regional and technological development are achieved.  
 
Conclusion 
The paper shows that knowledge networks are the crucial steps for capability development in the 
knowledge intensive bio-tech sector. Following our analysis of both primary data and secondary 
literature we found that small bio-tech firms in their early development stages faced with volatile 
market conditions can supplement their core competences when they engage in collaborative 
activities with other firms and knowledge network centres. This led us to conclude that knowledge 
networks have a significant impact on the innovative capabilities of bio-tech firms. Knowledge 
diversity and cognitive distance are key variables that hugely impact on a bio-tech firm’s economic 
growth. In the East Midlands region, knowledge centres have played an important role in forging the 
knowledge network of bio-tech start-ups. Small bio-tech firms are given the opportunity to establish, 
grow and develop which is achieved by creating specialist forums for problem solving, specific help 
and debate. BioCity the region’s most successful incubator use incubation as a means for bio-
enterprise and capability development. The technology incubator fosters the growth of new 
technology based ventures by helping them to close the gaps in the innovation process and correct 
market failures. In sum the knowledge network centres in the region act as new bio-tech firms’ 
“nurseries”, “accelerators” and “greenhouses”.  
 
There are limitations with the sample used for data collection. Indeed, as much as the chosen 
methods are deemed appropriate the authors are aware of the inherent limitations. Access to the 
target population was a problem faced during the data collection process. The study could have 
benefited from a larger sample of participants. However, key actors in the East Midlands region were 
targeted as data sources. In knowledge based industries the main agents such as knowledge centres 
have significant influence regarding what transpires in their resident network (Breschi and Malebra, 
2005).  
 
For future research, we recommend the study of the business incubation process of small bio-tech 
firms. Business Incubation is an enterprise development strategy which is a unique and highly flexible 
combination of business development processes, infrastructure, and people, designed to nurture and 
grow new and small bio-tech firms by supporting them through the early stages of development and 
change. An incubator can create quality jobs at reasonable net public subsidy cost, widen the tax 
base and reduce gestation and costs of entering market, while enhancing chances of success. In that 
context, a follow up study is necessary to explore whether there are any differences or similarities 
regarding how the East Midlands region’s knowledge networks nurture firms in their early 
development stages within their geographical proximity with world class clusters including Silicon 
Valley, Cambridge and the Boston biotechnology cluster.  
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